ground_truth
The human infectious dose of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unknown by all exposure routes.
The human infectious dose of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unknown by all exposure routes.
The human infectious dose of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unknown by all exposure routes.
The human infectious dose of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unknown by all exposure routes.
The human infectious dose of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unknown by all exposure routes.
The human infectious dose of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unknown by all exposure routes.
The human infectious dose of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unknown by all exposure routes.
Based on experimental studies with humans exposed to other coronaviruses, animals exposed to SARS-CoV-2, and modeling estimates, the median infectious dose is likely between 10 and 1,000 viral particles (plaque-forming units, PFU).
Based on experimental studies with humans exposed to other coronaviruses, animals exposed to SARS-CoV-2, and modeling estimates, the median infectious dose is likely between 10 and 1,000 viral particles (plaque-forming units, PFU).
Based on experimental studies with humans exposed to other coronaviruses, animals exposed to SARS-CoV-2, and modeling estimates, the median infectious dose is likely between 10 and 1,000 viral particles (plaque-forming units, PFU).
Based on experimental studies with humans exposed to other coronaviruses, animals exposed to SARS-CoV-2, and modeling estimates, the median infectious dose is likely between 10 and 1,000 viral particles (plaque-forming units, PFU).
Based on experimental studies with humans exposed to other coronaviruses, animals exposed to SARS-CoV-2, and modeling estimates, the median infectious dose is likely between 10 and 1,000 viral particles (plaque-forming units, PFU).
Based on experimental studies with humans exposed to other coronaviruses, animals exposed to SARS-CoV-2, and modeling estimates, the median infectious dose is likely between 10 and 1,000 viral particles (plaque-forming units, PFU).
Based on experimental studies with humans exposed to other coronaviruses, animals exposed to SARS-CoV-2, and modeling estimates, the median infectious dose is likely between 10 and 1,000 viral particles (plaque-forming units, PFU).
Based on experimental studies with humans exposed to other coronaviruses, animals exposed to SARS-CoV-2, and modeling estimates, the median infectious dose is likely between 10 and 1,000 viral particles (plaque-forming units, PFU).
Based on experimental studies with humans exposed to other coronaviruses, animals exposed to SARS-CoV-2, and modeling estimates, the median infectious dose is likely between 10 and 1,000 viral particles (plaque-forming units, PFU).
Based on experimental studies with humans exposed to other coronaviruses, animals exposed to SARS-CoV-2, and modeling estimates, the median infectious dose is likely between 10 and 1,000 viral particles (plaque-forming units, PFU).
A total dose of approximately 700,000 plaque-forming units (PFU) of the novel coronavirus SARS-CoV-2 infected cynomolgus macaques via combination intranasal and intratracheal exposure (106 TCID50 total dose).
A total dose of approximately 700,000 plaque-forming units (PFU) of the novel coronavirus SARS-CoV-2 infected cynomolgus macaques via combination intranasal and intratracheal exposure (106 TCID50 total dose).
A total dose of approximately 700,000 plaque-forming units (PFU) of the novel coronavirus SARS-CoV-2 infected cynomolgus macaques via combination intranasal and intratracheal exposure (106 TCID50 total dose).
A total dose of approximately 700,000 plaque-forming units (PFU) of the novel coronavirus SARS-CoV-2 infected cynomolgus macaques via combination intranasal and intratracheal exposure (106 TCID50 total dose).
A total dose of approximately 700,000 plaque-forming units (PFU) of the novel coronavirus SARS-CoV-2 infected cynomolgus macaques via combination intranasal and intratracheal exposure (106 TCID50 total dose).
A total dose of approximately 700,000 plaque-forming units (PFU) of the novel coronavirus SARS-CoV-2 infected cynomolgus macaques via combination intranasal and intratracheal exposure (106 TCID50 total dose).
A total dose of approximately 700,000 plaque-forming units (PFU) of the novel coronavirus SARS-CoV-2 infected cynomolgus macaques via combination intranasal and intratracheal exposure (106 TCID50 total dose).
A total dose of approximately 700,000 plaque-forming units (PFU) of the novel coronavirus SARS-CoV-2 infected cynomolgus macaques via combination intranasal and intratracheal exposure (106 TCID50 total dose).
A total dose of approximately 700,000 plaque-forming units (PFU) of the novel coronavirus SARS-CoV-2 infected cynomolgus macaques via combination intranasal and intratracheal exposure (106 TCID50 total dose).
A total dose of approximately 700,000 plaque-forming units (PFU) of the novel coronavirus SARS-CoV-2 infected cynomolgus macaques via combination intranasal and intratracheal exposure (106 TCID50 total dose).
Rhesus and cynomolgus macaques showed mild to moderate clinical infections at doses of 4.75x106 PFU (delivered through several routes), while marmosets developed mild infections when exposed to 1x106 PFU intranasally.
Rhesus and cynomolgus macaques showed mild to moderate clinical infections at doses of 4.75x106 PFU (delivered through several routes), while marmosets developed mild infections when exposed to 1x106 PFU intranasally.
Rhesus and cynomolgus macaques showed mild to moderate clinical infections at doses of 4.75x106 PFU (delivered through several routes), while marmosets developed mild infections when exposed to 1x106 PFU intranasally.
Rhesus and cynomolgus macaques showed mild to moderate clinical infections at doses of 4.75x106 PFU (delivered through several routes), while marmosets developed mild infections when exposed to 1x106 PFU intranasally.
Rhesus and cynomolgus macaques showed mild to moderate clinical infections at doses of 4.75x106 PFU (delivered through several routes), while marmosets developed mild infections when exposed to 1x106 PFU intranasally.
Rhesus and cynomolgus macaques showed mild to moderate clinical infections at doses of 4.75x106 PFU (delivered through several routes), while marmosets developed mild infections when exposed to 1x106 PFU intranasally.
Rhesus and cynomolgus macaques showed mild to moderate clinical infections at doses of 4.75x106 PFU (delivered through several routes), while marmosets developed mild infections when exposed to 1x106 PFU intranasally.
Rhesus and cynomolgus macaques showed mild to moderate clinical infections at doses of 4.75x106 PFU (delivered through several routes), while marmosets developed mild infections when exposed to 1x106 PFU intranasally.
Rhesus and cynomolgus macaques showed mild to moderate clinical infections at doses of 4.75x106 PFU (delivered through several routes), while marmosets developed mild infections when exposed to 1x106 PFU intranasally.
Rhesus and cynomolgus macaques showed mild to moderate clinical infections at doses of 4.75x106 PFU (delivered through several routes), while marmosets developed mild infections when exposed to 1x106 PFU intranasally.
Rhesus macaques are effectively infected with SARS-CoV-2 via the ocular conjunctival and intratracheal route at a dose of ~700,000 PFU (106 TCID50).
Rhesus macaques are effectively infected with SARS-CoV-2 via the ocular conjunctival and intratracheal route at a dose of ~700,000 PFU (106 TCID50).
Rhesus macaques are effectively infected with SARS-CoV-2 via the ocular conjunctival and intratracheal route at a dose of ~700,000 PFU (106 TCID50).
Rhesus macaques are effectively infected with SARS-CoV-2 via the ocular conjunctival and intratracheal route at a dose of ~700,000 PFU (106 TCID50).
Rhesus macaques are effectively infected with SARS-CoV-2 via the ocular conjunctival and intratracheal route at a dose of ~700,000 PFU (106 TCID50).
Rhesus macaques are effectively infected with SARS-CoV-2 via the ocular conjunctival and intratracheal route at a dose of ~700,000 PFU (106 TCID50).
Rhesus macaques are effectively infected with SARS-CoV-2 via the ocular conjunctival and intratracheal route at a dose of ~700,000 PFU (106 TCID50).
Rhesus macaques are effectively infected with SARS-CoV-2 via the ocular conjunctival and intratracheal route at a dose of ~700,000 PFU (106 TCID50).
Rhesus macaques are effectively infected with SARS-CoV-2 via the ocular conjunctival and intratracheal route at a dose of ~700,000 PFU (106 TCID50).
Rhesus macaques are effectively infected with SARS-CoV-2 via the ocular conjunctival and intratracheal route at a dose of ~700,000 PFU (106 TCID50).
Rhesus macaques infected with 2,600,000 TCID50 of SARS-CoV-2 by the intranasal, intratracheal, oral and ocular routes combined recapitulate moderate human disease.
Rhesus macaques infected with 2,600,000 TCID50 of SARS-CoV-2 by the intranasal, intratracheal, oral and ocular routes combined recapitulate moderate human disease.
Rhesus macaques infected with 2,600,000 TCID50 of SARS-CoV-2 by the intranasal, intratracheal, oral and ocular routes combined recapitulate moderate human disease.
Rhesus macaques infected with 2,600,000 TCID50 of SARS-CoV-2 by the intranasal, intratracheal, oral and ocular routes combined recapitulate moderate human disease.
Rhesus macaques infected with 2,600,000 TCID50 of SARS-CoV-2 by the intranasal, intratracheal, oral and ocular routes combined recapitulate moderate human disease.
Rhesus macaques infected with 2,600,000 TCID50 of SARS-CoV-2 by the intranasal, intratracheal, oral and ocular routes combined recapitulate moderate human disease.
Rhesus macaques infected with 2,600,000 TCID50 of SARS-CoV-2 by the intranasal, intratracheal, oral and ocular routes combined recapitulate moderate human disease.
Rhesus macaques infected with 2,600,000 TCID50 of SARS-CoV-2 by the intranasal, intratracheal, oral and ocular routes combined recapitulate moderate human disease.
Rhesus macaques infected with 2,600,000 TCID50 of SARS-CoV-2 by the intranasal, intratracheal, oral and ocular routes combined recapitulate moderate human disease.
Rhesus macaques infected with 2,600,000 TCID50 of SARS-CoV-2 by the intranasal, intratracheal, oral and ocular routes combined recapitulate moderate human disease.
A small study infected Rhesus macaques via ocular inoculation (1x106 TCID50), resulting in mild infection; however, gastric inoculation did not result in infection (same dose), suggesting a limited role of gastric transmission.Interpretation is limited due to the small scale.
A small study infected Rhesus macaques via ocular inoculation (1x106 TCID50), resulting in mild infection; however, gastric inoculation did not result in infection (same dose), suggesting a limited role of gastric transmission.Interpretation is limited due to the small scale.
A small study infected Rhesus macaques via ocular inoculation (1x106 TCID50), resulting in mild infection; however, gastric inoculation did not result in infection (same dose), suggesting a limited role of gastric transmission.Interpretation is limited due to the small scale.
A small study infected Rhesus macaques via ocular inoculation (1x106 TCID50), resulting in mild infection; however, gastric inoculation did not result in infection (same dose), suggesting a limited role of gastric transmission.Interpretation is limited due to the small scale.
A small study infected Rhesus macaques via ocular inoculation (1x106 TCID50), resulting in mild infection; however, gastric inoculation did not result in infection (same dose), suggesting a limited role of gastric transmission.Interpretation is limited due to the small scale.
A small study infected Rhesus macaques via ocular inoculation (1x106 TCID50), resulting in mild infection; however, gastric inoculation did not result in infection (same dose), suggesting a limited role of gastric transmission.Interpretation is limited due to the small scale.
A small study infected Rhesus macaques via ocular inoculation (1x106 TCID50), resulting in mild infection; however, gastric inoculation did not result in infection (same dose), suggesting a limited role of gastric transmission.Interpretation is limited due to the small scale.
A small study infected Rhesus macaques via ocular inoculation (1x106 TCID50), resulting in mild infection; however, gastric inoculation did not result in infection (same dose), suggesting a limited role of gastric transmission.Interpretation is limited due to the small scale.
A small study infected Rhesus macaques via ocular inoculation (1x106 TCID50), resulting in mild infection; however, gastric inoculation did not result in infection (same dose), suggesting a limited role of gastric transmission.Interpretation is limited due to the small scale.
A small study infected Rhesus macaques via ocular inoculation (1x106 TCID50), resulting in mild infection; however, gastric inoculation did not result in infection (same dose), suggesting a limited role of gastric transmission.Interpretation is limited due to the small scale.
African green monkeys replicate aspects of human disease, including severe pathological symptoms (exposed to 500,000 PFU via intranasal and intratracheal routes), mild clinical symptoms (aerosol exposures between 5,000 and 16,000 PFU), and acute respiratory distress syndrome (ARDS), with small particle aerosol exposure doses as low as 2,000 PFU.
African green monkeys replicate aspects of human disease, including severe pathological symptoms (exposed to 500,000 PFU via intranasal and intratracheal routes), mild clinical symptoms (aerosol exposures between 5,000 and 16,000 PFU), and acute respiratory distress syndrome (ARDS), with small particle aerosol exposure doses as low as 2,000 PFU.
African green monkeys replicate aspects of human disease, including severe pathological symptoms (exposed to 500,000 PFU via intranasal and intratracheal routes), mild clinical symptoms (aerosol exposures between 5,000 and 16,000 PFU), and acute respiratory distress syndrome (ARDS), with small particle aerosol exposure doses as low as 2,000 PFU.
African green monkeys replicate aspects of human disease, including severe pathological symptoms (exposed to 500,000 PFU via intranasal and intratracheal routes), mild clinical symptoms (aerosol exposures between 5,000 and 16,000 PFU), and acute respiratory distress syndrome (ARDS), with small particle aerosol exposure doses as low as 2,000 PFU.
African green monkeys replicate aspects of human disease, including severe pathological symptoms (exposed to 500,000 PFU via intranasal and intratracheal routes), mild clinical symptoms (aerosol exposures between 5,000 and 16,000 PFU), and acute respiratory distress syndrome (ARDS), with small particle aerosol exposure doses as low as 2,000 PFU.
African green monkeys replicate aspects of human disease, including severe pathological symptoms (exposed to 500,000 PFU via intranasal and intratracheal routes), mild clinical symptoms (aerosol exposures between 5,000 and 16,000 PFU), and acute respiratory distress syndrome (ARDS), with small particle aerosol exposure doses as low as 2,000 PFU.
African green monkeys replicate aspects of human disease, including severe pathological symptoms (exposed to 500,000 PFU via intranasal and intratracheal routes), mild clinical symptoms (aerosol exposures between 5,000 and 16,000 PFU), and acute respiratory distress syndrome (ARDS), with small particle aerosol exposure doses as low as 2,000 PFU.
African green monkeys replicate aspects of human disease, including severe pathological symptoms (exposed to 500,000 PFU via intranasal and intratracheal routes), mild clinical symptoms (aerosol exposures between 5,000 and 16,000 PFU), and acute respiratory distress syndrome (ARDS), with small particle aerosol exposure doses as low as 2,000 PFU.
African green monkeys replicate aspects of human disease, including severe pathological symptoms (exposed to 500,000 PFU via intranasal and intratracheal routes), mild clinical symptoms (aerosol exposures between 5,000 and 16,000 PFU), and acute respiratory distress syndrome (ARDS), with small particle aerosol exposure doses as low as 2,000 PFU.
African green monkeys replicate aspects of human disease, including severe pathological symptoms (exposed to 500,000 PFU via intranasal and intratracheal routes), mild clinical symptoms (aerosol exposures between 5,000 and 16,000 PFU), and acute respiratory distress syndrome (ARDS), with small particle aerosol exposure doses as low as 2,000 PFU.
Aerosol exposure of three primate species (African green monkeys, cynomolgus macaques, and rhesus macaques) via a Collison nebulizer resulted in mild clinical disease in all animals with doses between 28,700 and 48,600 PFU.
Aerosol exposure of three primate species (African green monkeys, cynomolgus macaques, and rhesus macaques) via a Collison nebulizer resulted in mild clinical disease in all animals with doses between 28,700 and 48,600 PFU.
Aerosol exposure of three primate species (African green monkeys, cynomolgus macaques, and rhesus macaques) via a Collison nebulizer resulted in mild clinical disease in all animals with doses between 28,700 and 48,600 PFU.
Aerosol exposure of three primate species (African green monkeys, cynomolgus macaques, and rhesus macaques) via a Collison nebulizer resulted in mild clinical disease in all animals with doses between 28,700 and 48,600 PFU.
Aerosol exposure of three primate species (African green monkeys, cynomolgus macaques, and rhesus macaques) via a Collison nebulizer resulted in mild clinical disease in all animals with doses between 28,700 and 48,600 PFU.
Aerosol exposure of three primate species (African green monkeys, cynomolgus macaques, and rhesus macaques) via a Collison nebulizer resulted in mild clinical disease in all animals with doses between 28,700 and 48,600 PFU.
Aerosol exposure of three primate species (African green monkeys, cynomolgus macaques, and rhesus macaques) via a Collison nebulizer resulted in mild clinical disease in all animals with doses between 28,700 and 48,600 PFU.
Aerosol exposure of three primate species (African green monkeys, cynomolgus macaques, and rhesus macaques) via a Collison nebulizer resulted in mild clinical disease in all animals with doses between 28,700 and 48,600 PFU.
Aerosol exposure of three primate species (African green monkeys, cynomolgus macaques, and rhesus macaques) via a Collison nebulizer resulted in mild clinical disease in all animals with doses between 28,700 and 48,600 PFU.
Aerosol exposure of three primate species (African green monkeys, cynomolgus macaques, and rhesus macaques) via a Collison nebulizer resulted in mild clinical disease in all animals with doses between 28,700 and 48,600 PFU.
Rhesus macaques have been suggested as the best non-human primate model of human COVID-19.
Rhesus macaques have been suggested as the best non-human primate model of human COVID-19.
Rhesus macaques have been suggested as the best non-human primate model of human COVID-19.
Rhesus macaques have been suggested as the best non-human primate model of human COVID-19.
Rhesus macaques have been suggested as the best non-human primate model of human COVID-19.
Rhesus macaques have been suggested as the best non-human primate model of human COVID-19.
Rhesus macaques have been suggested as the best non-human primate model of human COVID-19.
Rhesus macaques have been suggested as the best non-human primate model of human COVID-19.
Rhesus macaques have been suggested as the best non-human primate model of human COVID-19.
Rhesus macaques have been suggested as the best non-human primate model of human COVID-19.
Infectious SARS-CoV-2 has been isolated from rhesus macaque feces, suggesting possible fecal-oral transmission.
Infectious SARS-CoV-2 has been isolated from rhesus macaque feces, suggesting possible fecal-oral transmission.
Infectious SARS-CoV-2 has been isolated from rhesus macaque feces, suggesting possible fecal-oral transmission.
Infectious SARS-CoV-2 has been isolated from rhesus macaque feces, suggesting possible fecal-oral transmission.
Infectious SARS-CoV-2 has been isolated from rhesus macaque feces, suggesting possible fecal-oral transmission.
Infectious SARS-CoV-2 has been isolated from rhesus macaque feces, suggesting possible fecal-oral transmission.
Infectious SARS-CoV-2 has been isolated from rhesus macaque feces, suggesting possible fecal-oral transmission.
Infectious SARS-CoV-2 has been isolated from rhesus macaque feces, suggesting possible fecal-oral transmission.
Infectious SARS-CoV-2 has been isolated from rhesus macaque feces, suggesting possible fecal-oral transmission.
Infectious SARS-CoV-2 has been isolated from rhesus macaque feces, suggesting possible fecal-oral transmission.
The SARS-CoV-2 median infectious dose in Golden Syrian hamsters via the intranasal route was experimentally estimated at 5 TCID50 (~3.5 PFU).
The SARS-CoV-2 median infectious dose in Golden Syrian hamsters via the intranasal route was experimentally estimated at 5 TCID50 (~3.5 PFU).
The SARS-CoV-2 median infectious dose in Golden Syrian hamsters via the intranasal route was experimentally estimated at 5 TCID50 (~3.5 PFU).
The SARS-CoV-2 median infectious dose in Golden Syrian hamsters via the intranasal route was experimentally estimated at 5 TCID50 (~3.5 PFU).
The SARS-CoV-2 median infectious dose in Golden Syrian hamsters via the intranasal route was experimentally estimated at 5 TCID50 (~3.5 PFU).
The SARS-CoV-2 median infectious dose in Golden Syrian hamsters via the intranasal route was experimentally estimated at 5 TCID50 (~3.5 PFU).
The SARS-CoV-2 median infectious dose in Golden Syrian hamsters via the intranasal route was experimentally estimated at 5 TCID50 (~3.5 PFU).
The SARS-CoV-2 median infectious dose in Golden Syrian hamsters via the intranasal route was experimentally estimated at 5 TCID50 (~3.5 PFU).
The SARS-CoV-2 median infectious dose in Golden Syrian hamsters via the intranasal route was experimentally estimated at 5 TCID50 (~3.5 PFU).
The SARS-CoV-2 median infectious dose in Golden Syrian hamsters via the intranasal route was experimentally estimated at 5 TCID50 (~3.5 PFU).
Low-dose intranasal inoculation of ferrets (2,000 PFU) and Golden Syrian hamsters (1,800 PFU) with SARS-CoV-2 resulted in mild clinical symptoms, the production of infectious virus, and seroconversion.
Low-dose intranasal inoculation of ferrets (2,000 PFU) and Golden Syrian hamsters (1,800 PFU) with SARS-CoV-2 resulted in mild clinical symptoms, the production of infectious virus, and seroconversion.
Low-dose intranasal inoculation of ferrets (2,000 PFU) and Golden Syrian hamsters (1,800 PFU) with SARS-CoV-2 resulted in mild clinical symptoms, the production of infectious virus, and seroconversion.
Low-dose intranasal inoculation of ferrets (2,000 PFU) and Golden Syrian hamsters (1,800 PFU) with SARS-CoV-2 resulted in mild clinical symptoms, the production of infectious virus, and seroconversion.
Low-dose intranasal inoculation of ferrets (2,000 PFU) and Golden Syrian hamsters (1,800 PFU) with SARS-CoV-2 resulted in mild clinical symptoms, the production of infectious virus, and seroconversion.
Low-dose intranasal inoculation of ferrets (2,000 PFU) and Golden Syrian hamsters (1,800 PFU) with SARS-CoV-2 resulted in mild clinical symptoms, the production of infectious virus, and seroconversion.
Low-dose intranasal inoculation of ferrets (2,000 PFU) and Golden Syrian hamsters (1,800 PFU) with SARS-CoV-2 resulted in mild clinical symptoms, the production of infectious virus, and seroconversion.
Low-dose intranasal inoculation of ferrets (2,000 PFU) and Golden Syrian hamsters (1,800 PFU) with SARS-CoV-2 resulted in mild clinical symptoms, the production of infectious virus, and seroconversion.
Low-dose intranasal inoculation of ferrets (2,000 PFU) and Golden Syrian hamsters (1,800 PFU) with SARS-CoV-2 resulted in mild clinical symptoms, the production of infectious virus, and seroconversion.
Low-dose intranasal inoculation of ferrets (2,000 PFU) and Golden Syrian hamsters (1,800 PFU) with SARS-CoV-2 resulted in mild clinical symptoms, the production of infectious virus, and seroconversion.
Golden Syrian hamsters exposed to 80,000 TCID50 (~56,000 PFU) via the intranasal route developed clinical symptoms reminiscent of mild human infections (all hamsters infected).
Golden Syrian hamsters exposed to 80,000 TCID50 (~56,000 PFU) via the intranasal route developed clinical symptoms reminiscent of mild human infections (all hamsters infected).
Golden Syrian hamsters exposed to 80,000 TCID50 (~56,000 PFU) via the intranasal route developed clinical symptoms reminiscent of mild human infections (all hamsters infected).
Golden Syrian hamsters exposed to 80,000 TCID50 (~56,000 PFU) via the intranasal route developed clinical symptoms reminiscent of mild human infections (all hamsters infected).
Golden Syrian hamsters exposed to 80,000 TCID50 (~56,000 PFU) via the intranasal route developed clinical symptoms reminiscent of mild human infections (all hamsters infected).
Golden Syrian hamsters exposed to 80,000 TCID50 (~56,000 PFU) via the intranasal route developed clinical symptoms reminiscent of mild human infections (all hamsters infected).
Golden Syrian hamsters exposed to 80,000 TCID50 (~56,000 PFU) via the intranasal route developed clinical symptoms reminiscent of mild human infections (all hamsters infected).
Golden Syrian hamsters exposed to 80,000 TCID50 (~56,000 PFU) via the intranasal route developed clinical symptoms reminiscent of mild human infections (all hamsters infected).
Golden Syrian hamsters exposed to 80,000 TCID50 (~56,000 PFU) via the intranasal route developed clinical symptoms reminiscent of mild human infections (all hamsters infected).
Golden Syrian hamsters exposed to 80,000 TCID50 (~56,000 PFU) via the intranasal route developed clinical symptoms reminiscent of mild human infections (all hamsters infected).
Golden Syrian hamsters infected with 100,000 PFU intranasally exhibited mild clinical symptoms and developed neutralizing antibodies, and were also capable of infecting individuals in separate cages.
Golden Syrian hamsters infected with 100,000 PFU intranasally exhibited mild clinical symptoms and developed neutralizing antibodies, and were also capable of infecting individuals in separate cages.
Golden Syrian hamsters infected with 100,000 PFU intranasally exhibited mild clinical symptoms and developed neutralizing antibodies, and were also capable of infecting individuals in separate cages.
Golden Syrian hamsters infected with 100,000 PFU intranasally exhibited mild clinical symptoms and developed neutralizing antibodies, and were also capable of infecting individuals in separate cages.
Golden Syrian hamsters infected with 100,000 PFU intranasally exhibited mild clinical symptoms and developed neutralizing antibodies, and were also capable of infecting individuals in separate cages.
Golden Syrian hamsters infected with 100,000 PFU intranasally exhibited mild clinical symptoms and developed neutralizing antibodies, and were also capable of infecting individuals in separate cages.
Golden Syrian hamsters infected with 100,000 PFU intranasally exhibited mild clinical symptoms and developed neutralizing antibodies, and were also capable of infecting individuals in separate cages.
Golden Syrian hamsters infected with 100,000 PFU intranasally exhibited mild clinical symptoms and developed neutralizing antibodies, and were also capable of infecting individuals in separate cages.
Golden Syrian hamsters infected with 100,000 PFU intranasally exhibited mild clinical symptoms and developed neutralizing antibodies, and were also capable of infecting individuals in separate cages.
Golden Syrian hamsters infected with 100,000 PFU intranasally exhibited mild clinical symptoms and developed neutralizing antibodies, and were also capable of infecting individuals in separate cages.
Transgenic (hACE2) mice became infected after timed aerosol exposure (36 TCID50/minute) to between 900 and 1080 TCID50 (~630-756 PFU).
Transgenic (hACE2) mice became infected after timed aerosol exposure (36 TCID50/minute) to between 900 and 1080 TCID50 (~630-756 PFU).
Transgenic (hACE2) mice became infected after timed aerosol exposure (36 TCID50/minute) to between 900 and 1080 TCID50 (~630-756 PFU).
Transgenic (hACE2) mice became infected after timed aerosol exposure (36 TCID50/minute) to between 900 and 1080 TCID50 (~630-756 PFU).
Transgenic (hACE2) mice became infected after timed aerosol exposure (36 TCID50/minute) to between 900 and 1080 TCID50 (~630-756 PFU).
Transgenic (hACE2) mice became infected after timed aerosol exposure (36 TCID50/minute) to between 900 and 1080 TCID50 (~630-756 PFU).
Transgenic (hACE2) mice became infected after timed aerosol exposure (36 TCID50/minute) to between 900 and 1080 TCID50 (~630-756 PFU).
Transgenic (hACE2) mice became infected after timed aerosol exposure (36 TCID50/minute) to between 900 and 1080 TCID50 (~630-756 PFU).
Transgenic (hACE2) mice became infected after timed aerosol exposure (36 TCID50/minute) to between 900 and 1080 TCID50 (~630-756 PFU).
Transgenic (hACE2) mice became infected after timed aerosol exposure (36 TCID50/minute) to between 900 and 1080 TCID50 (~630-756 PFU).
All mice (4/4) exposed for 25-30 minutes became infected, while no mice (0/8) became infected after exposure for 0-20 minutes (up to 720 TCID50, ~504 PFU).
All mice (4/4) exposed for 25-30 minutes became infected, while no mice (0/8) became infected after exposure for 0-20 minutes (up to 720 TCID50, ~504 PFU).
All mice (4/4) exposed for 25-30 minutes became infected, while no mice (0/8) became infected after exposure for 0-20 minutes (up to 720 TCID50, ~504 PFU).
All mice (4/4) exposed for 25-30 minutes became infected, while no mice (0/8) became infected after exposure for 0-20 minutes (up to 720 TCID50, ~504 PFU).
All mice (4/4) exposed for 25-30 minutes became infected, while no mice (0/8) became infected after exposure for 0-20 minutes (up to 720 TCID50, ~504 PFU).
All mice (4/4) exposed for 25-30 minutes became infected, while no mice (0/8) became infected after exposure for 0-20 minutes (up to 720 TCID50, ~504 PFU).
All mice (4/4) exposed for 25-30 minutes became infected, while no mice (0/8) became infected after exposure for 0-20 minutes (up to 720 TCID50, ~504 PFU).
All mice (4/4) exposed for 25-30 minutes became infected, while no mice (0/8) became infected after exposure for 0-20 minutes (up to 720 TCID50, ~504 PFU).
All mice (4/4) exposed for 25-30 minutes became infected, while no mice (0/8) became infected after exposure for 0-20 minutes (up to 720 TCID50, ~504 PFU).
All mice (4/4) exposed for 25-30 minutes became infected, while no mice (0/8) became infected after exposure for 0-20 minutes (up to 720 TCID50, ~504 PFU).
Ferrets infected with 316,000 TCID50339 or 600,000 TCID50572 of SARS-CoV-2 by the intranasal route show similar symptoms to human disease.
Ferrets infected with 316,000 TCID50339 or 600,000 TCID50572 of SARS-CoV-2 by the intranasal route show similar symptoms to human disease.
Ferrets infected with 316,000 TCID50339 or 600,000 TCID50572 of SARS-CoV-2 by the intranasal route show similar symptoms to human disease.
Ferrets infected with 316,000 TCID50339 or 600,000 TCID50572 of SARS-CoV-2 by the intranasal route show similar symptoms to human disease.
Ferrets infected with 316,000 TCID50339 or 600,000 TCID50572 of SARS-CoV-2 by the intranasal route show similar symptoms to human disease.
Ferrets infected with 316,000 TCID50339 or 600,000 TCID50572 of SARS-CoV-2 by the intranasal route show similar symptoms to human disease.
Ferrets infected with 316,000 TCID50339 or 600,000 TCID50572 of SARS-CoV-2 by the intranasal route show similar symptoms to human disease.
Ferrets infected with 316,000 TCID50339 or 600,000 TCID50572 of SARS-CoV-2 by the intranasal route show similar symptoms to human disease.
Ferrets infected with 316,000 TCID50339 or 600,000 TCID50572 of SARS-CoV-2 by the intranasal route show similar symptoms to human disease.
Ferrets infected with 316,000 TCID50339 or 600,000 TCID50572 of SARS-CoV-2 by the intranasal route show similar symptoms to human disease.
Uninfected ferrets in direct contact with infected ferrets test positive and show disease as early as 2 days post-contact.
Uninfected ferrets in direct contact with infected ferrets test positive and show disease as early as 2 days post-contact.
Uninfected ferrets in direct contact with infected ferrets test positive and show disease as early as 2 days post-contact.
Uninfected ferrets in direct contact with infected ferrets test positive and show disease as early as 2 days post-contact.
Uninfected ferrets in direct contact with infected ferrets test positive and show disease as early as 2 days post-contact.
Uninfected ferrets in direct contact with infected ferrets test positive and show disease as early as 2 days post-contact.
Uninfected ferrets in direct contact with infected ferrets test positive and show disease as early as 2 days post-contact.
Uninfected ferrets in direct contact with infected ferrets test positive and show disease as early as 2 days post-contact.
Uninfected ferrets in direct contact with infected ferrets test positive and show disease as early as 2 days post-contact.
Uninfected ferrets in direct contact with infected ferrets test positive and show disease as early as 2 days post-contact.
In a separate ferret study, 1 in 6 individuals exposed to 102 PFU via the intranasal route became infected, while 12 out of 12 individuals exposed to >104 PFU became infected.
In a separate ferret study, 1 in 6 individuals exposed to 102 PFU via the intranasal route became infected, while 12 out of 12 individuals exposed to >104 PFU became infected.
In a separate ferret study, 1 in 6 individuals exposed to 102 PFU via the intranasal route became infected, while 12 out of 12 individuals exposed to >104 PFU became infected.
In a separate ferret study, 1 in 6 individuals exposed to 102 PFU via the intranasal route became infected, while 12 out of 12 individuals exposed to >104 PFU became infected.
In a separate ferret study, 1 in 6 individuals exposed to 102 PFU via the intranasal route became infected, while 12 out of 12 individuals exposed to >104 PFU became infected.
In a separate ferret study, 1 in 6 individuals exposed to 102 PFU via the intranasal route became infected, while 12 out of 12 individuals exposed to >104 PFU became infected.
In a separate ferret study, 1 in 6 individuals exposed to 102 PFU via the intranasal route became infected, while 12 out of 12 individuals exposed to >104 PFU became infected.
In a separate ferret study, 1 in 6 individuals exposed to 102 PFU via the intranasal route became infected, while 12 out of 12 individuals exposed to >104 PFU became infected.
In a separate ferret study, 1 in 6 individuals exposed to 102 PFU via the intranasal route became infected, while 12 out of 12 individuals exposed to >104 PFU became infected.
In a separate ferret study, 1 in 6 individuals exposed to 102 PFU via the intranasal route became infected, while 12 out of 12 individuals exposed to >104 PFU became infected.
The infectious dose of a pathogen can be estimated by the amount of genetic material passed between an infector and infectee (called ‚Äö√Ñ√∂‚àö√ë‚àö‚à´bottleneck‚Äö√Ñ√∂‚àö√ë‚àöœÄ size.
The infectious dose of a pathogen can be estimated by the amount of genetic material passed between an infector and infectee (called ‚Äö√Ñ√∂‚àö√ë‚àö‚à´bottleneck‚Äö√Ñ√∂‚àö√ë‚àöœÄ size.
The infectious dose of a pathogen can be estimated by the amount of genetic material passed between an infector and infectee (called ‚Äö√Ñ√∂‚àö√ë‚àö‚à´bottleneck‚Äö√Ñ√∂‚àö√ë‚àöœÄ size.
The infectious dose of a pathogen can be estimated by the amount of genetic material passed between an infector and infectee (called ‚Äö√Ñ√∂‚àö√ë‚àö‚à´bottleneck‚Äö√Ñ√∂‚àö√ë‚àöœÄ size.
The infectious dose of a pathogen can be estimated by the amount of genetic material passed between an infector and infectee (called ‚Äö√Ñ√∂‚àö√ë‚àö‚à´bottleneck‚Äö√Ñ√∂‚àö√ë‚àöœÄ size.
The infectious dose of a pathogen can be estimated by the amount of genetic material passed between an infector and infectee (called ‚Äö√Ñ√∂‚àö√ë‚àö‚à´bottleneck‚Äö√Ñ√∂‚àö√ë‚àöœÄ size.
The infectious dose of a pathogen can be estimated by the amount of genetic material passed between an infector and infectee (called ‚Äö√Ñ√∂‚àö√ë‚àö‚à´bottleneck‚Äö√Ñ√∂‚àö√ë‚àöœÄ size.
The infectious dose of a pathogen can be estimated by the amount of genetic material passed between an infector and infectee (called ‚Äö√Ñ√∂‚àö√ë‚àö‚à´bottleneck‚Äö√Ñ√∂‚àö√ë‚àöœÄ size.
The infectious dose of a pathogen can be estimated by the amount of genetic material passed between an infector and infectee (called ‚Äö√Ñ√∂‚àö√ë‚àö‚à´bottleneck‚Äö√Ñ√∂‚àö√ë‚àöœÄ size.
The infectious dose of a pathogen can be estimated by the amount of genetic material passed between an infector and infectee (called ‚Äö√Ñ√∂‚àö√ë‚àö‚à´bottleneck‚Äö√Ñ√∂‚àö√ë‚àöœÄ size.
using epidemiological data, sequencing data, and statistics, the average ‚Äö√Ñ√∂‚àö√ë‚àö‚à´bottleneck‚Äö√Ñ√∂‚àö√ë‚àöœÄ size for SARS-CoV-2 has been estimated as ~1,200 viral particles, though exposure routes were not possible to identify.
using epidemiological data, sequencing data, and statistics, the average ‚Äö√Ñ√∂‚àö√ë‚àö‚à´bottleneck‚Äö√Ñ√∂‚àö√ë‚àöœÄ size for SARS-CoV-2 has been estimated as ~1,200 viral particles, though exposure routes were not possible to identify.
using epidemiological data, sequencing data, and statistics, the average ‚Äö√Ñ√∂‚àö√ë‚àö‚à´bottleneck‚Äö√Ñ√∂‚àö√ë‚àöœÄ size for SARS-CoV-2 has been estimated as ~1,200 viral particles, though exposure routes were not possible to identify.
using epidemiological data, sequencing data, and statistics, the average ‚Äö√Ñ√∂‚àö√ë‚àö‚à´bottleneck‚Äö√Ñ√∂‚àö√ë‚àöœÄ size for SARS-CoV-2 has been estimated as ~1,200 viral particles, though exposure routes were not possible to identify.
using epidemiological data, sequencing data, and statistics, the average ‚Äö√Ñ√∂‚àö√ë‚àö‚à´bottleneck‚Äö√Ñ√∂‚àö√ë‚àöœÄ size for SARS-CoV-2 has been estimated as ~1,200 viral particles, though exposure routes were not possible to identify.
using epidemiological data, sequencing data, and statistics, the average ‚Äö√Ñ√∂‚àö√ë‚àö‚à´bottleneck‚Äö√Ñ√∂‚àö√ë‚àöœÄ size for SARS-CoV-2 has been estimated as ~1,200 viral particles, though exposure routes were not possible to identify.
using epidemiological data, sequencing data, and statistics, the average ‚Äö√Ñ√∂‚àö√ë‚àö‚à´bottleneck‚Äö√Ñ√∂‚àö√ë‚àöœÄ size for SARS-CoV-2 has been estimated as ~1,200 viral particles, though exposure routes were not possible to identify.
using epidemiological data, sequencing data, and statistics, the average ‚Äö√Ñ√∂‚àö√ë‚àö‚à´bottleneck‚Äö√Ñ√∂‚àö√ë‚àöœÄ size for SARS-CoV-2 has been estimated as ~1,200 viral particles, though exposure routes were not possible to identify.
using epidemiological data, sequencing data, and statistics, the average ‚Äö√Ñ√∂‚àö√ë‚àö‚à´bottleneck‚Äö√Ñ√∂‚àö√ë‚àöœÄ size for SARS-CoV-2 has been estimated as ~1,200 viral particles, though exposure routes were not possible to identify.
using epidemiological data, sequencing data, and statistics, the average ‚Äö√Ñ√∂‚àö√ë‚àö‚à´bottleneck‚Äö√Ñ√∂‚àö√ë‚àöœÄ size for SARS-CoV-2 has been estimated as ~1,200 viral particles, though exposure routes were not possible to identify.
Modeling aerosol exposures from 5 case studies suggests the inhalation ID50 for SARS-CoV-2 is approximately 361-2,000 viral particles, which is approximately 250-1,400 PFU.
Modeling aerosol exposures from 5 case studies suggests the inhalation ID50 for SARS-CoV-2 is approximately 361-2,000 viral particles, which is approximately 250-1,400 PFU.
Modeling aerosol exposures from 5 case studies suggests the inhalation ID50 for SARS-CoV-2 is approximately 361-2,000 viral particles, which is approximately 250-1,400 PFU.
Modeling aerosol exposures from 5 case studies suggests the inhalation ID50 for SARS-CoV-2 is approximately 361-2,000 viral particles, which is approximately 250-1,400 PFU.
Modeling aerosol exposures from 5 case studies suggests the inhalation ID50 for SARS-CoV-2 is approximately 361-2,000 viral particles, which is approximately 250-1,400 PFU.
Modeling aerosol exposures from 5 case studies suggests the inhalation ID50 for SARS-CoV-2 is approximately 361-2,000 viral particles, which is approximately 250-1,400 PFU.
Modeling aerosol exposures from 5 case studies suggests the inhalation ID50 for SARS-CoV-2 is approximately 361-2,000 viral particles, which is approximately 250-1,400 PFU.
Modeling aerosol exposures from 5 case studies suggests the inhalation ID50 for SARS-CoV-2 is approximately 361-2,000 viral particles, which is approximately 250-1,400 PFU.
Modeling aerosol exposures from 5 case studies suggests the inhalation ID50 for SARS-CoV-2 is approximately 361-2,000 viral particles, which is approximately 250-1,400 PFU.
Modeling aerosol exposures from 5 case studies suggests the inhalation ID50 for SARS-CoV-2 is approximately 361-2,000 viral particles, which is approximately 250-1,400 PFU.
Humans exposed intranasally to ~70 PFU of seasonal coronavirus 229E developed infections, with a plausible intranasal ID50 of 10 TCID50 (~7 PFU).
Humans exposed intranasally to ~70 PFU of seasonal coronavirus 229E developed infections, with a plausible intranasal ID50 of 10 TCID50 (~7 PFU).
Humans exposed intranasally to ~70 PFU of seasonal coronavirus 229E developed infections, with a plausible intranasal ID50 of 10 TCID50 (~7 PFU).
Humans exposed intranasally to ~70 PFU of seasonal coronavirus 229E developed infections, with a plausible intranasal ID50 of 10 TCID50 (~7 PFU).
Humans exposed intranasally to ~70 PFU of seasonal coronavirus 229E developed infections, with a plausible intranasal ID50 of 10 TCID50 (~7 PFU).
Humans exposed intranasally to ~70 PFU of seasonal coronavirus 229E developed infections, with a plausible intranasal ID50 of 10 TCID50 (~7 PFU).
Humans exposed intranasally to ~70 PFU of seasonal coronavirus 229E developed infections, with a plausible intranasal ID50 of 10 TCID50 (~7 PFU).
Humans exposed intranasally to ~70 PFU of seasonal coronavirus 229E developed infections, with a plausible intranasal ID50 of 10 TCID50 (~7 PFU).
Humans exposed intranasally to ~70 PFU of seasonal coronavirus 229E developed infections, with a plausible intranasal ID50 of 10 TCID50 (~7 PFU).
Humans exposed intranasally to ~70 PFU of seasonal coronavirus 229E developed infections, with a plausible intranasal ID50 of 10 TCID50 (~7 PFU).
The inhalation infectious dose of seasonal coronavirus 229E is unknown in humans.
The inhalation infectious dose of seasonal coronavirus 229E is unknown in humans.
The inhalation infectious dose of seasonal coronavirus 229E is unknown in humans.
The inhalation infectious dose of seasonal coronavirus 229E is unknown in humans.
The inhalation infectious dose of seasonal coronavirus 229E is unknown in humans.
The inhalation infectious dose of seasonal coronavirus 229E is unknown in humans.
The inhalation infectious dose of seasonal coronavirus 229E is unknown in humans.
The inhalation infectious dose of seasonal coronavirus 229E is unknown in humans.
The inhalation infectious dose of seasonal coronavirus 229E is unknown in humans.
The inhalation infectious dose of seasonal coronavirus 229E is unknown in humans.
The infectious dose for severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) in mice is estimated to be between 67-540 PFU (average 240 PFU, intranasal route).
The infectious dose for severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) in mice is estimated to be between 67-540 PFU (average 240 PFU, intranasal route).
The infectious dose for severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) in mice is estimated to be between 67-540 PFU (average 240 PFU, intranasal route).
The infectious dose for severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) in mice is estimated to be between 67-540 PFU (average 240 PFU, intranasal route).
The infectious dose for severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) in mice is estimated to be between 67-540 PFU (average 240 PFU, intranasal route).
The infectious dose for severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) in mice is estimated to be between 67-540 PFU (average 240 PFU, intranasal route).
The infectious dose for severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) in mice is estimated to be between 67-540 PFU (average 240 PFU, intranasal route).
The infectious dose for severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) in mice is estimated to be between 67-540 PFU (average 240 PFU, intranasal route).
The infectious dose for severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) in mice is estimated to be between 67-540 PFU (average 240 PFU, intranasal route).
The infectious dose for severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) in mice is estimated to be between 67-540 PFU (average 240 PFU, intranasal route).
Genetically modified mice exposed intranasally to Middle East respiratory syndrome coronavirus (MERS-CoV) between 100-500,000 PFU show signs of infection.
Genetically modified mice exposed intranasally to Middle East respiratory syndrome coronavirus (MERS-CoV) between 100-500,000 PFU show signs of infection.
Genetically modified mice exposed intranasally to Middle East respiratory syndrome coronavirus (MERS-CoV) between 100-500,000 PFU show signs of infection.
Genetically modified mice exposed intranasally to Middle East respiratory syndrome coronavirus (MERS-CoV) between 100-500,000 PFU show signs of infection.
Genetically modified mice exposed intranasally to Middle East respiratory syndrome coronavirus (MERS-CoV) between 100-500,000 PFU show signs of infection.
Genetically modified mice exposed intranasally to Middle East respiratory syndrome coronavirus (MERS-CoV) between 100-500,000 PFU show signs of infection.
Genetically modified mice exposed intranasally to Middle East respiratory syndrome coronavirus (MERS-CoV) between 100-500,000 PFU show signs of infection.
Genetically modified mice exposed intranasally to Middle East respiratory syndrome coronavirus (MERS-CoV) between 100-500,000 PFU show signs of infection.
Genetically modified mice exposed intranasally to Middle East respiratory syndrome coronavirus (MERS-CoV) between 100-500,000 PFU show signs of infection.
Genetically modified mice exposed intranasally to Middle East respiratory syndrome coronavirus (MERS-CoV) between 100-500,000 PFU show signs of infection.
Infection with higher doses result in severe syndromes.
Infection with higher doses result in severe syndromes.
Infection with higher doses result in severe syndromes.
Infection with higher doses result in severe syndromes.
Infection with higher doses result in severe syndromes.
Infection with higher doses result in severe syndromes.
Infection with higher doses result in severe syndromes.
Infection with higher doses result in severe syndromes.
Infection with higher doses result in severe syndromes.
Infection with higher doses result in severe syndromes.
SARS-CoV-2 is passed easily between humans through close contact and aerosol transmission.
SARS-CoV-2 is passed easily between humans through close contact and aerosol transmission.
SARS-CoV-2 is passed easily between humans through close contact and aerosol transmission.
SARS-CoV-2 is passed easily between humans through close contact and aerosol transmission.
SARS-CoV-2 is passed easily between humans through close contact and aerosol transmission.
SARS-CoV-2 is passed easily between humans through close contact and aerosol transmission.
SARS-CoV-2 is passed easily between humans through close contact and aerosol transmission.
SARS-CoV-2 is passed easily between humans through close contact and aerosol transmission.
SARS-CoV-2 is passed easily between humans through close contact and aerosol transmission.
SARS-CoV-2 is passed easily between humans through close contact and aerosol transmission.
As of 12/21/2020, pandemic COVID-19 has caused at least 77,074,469 infections and 1,697,679 deaths globally.
As of 12/21/2020, pandemic COVID-19 has caused at least 77,074,469 infections and 1,697,679 deaths globally.
As of 12/21/2020, pandemic COVID-19 has caused at least 77,074,469 infections and 1,697,679 deaths globally.
As of 12/21/2020, pandemic COVID-19 has caused at least 77,074,469 infections and 1,697,679 deaths globally.
As of 12/21/2020, pandemic COVID-19 has caused at least 77,074,469 infections and 1,697,679 deaths globally.
As of 12/21/2020, pandemic COVID-19 has caused at least 77,074,469 infections and 1,697,679 deaths globally.
As of 12/21/2020, pandemic COVID-19 has caused at least 77,074,469 infections and 1,697,679 deaths globally.
As of 12/21/2020, pandemic COVID-19 has caused at least 77,074,469 infections and 1,697,679 deaths globally.
As of 12/21/2020, pandemic COVID-19 has caused at least 77,074,469 infections and 1,697,679 deaths globally.
As of 12/21/2020, pandemic COVID-19 has caused at least 77,074,469 infections and 1,697,679 deaths globally.
In the US, there have been 17,862,876 confirmed COVID-19 cases and 317,858 confirmed deaths, though both cases and fatalities are underestimates.
In the US, there have been 17,862,876 confirmed COVID-19 cases and 317,858 confirmed deaths, though both cases and fatalities are underestimates.
In the US, there have been 17,862,876 confirmed COVID-19 cases and 317,858 confirmed deaths, though both cases and fatalities are underestimates.
In the US, there have been 17,862,876 confirmed COVID-19 cases and 317,858 confirmed deaths, though both cases and fatalities are underestimates.
In the US, there have been 17,862,876 confirmed COVID-19 cases and 317,858 confirmed deaths, though both cases and fatalities are underestimates.
In the US, there have been 17,862,876 confirmed COVID-19 cases and 317,858 confirmed deaths, though both cases and fatalities are underestimates.
In the US, there have been 17,862,876 confirmed COVID-19 cases and 317,858 confirmed deaths, though both cases and fatalities are underestimates.
In the US, there have been 17,862,876 confirmed COVID-19 cases and 317,858 confirmed deaths, though both cases and fatalities are underestimates.
In the US, there have been 17,862,876 confirmed COVID-19 cases and 317,858 confirmed deaths, though both cases and fatalities are underestimates.
In the US, there have been 17,862,876 confirmed COVID-19 cases and 317,858 confirmed deaths, though both cases and fatalities are underestimates.
Estimates of human transmissibility (R0) range from 2.2 to 3.1.
Estimates of human transmissibility (R0) range from 2.2 to 3.1.
Estimates of human transmissibility (R0) range from 2.2 to 3.1.
Estimates of human transmissibility (R0) range from 2.2 to 3.1.
Estimates of human transmissibility (R0) range from 2.2 to 3.1.
Estimates of human transmissibility (R0) range from 2.2 to 3.1.
Estimates of human transmissibility (R0) range from 2.2 to 3.1.
SARS-CoV-2 can spread via aerosol or ‚Äö√Ñ√∂‚àö√ë‚àö‚à´airborne‚Äö√Ñ√∂‚àö√ë‚àöœÄ transmission beyond 6 ft in certain situations such as enclosed spaces with inadequate ventilation.
SARS-CoV-2 can spread via aerosol or ‚Äö√Ñ√∂‚àö√ë‚àö‚à´airborne‚Äö√Ñ√∂‚àö√ë‚àöœÄ transmission beyond 6 ft in certain situations such as enclosed spaces with inadequate ventilation.
SARS-CoV-2 can spread via aerosol or ‚Äö√Ñ√∂‚àö√ë‚àö‚à´airborne‚Äö√Ñ√∂‚àö√ë‚àöœÄ transmission beyond 6 ft in certain situations such as enclosed spaces with inadequate ventilation.
SARS-CoV-2 can spread via aerosol or ‚Äö√Ñ√∂‚àö√ë‚àö‚à´airborne‚Äö√Ñ√∂‚àö√ë‚àöœÄ transmission beyond 6 ft in certain situations such as enclosed spaces with inadequate ventilation.
SARS-CoV-2 can spread via aerosol or ‚Äö√Ñ√∂‚àö√ë‚àö‚à´airborne‚Äö√Ñ√∂‚àö√ë‚àöœÄ transmission beyond 6 ft in certain situations such as enclosed spaces with inadequate ventilation.
SARS-CoV-2 can spread via aerosol or ‚Äö√Ñ√∂‚àö√ë‚àö‚à´airborne‚Äö√Ñ√∂‚àö√ë‚àöœÄ transmission beyond 6 ft in certain situations such as enclosed spaces with inadequate ventilation.
SARS-CoV-2 can spread via aerosol or ‚Äö√Ñ√∂‚àö√ë‚àö‚à´airborne‚Äö√Ñ√∂‚àö√ë‚àöœÄ transmission beyond 6 ft in certain situations such as enclosed spaces with inadequate ventilation.
SARS-CoV-2 can spread via aerosol or ‚Äö√Ñ√∂‚àö√ë‚àö‚à´airborne‚Äö√Ñ√∂‚àö√ë‚àöœÄ transmission beyond 6 ft in certain situations such as enclosed spaces with inadequate ventilation.
SARS-CoV-2 can spread via aerosol or ‚Äö√Ñ√∂‚àö√ë‚àö‚à´airborne‚Äö√Ñ√∂‚àö√ë‚àöœÄ transmission beyond 6 ft in certain situations such as enclosed spaces with inadequate ventilation.
SARS-CoV-2 can spread via aerosol or ‚Äö√Ñ√∂‚àö√ë‚àö‚à´airborne‚Äö√Ñ√∂‚àö√ë‚àöœÄ transmission beyond 6 ft in certain situations such as enclosed spaces with inadequate ventilation.
The risk of airborne infection from fomites is believed to be low.
The risk of airborne infection from fomites is believed to be low.
The risk of airborne infection from fomites is believed to be low.
The risk of airborne infection from fomites is believed to be low.
The risk of airborne infection from fomites is believed to be low.
The risk of airborne infection from fomites is believed to be low.
The risk of airborne infection from fomites is believed to be low.
The risk of airborne infection from fomites is believed to be low.
The risk of airborne infection from fomites is believed to be low.
The risk of airborne infection from fomites is believed to be low.
Exhaled breath may emit 105-107 genome copies per person per hour; the amount of infectious virus remains unknown.
Exhaled breath may emit 105-107 genome copies per person per hour; the amount of infectious virus remains unknown.
Exhaled breath may emit 105-107 genome copies per person per hour; the amount of infectious virus remains unknown.
Exhaled breath may emit 105-107 genome copies per person per hour; the amount of infectious virus remains unknown.
Exhaled breath may emit 105-107 genome copies per person per hour; the amount of infectious virus remains unknown.
Exhaled breath may emit 105-107 genome copies per person per hour; the amount of infectious virus remains unknown.
Exhaled breath may emit 105-107 genome copies per person per hour; the amount of infectious virus remains unknown.
Exhaled breath may emit 105-107 genome copies per person per hour; the amount of infectious virus remains unknown.
Exhaled breath may emit 105-107 genome copies per person per hour; the amount of infectious virus remains unknown.
Exhaled breath may emit 105-107 genome copies per person per hour; the amount of infectious virus remains unknown.
Vertical transmission from mother to fetus is possible but rare.
Vertical transmission from mother to fetus is possible but rare.
Vertical transmission from mother to fetus is possible but rare.
Vertical transmission from mother to fetus is possible but rare.
Vertical transmission from mother to fetus is possible but rare.
Vertical transmission from mother to fetus is possible but rare.
Vertical transmission from mother to fetus is possible but rare.
Vertical transmission from mother to fetus is possible but rare.
Vertical transmission from mother to fetus is possible but rare.
Vertical transmission from mother to fetus is possible but rare.
Asymptomatic or pre-symptomatic individuals can transmit SARS-CoV-2 and contribute significantly to new case growth.
Asymptomatic or pre-symptomatic individuals can transmit SARS-CoV-2 and contribute significantly to new case growth.
Asymptomatic or pre-symptomatic individuals can transmit SARS-CoV-2 and contribute significantly to new case growth.
Asymptomatic or pre-symptomatic individuals can transmit SARS-CoV-2 and contribute significantly to new case growth.
Asymptomatic or pre-symptomatic individuals can transmit SARS-CoV-2 and contribute significantly to new case growth.
Asymptomatic or pre-symptomatic individuals can transmit SARS-CoV-2 and contribute significantly to new case growth.
Asymptomatic or pre-symptomatic individuals can transmit SARS-CoV-2 and contribute significantly to new case growth.
Asymptomatic or pre-symptomatic individuals can transmit SARS-CoV-2 and contribute significantly to new case growth.
Asymptomatic or pre-symptomatic individuals can transmit SARS-CoV-2 and contribute significantly to new case growth.
Asymptomatic or pre-symptomatic individuals can transmit SARS-CoV-2 and contribute significantly to new case growth.
Individuals may be infectious for 1-3 days prior to symptom onset.
Individuals may be infectious for 1-3 days prior to symptom onset.
Individuals may be infectious for 1-3 days prior to symptom onset.
Individuals may be infectious for 1-3 days prior to symptom onset.
Individuals may be infectious for 1-3 days prior to symptom onset.
Individuals may be infectious for 1-3 days prior to symptom onset.
Individuals may be infectious for 1-3 days prior to symptom onset.
Individuals may be infectious for 1-3 days prior to symptom onset.
Individuals may be infectious for 1-3 days prior to symptom onset.
Individuals may be infectious for 1-3 days prior to symptom onset.
Pre-symptomatic or asymptomatic patients can transmit SARS-CoV-2.
Pre-symptomatic or asymptomatic patients can transmit SARS-CoV-2.
Pre-symptomatic or asymptomatic patients can transmit SARS-CoV-2.
Pre-symptomatic or asymptomatic patients can transmit SARS-CoV-2.
Pre-symptomatic or asymptomatic patients can transmit SARS-CoV-2.
Pre-symptomatic or asymptomatic patients can transmit SARS-CoV-2.
Pre-symptomatic or asymptomatic patients can transmit SARS-CoV-2.
Pre-symptomatic or asymptomatic patients can transmit SARS-CoV-2.
Pre-symptomatic or asymptomatic patients can transmit SARS-CoV-2.
Pre-symptomatic or asymptomatic patients can transmit SARS-CoV-2.
Between 15-56% of infections may be caused by pre- symptomatic transmission.
Between 15-56% of infections may be caused by pre- symptomatic transmission.
Between 15-56% of infections may be caused by pre- symptomatic transmission.
Between 15-56% of infections may be caused by pre- symptomatic transmission.
Between 15-56% of infections may be caused by pre- symptomatic transmission.
Between 15-56% of infections may be caused by pre- symptomatic transmission.
Between 15-56% of infections may be caused by pre- symptomatic transmission.
Between 15-56% of infections may be caused by pre- symptomatic transmission.
Between 15-56% of infections may be caused by pre- symptomatic transmission.
Between 15-56% of infections may be caused by pre- symptomatic transmission.
75.9% of transmission events in China were associated with pre-symptomatic or asymptomatic transmission.
75.9% of transmission events in China were associated with pre-symptomatic or asymptomatic transmission.
75.9% of transmission events in China were associated with pre-symptomatic or asymptomatic transmission.
75.9% of transmission events in China were associated with pre-symptomatic or asymptomatic transmission.
75.9% of transmission events in China were associated with pre-symptomatic or asymptomatic transmission.
75.9% of transmission events in China were associated with pre-symptomatic or asymptomatic transmission.
75.9% of transmission events in China were associated with pre-symptomatic or asymptomatic transmission.
75.9% of transmission events in China were associated with pre-symptomatic or asymptomatic transmission.
75.9% of transmission events in China were associated with pre-symptomatic or asymptomatic transmission.
75.9% of transmission events in China were associated with pre-symptomatic or asymptomatic transmission.
Most transmission occurs before symptoms begin and within 5 days of symptom onset.
Most transmission occurs before symptoms begin and within 5 days of symptom onset.
Most transmission occurs before symptoms begin and within 5 days of symptom onset.
Most transmission occurs before symptoms begin and within 5 days of symptom onset.
Most transmission occurs before symptoms begin and within 5 days of symptom onset.
Most transmission occurs before symptoms begin and within 5 days of symptom onset.
Most transmission occurs before symptoms begin and within 5 days of symptom onset.
Most transmission occurs before symptoms begin and within 5 days of symptom onset.
Most transmission occurs before symptoms begin and within 5 days of symptom onset.
Most transmission occurs before symptoms begin and within 5 days of symptom onset.
Asymptomatic individuals can transmit disease as soon as 2 days after infection.
Asymptomatic individuals can transmit disease as soon as 2 days after infection.
Asymptomatic individuals can transmit disease as soon as 2 days after infection.
Asymptomatic individuals can transmit disease as soon as 2 days after infection.
Asymptomatic individuals can transmit disease as soon as 2 days after infection.
Asymptomatic individuals can transmit disease as soon as 2 days after infection.
Asymptomatic individuals can transmit disease as soon as 2 days after infection.
Asymptomatic individuals can transmit disease as soon as 2 days after infection.
Asymptomatic individuals can transmit disease as soon as 2 days after infection.
Asymptomatic individuals can transmit disease as soon as 2 days after infection.
There is evidence that asymptomatic individuals transmit SARS-CoV-2 less often than symptomatic individuals.
There is evidence that asymptomatic individuals transmit SARS-CoV-2 less often than symptomatic individuals.
There is evidence that asymptomatic individuals transmit SARS-CoV-2 less often than symptomatic individuals.
There is evidence that asymptomatic individuals transmit SARS-CoV-2 less often than symptomatic individuals.
There is evidence that asymptomatic individuals transmit SARS-CoV-2 less often than symptomatic individuals.
There is evidence that asymptomatic individuals transmit SARS-CoV-2 less often than symptomatic individuals.
There is evidence that asymptomatic individuals transmit SARS-CoV-2 less often than symptomatic individuals.
There is evidence that asymptomatic individuals transmit SARS-CoV-2 less often than symptomatic individuals.
There is evidence that asymptomatic individuals transmit SARS-CoV-2 less often than symptomatic individuals.
There is evidence that asymptomatic individuals transmit SARS-CoV-2 less often than symptomatic individuals.
SARS-CoV-2 may be spread by conversation and exhalation in indoor areas such as restaurants.
SARS-CoV-2 may be spread by conversation and exhalation in indoor areas such as restaurants.
SARS-CoV-2 may be spread by conversation and exhalation in indoor areas such as restaurants.
Clusters are often associated with large indoor gatherings, including bars, restaurants, and gyms.
Clusters are often associated with large indoor gatherings, including bars, restaurants, and gyms.
Clusters are often associated with large indoor gatherings, including bars, restaurants, and gyms.
Clusters are often associated with large indoor gatherings, including bars, restaurants, and gyms.
Clusters are often associated with large indoor gatherings, including bars, restaurants, and gyms.
Clusters are often associated with large indoor gatherings, including bars, restaurants, and gyms.
Clusters are often associated with large indoor gatherings, including bars, restaurants, and gyms.
Clusters are often associated with large indoor gatherings, including bars, restaurants, and gyms.
Clusters are often associated with large indoor gatherings, including bars, restaurants, and gyms.
Clusters are often associated with large indoor gatherings, including bars, restaurants, and gyms.
Household transmission is rapid, and household contacts spread infection more than casual community contacts.
Household transmission is rapid, and household contacts spread infection more than casual community contacts.
Household transmission is rapid, and household contacts spread infection more than casual community contacts.
Household transmission is rapid, and household contacts spread infection more than casual community contacts.
Household transmission is rapid, and household contacts spread infection more than casual community contacts.
Household transmission is rapid, and household contacts spread infection more than casual community contacts.
Household transmission is rapid, and household contacts spread infection more than casual community contacts.
Household transmission is rapid, and household contacts spread infection more than casual community contacts.
Household transmission is rapid, and household contacts spread infection more than casual community contacts.
Household transmission is rapid, and household contacts spread infection more than casual community contacts.
On average, 16.6% to 18% of household contacts of infected index patients acquire SARS-CoV-2 (i.e., the ‚Äö√Ñ√∂‚àö√ë‚àö‚à´attack rate‚Äö√Ñ√∂‚àö√ë‚àöœÄ).
On average, 16.6% to 18% of household contacts of infected index patients acquire SARS-CoV-2 (i.e., the ‚Äö√Ñ√∂‚àö√ë‚àö‚à´attack rate‚Äö√Ñ√∂‚àö√ë‚àöœÄ).
On average, 16.6% to 18% of household contacts of infected index patients acquire SARS-CoV-2 (i.e., the ‚Äö√Ñ√∂‚àö√ë‚àö‚à´attack rate‚Äö√Ñ√∂‚àö√ë‚àöœÄ).
On average, 16.6% to 18% of household contacts of infected index patients acquire SARS-CoV-2 (i.e., the ‚Äö√Ñ√∂‚àö√ë‚àö‚à´attack rate‚Äö√Ñ√∂‚àö√ë‚àöœÄ).
On average, 16.6% to 18% of household contacts of infected index patients acquire SARS-CoV-2 (i.e., the ‚Äö√Ñ√∂‚àö√ë‚àö‚à´attack rate‚Äö√Ñ√∂‚àö√ë‚àöœÄ).
On average, 16.6% to 18% of household contacts of infected index patients acquire SARS-CoV-2 (i.e., the ‚Äö√Ñ√∂‚àö√ë‚àö‚à´attack rate‚Äö√Ñ√∂‚àö√ë‚àöœÄ).
On average, 16.6% to 18% of household contacts of infected index patients acquire SARS-CoV-2 (i.e., the ‚Äö√Ñ√∂‚àö√ë‚àö‚à´attack rate‚Äö√Ñ√∂‚àö√ë‚àöœÄ).
On average, 16.6% to 18% of household contacts of infected index patients acquire SARS-CoV-2 (i.e., the ‚Äö√Ñ√∂‚àö√ë‚àö‚à´attack rate‚Äö√Ñ√∂‚àö√ë‚àöœÄ).
On average, 16.6% to 18% of household contacts of infected index patients acquire SARS-CoV-2 (i.e., the ‚Äö√Ñ√∂‚àö√ë‚àö‚à´attack rate‚Äö√Ñ√∂‚àö√ë‚àöœÄ).
On average, 16.6% to 18% of household contacts of infected index patients acquire SARS-CoV-2 (i.e., the ‚Äö√Ñ√∂‚àö√ë‚àö‚à´attack rate‚Äö√Ñ√∂‚àö√ë‚àöœÄ).
Attack rates are higher for symptomatic index cases, spouses of index cases, and adults, though transmission to children may be underestimated.
Attack rates are higher for symptomatic index cases, spouses of index cases, and adults, though transmission to children may be underestimated.
Attack rates are higher for symptomatic index cases, spouses of index cases, and adults, though transmission to children may be underestimated.
Attack rates are higher for symptomatic index cases, spouses of index cases, and adults, though transmission to children may be underestimated.
Attack rates are higher for symptomatic index cases, spouses of index cases, and adults, though transmission to children may be underestimated.
Attack rates are higher for symptomatic index cases, spouses of index cases, and adults, though transmission to children may be underestimated.
Attack rates are higher for symptomatic index cases, spouses of index cases, and adults, though transmission to children may be underestimated.
Attack rates are higher for symptomatic index cases, spouses of index cases, and adults, though transmission to children may be underestimated.
Attack rates are higher for symptomatic index cases, spouses of index cases, and adults, though transmission to children may be underestimated.
Attack rates are higher for symptomatic index cases, spouses of index cases, and adults, though transmission to children may be underestimated.
75% of household infections occurred within 5 days of illness onset in the index case.
75% of household infections occurred within 5 days of illness onset in the index case.
75% of household infections occurred within 5 days of illness onset in the index case.
75% of household infections occurred within 5 days of illness onset in the index case.
75% of household infections occurred within 5 days of illness onset in the index case.
75% of household infections occurred within 5 days of illness onset in the index case.
75% of household infections occurred within 5 days of illness onset in the index case.
75% of household infections occurred within 5 days of illness onset in the index case.
75% of household infections occurred within 5 days of illness onset in the index case.
75% of household infections occurred within 5 days of illness onset in the index case.
In a US study, 31 of 58 households (54%) with a primary SARS-CoV-2 case showed evidence of secondary transmission; in 7 of these 31 households (23%), all members of the household became infected.
In a US study, 31 of 58 households (54%) with a primary SARS-CoV-2 case showed evidence of secondary transmission; in 7 of these 31 households (23%), all members of the household became infected.
In a US study, 31 of 58 households (54%) with a primary SARS-CoV-2 case showed evidence of secondary transmission; in 7 of these 31 households (23%), all members of the household became infected.
In a US study, 31 of 58 households (54%) with a primary SARS-CoV-2 case showed evidence of secondary transmission; in 7 of these 31 households (23%), all members of the household became infected.
In a US study, 31 of 58 households (54%) with a primary SARS-CoV-2 case showed evidence of secondary transmission; in 7 of these 31 households (23%), all members of the household became infected.
In a US study, 31 of 58 households (54%) with a primary SARS-CoV-2 case showed evidence of secondary transmission; in 7 of these 31 households (23%), all members of the household became infected.
In a US study, 31 of 58 households (54%) with a primary SARS-CoV-2 case showed evidence of secondary transmission; in 7 of these 31 households (23%), all members of the household became infected.
In a US study, 31 of 58 households (54%) with a primary SARS-CoV-2 case showed evidence of secondary transmission; in 7 of these 31 households (23%), all members of the household became infected.
In a US study, 31 of 58 households (54%) with a primary SARS-CoV-2 case showed evidence of secondary transmission; in 7 of these 31 households (23%), all members of the household became infected.
In a US study, 31 of 58 households (54%) with a primary SARS-CoV-2 case showed evidence of secondary transmission; in 7 of these 31 households (23%), all members of the household became infected.
Index patients who transmitted SARS-CoV-2 to secondary contacts had higher viral titers than secondary contacts who did not subsequently transmit illness, as quantified by nasal swab RT-qPCR.
Index patients who transmitted SARS-CoV-2 to secondary contacts had higher viral titers than secondary contacts who did not subsequently transmit illness, as quantified by nasal swab RT-qPCR.
Index patients who transmitted SARS-CoV-2 to secondary contacts had higher viral titers than secondary contacts who did not subsequently transmit illness, as quantified by nasal swab RT-qPCR.
Index patients who transmitted SARS-CoV-2 to secondary contacts had higher viral titers than secondary contacts who did not subsequently transmit illness, as quantified by nasal swab RT-qPCR.
Index patients who transmitted SARS-CoV-2 to secondary contacts had higher viral titers than secondary contacts who did not subsequently transmit illness, as quantified by nasal swab RT-qPCR.
Index patients who transmitted SARS-CoV-2 to secondary contacts had higher viral titers than secondary contacts who did not subsequently transmit illness, as quantified by nasal swab RT-qPCR.
Index patients who transmitted SARS-CoV-2 to secondary contacts had higher viral titers than secondary contacts who did not subsequently transmit illness, as quantified by nasal swab RT-qPCR.
Index patients who transmitted SARS-CoV-2 to secondary contacts had higher viral titers than secondary contacts who did not subsequently transmit illness, as quantified by nasal swab RT-qPCR.
Index patients who transmitted SARS-CoV-2 to secondary contacts had higher viral titers than secondary contacts who did not subsequently transmit illness, as quantified by nasal swab RT-qPCR.
Index patients who transmitted SARS-CoV-2 to secondary contacts had higher viral titers than secondary contacts who did not subsequently transmit illness, as quantified by nasal swab RT-qPCR.
Superspreading events (SSEs) appear common in SARS-CoV-2 transmission and may be crucial for controlling spread.
Superspreading events (SSEs) appear common in SARS-CoV-2 transmission and may be crucial for controlling spread.
Superspreading events (SSEs) appear common in SARS-CoV-2 transmission and may be crucial for controlling spread.
Superspreading events (SSEs) appear common in SARS-CoV-2 transmission and may be crucial for controlling spread.
Superspreading events (SSEs) appear common in SARS-CoV-2 transmission and may be crucial for controlling spread.
Superspreading events (SSEs) appear common in SARS-CoV-2 transmission and may be crucial for controlling spread.
Superspreading events (SSEs) appear common in SARS-CoV-2 transmission and may be crucial for controlling spread.
Superspreading events (SSEs) appear common in SARS-CoV-2 transmission and may be crucial for controlling spread.
Superspreading events (SSEs) appear common in SARS-CoV-2 transmission and may be crucial for controlling spread.
Superspreading events (SSEs) appear common in SARS-CoV-2 transmission and may be crucial for controlling spread.
Most new infections come from a few infectious individuals (overdispersion parameter k = 0.2-0.5).
Most new infections come from a few infectious individuals (overdispersion parameter k = 0.2-0.5).
Most new infections come from a few infectious individuals (overdispersion parameter k = 0.2-0.5).
Most new infections come from a few infectious individuals (overdispersion parameter k = 0.2-0.5).
Most new infections come from a few infectious individuals (overdispersion parameter k = 0.2-0.5).
Most new infections come from a few infectious individuals (overdispersion parameter k = 0.2-0.5).
Most new infections come from a few infectious individuals (overdispersion parameter k = 0.2-0.5).
Most new infections come from a few infectious individuals (overdispersion parameter k = 0.2-0.5).
Most new infections come from a few infectious individuals (overdispersion parameter k = 0.2-0.5).
Most new infections come from a few infectious individuals (overdispersion parameter k = 0.2-0.5).
Rates of transmission on public transit are unclear but appear low, but the US CDC recommends masks during travel.
Rates of transmission on public transit are unclear but appear low, but the US CDC recommends masks during travel.
Rates of transmission on public transit are unclear but appear low, but the US CDC recommends masks during travel.
Rates of transmission on public transit are unclear but appear low, but the US CDC recommends masks during travel.
Rates of transmission on public transit are unclear but appear low, but the US CDC recommends masks during travel.
Rates of transmission on public transit are unclear but appear low, but the US CDC recommends masks during travel.
Rates of transmission on public transit are unclear but appear low, but the US CDC recommends masks during travel.
Rates of transmission on public transit are unclear but appear low, but the US CDC recommends masks during travel.
Rates of transmission on public transit are unclear but appear low, but the US CDC recommends masks during travel.
Rates of transmission on public transit are unclear but appear low, but the US CDC recommends masks during travel.
Fluorescent tracer research on commercial airplanes suggests a low risk of aerosol or surface transmission during flights, though key parameters remain uncertain.
Fluorescent tracer research on commercial airplanes suggests a low risk of aerosol or surface transmission during flights, though key parameters remain uncertain.
Fluorescent tracer research on commercial airplanes suggests a low risk of aerosol or surface transmission during flights, though key parameters remain uncertain.
Fluorescent tracer research on commercial airplanes suggests a low risk of aerosol or surface transmission during flights, though key parameters remain uncertain.
Fluorescent tracer research on commercial airplanes suggests a low risk of aerosol or surface transmission during flights, though key parameters remain uncertain.
Fluorescent tracer research on commercial airplanes suggests a low risk of aerosol or surface transmission during flights, though key parameters remain uncertain.
Fluorescent tracer research on commercial airplanes suggests a low risk of aerosol or surface transmission during flights, though key parameters remain uncertain.
Fluorescent tracer research on commercial airplanes suggests a low risk of aerosol or surface transmission during flights, though key parameters remain uncertain.
Fluorescent tracer research on commercial airplanes suggests a low risk of aerosol or surface transmission during flights, though key parameters remain uncertain.
Fluorescent tracer research on commercial airplanes suggests a low risk of aerosol or surface transmission during flights, though key parameters remain uncertain.
On trains in China, transmission rates were high for those in the same row as an infectious individual (1.5-3.5% attack rate), though low for non-neighboring passengers.
On trains in China, transmission rates were high for those in the same row as an infectious individual (1.5-3.5% attack rate), though low for non-neighboring passengers.
On trains in China, transmission rates were high for those in the same row as an infectious individual (1.5-3.5% attack rate), though low for non-neighboring passengers.
On trains in China, transmission rates were high for those in the same row as an infectious individual (1.5-3.5% attack rate), though low for non-neighboring passengers.
On trains in China, transmission rates were high for those in the same row as an infectious individual (1.5-3.5% attack rate), though low for non-neighboring passengers.
On trains in China, transmission rates were high for those in the same row as an infectious individual (1.5-3.5% attack rate), though low for non-neighboring passengers.
On trains in China, transmission rates were high for those in the same row as an infectious individual (1.5-3.5% attack rate), though low for non-neighboring passengers.
On trains in China, transmission rates were high for those in the same row as an infectious individual (1.5-3.5% attack rate), though low for non-neighboring passengers.
On trains in China, transmission rates were high for those in the same row as an infectious individual (1.5-3.5% attack rate), though low for non-neighboring passengers.
On trains in China, transmission rates were high for those in the same row as an infectious individual (1.5-3.5% attack rate), though low for non-neighboring passengers.
Children of any age can acquire and transmit infection in homes, schools, and community settings, though there is some evidence that younger children (<10-15) are less susceptible and less infectious than older children and adults.
Children of any age can acquire and transmit infection in homes, schools, and community settings, though there is some evidence that younger children (<10-15) are less susceptible and less infectious than older children and adults.
Children of any age can acquire and transmit infection in homes, schools, and community settings, though there is some evidence that younger children (<10-15) are less susceptible and less infectious than older children and adults.
Children of any age can acquire and transmit infection in homes, schools, and community settings, though there is some evidence that younger children (<10-15) are less susceptible and less infectious than older children and adults.
Children of any age can acquire and transmit infection in homes, schools, and community settings, though there is some evidence that younger children (<10-15) are less susceptible and less infectious than older children and adults.
Children of any age can acquire and transmit infection in homes, schools, and community settings, though there is some evidence that younger children (<10-15) are less susceptible and less infectious than older children and adults.
Children of any age can acquire and transmit infection in homes, schools, and community settings, though there is some evidence that younger children (<10-15) are less susceptible and less infectious than older children and adults.
Children of any age can acquire and transmit infection in homes, schools, and community settings, though there is some evidence that younger children (<10-15) are less susceptible and less infectious than older children and adults.
Children of any age can acquire and transmit infection in homes, schools, and community settings, though there is some evidence that younger children (<10-15) are less susceptible and less infectious than older children and adults.
Children of any age can acquire and transmit infection in homes, schools, and community settings, though there is some evidence that younger children (<10-15) are less susceptible and less infectious than older children and adults.
There is evidence of high transmission rates among same-aged children, as well as transmission in the home, at school, and in the community.
There is evidence of high transmission rates among same-aged children, as well as transmission in the home, at school, and in the community.
There is evidence of high transmission rates among same-aged children, as well as transmission in the home, at school, and in the community.
There is evidence of high transmission rates among same-aged children, as well as transmission in the home, at school, and in the community.
There is evidence of high transmission rates among same-aged children, as well as transmission in the home, at school, and in the community.
There is evidence of high transmission rates among same-aged children, as well as transmission in the home, at school, and in the community.
There is evidence of high transmission rates among same-aged children, as well as transmission in the home, at school, and in the community.
There is evidence of high transmission rates among same-aged children, as well as transmission in the home, at school, and in the community.
There is evidence of high transmission rates among same-aged children, as well as transmission in the home, at school, and in the community.
There is evidence of high transmission rates among same-aged children, as well as transmission in the home, at school, and in the community.
However, there have also been suggestions that children are both less susceptible to COVID-19 (due to low PCR test positivity rates)430 and less infectious (because they are rarely identified as the index case in households).
However, there have also been suggestions that children are both less susceptible to COVID-19 (due to low PCR test positivity rates)430 and less infectious (because they are rarely identified as the index case in households).
However, there have also been suggestions that children are both less susceptible to COVID-19 (due to low PCR test positivity rates)430 and less infectious (because they are rarely identified as the index case in households).
However, there have also been suggestions that children are both less susceptible to COVID-19 (due to low PCR test positivity rates)430 and less infectious (because they are rarely identified as the index case in households).
However, there have also been suggestions that children are both less susceptible to COVID-19 (due to low PCR test positivity rates)430 and less infectious (because they are rarely identified as the index case in households).
However, there have also been suggestions that children are both less susceptible to COVID-19 (due to low PCR test positivity rates)430 and less infectious (because they are rarely identified as the index case in households).
However, there have also been suggestions that children are both less susceptible to COVID-19 (due to low PCR test positivity rates)430 and less infectious (because they are rarely identified as the index case in households).
However, there have also been suggestions that children are both less susceptible to COVID-19 (due to low PCR test positivity rates)430 and less infectious (because they are rarely identified as the index case in households).
However, there have also been suggestions that children are both less susceptible to COVID-19 (due to low PCR test positivity rates)430 and less infectious (because they are rarely identified as the index case in households).
However, there have also been suggestions that children are both less susceptible to COVID-19 (due to low PCR test positivity rates)430 and less infectious (because they are rarely identified as the index case in households).
Some emerging evidence suggests that young children (<10) are less susceptible and less infectious than adults, while older children and adolescents are more similar to adults.
Some emerging evidence suggests that young children (<10) are less susceptible and less infectious than adults, while older children and adolescents are more similar to adults.
Some emerging evidence suggests that young children (<10) are less susceptible and less infectious than adults, while older children and adolescents are more similar to adults.
Some emerging evidence suggests that young children (<10) are less susceptible and less infectious than adults, while older children and adolescents are more similar to adults.
Some emerging evidence suggests that young children (<10) are less susceptible and less infectious than adults, while older children and adolescents are more similar to adults.
Some emerging evidence suggests that young children (<10) are less susceptible and less infectious than adults, while older children and adolescents are more similar to adults.
Some emerging evidence suggests that young children (<10) are less susceptible and less infectious than adults, while older children and adolescents are more similar to adults.
Some emerging evidence suggests that young children (<10) are less susceptible and less infectious than adults, while older children and adolescents are more similar to adults.
Some emerging evidence suggests that young children (<10) are less susceptible and less infectious than adults, while older children and adolescents are more similar to adults.
Some emerging evidence suggests that young children (<10) are less susceptible and less infectious than adults, while older children and adolescents are more similar to adults.
Contact tracing in China, Iceland, and Israel has found lower rates of transmission to and from younger children (<10-15) compared to adults, but similar rates in older children.
Contact tracing in China, Iceland, and Israel has found lower rates of transmission to and from younger children (<10-15) compared to adults, but similar rates in older children.
Contact tracing in China, Iceland, and Israel has found lower rates of transmission to and from younger children (<10-15) compared to adults, but similar rates in older children.
Contact tracing in China, Iceland, and Israel has found lower rates of transmission to and from younger children (<10-15) compared to adults, but similar rates in older children.
Contact tracing in China, Iceland, and Israel has found lower rates of transmission to and from younger children (<10-15) compared to adults, but similar rates in older children.
Contact tracing in China, Iceland, and Israel has found lower rates of transmission to and from younger children (<10-15) compared to adults, but similar rates in older children.
Contact tracing in China, Iceland, and Israel has found lower rates of transmission to and from younger children (<10-15) compared to adults, but similar rates in older children.
Contact tracing in China, Iceland, and Israel has found lower rates of transmission to and from younger children (<10-15) compared to adults, but similar rates in older children.
Contact tracing in China, Iceland, and Israel has found lower rates of transmission to and from younger children (<10-15) compared to adults, but similar rates in older children.
Contact tracing in China, Iceland, and Israel has found lower rates of transmission to and from younger children (<10-15) compared to adults, but similar rates in older children.
After schools reopened in Italy, researchers found low attack rates in preschool (0%) and elementary school children (0.38%), but higher attack rates in middle and high school students (6.5%).
After schools reopened in Italy, researchers found low attack rates in preschool (0%) and elementary school children (0.38%), but higher attack rates in middle and high school students (6.5%).
After schools reopened in Italy, researchers found low attack rates in preschool (0%) and elementary school children (0.38%), but higher attack rates in middle and high school students (6.5%).
After schools reopened in Italy, researchers found low attack rates in preschool (0%) and elementary school children (0.38%), but higher attack rates in middle and high school students (6.5%).
After schools reopened in Italy, researchers found low attack rates in preschool (0%) and elementary school children (0.38%), but higher attack rates in middle and high school students (6.5%).
After schools reopened in Italy, researchers found low attack rates in preschool (0%) and elementary school children (0.38%), but higher attack rates in middle and high school students (6.5%).
After schools reopened in Italy, researchers found low attack rates in preschool (0%) and elementary school children (0.38%), but higher attack rates in middle and high school students (6.5%).
After schools reopened in Italy, researchers found low attack rates in preschool (0%) and elementary school children (0.38%), but higher attack rates in middle and high school students (6.5%).
After schools reopened in Italy, researchers found low attack rates in preschool (0%) and elementary school children (0.38%), but higher attack rates in middle and high school students (6.5%).
After schools reopened in Italy, researchers found low attack rates in preschool (0%) and elementary school children (0.38%), but higher attack rates in middle and high school students (6.5%).
Discrepancies regarding the susceptibility and infectivity of children may be partly explained by age.
Discrepancies regarding the susceptibility and infectivity of children may be partly explained by age.
Discrepancies regarding the susceptibility and infectivity of children may be partly explained by age.
Discrepancies regarding the susceptibility and infectivity of children may be partly explained by age.
Discrepancies regarding the susceptibility and infectivity of children may be partly explained by age.
Discrepancies regarding the susceptibility and infectivity of children may be partly explained by age.
Discrepancies regarding the susceptibility and infectivity of children may be partly explained by age.
Discrepancies regarding the susceptibility and infectivity of children may be partly explained by age.
Discrepancies regarding the susceptibility and infectivity of children may be partly explained by age.
Discrepancies regarding the susceptibility and infectivity of children may be partly explained by age.
Children are also less likely than adults to test positive for COVID-19 via RT-PCR despite being infected, underestimating pediatric COVID-19 infections.
Children are also less likely than adults to test positive for COVID-19 via RT-PCR despite being infected, underestimating pediatric COVID-19 infections.
Children are also less likely than adults to test positive for COVID-19 via RT-PCR despite being infected, underestimating pediatric COVID-19 infections.
Children are also less likely than adults to test positive for COVID-19 via RT-PCR despite being infected, underestimating pediatric COVID-19 infections.
Children are also less likely than adults to test positive for COVID-19 via RT-PCR despite being infected, underestimating pediatric COVID-19 infections.
Children are also less likely than adults to test positive for COVID-19 via RT-PCR despite being infected, underestimating pediatric COVID-19 infections.
Children are also less likely than adults to test positive for COVID-19 via RT-PCR despite being infected, underestimating pediatric COVID-19 infections.
Children are also less likely than adults to test positive for COVID-19 via RT-PCR despite being infected, underestimating pediatric COVID-19 infections.
Children are also less likely than adults to test positive for COVID-19 via RT-PCR despite being infected, underestimating pediatric COVID-19 infections.
Children are also less likely than adults to test positive for COVID-19 via RT-PCR despite being infected, underestimating pediatric COVID-19 infections.
Serological studies in Germany, Spain, and Italy found high rates of SARS-CoV-2 exposure in children, though the finding is not ubiquitous.
Serological studies in Germany, Spain, and Italy found high rates of SARS-CoV-2 exposure in children, though the finding is not ubiquitous.
Serological studies in Germany, Spain, and Italy found high rates of SARS-CoV-2 exposure in children, though the finding is not ubiquitous.
Serological studies in Germany, Spain, and Italy found high rates of SARS-CoV-2 exposure in children, though the finding is not ubiquitous.
Serological studies in Germany, Spain, and Italy found high rates of SARS-CoV-2 exposure in children, though the finding is not ubiquitous.
Serological studies in Germany, Spain, and Italy found high rates of SARS-CoV-2 exposure in children, though the finding is not ubiquitous.
Serological studies in Germany, Spain, and Italy found high rates of SARS-CoV-2 exposure in children, though the finding is not ubiquitous.
Serological studies in Germany, Spain, and Italy found high rates of SARS-CoV-2 exposure in children, though the finding is not ubiquitous.
Serological studies in Germany, Spain, and Italy found high rates of SARS-CoV-2 exposure in children, though the finding is not ubiquitous.
Serological studies in Germany, Spain, and Italy found high rates of SARS-CoV-2 exposure in children, though the finding is not ubiquitous.
Separating the effects of differential susceptibility, infectivity, test positivity, and testing likelihood by age is crucial to understand the role of children.
Separating the effects of differential susceptibility, infectivity, test positivity, and testing likelihood by age is crucial to understand the role of children.
Separating the effects of differential susceptibility, infectivity, test positivity, and testing likelihood by age is crucial to understand the role of children.
Separating the effects of differential susceptibility, infectivity, test positivity, and testing likelihood by age is crucial to understand the role of children.
Separating the effects of differential susceptibility, infectivity, test positivity, and testing likelihood by age is crucial to understand the role of children.
Separating the effects of differential susceptibility, infectivity, test positivity, and testing likelihood by age is crucial to understand the role of children.
Separating the effects of differential susceptibility, infectivity, test positivity, and testing likelihood by age is crucial to understand the role of children.
Separating the effects of differential susceptibility, infectivity, test positivity, and testing likelihood by age is crucial to understand the role of children.
Separating the effects of differential susceptibility, infectivity, test positivity, and testing likelihood by age is crucial to understand the role of children.
Separating the effects of differential susceptibility, infectivity, test positivity, and testing likelihood by age is crucial to understand the role of children.
Individuals who have clinically recovered but test positive for COVID-19 are unlikely to be infectious.
Individuals who have clinically recovered but test positive for COVID-19 are unlikely to be infectious.
Individuals who have clinically recovered but test positive for COVID-19 are unlikely to be infectious.
Individuals who have clinically recovered but test positive for COVID-19 are unlikely to be infectious.
Individuals who have clinically recovered but test positive for COVID-19 are unlikely to be infectious.
Individuals who have clinically recovered but test positive for COVID-19 are unlikely to be infectious.
Individuals who have clinically recovered but test positive for COVID-19 are unlikely to be infectious.
Individuals who have clinically recovered but test positive for COVID-19 are unlikely to be infectious.
Individuals who have clinically recovered but test positive for COVID-19 are unlikely to be infectious.
Individuals who have clinically recovered but test positive for COVID-19 are unlikely to be infectious.
SARS-CoV-2 is closely related to other coronaviruses circulating in bats in Southeast Asia.
SARS-CoV-2 is closely related to other coronaviruses circulating in bats in Southeast Asia.
SARS-CoV-2 is closely related to other coronaviruses circulating in bats in Southeast Asia.
SARS-CoV-2 is closely related to other coronaviruses circulating in bats in Southeast Asia.
SARS-CoV-2 is closely related to other coronaviruses circulating in bats in Southeast Asia.
SARS-CoV-2 is closely related to other coronaviruses circulating in bats in Southeast Asia.
SARS-CoV-2 is closely related to other coronaviruses circulating in bats in Southeast Asia.
SARS-CoV-2 is closely related to other coronaviruses circulating in bats in Southeast Asia.
SARS-CoV-2 is closely related to other coronaviruses circulating in bats in Southeast Asia.
SARS-CoV-2 is closely related to other coronaviruses circulating in bats in Southeast Asia.
Previous coronaviruses have passed through an intermediate mammal host before infecting humans, but the presence or identity of the SARS-CoV-2 intermediate host is unknown.
Previous coronaviruses have passed through an intermediate mammal host before infecting humans, but the presence or identity of the SARS-CoV-2 intermediate host is unknown.
Previous coronaviruses have passed through an intermediate mammal host before infecting humans, but the presence or identity of the SARS-CoV-2 intermediate host is unknown.
Previous coronaviruses have passed through an intermediate mammal host before infecting humans, but the presence or identity of the SARS-CoV-2 intermediate host is unknown.
Previous coronaviruses have passed through an intermediate mammal host before infecting humans, but the presence or identity of the SARS-CoV-2 intermediate host is unknown.
Previous coronaviruses have passed through an intermediate mammal host before infecting humans, but the presence or identity of the SARS-CoV-2 intermediate host is unknown.
Previous coronaviruses have passed through an intermediate mammal host before infecting humans, but the presence or identity of the SARS-CoV-2 intermediate host is unknown.
Previous coronaviruses have passed through an intermediate mammal host before infecting humans, but the presence or identity of the SARS-CoV-2 intermediate host is unknown.
Previous coronaviruses have passed through an intermediate mammal host before infecting humans, but the presence or identity of the SARS-CoV-2 intermediate host is unknown.
Previous coronaviruses have passed through an intermediate mammal host before infecting humans, but the presence or identity of the SARS-CoV-2 intermediate host is unknown.
Current evidence suggests a direct jump from bats to humans is plausible.
Current evidence suggests a direct jump from bats to humans is plausible.
Current evidence suggests a direct jump from bats to humans is plausible.
Current evidence suggests a direct jump from bats to humans is plausible.
Current evidence suggests a direct jump from bats to humans is plausible.
Current evidence suggests a direct jump from bats to humans is plausible.
Current evidence suggests a direct jump from bats to humans is plausible.
Current evidence suggests a direct jump from bats to humans is plausible.
Current evidence suggests a direct jump from bats to humans is plausible.
Current evidence suggests a direct jump from bats to humans is plausible.
Early genomic analysis indicates similarity to SARS-CoV-1, with a suggested bat origin.
Early genomic analysis indicates similarity to SARS-CoV-1, with a suggested bat origin.
Early genomic analysis indicates similarity to SARS-CoV-1, with a suggested bat origin.
Early genomic analysis indicates similarity to SARS-CoV-1, with a suggested bat origin.
Early genomic analysis indicates similarity to SARS-CoV-1, with a suggested bat origin.
Early genomic analysis indicates similarity to SARS-CoV-1, with a suggested bat origin.
Early genomic analysis indicates similarity to SARS-CoV-1, with a suggested bat origin.
Early genomic analysis indicates similarity to SARS-CoV-1, with a suggested bat origin.
Early genomic analysis indicates similarity to SARS-CoV-1, with a suggested bat origin.
Early genomic analysis indicates similarity to SARS-CoV-1, with a suggested bat origin.
Positive samples from the South China Seafood Market strongly suggests a wildlife source, though it is possible that the virus was circulating in humans before the disease was associated with the seafood market.
Positive samples from the South China Seafood Market strongly suggests a wildlife source, though it is possible that the virus was circulating in humans before the disease was associated with the seafood market.
Positive samples from the South China Seafood Market strongly suggests a wildlife source, though it is possible that the virus was circulating in humans before the disease was associated with the seafood market.
Positive samples from the South China Seafood Market strongly suggests a wildlife source, though it is possible that the virus was circulating in humans before the disease was associated with the seafood market.
Positive samples from the South China Seafood Market strongly suggests a wildlife source, though it is possible that the virus was circulating in humans before the disease was associated with the seafood market.
Positive samples from the South China Seafood Market strongly suggests a wildlife source, though it is possible that the virus was circulating in humans before the disease was associated with the seafood market.
Positive samples from the South China Seafood Market strongly suggests a wildlife source, though it is possible that the virus was circulating in humans before the disease was associated with the seafood market.
Positive samples from the South China Seafood Market strongly suggests a wildlife source, though it is possible that the virus was circulating in humans before the disease was associated with the seafood market.
Positive samples from the South China Seafood Market strongly suggests a wildlife source, though it is possible that the virus was circulating in humans before the disease was associated with the seafood market.
Positive samples from the South China Seafood Market strongly suggests a wildlife source, though it is possible that the virus was circulating in humans before the disease was associated with the seafood market.
Viruses similar to SARS-CoV-2 were present in pangolin samples collected several years ago, and pangolins positive for coronaviruses related to SARS-CoV-2 exhibited clinical symptoms such as cough and shortness of breath.
Viruses similar to SARS-CoV-2 were present in pangolin samples collected several years ago, and pangolins positive for coronaviruses related to SARS-CoV-2 exhibited clinical symptoms such as cough and shortness of breath.
Viruses similar to SARS-CoV-2 were present in pangolin samples collected several years ago, and pangolins positive for coronaviruses related to SARS-CoV-2 exhibited clinical symptoms such as cough and shortness of breath.
Viruses similar to SARS-CoV-2 were present in pangolin samples collected several years ago, and pangolins positive for coronaviruses related to SARS-CoV-2 exhibited clinical symptoms such as cough and shortness of breath.
Viruses similar to SARS-CoV-2 were present in pangolin samples collected several years ago, and pangolins positive for coronaviruses related to SARS-CoV-2 exhibited clinical symptoms such as cough and shortness of breath.
Viruses similar to SARS-CoV-2 were present in pangolin samples collected several years ago, and pangolins positive for coronaviruses related to SARS-CoV-2 exhibited clinical symptoms such as cough and shortness of breath.
Viruses similar to SARS-CoV-2 were present in pangolin samples collected several years ago, and pangolins positive for coronaviruses related to SARS-CoV-2 exhibited clinical symptoms such as cough and shortness of breath.
Viruses similar to SARS-CoV-2 were present in pangolin samples collected several years ago, and pangolins positive for coronaviruses related to SARS-CoV-2 exhibited clinical symptoms such as cough and shortness of breath.
Viruses similar to SARS-CoV-2 were present in pangolin samples collected several years ago, and pangolins positive for coronaviruses related to SARS-CoV-2 exhibited clinical symptoms such as cough and shortness of breath.
Viruses similar to SARS-CoV-2 were present in pangolin samples collected several years ago, and pangolins positive for coronaviruses related to SARS-CoV-2 exhibited clinical symptoms such as cough and shortness of breath.
However, SARS-CoV-2 uses the same receptor for cell entry as the SARS-CoV-1 coronavirus that circulated in 2002/2003.
However, SARS-CoV-2 uses the same receptor for cell entry as the SARS-CoV-1 coronavirus that circulated in 2002/2003.
However, SARS-CoV-2 uses the same receptor for cell entry as the SARS-CoV-1 coronavirus that circulated in 2002/2003.
However, SARS-CoV-2 uses the same receptor for cell entry as the SARS-CoV-1 coronavirus that circulated in 2002/2003.
However, SARS-CoV-2 uses the same receptor for cell entry as the SARS-CoV-1 coronavirus that circulated in 2002/2003.
However, SARS-CoV-2 uses the same receptor for cell entry as the SARS-CoV-1 coronavirus that circulated in 2002/2003.
However, SARS-CoV-2 uses the same receptor for cell entry as the SARS-CoV-1 coronavirus that circulated in 2002/2003.
However, SARS-CoV-2 uses the same receptor for cell entry as the SARS-CoV-1 coronavirus that circulated in 2002/2003.
However, SARS-CoV-2 uses the same receptor for cell entry as the SARS-CoV-1 coronavirus that circulated in 2002/2003.
However, SARS-CoV-2 uses the same receptor for cell entry as the SARS-CoV-1 coronavirus that circulated in 2002/2003.
Experiments show that SARS-CoV-2 Spike (S) receptor-binding domain binds the human cell receptor (ACE2) stronger than SARS-CoV-1, potentially explaining its high transmissibility.
Experiments show that SARS-CoV-2 Spike (S) receptor-binding domain binds the human cell receptor (ACE2) stronger than SARS-CoV-1, potentially explaining its high transmissibility.
Experiments show that SARS-CoV-2 Spike (S) receptor-binding domain binds the human cell receptor (ACE2) stronger than SARS-CoV-1, potentially explaining its high transmissibility.
Experiments show that SARS-CoV-2 Spike (S) receptor-binding domain binds the human cell receptor (ACE2) stronger than SARS-CoV-1, potentially explaining its high transmissibility.
Experiments show that SARS-CoV-2 Spike (S) receptor-binding domain binds the human cell receptor (ACE2) stronger than SARS-CoV-1, potentially explaining its high transmissibility.
Experiments show that SARS-CoV-2 Spike (S) receptor-binding domain binds the human cell receptor (ACE2) stronger than SARS-CoV-1, potentially explaining its high transmissibility.
Experiments show that SARS-CoV-2 Spike (S) receptor-binding domain binds the human cell receptor (ACE2) stronger than SARS-CoV-1, potentially explaining its high transmissibility.
Experiments show that SARS-CoV-2 Spike (S) receptor-binding domain binds the human cell receptor (ACE2) stronger than SARS-CoV-1, potentially explaining its high transmissibility.
Experiments show that SARS-CoV-2 Spike (S) receptor-binding domain binds the human cell receptor (ACE2) stronger than SARS-CoV-1, potentially explaining its high transmissibility.
Experiments show that SARS-CoV-2 Spike (S) receptor-binding domain binds the human cell receptor (ACE2) stronger than SARS-CoV-1, potentially explaining its high transmissibility.
Changes in proteolytic cleavage of the Spike protein can also affect cell entry and animal host range, in addition to receptor binding.
Changes in proteolytic cleavage of the Spike protein can also affect cell entry and animal host range, in addition to receptor binding.
Changes in proteolytic cleavage of the Spike protein can also affect cell entry and animal host range, in addition to receptor binding.
Changes in proteolytic cleavage of the Spike protein can also affect cell entry and animal host range, in addition to receptor binding.
Changes in proteolytic cleavage of the Spike protein can also affect cell entry and animal host range, in addition to receptor binding.
Changes in proteolytic cleavage of the Spike protein can also affect cell entry and animal host range, in addition to receptor binding.
Changes in proteolytic cleavage of the Spike protein can also affect cell entry and animal host range, in addition to receptor binding.
Changes in proteolytic cleavage of the Spike protein can also affect cell entry and animal host range, in addition to receptor binding.
Changes in proteolytic cleavage of the Spike protein can also affect cell entry and animal host range, in addition to receptor binding.
Changes in proteolytic cleavage of the Spike protein can also affect cell entry and animal host range, in addition to receptor binding.
Modeling suggests a wide range of animal hosts for SARS-CoV-2, though experimental studies are still needed.
Modeling suggests a wide range of animal hosts for SARS-CoV-2, though experimental studies are still needed.
Modeling suggests a wide range of animal hosts for SARS-CoV-2, though experimental studies are still needed.
Modeling suggests a wide range of animal hosts for SARS-CoV-2, though experimental studies are still needed.
Modeling suggests a wide range of animal hosts for SARS-CoV-2, though experimental studies are still needed.
Modeling suggests a wide range of animal hosts for SARS-CoV-2, though experimental studies are still needed.
Modeling suggests a wide range of animal hosts for SARS-CoV-2, though experimental studies are still needed.
Modeling suggests a wide range of animal hosts for SARS-CoV-2, though experimental studies are still needed.
Modeling suggests a wide range of animal hosts for SARS-CoV-2, though experimental studies are still needed.
Modeling suggests a wide range of animal hosts for SARS-CoV-2, though experimental studies are still needed.
Animals can transmit SARS-CoV-2 to humans, but the potential role of long-term reservoir species is unknown.
Animals can transmit SARS-CoV-2 to humans, but the potential role of long-term reservoir species is unknown.
Animals can transmit SARS-CoV-2 to humans, but the potential role of long-term reservoir species is unknown.
Animals can transmit SARS-CoV-2 to humans, but the potential role of long-term reservoir species is unknown.
Animals can transmit SARS-CoV-2 to humans, but the potential role of long-term reservoir species is unknown.
Animals can transmit SARS-CoV-2 to humans, but the potential role of long-term reservoir species is unknown.
Animals can transmit SARS-CoV-2 to humans, but the potential role of long-term reservoir species is unknown.
Animals can transmit SARS-CoV-2 to humans, but the potential role of long-term reservoir species is unknown.
Animals can transmit SARS-CoV-2 to humans, but the potential role of long-term reservoir species is unknown.
Animals can transmit SARS-CoV-2 to humans, but the potential role of long-term reservoir species is unknown.
Infected mink have been linked to human infections in workers at mink farms.
Infected mink have been linked to human infections in workers at mink farms.
Infected mink have been linked to human infections in workers at mink farms.
Infected mink have been linked to human infections in workers at mink farms.
Infected mink have been linked to human infections in workers at mink farms.
Infected mink have been linked to human infections in workers at mink farms.
Infected mink have been linked to human infections in workers at mink farms.
Infected mink have been linked to human infections in workers at mink farms.
Infected mink have been linked to human infections in workers at mink farms.
Infected mink have been linked to human infections in workers at mink farms.
In the US, researchers experimentally exposed big brown bats (Eptesicus fuscus) to SARS-CoV-2 via the oropharyngeal and nasal route and found no subsequent signs of infection, clinical symptoms, or transmission.
In the US, researchers experimentally exposed big brown bats (Eptesicus fuscus) to SARS-CoV-2 via the oropharyngeal and nasal route and found no subsequent signs of infection, clinical symptoms, or transmission.
In the US, researchers experimentally exposed big brown bats (Eptesicus fuscus) to SARS-CoV-2 via the oropharyngeal and nasal route and found no subsequent signs of infection, clinical symptoms, or transmission.
In the US, researchers experimentally exposed big brown bats (Eptesicus fuscus) to SARS-CoV-2 via the oropharyngeal and nasal route and found no subsequent signs of infection, clinical symptoms, or transmission.
In the US, researchers experimentally exposed big brown bats (Eptesicus fuscus) to SARS-CoV-2 via the oropharyngeal and nasal route and found no subsequent signs of infection, clinical symptoms, or transmission.
In the US, researchers experimentally exposed big brown bats (Eptesicus fuscus) to SARS-CoV-2 via the oropharyngeal and nasal route and found no subsequent signs of infection, clinical symptoms, or transmission.
In the US, researchers experimentally exposed big brown bats (Eptesicus fuscus) to SARS-CoV-2 via the oropharyngeal and nasal route and found no subsequent signs of infection, clinical symptoms, or transmission.
In the US, researchers experimentally exposed big brown bats (Eptesicus fuscus) to SARS-CoV-2 via the oropharyngeal and nasal route and found no subsequent signs of infection, clinical symptoms, or transmission.
In the US, researchers experimentally exposed big brown bats (Eptesicus fuscus) to SARS-CoV-2 via the oropharyngeal and nasal route and found no subsequent signs of infection, clinical symptoms, or transmission.
In the US, researchers experimentally exposed big brown bats (Eptesicus fuscus) to SARS-CoV-2 via the oropharyngeal and nasal route and found no subsequent signs of infection, clinical symptoms, or transmission.
Several animal species are susceptible to SARS-CoV-2 infection.
Several animal species are susceptible to SARS-CoV-2 infection.
Several animal species are susceptible to SARS-CoV-2 infection.
Several animal species are susceptible to SARS-CoV-2 infection.
Several animal species are susceptible to SARS-CoV-2 infection.
Several animal species are susceptible to SARS-CoV-2 infection.
Several animal species are susceptible to SARS-CoV-2 infection.
Several animal species are susceptible to SARS-CoV-2 infection.
Several animal species are susceptible to SARS-CoV-2 infection.
Several animal species are susceptible to SARS-CoV-2 infection.
Animal model studies suggest that Golden Syrian hamsters and ferrets are susceptible to infection.
Animal model studies suggest that Golden Syrian hamsters and ferrets are susceptible to infection.
Animal model studies suggest that Golden Syrian hamsters and ferrets are susceptible to infection.
Animal model studies suggest that Golden Syrian hamsters and ferrets are susceptible to infection.
Animal model studies suggest that Golden Syrian hamsters and ferrets are susceptible to infection.
Animal model studies suggest that Golden Syrian hamsters and ferrets are susceptible to infection.
Animal model studies suggest that Golden Syrian hamsters and ferrets are susceptible to infection.
Animal model studies suggest that Golden Syrian hamsters and ferrets are susceptible to infection.
Animal model studies suggest that Golden Syrian hamsters and ferrets are susceptible to infection.
Animal model studies suggest that Golden Syrian hamsters and ferrets are susceptible to infection.
In the Netherlands, farmed mink developed breathing and gastrointestinal issues, which was diagnosed as SARS-CoV-2 infection.
In the Netherlands, farmed mink developed breathing and gastrointestinal issues, which was diagnosed as SARS-CoV-2 infection.
In the Netherlands, farmed mink developed breathing and gastrointestinal issues, which was diagnosed as SARS-CoV-2 infection.
In the Netherlands, farmed mink developed breathing and gastrointestinal issues, which was diagnosed as SARS-CoV-2 infection.
In the Netherlands, farmed mink developed breathing and gastrointestinal issues, which was diagnosed as SARS-CoV-2 infection.
In the Netherlands, farmed mink developed breathing and gastrointestinal issues, which was diagnosed as SARS-CoV-2 infection.
In the Netherlands, farmed mink developed breathing and gastrointestinal issues, which was diagnosed as SARS-CoV-2 infection.
In the Netherlands, farmed mink developed breathing and gastrointestinal issues, which was diagnosed as SARS-CoV-2 infection.
In the Netherlands, farmed mink developed breathing and gastrointestinal issues, which was diagnosed as SARS-CoV-2 infection.
In the Netherlands, farmed mink developed breathing and gastrointestinal issues, which was diagnosed as SARS-CoV-2 infection.
SARS-CoV-2 cases in mink on US farms show high mortality rates, and farms have implemented strict biosecurity measures.
SARS-CoV-2 cases in mink on US farms show high mortality rates, and farms have implemented strict biosecurity measures.
SARS-CoV-2 cases in mink on US farms show high mortality rates, and farms have implemented strict biosecurity measures.
SARS-CoV-2 cases in mink on US farms show high mortality rates, and farms have implemented strict biosecurity measures.
SARS-CoV-2 cases in mink on US farms show high mortality rates, and farms have implemented strict biosecurity measures.
SARS-CoV-2 cases in mink on US farms show high mortality rates, and farms have implemented strict biosecurity measures.
SARS-CoV-2 cases in mink on US farms show high mortality rates, and farms have implemented strict biosecurity measures.
SARS-CoV-2 cases in mink on US farms show high mortality rates, and farms have implemented strict biosecurity measures.
SARS-CoV-2 cases in mink on US farms show high mortality rates, and farms have implemented strict biosecurity measures.
SARS-CoV-2 cases in mink on US farms show high mortality rates, and farms have implemented strict biosecurity measures.
Infected mink in the US have been linked to human infections.
Infected mink in the US have been linked to human infections.
Infected mink in the US have been linked to human infections.
Infected mink in the US have been linked to human infections.
Infected mink in the US have been linked to human infections.
Infected mink in the US have been linked to human infections.
Infected mink in the US have been linked to human infections.
Infected mink in the US have been linked to human infections.
Infected mink in the US have been linked to human infections.
Infected mink in the US have been linked to human infections.
Several non-human primates are also susceptible to infection with SARS-CoV-2 including cynomolgus macaques, African green monkeys, and Rhesus macaques.
Several non-human primates are also susceptible to infection with SARS-CoV-2 including cynomolgus macaques, African green monkeys, and Rhesus macaques.
Several non-human primates are also susceptible to infection with SARS-CoV-2 including cynomolgus macaques, African green monkeys, and Rhesus macaques.
Several non-human primates are also susceptible to infection with SARS-CoV-2 including cynomolgus macaques, African green monkeys, and Rhesus macaques.
Several non-human primates are also susceptible to infection with SARS-CoV-2 including cynomolgus macaques, African green monkeys, and Rhesus macaques.
Several non-human primates are also susceptible to infection with SARS-CoV-2 including cynomolgus macaques, African green monkeys, and Rhesus macaques.
Several non-human primates are also susceptible to infection with SARS-CoV-2 including cynomolgus macaques, African green monkeys, and Rhesus macaques.
Several non-human primates are also susceptible to infection with SARS-CoV-2 including cynomolgus macaques, African green monkeys, and Rhesus macaques.
Several non-human primates are also susceptible to infection with SARS-CoV-2 including cynomolgus macaques, African green monkeys, and Rhesus macaques.
Several non-human primates are also susceptible to infection with SARS-CoV-2 including cynomolgus macaques, African green monkeys, and Rhesus macaques.
Raccoon dogs (mammals related to foxes) are susceptible to COVID-19 (105 intranasal exposure dose) and were shown to transmit infection to other raccoon dogs in neighboring enclosures.
Raccoon dogs (mammals related to foxes) are susceptible to COVID-19 (105 intranasal exposure dose) and were shown to transmit infection to other raccoon dogs in neighboring enclosures.
Raccoon dogs (mammals related to foxes) are susceptible to COVID-19 (105 intranasal exposure dose) and were shown to transmit infection to other raccoon dogs in neighboring enclosures.
Raccoon dogs (mammals related to foxes) are susceptible to COVID-19 (105 intranasal exposure dose) and were shown to transmit infection to other raccoon dogs in neighboring enclosures.
Raccoon dogs (mammals related to foxes) are susceptible to COVID-19 (105 intranasal exposure dose) and were shown to transmit infection to other raccoon dogs in neighboring enclosures.
Raccoon dogs (mammals related to foxes) are susceptible to COVID-19 (105 intranasal exposure dose) and were shown to transmit infection to other raccoon dogs in neighboring enclosures.
Raccoon dogs (mammals related to foxes) are susceptible to COVID-19 (105 intranasal exposure dose) and were shown to transmit infection to other raccoon dogs in neighboring enclosures.
Raccoon dogs (mammals related to foxes) are susceptible to COVID-19 (105 intranasal exposure dose) and were shown to transmit infection to other raccoon dogs in neighboring enclosures.
Raccoon dogs (mammals related to foxes) are susceptible to COVID-19 (105 intranasal exposure dose) and were shown to transmit infection to other raccoon dogs in neighboring enclosures.
Raccoon dogs (mammals related to foxes) are susceptible to COVID-19 (105 intranasal exposure dose) and were shown to transmit infection to other raccoon dogs in neighboring enclosures.
Domestic cats are susceptible to infection with SARS-CoV-2 (100,000-520,000 PFU via the intranasal route or a combination of routes), and can transmit the virus to other cats via droplet or short-distance aerosol.
Domestic cats are susceptible to infection with SARS-CoV-2 (100,000-520,000 PFU via the intranasal route or a combination of routes), and can transmit the virus to other cats via droplet or short-distance aerosol.
Domestic cats are susceptible to infection with SARS-CoV-2 (100,000-520,000 PFU via the intranasal route or a combination of routes), and can transmit the virus to other cats via droplet or short-distance aerosol.
Domestic cats are susceptible to infection with SARS-CoV-2 (100,000-520,000 PFU via the intranasal route or a combination of routes), and can transmit the virus to other cats via droplet or short-distance aerosol.
Domestic cats are susceptible to infection with SARS-CoV-2 (100,000-520,000 PFU via the intranasal route or a combination of routes), and can transmit the virus to other cats via droplet or short-distance aerosol.
Domestic cats are susceptible to infection with SARS-CoV-2 (100,000-520,000 PFU via the intranasal route or a combination of routes), and can transmit the virus to other cats via droplet or short-distance aerosol.
Domestic cats are susceptible to infection with SARS-CoV-2 (100,000-520,000 PFU via the intranasal route or a combination of routes), and can transmit the virus to other cats via droplet or short-distance aerosol.
Domestic cats are susceptible to infection with SARS-CoV-2 (100,000-520,000 PFU via the intranasal route or a combination of routes), and can transmit the virus to other cats via droplet or short-distance aerosol.
Domestic cats are susceptible to infection with SARS-CoV-2 (100,000-520,000 PFU via the intranasal route or a combination of routes), and can transmit the virus to other cats via droplet or short-distance aerosol.
Domestic cats are susceptible to infection with SARS-CoV-2 (100,000-520,000 PFU via the intranasal route or a combination of routes), and can transmit the virus to other cats via droplet or short-distance aerosol.
Wild cats (tigers and lions) can be infected with SARS-CoV-2, although their ability to spread to humans is unknown.
Wild cats (tigers and lions) can be infected with SARS-CoV-2, although their ability to spread to humans is unknown.
Wild cats (tigers and lions) can be infected with SARS-CoV-2, although their ability to spread to humans is unknown.
Wild cats (tigers and lions) can be infected with SARS-CoV-2, although their ability to spread to humans is unknown.
Wild cats (tigers and lions) can be infected with SARS-CoV-2, although their ability to spread to humans is unknown.
Wild cats (tigers and lions) can be infected with SARS-CoV-2, although their ability to spread to humans is unknown.
Wild cats (tigers and lions) can be infected with SARS-CoV-2, although their ability to spread to humans is unknown.
Wild cats (tigers and lions) can be infected with SARS-CoV-2, although their ability to spread to humans is unknown.
Wild cats (tigers and lions) can be infected with SARS-CoV-2, although their ability to spread to humans is unknown.
Wild cats (tigers and lions) can be infected with SARS-CoV-2, although their ability to spread to humans is unknown.
Studies have confirmed that human keepers transmitted SARS-CoV-2 to tigers and lions at the Bronx Zoo.
Studies have confirmed that human keepers transmitted SARS-CoV-2 to tigers and lions at the Bronx Zoo.
Studies have confirmed that human keepers transmitted SARS-CoV-2 to tigers and lions at the Bronx Zoo.
Studies have confirmed that human keepers transmitted SARS-CoV-2 to tigers and lions at the Bronx Zoo.
Studies have confirmed that human keepers transmitted SARS-CoV-2 to tigers and lions at the Bronx Zoo.
Studies have confirmed that human keepers transmitted SARS-CoV-2 to tigers and lions at the Bronx Zoo.
Studies have confirmed that human keepers transmitted SARS-CoV-2 to tigers and lions at the Bronx Zoo.
Studies have confirmed that human keepers transmitted SARS-CoV-2 to tigers and lions at the Bronx Zoo.
Studies have confirmed that human keepers transmitted SARS-CoV-2 to tigers and lions at the Bronx Zoo.
Studies have confirmed that human keepers transmitted SARS-CoV-2 to tigers and lions at the Bronx Zoo.
Two cases of SARS-CoV-2 infection have been confirmed in pet domestic cats.
Two cases of SARS-CoV-2 infection have been confirmed in pet domestic cats.
Two cases of SARS-CoV-2 infection have been confirmed in pet domestic cats.
Two cases of SARS-CoV-2 infection have been confirmed in pet domestic cats.
Two cases of SARS-CoV-2 infection have been confirmed in pet domestic cats.
Two cases of SARS-CoV-2 infection have been confirmed in pet domestic cats.
Two cases of SARS-CoV-2 infection have been confirmed in pet domestic cats.
Two cases of SARS-CoV-2 infection have been confirmed in pet domestic cats.
Two cases of SARS-CoV-2 infection have been confirmed in pet domestic cats.
Two cases of SARS-CoV-2 infection have been confirmed in pet domestic cats.
Deer mice can be experimentally infected with SARS-CoV-2 via intranasal exposure (104 or 105 TCID50) and are able to transmit virus to uninfected deer mice through direct contact.
Deer mice can be experimentally infected with SARS-CoV-2 via intranasal exposure (104 or 105 TCID50) and are able to transmit virus to uninfected deer mice through direct contact.
Deer mice can be experimentally infected with SARS-CoV-2 via intranasal exposure (104 or 105 TCID50) and are able to transmit virus to uninfected deer mice through direct contact.
Deer mice can be experimentally infected with SARS-CoV-2 via intranasal exposure (104 or 105 TCID50) and are able to transmit virus to uninfected deer mice through direct contact.
Deer mice can be experimentally infected with SARS-CoV-2 via intranasal exposure (104 or 105 TCID50) and are able to transmit virus to uninfected deer mice through direct contact.
Deer mice can be experimentally infected with SARS-CoV-2 via intranasal exposure (104 or 105 TCID50) and are able to transmit virus to uninfected deer mice through direct contact.
Deer mice can be experimentally infected with SARS-CoV-2 via intranasal exposure (104 or 105 TCID50) and are able to transmit virus to uninfected deer mice through direct contact.
Deer mice can be experimentally infected with SARS-CoV-2 via intranasal exposure (104 or 105 TCID50) and are able to transmit virus to uninfected deer mice through direct contact.
Deer mice can be experimentally infected with SARS-CoV-2 via intranasal exposure (104 or 105 TCID50) and are able to transmit virus to uninfected deer mice through direct contact.
Deer mice can be experimentally infected with SARS-CoV-2 via intranasal exposure (104 or 105 TCID50) and are able to transmit virus to uninfected deer mice through direct contact.
Ducks, chickens, and pigs remained uninfected after experimental SARS-CoV-2 exposure (30,000 CFU for ducks and chickens, 100,000 PFU for pigs, ~70,000 PFU for pigs and chickens all via intranasal route).
Ducks, chickens, and pigs remained uninfected after experimental SARS-CoV-2 exposure (30,000 CFU for ducks and chickens, 100,000 PFU for pigs, ~70,000 PFU for pigs and chickens all via intranasal route).
Ducks, chickens, and pigs remained uninfected after experimental SARS-CoV-2 exposure (30,000 CFU for ducks and chickens, 100,000 PFU for pigs, ~70,000 PFU for pigs and chickens all via intranasal route).
Ducks, chickens, and pigs remained uninfected after experimental SARS-CoV-2 exposure (30,000 CFU for ducks and chickens, 100,000 PFU for pigs, ~70,000 PFU for pigs and chickens all via intranasal route).
Ducks, chickens, and pigs remained uninfected after experimental SARS-CoV-2 exposure (30,000 CFU for ducks and chickens, 100,000 PFU for pigs, ~70,000 PFU for pigs and chickens all via intranasal route).
Ducks, chickens, and pigs remained uninfected after experimental SARS-CoV-2 exposure (30,000 CFU for ducks and chickens, 100,000 PFU for pigs, ~70,000 PFU for pigs and chickens all via intranasal route).
Ducks, chickens, and pigs remained uninfected after experimental SARS-CoV-2 exposure (30,000 CFU for ducks and chickens, 100,000 PFU for pigs, ~70,000 PFU for pigs and chickens all via intranasal route).
Ducks, chickens, and pigs remained uninfected after experimental SARS-CoV-2 exposure (30,000 CFU for ducks and chickens, 100,000 PFU for pigs, ~70,000 PFU for pigs and chickens all via intranasal route).
Ducks, chickens, and pigs remained uninfected after experimental SARS-CoV-2 exposure (30,000 CFU for ducks and chickens, 100,000 PFU for pigs, ~70,000 PFU for pigs and chickens all via intranasal route).
Ducks, chickens, and pigs remained uninfected after experimental SARS-CoV-2 exposure (30,000 CFU for ducks and chickens, 100,000 PFU for pigs, ~70,000 PFU for pigs and chickens all via intranasal route).
When pigs were inoculated by the oronasal route (106 PFU), minimal to no signs of clinical disease were noted, suggesting limited transmission concerns.
When pigs were inoculated by the oronasal route (106 PFU), minimal to no signs of clinical disease were noted, suggesting limited transmission concerns.
When pigs were inoculated by the oronasal route (106 PFU), minimal to no signs of clinical disease were noted, suggesting limited transmission concerns.
When pigs were inoculated by the oronasal route (106 PFU), minimal to no signs of clinical disease were noted, suggesting limited transmission concerns.
When pigs were inoculated by the oronasal route (106 PFU), minimal to no signs of clinical disease were noted, suggesting limited transmission concerns.
When pigs were inoculated by the oronasal route (106 PFU), minimal to no signs of clinical disease were noted, suggesting limited transmission concerns.
When pigs were inoculated by the oronasal route (106 PFU), minimal to no signs of clinical disease were noted, suggesting limited transmission concerns.
When pigs were inoculated by the oronasal route (106 PFU), minimal to no signs of clinical disease were noted, suggesting limited transmission concerns.
When pigs were inoculated by the oronasal route (106 PFU), minimal to no signs of clinical disease were noted, suggesting limited transmission concerns.
When pigs were inoculated by the oronasal route (106 PFU), minimal to no signs of clinical disease were noted, suggesting limited transmission concerns.
Chicken, turkey, duck, quail, and geese were not susceptible to SARS-CoV-2 after experimental exposures.
Chicken, turkey, duck, quail, and geese were not susceptible to SARS-CoV-2 after experimental exposures.
Chicken, turkey, duck, quail, and geese were not susceptible to SARS-CoV-2 after experimental exposures.
Chicken, turkey, duck, quail, and geese were not susceptible to SARS-CoV-2 after experimental exposures.
Chicken, turkey, duck, quail, and geese were not susceptible to SARS-CoV-2 after experimental exposures.
Chicken, turkey, duck, quail, and geese were not susceptible to SARS-CoV-2 after experimental exposures.
Chicken, turkey, duck, quail, and geese were not susceptible to SARS-CoV-2 after experimental exposures.
Chicken, turkey, duck, quail, and geese were not susceptible to SARS-CoV-2 after experimental exposures.
Chicken, turkey, duck, quail, and geese were not susceptible to SARS-CoV-2 after experimental exposures.
Chicken, turkey, duck, quail, and geese were not susceptible to SARS-CoV-2 after experimental exposures.
Rabbits do not exhibit clinical symptoms after exposure to SARS-CoV-2, but do seroconvert.
Rabbits do not exhibit clinical symptoms after exposure to SARS-CoV-2, but do seroconvert.
Rabbits do not exhibit clinical symptoms after exposure to SARS-CoV-2, but do seroconvert.
Rabbits do not exhibit clinical symptoms after exposure to SARS-CoV-2, but do seroconvert.
Rabbits do not exhibit clinical symptoms after exposure to SARS-CoV-2, but do seroconvert.
Rabbits do not exhibit clinical symptoms after exposure to SARS-CoV-2, but do seroconvert.
Rabbits do not exhibit clinical symptoms after exposure to SARS-CoV-2, but do seroconvert.
Rabbits do not exhibit clinical symptoms after exposure to SARS-CoV-2, but do seroconvert.
Rabbits do not exhibit clinical symptoms after exposure to SARS-CoV-2, but do seroconvert.
Rabbits do not exhibit clinical symptoms after exposure to SARS-CoV-2, but do seroconvert.
Cattle exposed to SARS-CoV-2 showed no clinical disease but exhibited low levels of viral shedding in the nose, which could be residual virus from the exposure dose.
Cattle exposed to SARS-CoV-2 showed no clinical disease but exhibited low levels of viral shedding in the nose, which could be residual virus from the exposure dose.
Cattle exposed to SARS-CoV-2 showed no clinical disease but exhibited low levels of viral shedding in the nose, which could be residual virus from the exposure dose.
Cattle exposed to SARS-CoV-2 showed no clinical disease but exhibited low levels of viral shedding in the nose, which could be residual virus from the exposure dose.
Cattle exposed to SARS-CoV-2 showed no clinical disease but exhibited low levels of viral shedding in the nose, which could be residual virus from the exposure dose.
Cattle exposed to SARS-CoV-2 showed no clinical disease but exhibited low levels of viral shedding in the nose, which could be residual virus from the exposure dose.
Cattle exposed to SARS-CoV-2 showed no clinical disease but exhibited low levels of viral shedding in the nose, which could be residual virus from the exposure dose.
Cattle exposed to SARS-CoV-2 showed no clinical disease but exhibited low levels of viral shedding in the nose, which could be residual virus from the exposure dose.
Cattle exposed to SARS-CoV-2 showed no clinical disease but exhibited low levels of viral shedding in the nose, which could be residual virus from the exposure dose.
Cattle exposed to SARS-CoV-2 showed no clinical disease but exhibited low levels of viral shedding in the nose, which could be residual virus from the exposure dose.
Dogs exposed to SARS-CoV-2 produced anti-SARS-CoV-2 antibodies but exhibited no clinical symptoms.
Dogs exposed to SARS-CoV-2 produced anti-SARS-CoV-2 antibodies but exhibited no clinical symptoms.
Dogs exposed to SARS-CoV-2 produced anti-SARS-CoV-2 antibodies but exhibited no clinical symptoms.
Dogs exposed to SARS-CoV-2 produced anti-SARS-CoV-2 antibodies but exhibited no clinical symptoms.
Dogs exposed to SARS-CoV-2 produced anti-SARS-CoV-2 antibodies but exhibited no clinical symptoms.
Dogs exposed to SARS-CoV-2 produced anti-SARS-CoV-2 antibodies but exhibited no clinical symptoms.
Dogs exposed to SARS-CoV-2 produced anti-SARS-CoV-2 antibodies but exhibited no clinical symptoms.
Dogs exposed to SARS-CoV-2 produced anti-SARS-CoV-2 antibodies but exhibited no clinical symptoms.
Dogs exposed to SARS-CoV-2 produced anti-SARS-CoV-2 antibodies but exhibited no clinical symptoms.
Dogs exposed to SARS-CoV-2 produced anti-SARS-CoV-2 antibodies but exhibited no clinical symptoms.
In Italy, approximately 3-6% of domestic dogs and cats showed detectable neutralizing antibodies to SARS-CoV-2, though no animals showed clinical signs or positive RT-PCR tests in addition to the antibodies, and no evidence exists of transmission from dogs or cats to humans.
In Italy, approximately 3-6% of domestic dogs and cats showed detectable neutralizing antibodies to SARS-CoV-2, though no animals showed clinical signs or positive RT-PCR tests in addition to the antibodies, and no evidence exists of transmission from dogs or cats to humans.
In Italy, approximately 3-6% of domestic dogs and cats showed detectable neutralizing antibodies to SARS-CoV-2, though no animals showed clinical signs or positive RT-PCR tests in addition to the antibodies, and no evidence exists of transmission from dogs or cats to humans.
In Italy, approximately 3-6% of domestic dogs and cats showed detectable neutralizing antibodies to SARS-CoV-2, though no animals showed clinical signs or positive RT-PCR tests in addition to the antibodies, and no evidence exists of transmission from dogs or cats to humans.
In Italy, approximately 3-6% of domestic dogs and cats showed detectable neutralizing antibodies to SARS-CoV-2, though no animals showed clinical signs or positive RT-PCR tests in addition to the antibodies, and no evidence exists of transmission from dogs or cats to humans.
In Italy, approximately 3-6% of domestic dogs and cats showed detectable neutralizing antibodies to SARS-CoV-2, though no animals showed clinical signs or positive RT-PCR tests in addition to the antibodies, and no evidence exists of transmission from dogs or cats to humans.
In Italy, approximately 3-6% of domestic dogs and cats showed detectable neutralizing antibodies to SARS-CoV-2, though no animals showed clinical signs or positive RT-PCR tests in addition to the antibodies, and no evidence exists of transmission from dogs or cats to humans.
In Italy, approximately 3-6% of domestic dogs and cats showed detectable neutralizing antibodies to SARS-CoV-2, though no animals showed clinical signs or positive RT-PCR tests in addition to the antibodies, and no evidence exists of transmission from dogs or cats to humans.
In Italy, approximately 3-6% of domestic dogs and cats showed detectable neutralizing antibodies to SARS-CoV-2, though no animals showed clinical signs or positive RT-PCR tests in addition to the antibodies, and no evidence exists of transmission from dogs or cats to humans.
In Italy, approximately 3-6% of domestic dogs and cats showed detectable neutralizing antibodies to SARS-CoV-2, though no animals showed clinical signs or positive RT-PCR tests in addition to the antibodies, and no evidence exists of transmission from dogs or cats to humans.
survey of 334 pangolins did not identify coronavirus nucleic acid in ‚Äö√Ñ√∂‚àö√ë‚àö‚â§upstream‚Äö√Ñ√∂‚àö√ë‚àö¬• market chain samples, suggesting that positive samples from pangolins may be the result of exposure to infected humans, wildlife or other animals within the wildlife trade network.
survey of 334 pangolins did not identify coronavirus nucleic acid in ‚Äö√Ñ√∂‚àö√ë‚àö‚â§upstream‚Äö√Ñ√∂‚àö√ë‚àö¬• market chain samples, suggesting that positive samples from pangolins may be the result of exposure to infected humans, wildlife or other animals within the wildlife trade network.
survey of 334 pangolins did not identify coronavirus nucleic acid in ‚Äö√Ñ√∂‚àö√ë‚àö‚â§upstream‚Äö√Ñ√∂‚àö√ë‚àö¬• market chain samples, suggesting that positive samples from pangolins may be the result of exposure to infected humans, wildlife or other animals within the wildlife trade network.
survey of 334 pangolins did not identify coronavirus nucleic acid in ‚Äö√Ñ√∂‚àö√ë‚àö‚â§upstream‚Äö√Ñ√∂‚àö√ë‚àö¬• market chain samples, suggesting that positive samples from pangolins may be the result of exposure to infected humans, wildlife or other animals within the wildlife trade network.
survey of 334 pangolins did not identify coronavirus nucleic acid in ‚Äö√Ñ√∂‚àö√ë‚àö‚â§upstream‚Äö√Ñ√∂‚àö√ë‚àö¬• market chain samples, suggesting that positive samples from pangolins may be the result of exposure to infected humans, wildlife or other animals within the wildlife trade network.
survey of 334 pangolins did not identify coronavirus nucleic acid in ‚Äö√Ñ√∂‚àö√ë‚àö‚â§upstream‚Äö√Ñ√∂‚àö√ë‚àö¬• market chain samples, suggesting that positive samples from pangolins may be the result of exposure to infected humans, wildlife or other animals within the wildlife trade network.
survey of 334 pangolins did not identify coronavirus nucleic acid in ‚Äö√Ñ√∂‚àö√ë‚àö‚â§upstream‚Äö√Ñ√∂‚àö√ë‚àö¬• market chain samples, suggesting that positive samples from pangolins may be the result of exposure to infected humans, wildlife or other animals within the wildlife trade network.
survey of 334 pangolins did not identify coronavirus nucleic acid in ‚Äö√Ñ√∂‚àö√ë‚àö‚â§upstream‚Äö√Ñ√∂‚àö√ë‚àö¬• market chain samples, suggesting that positive samples from pangolins may be the result of exposure to infected humans, wildlife or other animals within the wildlife trade network.
survey of 334 pangolins did not identify coronavirus nucleic acid in ‚Äö√Ñ√∂‚àö√ë‚àö‚â§upstream‚Äö√Ñ√∂‚àö√ë‚àö¬• market chain samples, suggesting that positive samples from pangolins may be the result of exposure to infected humans, wildlife or other animals within the wildlife trade network.
survey of 334 pangolins did not identify coronavirus nucleic acid in ‚Äö√Ñ√∂‚àö√ë‚àö‚â§upstream‚Äö√Ñ√∂‚àö√ë‚àö¬• market chain samples, suggesting that positive samples from pangolins may be the result of exposure to infected humans, wildlife or other animals within the wildlife trade network.
These data suggest that pangolins are incidental hosts of coronaviruses.
These data suggest that pangolins are incidental hosts of coronaviruses.
These data suggest that pangolins are incidental hosts of coronaviruses.
These data suggest that pangolins are incidental hosts of coronaviruses.
These data suggest that pangolins are incidental hosts of coronaviruses.
These data suggest that pangolins are incidental hosts of coronaviruses.
These data suggest that pangolins are incidental hosts of coronaviruses.
These data suggest that pangolins are incidental hosts of coronaviruses.
These data suggest that pangolins are incidental hosts of coronaviruses.
These data suggest that pangolins are incidental hosts of coronaviruses.
On average, symptoms develop 5 days after exposure with a range of 2-14 days.
On average, symptoms develop 5 days after exposure with a range of 2-14 days.
On average, symptoms develop 5 days after exposure with a range of 2-14 days.
On average, symptoms develop 5 days after exposure with a range of 2-14 days.
On average, symptoms develop 5 days after exposure with a range of 2-14 days.
On average, symptoms develop 5 days after exposure with a range of 2-14 days.
On average, symptoms develop 5 days after exposure with a range of 2-14 days.
On average, symptoms develop 5 days after exposure with a range of 2-14 days.
On average, symptoms develop 5 days after exposure with a range of 2-14 days.
On average, symptoms develop 5 days after exposure with a range of 2-14 days.
Incubating individuals can transmit disease for several days before symptom onset.
Incubating individuals can transmit disease for several days before symptom onset.
Incubating individuals can transmit disease for several days before symptom onset.
Incubating individuals can transmit disease for several days before symptom onset.
Incubating individuals can transmit disease for several days before symptom onset.
Incubating individuals can transmit disease for several days before symptom onset.
Incubating individuals can transmit disease for several days before symptom onset.
Incubating individuals can transmit disease for several days before symptom onset.
Incubating individuals can transmit disease for several days before symptom onset.
Incubating individuals can transmit disease for several days before symptom onset.
Some individuals never develop symptoms but can still transmit disease.
Some individuals never develop symptoms but can still transmit disease.
Some individuals never develop symptoms but can still transmit disease.
Some individuals never develop symptoms but can still transmit disease.
Some individuals never develop symptoms but can still transmit disease.
Some individuals never develop symptoms but can still transmit disease.
Some individuals never develop symptoms but can still transmit disease.
Some individuals never develop symptoms but can still transmit disease.
Some individuals never develop symptoms but can still transmit disease.
Some individuals never develop symptoms but can still transmit disease.
By general consensus, the incubation period of COVID-19 is between 5 and 6 days.
By general consensus, the incubation period of COVID-19 is between 5 and 6 days.
By general consensus, the incubation period of COVID-19 is between 5 and 6 days.
By general consensus, the incubation period of COVID-19 is between 5 and 6 days.
By general consensus, the incubation period of COVID-19 is between 5 and 6 days.
By general consensus, the incubation period of COVID-19 is between 5 and 6 days.
By general consensus, the incubation period of COVID-19 is between 5 and 6 days.
By general consensus, the incubation period of COVID-19 is between 5 and 6 days.
By general consensus, the incubation period of COVID-19 is between 5 and 6 days.
By general consensus, the incubation period of COVID-19 is between 5 and 6 days.
Fewer than 2.5% of infected individuals show symptoms sooner than 2 days after exposure.
Fewer than 2.5% of infected individuals show symptoms sooner than 2 days after exposure.
Fewer than 2.5% of infected individuals show symptoms sooner than 2 days after exposure.
Fewer than 2.5% of infected individuals show symptoms sooner than 2 days after exposure.
Fewer than 2.5% of infected individuals show symptoms sooner than 2 days after exposure.
Fewer than 2.5% of infected individuals show symptoms sooner than 2 days after exposure.
Fewer than 2.5% of infected individuals show symptoms sooner than 2 days after exposure.
Fewer than 2.5% of infected individuals show symptoms sooner than 2 days after exposure.
Fewer than 2.5% of infected individuals show symptoms sooner than 2 days after exposure.
Fewer than 2.5% of infected individuals show symptoms sooner than 2 days after exposure.
However, more recent estimates using different models calculate a longer incubation period, between 7 and 8 days.
However, more recent estimates using different models calculate a longer incubation period, between 7 and 8 days.
However, more recent estimates using different models calculate a longer incubation period, between 7 and 8 days.
However, more recent estimates using different models calculate a longer incubation period, between 7 and 8 days.
However, more recent estimates using different models calculate a longer incubation period, between 7 and 8 days.
However, more recent estimates using different models calculate a longer incubation period, between 7 and 8 days.
However, more recent estimates using different models calculate a longer incubation period, between 7 and 8 days.
However, more recent estimates using different models calculate a longer incubation period, between 7 and 8 days.
However, more recent estimates using different models calculate a longer incubation period, between 7 and 8 days.
However, more recent estimates using different models calculate a longer incubation period, between 7 and 8 days.
This could mean that 5-10% of individuals undergoing a 14- day quarantine are still infectious at the end.
This could mean that 5-10% of individuals undergoing a 14- day quarantine are still infectious at the end.
This could mean that 5-10% of individuals undergoing a 14- day quarantine are still infectious at the end.
This could mean that 5-10% of individuals undergoing a 14- day quarantine are still infectious at the end.
This could mean that 5-10% of individuals undergoing a 14- day quarantine are still infectious at the end.
This could mean that 5-10% of individuals undergoing a 14- day quarantine are still infectious at the end.
This could mean that 5-10% of individuals undergoing a 14- day quarantine are still infectious at the end.
This could mean that 5-10% of individuals undergoing a 14- day quarantine are still infectious at the end.
This could mean that 5-10% of individuals undergoing a 14- day quarantine are still infectious at the end.
This could mean that 5-10% of individuals undergoing a 14- day quarantine are still infectious at the end.
There is evidence that younger (<14) and older (>75) individuals have longer COVID-19 incubation periods, creating a U- shaped relationship between incubation period length and patient age while adolescent and young adult populations (15-24 years old) have been estimated at ~2 days.
There is evidence that younger (<14) and older (>75) individuals have longer COVID-19 incubation periods, creating a U- shaped relationship between incubation period length and patient age while adolescent and young adult populations (15-24 years old) have been estimated at ~2 days.
There is evidence that younger (<14) and older (>75) individuals have longer COVID-19 incubation periods, creating a U- shaped relationship between incubation period length and patient age while adolescent and young adult populations (15-24 years old) have been estimated at ~2 days.
There is evidence that younger (<14) and older (>75) individuals have longer COVID-19 incubation periods, creating a U- shaped relationship between incubation period length and patient age while adolescent and young adult populations (15-24 years old) have been estimated at ~2 days.
There is evidence that younger (<14) and older (>75) individuals have longer COVID-19 incubation periods, creating a U- shaped relationship between incubation period length and patient age while adolescent and young adult populations (15-24 years old) have been estimated at ~2 days.
There is evidence that younger (<14) and older (>75) individuals have longer COVID-19 incubation periods, creating a U- shaped relationship between incubation period length and patient age while adolescent and young adult populations (15-24 years old) have been estimated at ~2 days.
There is evidence that younger (<14) and older (>75) individuals have longer COVID-19 incubation periods, creating a U- shaped relationship between incubation period length and patient age while adolescent and young adult populations (15-24 years old) have been estimated at ~2 days.
There is evidence that younger (<14) and older (>75) individuals have longer COVID-19 incubation periods, creating a U- shaped relationship between incubation period length and patient age while adolescent and young adult populations (15-24 years old) have been estimated at ~2 days.
There is evidence that younger (<14) and older (>75) individuals have longer COVID-19 incubation periods, creating a U- shaped relationship between incubation period length and patient age while adolescent and young adult populations (15-24 years old) have been estimated at ~2 days.
There is evidence that younger (<14) and older (>75) individuals have longer COVID-19 incubation periods, creating a U- shaped relationship between incubation period length and patient age while adolescent and young adult populations (15-24 years old) have been estimated at ~2 days.
Individuals can test positive for COVID-19 even if they lack clinical symptoms.
Individuals can test positive for COVID-19 even if they lack clinical symptoms.
Individuals can test positive for COVID-19 even if they lack clinical symptoms.
Individuals can test positive for COVID-19 even if they lack clinical symptoms.
Individuals can test positive for COVID-19 even if they lack clinical symptoms.
Individuals can test positive for COVID-19 even if they lack clinical symptoms.
Individuals can test positive for COVID-19 even if they lack clinical symptoms.
Individuals can test positive for COVID-19 even if they lack clinical symptoms.
Individuals can test positive for COVID-19 even if they lack clinical symptoms.
Individuals can test positive for COVID-19 even if they lack clinical symptoms.
Peak infectiousness may be during the incubation period, one day before symptoms develop.
Peak infectiousness may be during the incubation period, one day before symptoms develop.
Peak infectiousness may be during the incubation period, one day before symptoms develop.
Peak infectiousness may be during the incubation period, one day before symptoms develop.
Peak infectiousness may be during the incubation period, one day before symptoms develop.
Peak infectiousness may be during the incubation period, one day before symptoms develop.
Peak infectiousness may be during the incubation period, one day before symptoms develop.
Peak infectiousness may be during the incubation period, one day before symptoms develop.
Peak infectiousness may be during the incubation period, one day before symptoms develop.
Peak infectiousness may be during the incubation period, one day before symptoms develop.
Infectious virus has been cultured in patients up to 6 days before the development of symptoms.
Infectious virus has been cultured in patients up to 6 days before the development of symptoms.
Infectious virus has been cultured in patients up to 6 days before the development of symptoms.
Infectious virus has been cultured in patients up to 6 days before the development of symptoms.
Infectious virus has been cultured in patients up to 6 days before the development of symptoms.
Infectious virus has been cultured in patients up to 6 days before the development of symptoms.
Infectious virus has been cultured in patients up to 6 days before the development of symptoms.
Infectious virus has been cultured in patients up to 6 days before the development of symptoms.
Infectious virus has been cultured in patients up to 6 days before the development of symptoms.
Infectious virus has been cultured in patients up to 6 days before the development of symptoms.
It is estimated that most individuals are no longer infectious beyond 10 days after symptom onset.
It is estimated that most individuals are no longer infectious beyond 10 days after symptom onset.
It is estimated that most individuals are no longer infectious beyond 10 days after symptom onset.
It is estimated that most individuals are no longer infectious beyond 10 days after symptom onset.
It is estimated that most individuals are no longer infectious beyond 10 days after symptom onset.
It is estimated that most individuals are no longer infectious beyond 10 days after symptom onset.
It is estimated that most individuals are no longer infectious beyond 10 days after symptom onset.
It is estimated that most individuals are no longer infectious beyond 10 days after symptom onset.
It is estimated that most individuals are no longer infectious beyond 10 days after symptom onset.
It is estimated that most individuals are no longer infectious beyond 10 days after symptom onset.
A systematic review of published studies on SARS-CoV-1, SARS-CoV-2, and MERS-CoV found none that reported isolation of infectious virus from COVID-19 patients beyond 9 days from symptom onset, despite high viral loads by genetic tests.
A systematic review of published studies on SARS-CoV-1, SARS-CoV-2, and MERS-CoV found none that reported isolation of infectious virus from COVID-19 patients beyond 9 days from symptom onset, despite high viral loads by genetic tests.
A systematic review of published studies on SARS-CoV-1, SARS-CoV-2, and MERS-CoV found none that reported isolation of infectious virus from COVID-19 patients beyond 9 days from symptom onset, despite high viral loads by genetic tests.
A systematic review of published studies on SARS-CoV-1, SARS-CoV-2, and MERS-CoV found none that reported isolation of infectious virus from COVID-19 patients beyond 9 days from symptom onset, despite high viral loads by genetic tests.
A systematic review of published studies on SARS-CoV-1, SARS-CoV-2, and MERS-CoV found none that reported isolation of infectious virus from COVID-19 patients beyond 9 days from symptom onset, despite high viral loads by genetic tests.
A systematic review of published studies on SARS-CoV-1, SARS-CoV-2, and MERS-CoV found none that reported isolation of infectious virus from COVID-19 patients beyond 9 days from symptom onset, despite high viral loads by genetic tests.
A systematic review of published studies on SARS-CoV-1, SARS-CoV-2, and MERS-CoV found none that reported isolation of infectious virus from COVID-19 patients beyond 9 days from symptom onset, despite high viral loads by genetic tests.
A systematic review of published studies on SARS-CoV-1, SARS-CoV-2, and MERS-CoV found none that reported isolation of infectious virus from COVID-19 patients beyond 9 days from symptom onset, despite high viral loads by genetic tests.
A systematic review of published studies on SARS-CoV-1, SARS-CoV-2, and MERS-CoV found none that reported isolation of infectious virus from COVID-19 patients beyond 9 days from symptom onset, despite high viral loads by genetic tests.
A systematic review of published studies on SARS-CoV-1, SARS-CoV-2, and MERS-CoV found none that reported isolation of infectious virus from COVID-19 patients beyond 9 days from symptom onset, despite high viral loads by genetic tests.
individuals can also transmit infection before symptoms appear.
individuals can also transmit infection before symptoms appear.
individuals can also transmit infection before symptoms appear.
individuals can also transmit infection before symptoms appear.
individuals can also transmit infection before symptoms appear.
individuals can also transmit infection before symptoms appear.
individuals can also transmit infection before symptoms appear.
individuals can also transmit infection before symptoms appear.
individuals can also transmit infection before symptoms appear.
individuals can also transmit infection before symptoms appear.
Asymptomatic individuals are estimated to be infectious for a median of 9.5 days.
Asymptomatic individuals are estimated to be infectious for a median of 9.5 days.
Asymptomatic individuals are estimated to be infectious for a median of 9.5 days.
Asymptomatic individuals are estimated to be infectious for a median of 9.5 days.
Asymptomatic individuals are estimated to be infectious for a median of 9.5 days.
Asymptomatic individuals are estimated to be infectious for a median of 9.5 days.
Asymptomatic individuals are estimated to be infectious for a median of 9.5 days.
Asymptomatic individuals are estimated to be infectious for a median of 9.5 days.
Asymptomatic individuals are estimated to be infectious for a median of 9.5 days.
Asymptomatic individuals are estimated to be infectious for a median of 9.5 days.
The average time between symptom onset in successive cases (i.e., the serial interval) is approximately 5 days.
The average time between symptom onset in successive cases (i.e., the serial interval) is approximately 5 days.
The average time between symptom onset in successive cases (i.e., the serial interval) is approximately 5 days.
The average time between symptom onset in successive cases (i.e., the serial interval) is approximately 5 days.
The average time between symptom onset in successive cases (i.e., the serial interval) is approximately 5 days.
The average time between symptom onset in successive cases (i.e., the serial interval) is approximately 5 days.
The average time between symptom onset in successive cases (i.e., the serial interval) is approximately 5 days.
The average time between symptom onset in successive cases (i.e., the serial interval) is approximately 5 days.
The average time between symptom onset in successive cases (i.e., the serial interval) is approximately 5 days.
The average time between symptom onset in successive cases (i.e., the serial interval) is approximately 5 days.
On average, there are approximately 4 to 7.5 days between symptom onset in successive cases of a single transmission chain (i.e., the serial interval).
On average, there are approximately 4 to 7.5 days between symptom onset in successive cases of a single transmission chain (i.e., the serial interval).
On average, there are approximately 4 to 7.5 days between symptom onset in successive cases of a single transmission chain (i.e., the serial interval).
On average, there are approximately 4 to 7.5 days between symptom onset in successive cases of a single transmission chain (i.e., the serial interval).
On average, there are approximately 4 to 7.5 days between symptom onset in successive cases of a single transmission chain (i.e., the serial interval).
On average, there are approximately 4 to 7.5 days between symptom onset in successive cases of a single transmission chain (i.e., the serial interval).
On average, there are approximately 4 to 7.5 days between symptom onset in successive cases of a single transmission chain (i.e., the serial interval).
On average, there are approximately 4 to 7.5 days between symptom onset in successive cases of a single transmission chain (i.e., the serial interval).
On average, there are approximately 4 to 7.5 days between symptom onset in successive cases of a single transmission chain (i.e., the serial interval).
On average, there are approximately 4 to 7.5 days between symptom onset in successive cases of a single transmission chain (i.e., the serial interval).
Based on data from 339 transmission chains in China and additional meta-analysis, the mean serial interval is between 4.4 and 6.0 days.
Based on data from 339 transmission chains in China and additional meta-analysis, the mean serial interval is between 4.4 and 6.0 days.
Based on data from 339 transmission chains in China and additional meta-analysis, the mean serial interval is between 4.4 and 6.0 days.
Based on data from 339 transmission chains in China and additional meta-analysis, the mean serial interval is between 4.4 and 6.0 days.
Based on data from 339 transmission chains in China and additional meta-analysis, the mean serial interval is between 4.4 and 6.0 days.
Based on data from 339 transmission chains in China and additional meta-analysis, the mean serial interval is between 4.4 and 6.0 days.
Based on data from 339 transmission chains in China and additional meta-analysis, the mean serial interval is between 4.4 and 6.0 days.
Based on data from 339 transmission chains in China and additional meta-analysis, the mean serial interval is between 4.4 and 6.0 days.
Based on data from 339 transmission chains in China and additional meta-analysis, the mean serial interval is between 4.4 and 6.0 days.
Based on data from 339 transmission chains in China and additional meta-analysis, the mean serial interval is between 4.4 and 6.0 days.
The serial interval of COVID-19 has declined substantially over time as a result of increased case isolation, meaning individuals tend to transmit virus for less time.
The serial interval of COVID-19 has declined substantially over time as a result of increased case isolation, meaning individuals tend to transmit virus for less time.
The serial interval of COVID-19 has declined substantially over time as a result of increased case isolation, meaning individuals tend to transmit virus for less time.
The serial interval of COVID-19 has declined substantially over time as a result of increased case isolation, meaning individuals tend to transmit virus for less time.
The serial interval of COVID-19 has declined substantially over time as a result of increased case isolation, meaning individuals tend to transmit virus for less time.
The serial interval of COVID-19 has declined substantially over time as a result of increased case isolation, meaning individuals tend to transmit virus for less time.
The serial interval of COVID-19 has declined substantially over time as a result of increased case isolation, meaning individuals tend to transmit virus for less time.
The serial interval of COVID-19 has declined substantially over time as a result of increased case isolation, meaning individuals tend to transmit virus for less time.
The serial interval of COVID-19 has declined substantially over time as a result of increased case isolation, meaning individuals tend to transmit virus for less time.
The serial interval of COVID-19 has declined substantially over time as a result of increased case isolation, meaning individuals tend to transmit virus for less time.
The generation time (time between infection events in a chain of transmission) for SARS-CoV-2 is estimated as 4-5 days.
The generation time (time between infection events in a chain of transmission) for SARS-CoV-2 is estimated as 4-5 days.
The generation time (time between infection events in a chain of transmission) for SARS-CoV-2 is estimated as 4-5 days.
The generation time (time between infection events in a chain of transmission) for SARS-CoV-2 is estimated as 4-5 days.
The generation time (time between infection events in a chain of transmission) for SARS-CoV-2 is estimated as 4-5 days.
The generation time (time between infection events in a chain of transmission) for SARS-CoV-2 is estimated as 4-5 days.
The generation time (time between infection events in a chain of transmission) for SARS-CoV-2 is estimated as 4-5 days.
The generation time (time between infection events in a chain of transmission) for SARS-CoV-2 is estimated as 4-5 days.
The generation time (time between infection events in a chain of transmission) for SARS-CoV-2 is estimated as 4-5 days.
The generation time (time between infection events in a chain of transmission) for SARS-CoV-2 is estimated as 4-5 days.
Individuals can shed virus for several weeks, though it is not necessarily infectious.
Individuals can shed virus for several weeks, though it is not necessarily infectious.
Individuals can shed virus for several weeks, though it is not necessarily infectious.
Individuals can shed virus for several weeks, though it is not necessarily infectious.
Individuals can shed virus for several weeks, though it is not necessarily infectious.
Individuals can shed virus for several weeks, though it is not necessarily infectious.
Individuals can shed virus for several weeks, though it is not necessarily infectious.
Individuals can shed virus for several weeks, though it is not necessarily infectious.
Individuals can shed virus for several weeks, though it is not necessarily infectious.
Individuals can shed virus for several weeks, though it is not necessarily infectious.
Viral RNA loads in the upper respiratory tract tend to peak within a few days of symptom onset and become undetectable approximately two weeks after symptoms begin.
Viral RNA loads in the upper respiratory tract tend to peak within a few days of symptom onset and become undetectable approximately two weeks after symptoms begin.
Viral RNA loads in the upper respiratory tract tend to peak within a few days of symptom onset and become undetectable approximately two weeks after symptoms begin.
Viral RNA loads in the upper respiratory tract tend to peak within a few days of symptom onset and become undetectable approximately two weeks after symptoms begin.
Viral RNA loads in the upper respiratory tract tend to peak within a few days of symptom onset and become undetectable approximately two weeks after symptoms begin.
Viral RNA loads in the upper respiratory tract tend to peak within a few days of symptom onset and become undetectable approximately two weeks after symptoms begin.
Viral RNA loads in the upper respiratory tract tend to peak within a few days of symptom onset and become undetectable approximately two weeks after symptoms begin.
Viral RNA loads in the upper respiratory tract tend to peak within a few days of symptom onset and become undetectable approximately two weeks after symptoms begin.
Viral RNA loads in the upper respiratory tract tend to peak within a few days of symptom onset and become undetectable approximately two weeks after symptoms begin.
Viral RNA loads in the upper respiratory tract tend to peak within a few days of symptom onset and become undetectable approximately two weeks after symptoms begin.
The duration of the infectious period is unknown, though patients can test positive for SARS-CoV-2 viral RNA for extended periods of time, particularly in stool samples.
The duration of the infectious period is unknown, though patients can test positive for SARS-CoV-2 viral RNA for extended periods of time, particularly in stool samples.
The duration of the infectious period is unknown, though patients can test positive for SARS-CoV-2 viral RNA for extended periods of time, particularly in stool samples.
The duration of the infectious period is unknown, though patients can test positive for SARS-CoV-2 viral RNA for extended periods of time, particularly in stool samples.
The duration of the infectious period is unknown, though patients can test positive for SARS-CoV-2 viral RNA for extended periods of time, particularly in stool samples.
The duration of the infectious period is unknown, though patients can test positive for SARS-CoV-2 viral RNA for extended periods of time, particularly in stool samples.
The duration of the infectious period is unknown, though patients can test positive for SARS-CoV-2 viral RNA for extended periods of time, particularly in stool samples.
The duration of the infectious period is unknown, though patients can test positive for SARS-CoV-2 viral RNA for extended periods of time, particularly in stool samples.
The duration of the infectious period is unknown, though patients can test positive for SARS-CoV-2 viral RNA for extended periods of time, particularly in stool samples.
The duration of the infectious period is unknown, though patients can test positive for SARS-CoV-2 viral RNA for extended periods of time, particularly in stool samples.
Most symptomatic cases are mild, but severe disease can be found in any age group.
Most symptomatic cases are mild, but severe disease can be found in any age group.
Most symptomatic cases are mild, but severe disease can be found in any age group.
Most symptomatic cases are mild, but severe disease can be found in any age group.
Most symptomatic cases are mild, but severe disease can be found in any age group.
Most symptomatic cases are mild, but severe disease can be found in any age group.
Most symptomatic cases are mild, but severe disease can be found in any age group.
Most symptomatic cases are mild, but severe disease can be found in any age group.
Most symptomatic cases are mild, but severe disease can be found in any age group.
Most symptomatic cases are mild, but severe disease can be found in any age group.
Older individuals and those with underlying conditions are at higher risk of serious illness and death, as are men.
Older individuals and those with underlying conditions are at higher risk of serious illness and death, as are men.
Older individuals and those with underlying conditions are at higher risk of serious illness and death, as are men.
Older individuals and those with underlying conditions are at higher risk of serious illness and death, as are men.
Older individuals and those with underlying conditions are at higher risk of serious illness and death, as are men.
Older individuals and those with underlying conditions are at higher risk of serious illness and death, as are men.
Older individuals and those with underlying conditions are at higher risk of serious illness and death, as are men.
Older individuals and those with underlying conditions are at higher risk of serious illness and death, as are men.
Older individuals and those with underlying conditions are at higher risk of serious illness and death, as are men.
Older individuals and those with underlying conditions are at higher risk of serious illness and death, as are men.
Most symptomatic COVID-19 cases are mild (81%).
Most symptomatic COVID-19 cases are mild (81%).
Most symptomatic COVID-19 cases are mild (81%).
Most symptomatic COVID-19 cases are mild (81%).
Most symptomatic COVID-19 cases are mild (81%).
Most symptomatic COVID-19 cases are mild (81%).
Most symptomatic COVID-19 cases are mild (81%).
Most symptomatic COVID-19 cases are mild (81%).
Most symptomatic COVID-19 cases are mild (81%).
Most symptomatic COVID-19 cases are mild (81%).
Fever, cough, and shortness of breath are the most common symptoms, followed by malaise, fatigue, and sputum/secretion.
Fever, cough, and shortness of breath are the most common symptoms, followed by malaise, fatigue, and sputum/secretion.
Fever, cough, and shortness of breath are the most common symptoms, followed by malaise, fatigue, and sputum/secretion.
Fever, cough, and shortness of breath are the most common symptoms, followed by malaise, fatigue, and sputum/secretion.
Fever, cough, and shortness of breath are the most common symptoms, followed by malaise, fatigue, and sputum/secretion.
Fever, cough, and shortness of breath are the most common symptoms, followed by malaise, fatigue, and sputum/secretion.
Fever, cough, and shortness of breath are the most common symptoms, followed by malaise, fatigue, and sputum/secretion.
Fever, cough, and shortness of breath are the most common symptoms, followed by malaise, fatigue, and sputum/secretion.
Fever, cough, and shortness of breath are the most common symptoms, followed by malaise, fatigue, and sputum/secretion.
Fever, cough, and shortness of breath are the most common symptoms, followed by malaise, fatigue, and sputum/secretion.
In at least one cohort, however (n=1,564), muscle pain (55%) and headache (51%) were more common than cough (49%).
In at least one cohort, however (n=1,564), muscle pain (55%) and headache (51%) were more common than cough (49%).
In at least one cohort, however (n=1,564), muscle pain (55%) and headache (51%) were more common than cough (49%).
In at least one cohort, however (n=1,564), muscle pain (55%) and headache (51%) were more common than cough (49%).
In at least one cohort, however (n=1,564), muscle pain (55%) and headache (51%) were more common than cough (49%).
In at least one cohort, however (n=1,564), muscle pain (55%) and headache (51%) were more common than cough (49%).
In at least one cohort, however (n=1,564), muscle pain (55%) and headache (51%) were more common than cough (49%).
In at least one cohort, however (n=1,564), muscle pain (55%) and headache (51%) were more common than cough (49%).
In at least one cohort, however (n=1,564), muscle pain (55%) and headache (51%) were more common than cough (49%).
In at least one cohort, however (n=1,564), muscle pain (55%) and headache (51%) were more common than cough (49%).
Chills, muscle pain, sore throat, loss of taste or smell, gastrointestinal symptoms, neurological symptoms, and dermatological symptoms also occur with COVID-19, and atypical symptoms such as unexplained limb pain may also present with COVID-19.
Chills, muscle pain, sore throat, loss of taste or smell, gastrointestinal symptoms, neurological symptoms, and dermatological symptoms also occur with COVID-19, and atypical symptoms such as unexplained limb pain may also present with COVID-19.
Chills, muscle pain, sore throat, loss of taste or smell, gastrointestinal symptoms, neurological symptoms, and dermatological symptoms also occur with COVID-19, and atypical symptoms such as unexplained limb pain may also present with COVID-19.
Chills, muscle pain, sore throat, loss of taste or smell, gastrointestinal symptoms, neurological symptoms, and dermatological symptoms also occur with COVID-19, and atypical symptoms such as unexplained limb pain may also present with COVID-19.
Chills, muscle pain, sore throat, loss of taste or smell, gastrointestinal symptoms, neurological symptoms, and dermatological symptoms also occur with COVID-19, and atypical symptoms such as unexplained limb pain may also present with COVID-19.
Chills, muscle pain, sore throat, loss of taste or smell, gastrointestinal symptoms, neurological symptoms, and dermatological symptoms also occur with COVID-19, and atypical symptoms such as unexplained limb pain may also present with COVID-19.
Chills, muscle pain, sore throat, loss of taste or smell, gastrointestinal symptoms, neurological symptoms, and dermatological symptoms also occur with COVID-19, and atypical symptoms such as unexplained limb pain may also present with COVID-19.
Chills, muscle pain, sore throat, loss of taste or smell, gastrointestinal symptoms, neurological symptoms, and dermatological symptoms also occur with COVID-19, and atypical symptoms such as unexplained limb pain may also present with COVID-19.
Chills, muscle pain, sore throat, loss of taste or smell, gastrointestinal symptoms, neurological symptoms, and dermatological symptoms also occur with COVID-19, and atypical symptoms such as unexplained limb pain may also present with COVID-19.
Chills, muscle pain, sore throat, loss of taste or smell, gastrointestinal symptoms, neurological symptoms, and dermatological symptoms also occur with COVID-19, and atypical symptoms such as unexplained limb pain may also present with COVID-19.
Headaches are common, may persist for weeks, and may be associated with shorter disease duration.
Headaches are common, may persist for weeks, and may be associated with shorter disease duration.
Headaches are common, may persist for weeks, and may be associated with shorter disease duration.
Headaches are common, may persist for weeks, and may be associated with shorter disease duration.
Headaches are common, may persist for weeks, and may be associated with shorter disease duration.
Headaches are common, may persist for weeks, and may be associated with shorter disease duration.
Headaches are common, may persist for weeks, and may be associated with shorter disease duration.
Headaches are common, may persist for weeks, and may be associated with shorter disease duration.
Headaches are common, may persist for weeks, and may be associated with shorter disease duration.
Headaches are common, may persist for weeks, and may be associated with shorter disease duration.
In children, loss of taste or smell, nausea or vomiting, headache, and fever were predictive of COVID-19 infection.
In children, loss of taste or smell, nausea or vomiting, headache, and fever were predictive of COVID-19 infection.
In children, loss of taste or smell, nausea or vomiting, headache, and fever were predictive of COVID-19 infection.
In children, loss of taste or smell, nausea or vomiting, headache, and fever were predictive of COVID-19 infection.
In children, loss of taste or smell, nausea or vomiting, headache, and fever were predictive of COVID-19 infection.
In children, loss of taste or smell, nausea or vomiting, headache, and fever were predictive of COVID-19 infection.
In children, loss of taste or smell, nausea or vomiting, headache, and fever were predictive of COVID-19 infection.
In children, loss of taste or smell, nausea or vomiting, headache, and fever were predictive of COVID-19 infection.
In children, loss of taste or smell, nausea or vomiting, headache, and fever were predictive of COVID-19 infection.
In children, loss of taste or smell, nausea or vomiting, headache, and fever were predictive of COVID-19 infection.
Children were less likely to exhibit cough and loss of taste or smell than adults, but more likely to show sore throat.
Children were less likely to exhibit cough and loss of taste or smell than adults, but more likely to show sore throat.
Children were less likely to exhibit cough and loss of taste or smell than adults, but more likely to show sore throat.
Children were less likely to exhibit cough and loss of taste or smell than adults, but more likely to show sore throat.
Children were less likely to exhibit cough and loss of taste or smell than adults, but more likely to show sore throat.
Children were less likely to exhibit cough and loss of taste or smell than adults, but more likely to show sore throat.
Children were less likely to exhibit cough and loss of taste or smell than adults, but more likely to show sore throat.
Children were less likely to exhibit cough and loss of taste or smell than adults, but more likely to show sore throat.
Children were less likely to exhibit cough and loss of taste or smell than adults, but more likely to show sore throat.
Children were less likely to exhibit cough and loss of taste or smell than adults, but more likely to show sore throat.
COVID-19 generally begins with fever, then cough and malaise.
COVID-19 generally begins with fever, then cough and malaise.
COVID-19 generally begins with fever, then cough and malaise.
COVID-19 generally begins with fever, then cough and malaise.
COVID-19 generally begins with fever, then cough and malaise.
COVID-19 generally begins with fever, then cough and malaise.
COVID-19 generally begins with fever, then cough and malaise.
COVID-19 generally begins with fever, then cough and malaise.
COVID-19 generally begins with fever, then cough and malaise.
COVID-19 generally begins with fever, then cough and malaise.
In 49 children with COVID-19 (0-22 years), however, only 51% developed fever.
In 49 children with COVID-19 (0-22 years), however, only 51% developed fever.
In 49 children with COVID-19 (0-22 years), however, only 51% developed fever.
In 49 children with COVID-19 (0-22 years), however, only 51% developed fever.
In 49 children with COVID-19 (0-22 years), however, only 51% developed fever.
In 49 children with COVID-19 (0-22 years), however, only 51% developed fever.
In 49 children with COVID-19 (0-22 years), however, only 51% developed fever.
In 49 children with COVID-19 (0-22 years), however, only 51% developed fever.
In 49 children with COVID-19 (0-22 years), however, only 51% developed fever.
In 49 children with COVID-19 (0-22 years), however, only 51% developed fever.
Only 20% of emergency department patients testing positive for COVID-19 had fevers >100¬¨¬®‚Äö√†√ªF.
Only 20% of emergency department patients testing positive for COVID-19 had fevers >100¬¨¬®‚Äö√†√ªF.
Only 20% of emergency department patients testing positive for COVID-19 had fevers >100¬¨¬®‚Äö√†√ªF.
Only 20% of emergency department patients testing positive for COVID-19 had fevers >100¬¨¬®‚Äö√†√ªF.
Only 20% of emergency department patients testing positive for COVID-19 had fevers >100¬¨¬®‚Äö√†√ªF.
Only 20% of emergency department patients testing positive for COVID-19 had fevers >100¬¨¬®‚Äö√†√ªF.
Only 20% of emergency department patients testing positive for COVID-19 had fevers >100¬¨¬®‚Äö√†√ªF.
Only 20% of emergency department patients testing positive for COVID-19 had fevers >100¬¨¬®‚Äö√†√ªF.
Only 20% of emergency department patients testing positive for COVID-19 had fevers >100¬¨¬®‚Äö√†√ªF.
Only 20% of emergency department patients testing positive for COVID-19 had fevers >100¬¨¬®‚Äö√†√ªF.
In older patients, delirium should be considered a symptom of COVID-19 with or without other typical signs.
In older patients, delirium should be considered a symptom of COVID-19 with or without other typical signs.
In older patients, delirium should be considered a symptom of COVID-19 with or without other typical signs.
In older patients, delirium should be considered a symptom of COVID-19 with or without other typical signs.
In older patients, delirium should be considered a symptom of COVID-19 with or without other typical signs.
In older patients, delirium should be considered a symptom of COVID-19 with or without other typical signs.
In older patients, delirium should be considered a symptom of COVID-19 with or without other typical signs.
In older patients, delirium should be considered a symptom of COVID-19 with or without other typical signs.
In older patients, delirium should be considered a symptom of COVID-19 with or without other typical signs.
In older patients, delirium should be considered a symptom of COVID-19 with or without other typical signs.
COVID-19 is more severe than seasonal influenza, evidenced by higher ICU admission and mortality rates.
COVID-19 is more severe than seasonal influenza, evidenced by higher ICU admission and mortality rates.
COVID-19 is more severe than seasonal influenza, evidenced by higher ICU admission and mortality rates.
COVID-19 is more severe than seasonal influenza, evidenced by higher ICU admission and mortality rates.
COVID-19 is more severe than seasonal influenza, evidenced by higher ICU admission and mortality rates.
COVID-19 is more severe than seasonal influenza, evidenced by higher ICU admission and mortality rates.
COVID-19 is more severe than seasonal influenza, evidenced by higher ICU admission and mortality rates.
COVID-19 is more severe than seasonal influenza, evidenced by higher ICU admission and mortality rates.
COVID-19 is more severe than seasonal influenza, evidenced by higher ICU admission and mortality rates.
COVID-19 is more severe than seasonal influenza, evidenced by higher ICU admission and mortality rates.
Higher SARS-CoV-2 RNA loads on admission have been associated with greater risk of death.
Higher SARS-CoV-2 RNA loads on admission have been associated with greater risk of death.
Higher SARS-CoV-2 RNA loads on admission have been associated with greater risk of death.
Higher SARS-CoV-2 RNA loads on admission have been associated with greater risk of death.
Higher SARS-CoV-2 RNA loads on admission have been associated with greater risk of death.
Higher SARS-CoV-2 RNA loads on admission have been associated with greater risk of death.
Higher SARS-CoV-2 RNA loads on admission have been associated with greater risk of death.
Higher SARS-CoV-2 RNA loads on admission have been associated with greater risk of death.
Higher SARS-CoV-2 RNA loads on admission have been associated with greater risk of death.
Higher SARS-CoV-2 RNA loads on admission have been associated with greater risk of death.
Individuals of any age can develop severe symptoms and require ICU care.
Individuals of any age can develop severe symptoms and require ICU care.
Individuals of any age can develop severe symptoms and require ICU care.
Individuals of any age can develop severe symptoms and require ICU care.
Individuals of any age can develop severe symptoms and require ICU care.
Individuals of any age can develop severe symptoms and require ICU care.
Individuals of any age can develop severe symptoms and require ICU care.
Individuals of any age can develop severe symptoms and require ICU care.
Individuals of any age can develop severe symptoms and require ICU care.
Individuals of any age can develop severe symptoms and require ICU care.
Males are associated with worse outcomes compared to females.
Males are associated with worse outcomes compared to females.
Males are associated with worse outcomes compared to females.
Males are associated with worse outcomes compared to females.
Males are associated with worse outcomes compared to females.
Males are associated with worse outcomes compared to females.
Males are associated with worse outcomes compared to females.
Males are associated with worse outcomes compared to females.
Males are associated with worse outcomes compared to females.
Males are associated with worse outcomes compared to females.
SARS-CoV-2 attacks blood vessels in the lung, leading to clotting complications and ARDS.
SARS-CoV-2 attacks blood vessels in the lung, leading to clotting complications and ARDS.
SARS-CoV-2 attacks blood vessels in the lung, leading to clotting complications and ARDS.
SARS-CoV-2 attacks blood vessels in the lung, leading to clotting complications and ARDS.
SARS-CoV-2 attacks blood vessels in the lung, leading to clotting complications and ARDS.
Clotting affects multiple organs and is present in 15-27% of cases.
Clotting affects multiple organs and is present in 15-27% of cases.
Clotting affects multiple organs and is present in 15-27% of cases.
Clotting affects multiple organs and is present in 15-27% of cases.
Clotting affects multiple organs and is present in 15-27% of cases.
Clotting affects multiple organs and is present in 15-27% of cases.
Clotting affects multiple organs and is present in 15-27% of cases.
Clotting affects multiple organs and is present in 15-27% of cases.
Clotting affects multiple organs and is present in 15-27% of cases.
Clotting affects multiple organs and is present in 15-27% of cases.
COVID-19 also causes pneumonia, cardiac injury, secondary infection, kidney damage, pancreatitis, arrhythmia, sepsis, stroke, respiratory complications, and shock.
COVID-19 also causes pneumonia, cardiac injury, secondary infection, kidney damage, pancreatitis, arrhythmia, sepsis, stroke, respiratory complications, and shock.
COVID-19 also causes pneumonia, cardiac injury, secondary infection, kidney damage, pancreatitis, arrhythmia, sepsis, stroke, respiratory complications, and shock.
COVID-19 also causes pneumonia, cardiac injury, secondary infection, kidney damage, pancreatitis, arrhythmia, sepsis, stroke, respiratory complications, and shock.
COVID-19 also causes pneumonia, cardiac injury, secondary infection, kidney damage, pancreatitis, arrhythmia, sepsis, stroke, respiratory complications, and shock.
COVID-19 also causes pneumonia, cardiac injury, secondary infection, kidney damage, pancreatitis, arrhythmia, sepsis, stroke, respiratory complications, and shock.
COVID-19 also causes pneumonia, cardiac injury, secondary infection, kidney damage, pancreatitis, arrhythmia, sepsis, stroke, respiratory complications, and shock.
COVID-19 also causes pneumonia, cardiac injury, secondary infection, kidney damage, pancreatitis, arrhythmia, sepsis, stroke, respiratory complications, and shock.
COVID-19 also causes pneumonia, cardiac injury, secondary infection, kidney damage, pancreatitis, arrhythmia, sepsis, stroke, respiratory complications, and shock.
COVID-19 also causes pneumonia, cardiac injury, secondary infection, kidney damage, pancreatitis, arrhythmia, sepsis, stroke, respiratory complications, and shock.
COVID-19 symptoms like fatigue and shortness of breath commonly persist for weeks to months after initial onset.
COVID-19 symptoms like fatigue and shortness of breath commonly persist for weeks to months after initial onset.
COVID-19 symptoms like fatigue and shortness of breath commonly persist for weeks to months after initial onset.
COVID-19 symptoms like fatigue and shortness of breath commonly persist for weeks to months after initial onset.
COVID-19 symptoms like fatigue and shortness of breath commonly persist for weeks to months after initial onset.
COVID-19 symptoms like fatigue and shortness of breath commonly persist for weeks to months after initial onset.
COVID-19 symptoms like fatigue and shortness of breath commonly persist for weeks to months after initial onset.
COVID-19 symptoms like fatigue and shortness of breath commonly persist for weeks to months after initial onset.
COVID-19 symptoms like fatigue and shortness of breath commonly persist for weeks to months after initial onset.
COVID-19 symptoms like fatigue and shortness of breath commonly persist for weeks to months after initial onset.
Most (88%) individuals infected with COVID-19 (n=86) showed evidence of lung damage six weeks after clinical recovery.
Most (88%) individuals infected with COVID-19 (n=86) showed evidence of lung damage six weeks after clinical recovery.
Most (88%) individuals infected with COVID-19 (n=86) showed evidence of lung damage six weeks after clinical recovery.
Most (88%) individuals infected with COVID-19 (n=86) showed evidence of lung damage six weeks after clinical recovery.
Most (88%) individuals infected with COVID-19 (n=86) showed evidence of lung damage six weeks after clinical recovery.
Most (88%) individuals infected with COVID-19 (n=86) showed evidence of lung damage six weeks after clinical recovery.
Most (88%) individuals infected with COVID-19 (n=86) showed evidence of lung damage six weeks after clinical recovery.
Most (88%) individuals infected with COVID-19 (n=86) showed evidence of lung damage six weeks after clinical recovery.
Most (88%) individuals infected with COVID-19 (n=86) showed evidence of lung damage six weeks after clinical recovery.
Most (88%) individuals infected with COVID-19 (n=86) showed evidence of lung damage six weeks after clinical recovery.
Approximately 9% of hospitalized patients experience at least 1 hospital readmission (from any cause) within 2 months of COVID-19 recovery, with individuals over 65 showing slightly higher odds of readmission.
Approximately 9% of hospitalized patients experience at least 1 hospital readmission (from any cause) within 2 months of COVID-19 recovery, with individuals over 65 showing slightly higher odds of readmission.
Approximately 9% of hospitalized patients experience at least 1 hospital readmission (from any cause) within 2 months of COVID-19 recovery, with individuals over 65 showing slightly higher odds of readmission.
Approximately 9% of hospitalized patients experience at least 1 hospital readmission (from any cause) within 2 months of COVID-19 recovery, with individuals over 65 showing slightly higher odds of readmission.
Approximately 9% of hospitalized patients experience at least 1 hospital readmission (from any cause) within 2 months of COVID-19 recovery, with individuals over 65 showing slightly higher odds of readmission.
Approximately 9% of hospitalized patients experience at least 1 hospital readmission (from any cause) within 2 months of COVID-19 recovery, with individuals over 65 showing slightly higher odds of readmission.
Approximately 9% of hospitalized patients experience at least 1 hospital readmission (from any cause) within 2 months of COVID-19 recovery, with individuals over 65 showing slightly higher odds of readmission.
Approximately 9% of hospitalized patients experience at least 1 hospital readmission (from any cause) within 2 months of COVID-19 recovery, with individuals over 65 showing slightly higher odds of readmission.
Approximately 9% of hospitalized patients experience at least 1 hospital readmission (from any cause) within 2 months of COVID-19 recovery, with individuals over 65 showing slightly higher odds of readmission.
Approximately 9% of hospitalized patients experience at least 1 hospital readmission (from any cause) within 2 months of COVID-19 recovery, with individuals over 65 showing slightly higher odds of readmission.
Between 16% and 76% of cases are asymptomatic throughout the course of their infection, though changing symptom definitions make it difficult to compare asymptomatic fractions through time.
Between 16% and 76% of cases are asymptomatic throughout the course of their infection, though changing symptom definitions make it difficult to compare asymptomatic fractions through time.
Between 16% and 76% of cases are asymptomatic throughout the course of their infection, though changing symptom definitions make it difficult to compare asymptomatic fractions through time.
Between 16% and 76% of cases are asymptomatic throughout the course of their infection, though changing symptom definitions make it difficult to compare asymptomatic fractions through time.
Between 16% and 76% of cases are asymptomatic throughout the course of their infection, though changing symptom definitions make it difficult to compare asymptomatic fractions through time.
Between 16% and 76% of cases are asymptomatic throughout the course of their infection, though changing symptom definitions make it difficult to compare asymptomatic fractions through time.
Between 16% and 76% of cases are asymptomatic throughout the course of their infection, though changing symptom definitions make it difficult to compare asymptomatic fractions through time.
Between 16% and 76% of cases are asymptomatic throughout the course of their infection, though changing symptom definitions make it difficult to compare asymptomatic fractions through time.
Between 16% and 76% of cases are asymptomatic throughout the course of their infection, though changing symptom definitions make it difficult to compare asymptomatic fractions through time.
Between 16% and 76% of cases are asymptomatic throughout the course of their infection, though changing symptom definitions make it difficult to compare asymptomatic fractions through time.
The case fatality rate (CFR) is unknown, but adults >60 and those with comorbidities are at elevated risk of death.
The case fatality rate (CFR) is unknown, but adults >60 and those with comorbidities are at elevated risk of death.
The case fatality rate (CFR) is unknown, but adults >60 and those with comorbidities are at elevated risk of death.
The case fatality rate (CFR) is unknown, but adults >60 and those with comorbidities are at elevated risk of death.
The case fatality rate (CFR) is unknown, but adults >60 and those with comorbidities are at elevated risk of death.
The case fatality rate (CFR) is unknown, but adults >60 and those with comorbidities are at elevated risk of death.
The case fatality rate (CFR) is unknown, but adults >60 and those with comorbidities are at elevated risk of death.
The case fatality rate (CFR) is unknown, but adults >60 and those with comorbidities are at elevated risk of death.
The case fatality rate (CFR) is unknown, but adults >60 and those with comorbidities are at elevated risk of death.
The case fatality rate (CFR) is unknown, but adults >60 and those with comorbidities are at elevated risk of death.
Cardiovascular disease, obesity, hypertension, diabetes, cancer, down syndrome, and respiratory conditions all increase the CFR.
Cardiovascular disease, obesity, hypertension, diabetes, cancer, down syndrome, and respiratory conditions all increase the CFR.
Cardiovascular disease, obesity, hypertension, diabetes, cancer, down syndrome, and respiratory conditions all increase the CFR.
Cardiovascular disease, obesity, hypertension, diabetes, cancer, down syndrome, and respiratory conditions all increase the CFR.
Cardiovascular disease, obesity, hypertension, diabetes, cancer, down syndrome, and respiratory conditions all increase the CFR.
Cardiovascular disease, obesity, hypertension, diabetes, cancer, down syndrome, and respiratory conditions all increase the CFR.
Cardiovascular disease, obesity, hypertension, diabetes, cancer, down syndrome, and respiratory conditions all increase the CFR.
Cardiovascular disease, obesity, hypertension, diabetes, cancer, down syndrome, and respiratory conditions all increase the CFR.
Cardiovascular disease, obesity, hypertension, diabetes, cancer, down syndrome, and respiratory conditions all increase the CFR.
Cardiovascular disease, obesity, hypertension, diabetes, cancer, down syndrome, and respiratory conditions all increase the CFR.
Prior kidney disease may increase disease severity, though age may be the dominant factor.
Prior kidney disease may increase disease severity, though age may be the dominant factor.
Prior kidney disease may increase disease severity, though age may be the dominant factor.
Prior kidney disease may increase disease severity, though age may be the dominant factor.
Prior kidney disease may increase disease severity, though age may be the dominant factor.
Prior kidney disease may increase disease severity, though age may be the dominant factor.
Prior kidney disease may increase disease severity, though age may be the dominant factor.
Prior kidney disease may increase disease severity, though age may be the dominant factor.
Prior kidney disease may increase disease severity, though age may be the dominant factor.
Prior kidney disease may increase disease severity, though age may be the dominant factor.
In Iceland, the overall CFR has been estimated at 0.3-0.6% but increases to ~4% in those over 70 years old.
In Iceland, the overall CFR has been estimated at 0.3-0.6% but increases to ~4% in those over 70 years old.
In Iceland, the overall CFR has been estimated at 0.3-0.6% but increases to ~4% in those over 70 years old.
In Iceland, the overall CFR has been estimated at 0.3-0.6% but increases to ~4% in those over 70 years old.
In Iceland, the overall CFR has been estimated at 0.3-0.6% but increases to ~4% in those over 70 years old.
In Iceland, the overall CFR has been estimated at 0.3-0.6% but increases to ~4% in those over 70 years old.
In Iceland, the overall CFR has been estimated at 0.3-0.6% but increases to ~4% in those over 70 years old.
In Iceland, the overall CFR has been estimated at 0.3-0.6% but increases to ~4% in those over 70 years old.
In Iceland, the overall CFR has been estimated at 0.3-0.6% but increases to ~4% in those over 70 years old.
In Iceland, the overall CFR has been estimated at 0.3-0.6% but increases to ~4% in those over 70 years old.
An estimated overall infection fatality rate for Indiana was calculated as 0.26%, increasing to 1.71% for those >65 years old.
An estimated overall infection fatality rate for Indiana was calculated as 0.26%, increasing to 1.71% for those >65 years old.
An estimated overall infection fatality rate for Indiana was calculated as 0.26%, increasing to 1.71% for those >65 years old.
An estimated overall infection fatality rate for Indiana was calculated as 0.26%, increasing to 1.71% for those >65 years old.
An estimated overall infection fatality rate for Indiana was calculated as 0.26%, increasing to 1.71% for those >65 years old.
An estimated overall infection fatality rate for Indiana was calculated as 0.26%, increasing to 1.71% for those >65 years old.
An estimated overall infection fatality rate for Indiana was calculated as 0.26%, increasing to 1.71% for those >65 years old.
An estimated overall infection fatality rate for Indiana was calculated as 0.26%, increasing to 1.71% for those >65 years old.
An estimated overall infection fatality rate for Indiana was calculated as 0.26%, increasing to 1.71% for those >65 years old.
An estimated overall infection fatality rate for Indiana was calculated as 0.26%, increasing to 1.71% for those >65 years old.
Minority populations and essential workers are disproportionately affected by COVID-19.
Minority populations and essential workers are disproportionately affected by COVID-19.
Minority populations and essential workers are disproportionately affected by COVID-19.
Minority populations and essential workers are disproportionately affected by COVID-19.
Minority populations and essential workers are disproportionately affected by COVID-19.
Minority populations and essential workers are disproportionately affected by COVID-19.
Minority populations and essential workers are disproportionately affected by COVID-19.
Minority populations and essential workers are disproportionately affected by COVID-19.
Minority populations and essential workers are disproportionately affected by COVID-19.
Minority populations and essential workers are disproportionately affected by COVID-19.
Black, Asian, and Minority Ethnic populations, including children, acquire SARS-CoV-2 infection at higher rates than other groups and are hospitalized and die disproportionately.
Black, Asian, and Minority Ethnic populations, including children, acquire SARS-CoV-2 infection at higher rates than other groups and are hospitalized and die disproportionately.
Black, Asian, and Minority Ethnic populations, including children, acquire SARS-CoV-2 infection at higher rates than other groups and are hospitalized and die disproportionately.
Black, Asian, and Minority Ethnic populations, including children, acquire SARS-CoV-2 infection at higher rates than other groups and are hospitalized and die disproportionately.
Black, Asian, and Minority Ethnic populations, including children, acquire SARS-CoV-2 infection at higher rates than other groups and are hospitalized and die disproportionately.
Black, Asian, and Minority Ethnic populations, including children, acquire SARS-CoV-2 infection at higher rates than other groups and are hospitalized and die disproportionately.
Black, Asian, and Minority Ethnic populations, including children, acquire SARS-CoV-2 infection at higher rates than other groups and are hospitalized and die disproportionately.
Black, Asian, and Minority Ethnic populations, including children, acquire SARS-CoV-2 infection at higher rates than other groups and are hospitalized and die disproportionately.
Black, Asian, and Minority Ethnic populations, including children, acquire SARS-CoV-2 infection at higher rates than other groups and are hospitalized and die disproportionately.
Black, Asian, and Minority Ethnic populations, including children, acquire SARS-CoV-2 infection at higher rates than other groups and are hospitalized and die disproportionately.
Hispanic and Black COVID-19 patients tend to die at younger ages than white patients.
Hispanic and Black COVID-19 patients tend to die at younger ages than white patients.
Hispanic and Black COVID-19 patients tend to die at younger ages than white patients.
Hispanic and Black COVID-19 patients tend to die at younger ages than white patients.
Hispanic and Black COVID-19 patients tend to die at younger ages than white patients.
Hispanic and Black COVID-19 patients tend to die at younger ages than white patients.
Hispanic and Black COVID-19 patients tend to die at younger ages than white patients.
Hispanic and Black COVID-19 patients tend to die at younger ages than white patients.
Hispanic and Black COVID-19 patients tend to die at younger ages than white patients.
Hispanic and Black COVID-19 patients tend to die at younger ages than white patients.
Hispanic, Black, and American Indian children accounted for 78% of early US pediatric deaths (n=121).
Hispanic, Black, and American Indian children accounted for 78% of early US pediatric deaths (n=121).
Hispanic, Black, and American Indian children accounted for 78% of early US pediatric deaths (n=121).
Hispanic, Black, and American Indian children accounted for 78% of early US pediatric deaths (n=121).
Hispanic, Black, and American Indian children accounted for 78% of early US pediatric deaths (n=121).
Hispanic, Black, and American Indian children accounted for 78% of early US pediatric deaths (n=121).
Hispanic, Black, and American Indian children accounted for 78% of early US pediatric deaths (n=121).
Hispanic, Black, and American Indian children accounted for 78% of early US pediatric deaths (n=121).
Hispanic, Black, and American Indian children accounted for 78% of early US pediatric deaths (n=121).
Hispanic, Black, and American Indian children accounted for 78% of early US pediatric deaths (n=121).
Social vulnerability is associated with greater SARS-CoV-2 transmission risk.
Social vulnerability is associated with greater SARS-CoV-2 transmission risk.
Social vulnerability is associated with greater SARS-CoV-2 transmission risk.
Social vulnerability is associated with greater SARS-CoV-2 transmission risk.
Social vulnerability is associated with greater SARS-CoV-2 transmission risk.
Social vulnerability is associated with greater SARS-CoV-2 transmission risk.
Social vulnerability is associated with greater SARS-CoV-2 transmission risk.
Social vulnerability is associated with greater SARS-CoV-2 transmission risk.
Social vulnerability is associated with greater SARS-CoV-2 transmission risk.
Social vulnerability is associated with greater SARS-CoV-2 transmission risk.
Pregnant women with COVID-19 require ICU care at similar rates as non-pregnant women and are less likely to present with fever and myalgia, but have higher rates of preterm delivery.
Pregnant women with COVID-19 require ICU care at similar rates as non-pregnant women and are less likely to present with fever and myalgia, but have higher rates of preterm delivery.
Pregnant women with COVID-19 require ICU care at similar rates as non-pregnant women and are less likely to present with fever and myalgia, but have higher rates of preterm delivery.
Pregnant women with COVID-19 require ICU care at similar rates as non-pregnant women and are less likely to present with fever and myalgia, but have higher rates of preterm delivery.
Pregnant women with COVID-19 require ICU care at similar rates as non-pregnant women and are less likely to present with fever and myalgia, but have higher rates of preterm delivery.
Pregnant women with COVID-19 require ICU care at similar rates as non-pregnant women and are less likely to present with fever and myalgia, but have higher rates of preterm delivery.
Pregnant women with COVID-19 require ICU care at similar rates as non-pregnant women and are less likely to present with fever and myalgia, but have higher rates of preterm delivery.
Pregnant women with COVID-19 require ICU care at similar rates as non-pregnant women and are less likely to present with fever and myalgia, but have higher rates of preterm delivery.
Pregnant women with COVID-19 require ICU care at similar rates as non-pregnant women and are less likely to present with fever and myalgia, but have higher rates of preterm delivery.
Pregnant women with COVID-19 require ICU care at similar rates as non-pregnant women and are less likely to present with fever and myalgia, but have higher rates of preterm delivery.
Severity in pregnant women may be associated with underlying conditions such as obesity, and symptom severity may be predicted early.
Severity in pregnant women may be associated with underlying conditions such as obesity, and symptom severity may be predicted early.
Severity in pregnant women may be associated with underlying conditions such as obesity, and symptom severity may be predicted early.
Severity in pregnant women may be associated with underlying conditions such as obesity, and symptom severity may be predicted early.
Severity in pregnant women may be associated with underlying conditions such as obesity, and symptom severity may be predicted early.
Severity in pregnant women may be associated with underlying conditions such as obesity, and symptom severity may be predicted early.
Severity in pregnant women may be associated with underlying conditions such as obesity, and symptom severity may be predicted early.
Severity in pregnant women may be associated with underlying conditions such as obesity, and symptom severity may be predicted early.
Severity in pregnant women may be associated with underlying conditions such as obesity, and symptom severity may be predicted early.
Severity in pregnant women may be associated with underlying conditions such as obesity, and symptom severity may be predicted early.
Preterm births are more likely in symptomatic patients.
Preterm births are more likely in symptomatic patients.
Preterm births are more likely in symptomatic patients.
Preterm births are more likely in symptomatic patients.
Preterm births are more likely in symptomatic patients.
Approximately 25% of pregnant COVID-19 patients had symptoms for at least 8 weeks.
Approximately 25% of pregnant COVID-19 patients had symptoms for at least 8 weeks.
Approximately 25% of pregnant COVID-19 patients had symptoms for at least 8 weeks.
Approximately 25% of pregnant COVID-19 patients had symptoms for at least 8 weeks.
Approximately 25% of pregnant COVID-19 patients had symptoms for at least 8 weeks.
Approximately 25% of pregnant COVID-19 patients had symptoms for at least 8 weeks.
Approximately 25% of pregnant COVID-19 patients had symptoms for at least 8 weeks.
Approximately 25% of pregnant COVID-19 patients had symptoms for at least 8 weeks.
Approximately 25% of pregnant COVID-19 patients had symptoms for at least 8 weeks.
Approximately 25% of pregnant COVID-19 patients had symptoms for at least 8 weeks.
In the UK, healthcare workers are >7 times more likely to develop severe COVID-19 than non-essential employees.
In the UK, healthcare workers are >7 times more likely to develop severe COVID-19 than non-essential employees.
In the UK, healthcare workers are >7 times more likely to develop severe COVID-19 than non-essential employees.
In the UK, healthcare workers are >7 times more likely to develop severe COVID-19 than non-essential employees.
In the UK, healthcare workers are >7 times more likely to develop severe COVID-19 than non-essential employees.
In the UK, healthcare workers are >7 times more likely to develop severe COVID-19 than non-essential employees.
In the UK, healthcare workers are >7 times more likely to develop severe COVID-19 than non-essential employees.
In the UK, healthcare workers are >7 times more likely to develop severe COVID-19 than non-essential employees.
In the UK, healthcare workers are >7 times more likely to develop severe COVID-19 than non-essential employees.
In the UK, healthcare workers are >7 times more likely to develop severe COVID-19 than non-essential employees.
Children are susceptible to COVID-19, though generally show milder or no symptoms.
Children are susceptible to COVID-19, though generally show milder or no symptoms.
Children are susceptible to COVID-19, though generally show milder or no symptoms.
Children are susceptible to COVID-19, though generally show milder or no symptoms.
Children are susceptible to COVID-19, though generally show milder or no symptoms.
Children are susceptible to COVID-19, though generally show milder or no symptoms.
Children are susceptible to COVID-19, though generally show milder or no symptoms.
Children are susceptible to COVID-19, though generally show milder or no symptoms.
Children are susceptible to COVID-19, though generally show milder or no symptoms.
Children are susceptible to COVID-19, though generally show milder or no symptoms.
21% to 28% of children (<19 years old) may be asymptomatic.
21% to 28% of children (<19 years old) may be asymptomatic.
21% to 28% of children (<19 years old) may be asymptomatic.
21% to 28% of children (<19 years old) may be asymptomatic.
21% to 28% of children (<19 years old) may be asymptomatic.
21% to 28% of children (<19 years old) may be asymptomatic.
21% to 28% of children (<19 years old) may be asymptomatic.
21% to 28% of children (<19 years old) may be asymptomatic.
21% to 28% of children (<19 years old) may be asymptomatic.
21% to 28% of children (<19 years old) may be asymptomatic.
Most symptomatic children show mild or moderate symptoms.
Most symptomatic children show mild or moderate symptoms.
Most symptomatic children show mild or moderate symptoms.
Most symptomatic children show mild or moderate symptoms.
Most symptomatic children show mild or moderate symptoms.
Most symptomatic children show mild or moderate symptoms.
Most symptomatic children show mild or moderate symptoms.
Most symptomatic children show mild or moderate symptoms.
Most symptomatic children show mild or moderate symptoms.
Most symptomatic children show mild or moderate symptoms.
Severe symptoms in children and infants are more likely in those with complex medical histories.
Severe symptoms in children and infants are more likely in those with complex medical histories.
Severe symptoms in children and infants are more likely in those with complex medical histories.
Severe symptoms in children and infants are more likely in those with complex medical histories.
Severe symptoms in children and infants are more likely in those with complex medical histories.
Severe symptoms in children and infants are more likely in those with complex medical histories.
Severe symptoms in children and infants are more likely in those with complex medical histories.
Severe symptoms in children and infants are more likely in those with complex medical histories.
Severe symptoms in children and infants are more likely in those with complex medical histories.
Severe symptoms in children and infants are more likely in those with complex medical histories.
WHO and US CDC have identified a rare condition in children (Pediatric Multi-System Inflammatory Syndrome, MIS-C) linked to COVID-19 infection.
WHO and US CDC have identified a rare condition in children (Pediatric Multi-System Inflammatory Syndrome, MIS-C) linked to COVID-19 infection.
WHO and US CDC have identified a rare condition in children (Pediatric Multi-System Inflammatory Syndrome, MIS-C) linked to COVID-19 infection.
WHO and US CDC have identified a rare condition in children (Pediatric Multi-System Inflammatory Syndrome, MIS-C) linked to COVID-19 infection.
WHO and US CDC have identified a rare condition in children (Pediatric Multi-System Inflammatory Syndrome, MIS-C) linked to COVID-19 infection.
WHO and US CDC have identified a rare condition in children (Pediatric Multi-System Inflammatory Syndrome, MIS-C) linked to COVID-19 infection.
WHO and US CDC have identified a rare condition in children (Pediatric Multi-System Inflammatory Syndrome, MIS-C) linked to COVID-19 infection.
WHO and US CDC have identified a rare condition in children (Pediatric Multi-System Inflammatory Syndrome, MIS-C) linked to COVID-19 infection.
WHO and US CDC have identified a rare condition in children (Pediatric Multi-System Inflammatory Syndrome, MIS-C) linked to COVID-19 infection.
WHO and US CDC have identified a rare condition in children (Pediatric Multi-System Inflammatory Syndrome, MIS-C) linked to COVID-19 infection.
The prevalence of Pediatric Multi-System Inflammatory Syndrome MIS-Cis unknown.
The prevalence of Pediatric Multi-System Inflammatory Syndrome MIS-Cis unknown.
The prevalence of Pediatric Multi-System Inflammatory Syndrome MIS-Cis unknown.
The prevalence of Pediatric Multi-System Inflammatory Syndrome MIS-Cis unknown.
The prevalence of Pediatric Multi-System Inflammatory Syndrome MIS-Cis unknown.
The prevalence of Pediatric Multi-System Inflammatory Syndrome MIS-Cis unknown.
The prevalence of Pediatric Multi-System Inflammatory Syndrome MIS-Cis unknown.
The prevalence of Pediatric Multi-System Inflammatory Syndrome MIS-Cis unknown.
The prevalence of Pediatric Multi-System Inflammatory Syndrome MIS-Cis unknown.
The prevalence of Pediatric Multi-System Inflammatory Syndrome MIS-Cis unknown.
Children with both severe and moderate initial symptoms can progress to MIS-C.
Children with both severe and moderate initial symptoms can progress to MIS-C.
Children with both severe and moderate initial symptoms can progress to MIS-C.
Children with both severe and moderate initial symptoms can progress to MIS-C.
Children with both severe and moderate initial symptoms can progress to MIS-C.
Children with both severe and moderate initial symptoms can progress to MIS-C.
Children with both severe and moderate initial symptoms can progress to MIS-C.
Children with both severe and moderate initial symptoms can progress to MIS-C.
Children with both severe and moderate initial symptoms can progress to MIS-C.
Children with both severe and moderate initial symptoms can progress to MIS-C.
Black children are overrepresented among MIS-C patients.
Black children are overrepresented among MIS-C patients.
Black children are overrepresented among MIS-C patients.
Black children are overrepresented among MIS-C patients.
Black children are overrepresented among MIS-C patients.
Black children are overrepresented among MIS-C patients.
Black children are overrepresented among MIS-C patients.
Black children are overrepresented among MIS-C patients.
Black children are overrepresented among MIS-C patients.
Black children are overrepresented among MIS-C patients.
Infected patients show productive immune responses, but the duration of any protection is unknown.
Infected patients show productive immune responses, but the duration of any protection is unknown.
Infected patients show productive immune responses, but the duration of any protection is unknown.
Infected patients show productive immune responses, but the duration of any protection is unknown.
Infected patients show productive immune responses, but the duration of any protection is unknown.
Infected patients show productive immune responses, but the duration of any protection is unknown.
Infected patients show productive immune responses, but the duration of any protection is unknown.
Infected patients show productive immune responses, but the duration of any protection is unknown.
Infected patients show productive immune responses, but the duration of any protection is unknown.
Infected patients show productive immune responses, but the duration of any protection is unknown.
The longevity of antibody responses and T-cell responses is unknown but appears to be at least several months.
The longevity of antibody responses and T-cell responses is unknown but appears to be at least several months.
The longevity of antibody responses and T-cell responses is unknown but appears to be at least several months.
The longevity of antibody responses and T-cell responses is unknown but appears to be at least several months.
The longevity of antibody responses and T-cell responses is unknown but appears to be at least several months.
The longevity of antibody responses and T-cell responses is unknown but appears to be at least several months.
The longevity of antibody responses and T-cell responses is unknown but appears to be at least several months.
The longevity of antibody responses and T-cell responses is unknown but appears to be at least several months.
The longevity of antibody responses and T-cell responses is unknown but appears to be at least several months.
The longevity of antibody responses and T-cell responses is unknown but appears to be at least several months.
In a study of healthcare workers in the UK, those with SARS-CoV-2 antibodies from prior exposure (n=1,167) were protected from reinfection for a median of 127 days (no symptomatic reinfection, 3 subsequent positive PCR tests).
In a study of healthcare workers in the UK, those with SARS-CoV-2 antibodies from prior exposure (n=1,167) were protected from reinfection for a median of 127 days (no symptomatic reinfection, 3 subsequent positive PCR tests).
In a study of healthcare workers in the UK, those with SARS-CoV-2 antibodies from prior exposure (n=1,167) were protected from reinfection for a median of 127 days (no symptomatic reinfection, 3 subsequent positive PCR tests).
In a study of healthcare workers in the UK, those with SARS-CoV-2 antibodies from prior exposure (n=1,167) were protected from reinfection for a median of 127 days (no symptomatic reinfection, 3 subsequent positive PCR tests).
In a study of healthcare workers in the UK, those with SARS-CoV-2 antibodies from prior exposure (n=1,167) were protected from reinfection for a median of 127 days (no symptomatic reinfection, 3 subsequent positive PCR tests).
In a study of healthcare workers in the UK, those with SARS-CoV-2 antibodies from prior exposure (n=1,167) were protected from reinfection for a median of 127 days (no symptomatic reinfection, 3 subsequent positive PCR tests).
In a study of healthcare workers in the UK, those with SARS-CoV-2 antibodies from prior exposure (n=1,167) were protected from reinfection for a median of 127 days (no symptomatic reinfection, 3 subsequent positive PCR tests).
In a study of healthcare workers in the UK, those with SARS-CoV-2 antibodies from prior exposure (n=1,167) were protected from reinfection for a median of 127 days (no symptomatic reinfection, 3 subsequent positive PCR tests).
In a study of healthcare workers in the UK, those with SARS-CoV-2 antibodies from prior exposure (n=1,167) were protected from reinfection for a median of 127 days (no symptomatic reinfection, 3 subsequent positive PCR tests).
In a study of healthcare workers in the UK, those with SARS-CoV-2 antibodies from prior exposure (n=1,167) were protected from reinfection for a median of 127 days (no symptomatic reinfection, 3 subsequent positive PCR tests).
Researchers have found SARS-CoV-2 antibodies circulating in patients for 3-6 months after infection.
Researchers have found SARS-CoV-2 antibodies circulating in patients for 3-6 months after infection.
Researchers have found SARS-CoV-2 antibodies circulating in patients for 3-6 months after infection.
Researchers have found SARS-CoV-2 antibodies circulating in patients for 3-6 months after infection.
Researchers have found SARS-CoV-2 antibodies circulating in patients for 3-6 months after infection.
Researchers have found SARS-CoV-2 antibodies circulating in patients for 3-6 months after infection.
Researchers have found SARS-CoV-2 antibodies circulating in patients for 3-6 months after infection.
Researchers have found SARS-CoV-2 antibodies circulating in patients for 3-6 months after infection.
Researchers have found SARS-CoV-2 antibodies circulating in patients for 3-6 months after infection.
Researchers have found SARS-CoV-2 antibodies circulating in patients for 3-6 months after infection.
Mild COVID-19 infections can induce detectable immune responses for at least 3 months.
Mild COVID-19 infections can induce detectable immune responses for at least 3 months.
Mild COVID-19 infections can induce detectable immune responses for at least 3 months.
Mild COVID-19 infections can induce detectable immune responses for at least 3 months.
Mild COVID-19 infections can induce detectable immune responses for at least 3 months.
Mild COVID-19 infections can induce detectable immune responses for at least 3 months.
Mild COVID-19 infections can induce detectable immune responses for at least 3 months.
Mild COVID-19 infections can induce detectable immune responses for at least 3 months.
Mild COVID-19 infections can induce detectable immune responses for at least 3 months.
Mild COVID-19 infections can induce detectable immune responses for at least 3 months.
Antibody levels increase with disease severity and are largely unaffected by patient age.
Antibody levels increase with disease severity and are largely unaffected by patient age.
Antibody levels increase with disease severity and are largely unaffected by patient age.
Antibody levels increase with disease severity and are largely unaffected by patient age.
Antibody levels increase with disease severity and are largely unaffected by patient age.
Antibody levels increase with disease severity and are largely unaffected by patient age.
Antibody levels increase with disease severity and are largely unaffected by patient age.
Antibody levels increase with disease severity and are largely unaffected by patient age.
Antibody levels increase with disease severity and are largely unaffected by patient age.
Antibody levels increase with disease severity and are largely unaffected by patient age.
A UK study found evidence of antibody levels waning after 4-6 months, though the study looked at population-level seroprevalence and not individual antibody levels.
A UK study found evidence of antibody levels waning after 4-6 months, though the study looked at population-level seroprevalence and not individual antibody levels.
A UK study found evidence of antibody levels waning after 4-6 months, though the study looked at population-level seroprevalence and not individual antibody levels.
A UK study found evidence of antibody levels waning after 4-6 months, though the study looked at population-level seroprevalence and not individual antibody levels.
A UK study found evidence of antibody levels waning after 4-6 months, though the study looked at population-level seroprevalence and not individual antibody levels.
A UK study found evidence of antibody levels waning after 4-6 months, though the study looked at population-level seroprevalence and not individual antibody levels.
A UK study found evidence of antibody levels waning after 4-6 months, though the study looked at population-level seroprevalence and not individual antibody levels.
A UK study found evidence of antibody levels waning after 4-6 months, though the study looked at population-level seroprevalence and not individual antibody levels.
A UK study found evidence of antibody levels waning after 4-6 months, though the study looked at population-level seroprevalence and not individual antibody levels.
A UK study found evidence of antibody levels waning after 4-6 months, though the study looked at population-level seroprevalence and not individual antibody levels.
Neutralizing antibody responses are present within 8-19 days after symptom onset and can persist for months.
Neutralizing antibody responses are present within 8-19 days after symptom onset and can persist for months.
Neutralizing antibody responses are present within 8-19 days after symptom onset and can persist for months.
Neutralizing antibody responses are present within 8-19 days after symptom onset and can persist for months.
Neutralizing antibody responses are present within 8-19 days after symptom onset and can persist for months.
Neutralizing antibody responses are present within 8-19 days after symptom onset and can persist for months.
Neutralizing antibody responses are present within 8-19 days after symptom onset and can persist for months.
Neutralizing antibody responses are present within 8-19 days after symptom onset and can persist for months.
Neutralizing antibody responses are present within 8-19 days after symptom onset and can persist for months.
Neutralizing antibody responses are present within 8-19 days after symptom onset and can persist for months.
Individuals with more severe infections developed higher neutralizing antibody levels that persisted longer than those with asymptomatic or mild infections.
Individuals with more severe infections developed higher neutralizing antibody levels that persisted longer than those with asymptomatic or mild infections.
Individuals with more severe infections developed higher neutralizing antibody levels that persisted longer than those with asymptomatic or mild infections.
Individuals with more severe infections developed higher neutralizing antibody levels that persisted longer than those with asymptomatic or mild infections.
Individuals with more severe infections developed higher neutralizing antibody levels that persisted longer than those with asymptomatic or mild infections.
Individuals with more severe infections developed higher neutralizing antibody levels that persisted longer than those with asymptomatic or mild infections.
Individuals with more severe infections developed higher neutralizing antibody levels that persisted longer than those with asymptomatic or mild infections.
Individuals with more severe infections developed higher neutralizing antibody levels that persisted longer than those with asymptomatic or mild infections.
Individuals with more severe infections developed higher neutralizing antibody levels that persisted longer than those with asymptomatic or mild infections.
Individuals with more severe infections developed higher neutralizing antibody levels that persisted longer than those with asymptomatic or mild infections.
The antibody IgM appears to contribute substantially to SARS-CoV-2 neutralizing ability, with IgG also contributing to a lesser extent.
The antibody IgM appears to contribute substantially to SARS-CoV-2 neutralizing ability, with IgG also contributing to a lesser extent.
The antibody IgM appears to contribute substantially to SARS-CoV-2 neutralizing ability, with IgG also contributing to a lesser extent.
The antibody IgM appears to contribute substantially to SARS-CoV-2 neutralizing ability, with IgG also contributing to a lesser extent.
The antibody IgM appears to contribute substantially to SARS-CoV-2 neutralizing ability, with IgG also contributing to a lesser extent.
The antibody IgM appears to contribute substantially to SARS-CoV-2 neutralizing ability, with IgG also contributing to a lesser extent.
The antibody IgM appears to contribute substantially to SARS-CoV-2 neutralizing ability, with IgG also contributing to a lesser extent.
The antibody IgM appears to contribute substantially to SARS-CoV-2 neutralizing ability, with IgG also contributing to a lesser extent.
The antibody IgM appears to contribute substantially to SARS-CoV-2 neutralizing ability, with IgG also contributing to a lesser extent.
The antibody IgM appears to contribute substantially to SARS-CoV-2 neutralizing ability, with IgG also contributing to a lesser extent.
Asymptomatic cases generate weaker antibody responses to SARS-CoV-2.
Asymptomatic cases generate weaker antibody responses to SARS-CoV-2.
Asymptomatic cases generate weaker antibody responses to SARS-CoV-2.
Antibody levels declined in 156 healthcare workers who tested positive for SARS-CoV-2, with 28% dropping below detectable levels when tested after 60 days, suggesting caution in single time-point assays to detect prior SARS-CoV-2 infection.
Antibody levels declined in 156 healthcare workers who tested positive for SARS-CoV-2, with 28% dropping below detectable levels when tested after 60 days, suggesting caution in single time-point assays to detect prior SARS-CoV-2 infection.
Antibody levels declined in 156 healthcare workers who tested positive for SARS-CoV-2, with 28% dropping below detectable levels when tested after 60 days, suggesting caution in single time-point assays to detect prior SARS-CoV-2 infection.
Antibody levels declined in 156 healthcare workers who tested positive for SARS-CoV-2, with 28% dropping below detectable levels when tested after 60 days, suggesting caution in single time-point assays to detect prior SARS-CoV-2 infection.
Antibody levels declined in 156 healthcare workers who tested positive for SARS-CoV-2, with 28% dropping below detectable levels when tested after 60 days, suggesting caution in single time-point assays to detect prior SARS-CoV-2 infection.
Antibody levels declined in 156 healthcare workers who tested positive for SARS-CoV-2, with 28% dropping below detectable levels when tested after 60 days, suggesting caution in single time-point assays to detect prior SARS-CoV-2 infection.
Antibody levels declined in 156 healthcare workers who tested positive for SARS-CoV-2, with 28% dropping below detectable levels when tested after 60 days, suggesting caution in single time-point assays to detect prior SARS-CoV-2 infection.
Antibody levels declined in 156 healthcare workers who tested positive for SARS-CoV-2, with 28% dropping below detectable levels when tested after 60 days, suggesting caution in single time-point assays to detect prior SARS-CoV-2 infection.
Antibody levels declined in 156 healthcare workers who tested positive for SARS-CoV-2, with 28% dropping below detectable levels when tested after 60 days, suggesting caution in single time-point assays to detect prior SARS-CoV-2 infection.
Antibody levels declined in 156 healthcare workers who tested positive for SARS-CoV-2, with 28% dropping below detectable levels when tested after 60 days, suggesting caution in single time-point assays to detect prior SARS-CoV-2 infection.
Strong, early inflammatory immune responses are associated with more severe clinical presentation.
Strong, early inflammatory immune responses are associated with more severe clinical presentation.
Strong, early inflammatory immune responses are associated with more severe clinical presentation.
Strong, early inflammatory immune responses are associated with more severe clinical presentation.
Strong, early inflammatory immune responses are associated with more severe clinical presentation.
Strong, early inflammatory immune responses are associated with more severe clinical presentation.
Strong, early inflammatory immune responses are associated with more severe clinical presentation.
Strong, early inflammatory immune responses are associated with more severe clinical presentation.
Strong, early inflammatory immune responses are associated with more severe clinical presentation.
Strong, early inflammatory immune responses are associated with more severe clinical presentation.
There appear to be several distinct immunological phenotypes associated with COVID-19, with cytokine storm syndrome present in ~3-4% of patients.
There appear to be several distinct immunological phenotypes associated with COVID-19, with cytokine storm syndrome present in ~3-4% of patients.
There appear to be several distinct immunological phenotypes associated with COVID-19, with cytokine storm syndrome present in ~3-4% of patients.
There appear to be several distinct immunological phenotypes associated with COVID-19, with cytokine storm syndrome present in ~3-4% of patients.
There appear to be several distinct immunological phenotypes associated with COVID-19, with cytokine storm syndrome present in ~3-4% of patients.
There appear to be several distinct immunological phenotypes associated with COVID-19, with cytokine storm syndrome present in ~3-4% of patients.
There appear to be several distinct immunological phenotypes associated with COVID-19, with cytokine storm syndrome present in ~3-4% of patients.
There appear to be several distinct immunological phenotypes associated with COVID-19, with cytokine storm syndrome present in ~3-4% of patients.
There appear to be several distinct immunological phenotypes associated with COVID-19, with cytokine storm syndrome present in ~3-4% of patients.
There appear to be several distinct immunological phenotypes associated with COVID-19, with cytokine storm syndrome present in ~3-4% of patients.
A more common phenotype is characterized by a lack of Type I interferon response and general immunosuppression, which may help to explain variability in corticosteroid treatment effects.
A more common phenotype is characterized by a lack of Type I interferon response and general immunosuppression, which may help to explain variability in corticosteroid treatment effects.
A more common phenotype is characterized by a lack of Type I interferon response and general immunosuppression, which may help to explain variability in corticosteroid treatment effects.
A more common phenotype is characterized by a lack of Type I interferon response and general immunosuppression, which may help to explain variability in corticosteroid treatment effects.
A more common phenotype is characterized by a lack of Type I interferon response and general immunosuppression, which may help to explain variability in corticosteroid treatment effects.
A more common phenotype is characterized by a lack of Type I interferon response and general immunosuppression, which may help to explain variability in corticosteroid treatment effects.
A more common phenotype is characterized by a lack of Type I interferon response and general immunosuppression, which may help to explain variability in corticosteroid treatment effects.
A more common phenotype is characterized by a lack of Type I interferon response and general immunosuppression, which may help to explain variability in corticosteroid treatment effects.
A more common phenotype is characterized by a lack of Type I interferon response and general immunosuppression, which may help to explain variability in corticosteroid treatment effects.
A more common phenotype is characterized by a lack of Type I interferon response and general immunosuppression, which may help to explain variability in corticosteroid treatment effects.
SARS-CoV-2 specific memory B cells are involved in the human immune response, and provide evidence of B cell-mediated immunity after mild-moderate COVID-19 infection.
SARS-CoV-2 specific memory B cells are involved in the human immune response, and provide evidence of B cell-mediated immunity after mild-moderate COVID-19 infection.
SARS-CoV-2 specific memory B cells are involved in the human immune response, and provide evidence of B cell-mediated immunity after mild-moderate COVID-19 infection.
SARS-CoV-2 specific memory B cells are involved in the human immune response, and provide evidence of B cell-mediated immunity after mild-moderate COVID-19 infection.
SARS-CoV-2 specific memory B cells are involved in the human immune response, and provide evidence of B cell-mediated immunity after mild-moderate COVID-19 infection.
SARS-CoV-2 specific memory B cells are involved in the human immune response, and provide evidence of B cell-mediated immunity after mild-moderate COVID-19 infection.
SARS-CoV-2 specific memory B cells are involved in the human immune response, and provide evidence of B cell-mediated immunity after mild-moderate COVID-19 infection.
SARS-CoV-2 specific memory B cells are involved in the human immune response, and provide evidence of B cell-mediated immunity after mild-moderate COVID-19 infection.
SARS-CoV-2 specific memory B cells are involved in the human immune response, and provide evidence of B cell-mediated immunity after mild-moderate COVID-19 infection.
SARS-CoV-2 specific memory B cells are involved in the human immune response, and provide evidence of B cell-mediated immunity after mild-moderate COVID-19 infection.
T-cell responses may persist for at least 6 months, though they appear stronger in individuals with more severe COVID-19 cases.
T-cell responses may persist for at least 6 months, though they appear stronger in individuals with more severe COVID-19 cases.
T-cell responses may persist for at least 6 months, though they appear stronger in individuals with more severe COVID-19 cases.
T-cell responses may persist for at least 6 months, though they appear stronger in individuals with more severe COVID-19 cases.
T-cell responses may persist for at least 6 months, though they appear stronger in individuals with more severe COVID-19 cases.
T-cell responses may persist for at least 6 months, though they appear stronger in individuals with more severe COVID-19 cases.
T-cell responses may persist for at least 6 months, though they appear stronger in individuals with more severe COVID-19 cases.
T-cell responses may persist for at least 6 months, though they appear stronger in individuals with more severe COVID-19 cases.
T-cell responses may persist for at least 6 months, though they appear stronger in individuals with more severe COVID-19 cases.
T-cell responses may persist for at least 6 months, though they appear stronger in individuals with more severe COVID-19 cases.
Immune responses appear to differ between symptomatic and asymptomatic COVID-19 patients.
Immune responses appear to differ between symptomatic and asymptomatic COVID-19 patients.
Immune responses appear to differ between symptomatic and asymptomatic COVID-19 patients.
Immune responses appear to differ between symptomatic and asymptomatic COVID-19 patients.
Immune responses appear to differ between symptomatic and asymptomatic COVID-19 patients.
Immune responses appear to differ between symptomatic and asymptomatic COVID-19 patients.
Immune responses appear to differ between symptomatic and asymptomatic COVID-19 patients.
Immune responses appear to differ between symptomatic and asymptomatic COVID-19 patients.
Immune responses appear to differ between symptomatic and asymptomatic COVID-19 patients.
Immune responses appear to differ between symptomatic and asymptomatic COVID-19 patients.
asymptomatic patients appear to mount robust T-cell responses, express higher levels of interferon-gamma and interleukin-2, and have more coordinated production of pro-inflammatory and regulatory cytokines than symptomatic patients.
asymptomatic patients appear to mount robust T-cell responses, express higher levels of interferon-gamma and interleukin-2, and have more coordinated production of pro-inflammatory and regulatory cytokines than symptomatic patients.
asymptomatic patients appear to mount robust T-cell responses, express higher levels of interferon-gamma and interleukin-2, and have more coordinated production of pro-inflammatory and regulatory cytokines than symptomatic patients.
asymptomatic patients appear to mount robust T-cell responses, express higher levels of interferon-gamma and interleukin-2, and have more coordinated production of pro-inflammatory and regulatory cytokines than symptomatic patients.
asymptomatic patients appear to mount robust T-cell responses, express higher levels of interferon-gamma and interleukin-2, and have more coordinated production of pro-inflammatory and regulatory cytokines than symptomatic patients.
asymptomatic patients appear to mount robust T-cell responses, express higher levels of interferon-gamma and interleukin-2, and have more coordinated production of pro-inflammatory and regulatory cytokines than symptomatic patients.
asymptomatic patients appear to mount robust T-cell responses, express higher levels of interferon-gamma and interleukin-2, and have more coordinated production of pro-inflammatory and regulatory cytokines than symptomatic patients.
asymptomatic patients appear to mount robust T-cell responses, express higher levels of interferon-gamma and interleukin-2, and have more coordinated production of pro-inflammatory and regulatory cytokines than symptomatic patients.
asymptomatic patients appear to mount robust T-cell responses, express higher levels of interferon-gamma and interleukin-2, and have more coordinated production of pro-inflammatory and regulatory cytokines than symptomatic patients.
asymptomatic patients appear to mount robust T-cell responses, express higher levels of interferon-gamma and interleukin-2, and have more coordinated production of pro-inflammatory and regulatory cytokines than symptomatic patients.
In a 35-year study of 10 men, reinfection with seasonal coronaviruses occurred 1-3 years after initial infection.
In a 35-year study of 10 men, reinfection with seasonal coronaviruses occurred 1-3 years after initial infection.
In a 35-year study of 10 men, reinfection with seasonal coronaviruses occurred 1-3 years after initial infection.
In a 35-year study of 10 men, reinfection with seasonal coronaviruses occurred 1-3 years after initial infection.
In a 35-year study of 10 men, reinfection with seasonal coronaviruses occurred 1-3 years after initial infection.
In a 35-year study of 10 men, reinfection with seasonal coronaviruses occurred 1-3 years after initial infection.
In a 35-year study of 10 men, reinfection with seasonal coronaviruses occurred 1-3 years after initial infection.
In a 35-year study of 10 men, reinfection with seasonal coronaviruses occurred 1-3 years after initial infection.
In a 35-year study of 10 men, reinfection with seasonal coronaviruses occurred 1-3 years after initial infection.
In a 35-year study of 10 men, reinfection with seasonal coronaviruses occurred 1-3 years after initial infection.
Previous studies on coronavirus immunity suggest that neutralizing antibodies may wane after several years.
Previous studies on coronavirus immunity suggest that neutralizing antibodies may wane after several years.
Previous studies on coronavirus immunity suggest that neutralizing antibodies may wane after several years.
Previous studies on coronavirus immunity suggest that neutralizing antibodies may wane after several years.
Previous studies on coronavirus immunity suggest that neutralizing antibodies may wane after several years.
Previous studies on coronavirus immunity suggest that neutralizing antibodies may wane after several years.
Previous studies on coronavirus immunity suggest that neutralizing antibodies may wane after several years.
Previous studies on coronavirus immunity suggest that neutralizing antibodies may wane after several years.
Previous studies on coronavirus immunity suggest that neutralizing antibodies may wane after several years.
Previous studies on coronavirus immunity suggest that neutralizing antibodies may wane after several years.
Researchers in Hong Kong and the US have identified COVID-19 reinfections.
Researchers in Hong Kong and the US have identified COVID-19 reinfections.
Researchers in Hong Kong and the US have identified COVID-19 reinfections.
Researchers in Hong Kong and the US have identified COVID-19 reinfections.
Researchers in Hong Kong and the US have identified COVID-19 reinfections.
Researchers in Hong Kong and the US have identified COVID-19 reinfections.
Researchers in Hong Kong and the US have identified COVID-19 reinfections.
Researchers in Hong Kong and the US have identified COVID-19 reinfections.
Researchers in Hong Kong and the US have identified COVID-19 reinfections.
Researchers in Hong Kong and the US have identified COVID-19 reinfections.
Reinfections have been either less or more severe than the initial infection.
Reinfections have been either less or more severe than the initial infection.
Reinfections have been either less or more severe than the initial infection.
Reinfections have been either less or more severe than the initial infection.
Reinfections have been either less or more severe than the initial infection.
Reinfections have been either less or more severe than the initial infection.
Reinfections have been either less or more severe than the initial infection.
Reinfections have been either less or more severe than the initial infection.
Reinfections have been either less or more severe than the initial infection.
Reinfections have been either less or more severe than the initial infection.
Two studies suggest limited reinfection potential in macaques, with re-challenge 28 days or 35 days after initial exposure resulting in no clinical symptoms.
Two studies suggest limited reinfection potential in macaques, with re-challenge 28 days or 35 days after initial exposure resulting in no clinical symptoms.
Two studies suggest limited reinfection potential in macaques, with re-challenge 28 days or 35 days after initial exposure resulting in no clinical symptoms.
Two studies suggest limited reinfection potential in macaques, with re-challenge 28 days or 35 days after initial exposure resulting in no clinical symptoms.
Two studies suggest limited reinfection potential in macaques, with re-challenge 28 days or 35 days after initial exposure resulting in no clinical symptoms.
Two studies suggest limited reinfection potential in macaques, with re-challenge 28 days or 35 days after initial exposure resulting in no clinical symptoms.
Two studies suggest limited reinfection potential in macaques, with re-challenge 28 days or 35 days after initial exposure resulting in no clinical symptoms.
Two studies suggest limited reinfection potential in macaques, with re-challenge 28 days or 35 days after initial exposure resulting in no clinical symptoms.
Two studies suggest limited reinfection potential in macaques, with re-challenge 28 days or 35 days after initial exposure resulting in no clinical symptoms.
Two studies suggest limited reinfection potential in macaques, with re-challenge 28 days or 35 days after initial exposure resulting in no clinical symptoms.
Ferrets infected with 102-104 PFU were protected from acute lung injury following secondary challenge with SARS-CoV-2 28 days after initial exposure, but they did exhibit clinical symptoms.
Ferrets infected with 102-104 PFU were protected from acute lung injury following secondary challenge with SARS-CoV-2 28 days after initial exposure, but they did exhibit clinical symptoms.
Ferrets infected with 102-104 PFU were protected from acute lung injury following secondary challenge with SARS-CoV-2 28 days after initial exposure, but they did exhibit clinical symptoms.
Ferrets infected with 102-104 PFU were protected from acute lung injury following secondary challenge with SARS-CoV-2 28 days after initial exposure, but they did exhibit clinical symptoms.
Ferrets infected with 102-104 PFU were protected from acute lung injury following secondary challenge with SARS-CoV-2 28 days after initial exposure, but they did exhibit clinical symptoms.
Ferrets infected with 102-104 PFU were protected from acute lung injury following secondary challenge with SARS-CoV-2 28 days after initial exposure, but they did exhibit clinical symptoms.
Ferrets infected with 102-104 PFU were protected from acute lung injury following secondary challenge with SARS-CoV-2 28 days after initial exposure, but they did exhibit clinical symptoms.
Ferrets infected with 102-104 PFU were protected from acute lung injury following secondary challenge with SARS-CoV-2 28 days after initial exposure, but they did exhibit clinical symptoms.
Ferrets infected with 102-104 PFU were protected from acute lung injury following secondary challenge with SARS-CoV-2 28 days after initial exposure, but they did exhibit clinical symptoms.
Ferrets infected with 102-104 PFU were protected from acute lung injury following secondary challenge with SARS-CoV-2 28 days after initial exposure, but they did exhibit clinical symptoms.
The contribution of historical coronavirus exposure to SARS-CoV-2 immunity is unknown.
The contribution of historical coronavirus exposure to SARS-CoV-2 immunity is unknown.
The contribution of historical coronavirus exposure to SARS-CoV-2 immunity is unknown.
The contribution of historical coronavirus exposure to SARS-CoV-2 immunity is unknown.
The contribution of historical coronavirus exposure to SARS-CoV-2 immunity is unknown.
The contribution of historical coronavirus exposure to SARS-CoV-2 immunity is unknown.
The contribution of historical coronavirus exposure to SARS-CoV-2 immunity is unknown.
The contribution of historical coronavirus exposure to SARS-CoV-2 immunity is unknown.
The contribution of historical coronavirus exposure to SARS-CoV-2 immunity is unknown.
The contribution of historical coronavirus exposure to SARS-CoV-2 immunity is unknown.
Cross-reactivity in T-cell responses between other human coronaviruses and SARS-CoV-2 may explain some variation in symptom severity among patients.
Cross-reactivity in T-cell responses between other human coronaviruses and SARS-CoV-2 may explain some variation in symptom severity among patients.
Cross-reactivity in T-cell responses between other human coronaviruses and SARS-CoV-2 may explain some variation in symptom severity among patients.
Cross-reactivity in T-cell responses between other human coronaviruses and SARS-CoV-2 may explain some variation in symptom severity among patients.
Cross-reactivity in T-cell responses between other human coronaviruses and SARS-CoV-2 may explain some variation in symptom severity among patients.
Cross-reactivity in T-cell responses between other human coronaviruses and SARS-CoV-2 may explain some variation in symptom severity among patients.
Cross-reactivity in T-cell responses between other human coronaviruses and SARS-CoV-2 may explain some variation in symptom severity among patients.
Cross-reactivity in T-cell responses between other human coronaviruses and SARS-CoV-2 may explain some variation in symptom severity among patients.
Cross-reactivity in T-cell responses between other human coronaviruses and SARS-CoV-2 may explain some variation in symptom severity among patients.
Cross-reactivity in T-cell responses between other human coronaviruses and SARS-CoV-2 may explain some variation in symptom severity among patients.
Key components of the human immune response (memory B cells) are activated by SARS-CoV-2, and may persist for decades to offset any waning antibody immunity.
Key components of the human immune response (memory B cells) are activated by SARS-CoV-2, and may persist for decades to offset any waning antibody immunity.
Key components of the human immune response (memory B cells) are activated by SARS-CoV-2, and may persist for decades to offset any waning antibody immunity.
Key components of the human immune response (memory B cells) are activated by SARS-CoV-2, and may persist for decades to offset any waning antibody immunity.
Key components of the human immune response (memory B cells) are activated by SARS-CoV-2, and may persist for decades to offset any waning antibody immunity.
Key components of the human immune response (memory B cells) are activated by SARS-CoV-2, and may persist for decades to offset any waning antibody immunity.
Key components of the human immune response (memory B cells) are activated by SARS-CoV-2, and may persist for decades to offset any waning antibody immunity.
Key components of the human immune response (memory B cells) are activated by SARS-CoV-2, and may persist for decades to offset any waning antibody immunity.
Key components of the human immune response (memory B cells) are activated by SARS-CoV-2, and may persist for decades to offset any waning antibody immunity.
Key components of the human immune response (memory B cells) are activated by SARS-CoV-2, and may persist for decades to offset any waning antibody immunity.
Two studies identified key components of the adaptive immune system (CD4+ T cells) in the majority of recovered COVID-19 patients, and these cells reacted to SARS-CoV-2 Spike protein.
Two studies identified key components of the adaptive immune system (CD4+ T cells) in the majority of recovered COVID-19 patients, and these cells reacted to SARS-CoV-2 Spike protein.
Two studies identified key components of the adaptive immune system (CD4+ T cells) in the majority of recovered COVID-19 patients, and these cells reacted to SARS-CoV-2 Spike protein.
Two studies identified key components of the adaptive immune system (CD4+ T cells) in the majority of recovered COVID-19 patients, and these cells reacted to SARS-CoV-2 Spike protein.
Two studies identified key components of the adaptive immune system (CD4+ T cells) in the majority of recovered COVID-19 patients, and these cells reacted to SARS-CoV-2 Spike protein.
Two studies identified key components of the adaptive immune system (CD4+ T cells) in the majority of recovered COVID-19 patients, and these cells reacted to SARS-CoV-2 Spike protein.
Two studies identified key components of the adaptive immune system (CD4+ T cells) in the majority of recovered COVID-19 patients, and these cells reacted to SARS-CoV-2 Spike protein.
Two studies identified key components of the adaptive immune system (CD4+ T cells) in the majority of recovered COVID-19 patients, and these cells reacted to SARS-CoV-2 Spike protein.
Two studies identified key components of the adaptive immune system (CD4+ T cells) in the majority of recovered COVID-19 patients, and these cells reacted to SARS-CoV-2 Spike protein.
Two studies identified key components of the adaptive immune system (CD4+ T cells) in the majority of recovered COVID-19 patients, and these cells reacted to SARS-CoV-2 Spike protein.
These studies also identified Spike protein responses in CD4+ T cells of ~30-40% of unexposed patients, suggesting some cross-reactivity between other circulating human coronaviruses and SARS-CoV-2.
These studies also identified Spike protein responses in CD4+ T cells of ~30-40% of unexposed patients, suggesting some cross-reactivity between other circulating human coronaviruses and SARS-CoV-2.
These studies also identified Spike protein responses in CD4+ T cells of ~30-40% of unexposed patients, suggesting some cross-reactivity between other circulating human coronaviruses and SARS-CoV-2.
These studies also identified Spike protein responses in CD4+ T cells of ~30-40% of unexposed patients, suggesting some cross-reactivity between other circulating human coronaviruses and SARS-CoV-2.
These studies also identified Spike protein responses in CD4+ T cells of ~30-40% of unexposed patients, suggesting some cross-reactivity between other circulating human coronaviruses and SARS-CoV-2.
These studies also identified Spike protein responses in CD4+ T cells of ~30-40% of unexposed patients, suggesting some cross-reactivity between other circulating human coronaviruses and SARS-CoV-2.
These studies also identified Spike protein responses in CD4+ T cells of ~30-40% of unexposed patients, suggesting some cross-reactivity between other circulating human coronaviruses and SARS-CoV-2.
These studies also identified Spike protein responses in CD4+ T cells of ~30-40% of unexposed patients, suggesting some cross-reactivity between other circulating human coronaviruses and SARS-CoV-2.
These studies also identified Spike protein responses in CD4+ T cells of ~30-40% of unexposed patients, suggesting some cross-reactivity between other circulating human coronaviruses and SARS-CoV-2.
These studies also identified Spike protein responses in CD4+ T cells of ~30-40% of unexposed patients, suggesting some cross-reactivity between other circulating human coronaviruses and SARS-CoV-2.
Long-lasting T-cell responses have been seen in SARS-CoV-1 patients, and T-cell cross- reactivity between other coronaviruses and SARS-CoV-2 suggest additional immune protection.
Long-lasting T-cell responses have been seen in SARS-CoV-1 patients, and T-cell cross- reactivity between other coronaviruses and SARS-CoV-2 suggest additional immune protection.
Long-lasting T-cell responses have been seen in SARS-CoV-1 patients, and T-cell cross- reactivity between other coronaviruses and SARS-CoV-2 suggest additional immune protection.
Long-lasting T-cell responses have been seen in SARS-CoV-1 patients, and T-cell cross- reactivity between other coronaviruses and SARS-CoV-2 suggest additional immune protection.
Long-lasting T-cell responses have been seen in SARS-CoV-1 patients, and T-cell cross- reactivity between other coronaviruses and SARS-CoV-2 suggest additional immune protection.
Long-lasting T-cell responses have been seen in SARS-CoV-1 patients, and T-cell cross- reactivity between other coronaviruses and SARS-CoV-2 suggest additional immune protection.
Long-lasting T-cell responses have been seen in SARS-CoV-1 patients, and T-cell cross- reactivity between other coronaviruses and SARS-CoV-2 suggest additional immune protection.
Long-lasting T-cell responses have been seen in SARS-CoV-1 patients, and T-cell cross- reactivity between other coronaviruses and SARS-CoV-2 suggest additional immune protection.
Long-lasting T-cell responses have been seen in SARS-CoV-1 patients, and T-cell cross- reactivity between other coronaviruses and SARS-CoV-2 suggest additional immune protection.
Long-lasting T-cell responses have been seen in SARS-CoV-1 patients, and T-cell cross- reactivity between other coronaviruses and SARS-CoV-2 suggest additional immune protection.
Children do not appear to be protected from SARS-CoV-2 infection by historical exposure to seasonal coronaviruses.
Children do not appear to be protected from SARS-CoV-2 infection by historical exposure to seasonal coronaviruses.
Children do not appear to be protected from SARS-CoV-2 infection by historical exposure to seasonal coronaviruses.
Children do not appear to be protected from SARS-CoV-2 infection by historical exposure to seasonal coronaviruses.
Children do not appear to be protected from SARS-CoV-2 infection by historical exposure to seasonal coronaviruses.
Children do not appear to be protected from SARS-CoV-2 infection by historical exposure to seasonal coronaviruses.
Children do not appear to be protected from SARS-CoV-2 infection by historical exposure to seasonal coronaviruses.
Children do not appear to be protected from SARS-CoV-2 infection by historical exposure to seasonal coronaviruses.
Children do not appear to be protected from SARS-CoV-2 infection by historical exposure to seasonal coronaviruses.
Children do not appear to be protected from SARS-CoV-2 infection by historical exposure to seasonal coronaviruses.
Serum from patients exposed to seasonal coronaviruses did not neutralize SARS-CoV-2, though there has been some cross-reactivity between seasonal coronaviruses and SARS-CoV-2 nucleocapsid (N) protein.
Serum from patients exposed to seasonal coronaviruses did not neutralize SARS-CoV-2, though there has been some cross-reactivity between seasonal coronaviruses and SARS-CoV-2 nucleocapsid (N) protein.
Serum from patients exposed to seasonal coronaviruses did not neutralize SARS-CoV-2, though there has been some cross-reactivity between seasonal coronaviruses and SARS-CoV-2 nucleocapsid (N) protein.
Serum from patients exposed to seasonal coronaviruses did not neutralize SARS-CoV-2, though there has been some cross-reactivity between seasonal coronaviruses and SARS-CoV-2 nucleocapsid (N) protein.
Serum from patients exposed to seasonal coronaviruses did not neutralize SARS-CoV-2, though there has been some cross-reactivity between seasonal coronaviruses and SARS-CoV-2 nucleocapsid (N) protein.
Serum from patients exposed to seasonal coronaviruses did not neutralize SARS-CoV-2, though there has been some cross-reactivity between seasonal coronaviruses and SARS-CoV-2 nucleocapsid (N) protein.
Serum from patients exposed to seasonal coronaviruses did not neutralize SARS-CoV-2, though there has been some cross-reactivity between seasonal coronaviruses and SARS-CoV-2 nucleocapsid (N) protein.
Serum from patients exposed to seasonal coronaviruses did not neutralize SARS-CoV-2, though there has been some cross-reactivity between seasonal coronaviruses and SARS-CoV-2 nucleocapsid (N) protein.
Serum from patients exposed to seasonal coronaviruses did not neutralize SARS-CoV-2, though there has been some cross-reactivity between seasonal coronaviruses and SARS-CoV-2 nucleocapsid (N) protein.
Serum from patients exposed to seasonal coronaviruses did not neutralize SARS-CoV-2, though there has been some cross-reactivity between seasonal coronaviruses and SARS-CoV-2 nucleocapsid (N) protein.
Diagnosis of COVID-19 is based on symptoms consistent with COVID-19, PCR-based testing of active cases, and/or the presence of SARS-CoV-2 antibodies in individuals.
Diagnosis of COVID-19 is based on symptoms consistent with COVID-19, PCR-based testing of active cases, and/or the presence of SARS-CoV-2 antibodies in individuals.
Diagnosis of COVID-19 is based on symptoms consistent with COVID-19, PCR-based testing of active cases, and/or the presence of SARS-CoV-2 antibodies in individuals.
Diagnosis of COVID-19 is based on symptoms consistent with COVID-19, PCR-based testing of active cases, and/or the presence of SARS-CoV-2 antibodies in individuals.
Diagnosis of COVID-19 is based on symptoms consistent with COVID-19, PCR-based testing of active cases, and/or the presence of SARS-CoV-2 antibodies in individuals.
Diagnosis of COVID-19 is based on symptoms consistent with COVID-19, PCR-based testing of active cases, and/or the presence of SARS-CoV-2 antibodies in individuals.
Diagnosis of COVID-19 is based on symptoms consistent with COVID-19, PCR-based testing of active cases, and/or the presence of SARS-CoV-2 antibodies in individuals.
Diagnosis of COVID-19 is based on symptoms consistent with COVID-19, PCR-based testing of active cases, and/or the presence of SARS-CoV-2 antibodies in individuals.
Diagnosis of COVID-19 is based on symptoms consistent with COVID-19, PCR-based testing of active cases, and/or the presence of SARS-CoV-2 antibodies in individuals.
Diagnosis of COVID-19 is based on symptoms consistent with COVID-19, PCR-based testing of active cases, and/or the presence of SARS-CoV-2 antibodies in individuals.
Screening solely by temperature or other symptoms is unreliable.
Screening solely by temperature or other symptoms is unreliable.
Screening solely by temperature or other symptoms is unreliable.
Screening solely by temperature or other symptoms is unreliable.
Screening solely by temperature or other symptoms is unreliable.
Screening solely by temperature or other symptoms is unreliable.
Screening solely by temperature or other symptoms is unreliable.
Screening solely by temperature or other symptoms is unreliable.
Screening solely by temperature or other symptoms is unreliable.
Screening solely by temperature or other symptoms is unreliable.
As of 12/16/2020, the FDA has granted EUAs to 303 diagnostic tests, including 231 molecular, 62 antibody, and 10 antigen tests, which include one for detecting neutralizing antibodies from prior SARS-CoV-2 infection and at-home diagnostic assays for SARS-CoV-2 infection.
As of 12/16/2020, the FDA has granted EUAs to 303 diagnostic tests, including 231 molecular, 62 antibody, and 10 antigen tests, which include one for detecting neutralizing antibodies from prior SARS-CoV-2 infection and at-home diagnostic assays for SARS-CoV-2 infection.
As of 12/16/2020, the FDA has granted EUAs to 303 diagnostic tests, including 231 molecular, 62 antibody, and 10 antigen tests, which include one for detecting neutralizing antibodies from prior SARS-CoV-2 infection and at-home diagnostic assays for SARS-CoV-2 infection.
As of 12/16/2020, the FDA has granted EUAs to 303 diagnostic tests, including 231 molecular, 62 antibody, and 10 antigen tests, which include one for detecting neutralizing antibodies from prior SARS-CoV-2 infection and at-home diagnostic assays for SARS-CoV-2 infection.
As of 12/16/2020, the FDA has granted EUAs to 303 diagnostic tests, including 231 molecular, 62 antibody, and 10 antigen tests, which include one for detecting neutralizing antibodies from prior SARS-CoV-2 infection and at-home diagnostic assays for SARS-CoV-2 infection.
As of 12/16/2020, the FDA has granted EUAs to 303 diagnostic tests, including 231 molecular, 62 antibody, and 10 antigen tests, which include one for detecting neutralizing antibodies from prior SARS-CoV-2 infection and at-home diagnostic assays for SARS-CoV-2 infection.
As of 12/16/2020, the FDA has granted EUAs to 303 diagnostic tests, including 231 molecular, 62 antibody, and 10 antigen tests, which include one for detecting neutralizing antibodies from prior SARS-CoV-2 infection and at-home diagnostic assays for SARS-CoV-2 infection.
As of 12/16/2020, the FDA has granted EUAs to 303 diagnostic tests, including 231 molecular, 62 antibody, and 10 antigen tests, which include one for detecting neutralizing antibodies from prior SARS-CoV-2 infection and at-home diagnostic assays for SARS-CoV-2 infection.
As of 12/16/2020, the FDA has granted EUAs to 303 diagnostic tests, including 231 molecular, 62 antibody, and 10 antigen tests, which include one for detecting neutralizing antibodies from prior SARS-CoV-2 infection and at-home diagnostic assays for SARS-CoV-2 infection.
As of 12/16/2020, the FDA has granted EUAs to 303 diagnostic tests, including 231 molecular, 62 antibody, and 10 antigen tests, which include one for detecting neutralizing antibodies from prior SARS-CoV-2 infection and at-home diagnostic assays for SARS-CoV-2 infection.
The US CDC recommends that anyone who has been in contact with a positive COVID-19 case should be tested.
The US CDC recommends that anyone who has been in contact with a positive COVID-19 case should be tested.
The US CDC recommends that anyone who has been in contact with a positive COVID-19 case should be tested.
The US CDC recommends that anyone who has been in contact with a positive COVID-19 case should be tested.
The US CDC recommends that anyone who has been in contact with a positive COVID-19 case should be tested.
The US CDC recommends that anyone who has been in contact with a positive COVID-19 case should be tested.
The US CDC recommends that anyone who has been in contact with a positive COVID-19 case should be tested.
The US CDC recommends that anyone who has been in contact with a positive COVID-19 case should be tested.
The US CDC recommends that anyone who has been in contact with a positive COVID-19 case should be tested.
The US CDC recommends that anyone who has been in contact with a positive COVID-19 case should be tested.
The timing of diagnostic PCR tests impacts results.
The timing of diagnostic PCR tests impacts results.
The timing of diagnostic PCR tests impacts results.
The timing of diagnostic PCR tests impacts results.
The timing of diagnostic PCR tests impacts results.
The timing of diagnostic PCR tests impacts results.
The timing of diagnostic PCR tests impacts results.
The timing of diagnostic PCR tests impacts results.
The timing of diagnostic PCR tests impacts results.
The timing of diagnostic PCR tests impacts results.
Low viral loads can lead to false-negative RT-PCR tests, and viral loads are lower in late stage infections as well as at the end of a given day.
Low viral loads can lead to false-negative RT-PCR tests, and viral loads are lower in late stage infections as well as at the end of a given day.
Low viral loads can lead to false-negative RT-PCR tests, and viral loads are lower in late stage infections as well as at the end of a given day.
Low viral loads can lead to false-negative RT-PCR tests, and viral loads are lower in late stage infections as well as at the end of a given day.
Low viral loads can lead to false-negative RT-PCR tests, and viral loads are lower in late stage infections as well as at the end of a given day.
Low viral loads can lead to false-negative RT-PCR tests, and viral loads are lower in late stage infections as well as at the end of a given day.
Low viral loads can lead to false-negative RT-PCR tests, and viral loads are lower in late stage infections as well as at the end of a given day.
Low viral loads can lead to false-negative RT-PCR tests, and viral loads are lower in late stage infections as well as at the end of a given day.
Low viral loads can lead to false-negative RT-PCR tests, and viral loads are lower in late stage infections as well as at the end of a given day.
Low viral loads can lead to false-negative RT-PCR tests, and viral loads are lower in late stage infections as well as at the end of a given day.
The duration of PCR-detectable viral samples is longer in the lower respiratory tract than the upper respiratory tract; nasopharyngeal sampling is most effective (89%) between 0 and 4 days after symptom onset but falls significantly (to 54%) by 10 to 14 days.
The duration of PCR-detectable viral samples is longer in the lower respiratory tract than the upper respiratory tract; nasopharyngeal sampling is most effective (89%) between 0 and 4 days after symptom onset but falls significantly (to 54%) by 10 to 14 days.
The duration of PCR-detectable viral samples is longer in the lower respiratory tract than the upper respiratory tract; nasopharyngeal sampling is most effective (89%) between 0 and 4 days after symptom onset but falls significantly (to 54%) by 10 to 14 days.
The duration of PCR-detectable viral samples is longer in the lower respiratory tract than the upper respiratory tract; nasopharyngeal sampling is most effective (89%) between 0 and 4 days after symptom onset but falls significantly (to 54%) by 10 to 14 days.
The duration of PCR-detectable viral samples is longer in the lower respiratory tract than the upper respiratory tract; nasopharyngeal sampling is most effective (89%) between 0 and 4 days after symptom onset but falls significantly (to 54%) by 10 to 14 days.
The duration of PCR-detectable viral samples is longer in the lower respiratory tract than the upper respiratory tract; nasopharyngeal sampling is most effective (89%) between 0 and 4 days after symptom onset but falls significantly (to 54%) by 10 to 14 days.
The duration of PCR-detectable viral samples is longer in the lower respiratory tract than the upper respiratory tract; nasopharyngeal sampling is most effective (89%) between 0 and 4 days after symptom onset but falls significantly (to 54%) by 10 to 14 days.
The duration of PCR-detectable viral samples is longer in the lower respiratory tract than the upper respiratory tract; nasopharyngeal sampling is most effective (89%) between 0 and 4 days after symptom onset but falls significantly (to 54%) by 10 to 14 days.
The duration of PCR-detectable viral samples is longer in the lower respiratory tract than the upper respiratory tract; nasopharyngeal sampling is most effective (89%) between 0 and 4 days after symptom onset but falls significantly (to 54%) by 10 to 14 days.
The duration of PCR-detectable viral samples is longer in the lower respiratory tract than the upper respiratory tract; nasopharyngeal sampling is most effective (89%) between 0 and 4 days after symptom onset but falls significantly (to 54%) by 10 to 14 days.
After 10 days, alternative testing methods (e.g., lower respiratory samples) may be necessary.
After 10 days, alternative testing methods (e.g., lower respiratory samples) may be necessary.
After 10 days, alternative testing methods (e.g., lower respiratory samples) may be necessary.
After 10 days, alternative testing methods (e.g., lower respiratory samples) may be necessary.
After 10 days, alternative testing methods (e.g., lower respiratory samples) may be necessary.
After 10 days, alternative testing methods (e.g., lower respiratory samples) may be necessary.
After 10 days, alternative testing methods (e.g., lower respiratory samples) may be necessary.
After 10 days, alternative testing methods (e.g., lower respiratory samples) may be necessary.
After 10 days, alternative testing methods (e.g., lower respiratory samples) may be necessary.
After 10 days, alternative testing methods (e.g., lower respiratory samples) may be necessary.
Nasal and pharyngeal swabs may be less effective diagnostically than sputum and bronchoalveolar lavage fluid, although evidence is mixed.
Nasal and pharyngeal swabs may be less effective diagnostically than sputum and bronchoalveolar lavage fluid, although evidence is mixed.
Nasal and pharyngeal swabs may be less effective diagnostically than sputum and bronchoalveolar lavage fluid, although evidence is mixed.
Nasal and pharyngeal swabs may be less effective diagnostically than sputum and bronchoalveolar lavage fluid, although evidence is mixed.
Nasal and pharyngeal swabs may be less effective diagnostically than sputum and bronchoalveolar lavage fluid, although evidence is mixed.
Nasal and pharyngeal swabs may be less effective diagnostically than sputum and bronchoalveolar lavage fluid, although evidence is mixed.
Nasal and pharyngeal swabs may be less effective diagnostically than sputum and bronchoalveolar lavage fluid, although evidence is mixed.
Nasal and pharyngeal swabs may be less effective diagnostically than sputum and bronchoalveolar lavage fluid, although evidence is mixed.
Nasal and pharyngeal swabs may be less effective diagnostically than sputum and bronchoalveolar lavage fluid, although evidence is mixed.
Nasal and pharyngeal swabs may be less effective diagnostically than sputum and bronchoalveolar lavage fluid, although evidence is mixed.
Assays targeting antibodies against the nucleocapsid protein (N) instead of the Spike protein (S) of SARS-CoV-2 may improve detection.
Assays targeting antibodies against the nucleocapsid protein (N) instead of the Spike protein (S) of SARS-CoV-2 may improve detection.
Assays targeting antibodies against the nucleocapsid protein (N) instead of the Spike protein (S) of SARS-CoV-2 may improve detection.
Assays targeting antibodies against the nucleocapsid protein (N) instead of the Spike protein (S) of SARS-CoV-2 may improve detection.
Assays targeting antibodies against the nucleocapsid protein (N) instead of the Spike protein (S) of SARS-CoV-2 may improve detection.
Assays targeting antibodies against the nucleocapsid protein (N) instead of the Spike protein (S) of SARS-CoV-2 may improve detection.
Assays targeting antibodies against the nucleocapsid protein (N) instead of the Spike protein (S) of SARS-CoV-2 may improve detection.
Assays targeting antibodies against the nucleocapsid protein (N) instead of the Spike protein (S) of SARS-CoV-2 may improve detection.
Assays targeting antibodies against the nucleocapsid protein (N) instead of the Spike protein (S) of SARS-CoV-2 may improve detection.
Assays targeting antibodies against the nucleocapsid protein (N) instead of the Spike protein (S) of SARS-CoV-2 may improve detection.
Newer tests target up to three viral components, demonstrating high sensitivity and specificity.
Newer tests target up to three viral components, demonstrating high sensitivity and specificity.
Newer tests target up to three viral components, demonstrating high sensitivity and specificity.
Newer tests target up to three viral components, demonstrating high sensitivity and specificity.
Newer tests target up to three viral components, demonstrating high sensitivity and specificity.
Newer tests target up to three viral components, demonstrating high sensitivity and specificity.
Newer tests target up to three viral components, demonstrating high sensitivity and specificity.
Newer tests target up to three viral components, demonstrating high sensitivity and specificity.
Newer tests target up to three viral components, demonstrating high sensitivity and specificity.
Newer tests target up to three viral components, demonstrating high sensitivity and specificity.
Exhaled breath condensate may be an effective supplement to nasopharyngeal swab-based PCR, and other work examining breath-based samplers is ongoing.
Exhaled breath condensate may be an effective supplement to nasopharyngeal swab-based PCR, and other work examining breath-based samplers is ongoing.
Exhaled breath condensate may be an effective supplement to nasopharyngeal swab-based PCR, and other work examining breath-based samplers is ongoing.
Exhaled breath condensate may be an effective supplement to nasopharyngeal swab-based PCR, and other work examining breath-based samplers is ongoing.
Exhaled breath condensate may be an effective supplement to nasopharyngeal swab-based PCR, and other work examining breath-based samplers is ongoing.
Exhaled breath condensate may be an effective supplement to nasopharyngeal swab-based PCR, and other work examining breath-based samplers is ongoing.
Exhaled breath condensate may be an effective supplement to nasopharyngeal swab-based PCR, and other work examining breath-based samplers is ongoing.
Exhaled breath condensate may be an effective supplement to nasopharyngeal swab-based PCR, and other work examining breath-based samplers is ongoing.
Exhaled breath condensate may be an effective supplement to nasopharyngeal swab-based PCR, and other work examining breath-based samplers is ongoing.
Exhaled breath condensate may be an effective supplement to nasopharyngeal swab-based PCR, and other work examining breath-based samplers is ongoing.
Foam swabs lead to more accurate diagnostic tests than polyester swabs for collecting patient samples, though polyester swabs are good enough to be used in case of a shortage in foam swabs.
Foam swabs lead to more accurate diagnostic tests than polyester swabs for collecting patient samples, though polyester swabs are good enough to be used in case of a shortage in foam swabs.
Foam swabs lead to more accurate diagnostic tests than polyester swabs for collecting patient samples, though polyester swabs are good enough to be used in case of a shortage in foam swabs.
Foam swabs lead to more accurate diagnostic tests than polyester swabs for collecting patient samples, though polyester swabs are good enough to be used in case of a shortage in foam swabs.
Foam swabs lead to more accurate diagnostic tests than polyester swabs for collecting patient samples, though polyester swabs are good enough to be used in case of a shortage in foam swabs.
Foam swabs lead to more accurate diagnostic tests than polyester swabs for collecting patient samples, though polyester swabs are good enough to be used in case of a shortage in foam swabs.
Foam swabs lead to more accurate diagnostic tests than polyester swabs for collecting patient samples, though polyester swabs are good enough to be used in case of a shortage in foam swabs.
Foam swabs lead to more accurate diagnostic tests than polyester swabs for collecting patient samples, though polyester swabs are good enough to be used in case of a shortage in foam swabs.
Foam swabs lead to more accurate diagnostic tests than polyester swabs for collecting patient samples, though polyester swabs are good enough to be used in case of a shortage in foam swabs.
Foam swabs lead to more accurate diagnostic tests than polyester swabs for collecting patient samples, though polyester swabs are good enough to be used in case of a shortage in foam swabs.
Asymptomatic individuals are more likely to test negative for a specific antibody (IgG) compared to symptomatic patients.
Asymptomatic individuals are more likely to test negative for a specific antibody (IgG) compared to symptomatic patients.
Asymptomatic individuals are more likely to test negative for a specific antibody (IgG) compared to symptomatic patients.
Asymptomatic individuals are more likely to test negative for a specific antibody (IgG) compared to symptomatic patients.
Asymptomatic individuals are more likely to test negative for a specific antibody (IgG) compared to symptomatic patients.
Asymptomatic individuals are more likely to test negative for a specific antibody (IgG) compared to symptomatic patients.
Asymptomatic individuals are more likely to test negative for a specific antibody (IgG) compared to symptomatic patients.
Asymptomatic individuals are more likely to test negative for a specific antibody (IgG) compared to symptomatic patients.
Asymptomatic individuals are more likely to test negative for a specific antibody (IgG) compared to symptomatic patients.
Asymptomatic individuals are more likely to test negative for a specific antibody (IgG) compared to symptomatic patients.
The CRISPR-Cas12a system is being used to develop fluorescence-based COVID-19 diagnostic tests.
The CRISPR-Cas12a system is being used to develop fluorescence-based COVID-19 diagnostic tests.
India has approved a rapid CRISPR-based test paper capable of accurate results within an hour of nasopharyngeal swab.
India has approved a rapid CRISPR-based test paper capable of accurate results within an hour of nasopharyngeal swab.
India has approved a rapid CRISPR-based test paper capable of accurate results within an hour of nasopharyngeal swab.
India has approved a rapid CRISPR-based test paper capable of accurate results within an hour of nasopharyngeal swab.
India has approved a rapid CRISPR-based test paper capable of accurate results within an hour of nasopharyngeal swab.
India has approved a rapid CRISPR-based test paper capable of accurate results within an hour of nasopharyngeal swab.
India has approved a rapid CRISPR-based test paper capable of accurate results within an hour of nasopharyngeal swab.
India has approved a rapid CRISPR-based test paper capable of accurate results within an hour of nasopharyngeal swab.
India has approved a rapid CRISPR-based test paper capable of accurate results within an hour of nasopharyngeal swab.
India has approved a rapid CRISPR-based test paper capable of accurate results within an hour of nasopharyngeal swab.
Low-sensitivity tests (like lateral flow assays) may be beneficial despite lower accuracy, because they reduce the time necessary to identify and subsequently contain potential outbreaks.
Low-sensitivity tests (like lateral flow assays) may be beneficial despite lower accuracy, because they reduce the time necessary to identify and subsequently contain potential outbreaks.
Low-sensitivity tests (like lateral flow assays) may be beneficial despite lower accuracy, because they reduce the time necessary to identify and subsequently contain potential outbreaks.
Low-sensitivity tests (like lateral flow assays) may be beneficial despite lower accuracy, because they reduce the time necessary to identify and subsequently contain potential outbreaks.
Low-sensitivity tests (like lateral flow assays) may be beneficial despite lower accuracy, because they reduce the time necessary to identify and subsequently contain potential outbreaks.
Low-sensitivity tests (like lateral flow assays) may be beneficial despite lower accuracy, because they reduce the time necessary to identify and subsequently contain potential outbreaks.
Low-sensitivity tests (like lateral flow assays) may be beneficial despite lower accuracy, because they reduce the time necessary to identify and subsequently contain potential outbreaks.
Low-sensitivity tests (like lateral flow assays) may be beneficial despite lower accuracy, because they reduce the time necessary to identify and subsequently contain potential outbreaks.
Low-sensitivity tests (like lateral flow assays) may be beneficial despite lower accuracy, because they reduce the time necessary to identify and subsequently contain potential outbreaks.
Low-sensitivity tests (like lateral flow assays) may be beneficial despite lower accuracy, because they reduce the time necessary to identify and subsequently contain potential outbreaks.
Immunological indicators, blood glucose levels, oxygen levels and bilirubin levels may help identify future severe cases, and decision-support tools for diagnosing severe infections exist.
Immunological indicators, blood glucose levels, oxygen levels and bilirubin levels may help identify future severe cases, and decision-support tools for diagnosing severe infections exist.
Immunological indicators, blood glucose levels, oxygen levels and bilirubin levels may help identify future severe cases, and decision-support tools for diagnosing severe infections exist.
Immunological indicators, blood glucose levels, oxygen levels and bilirubin levels may help identify future severe cases, and decision-support tools for diagnosing severe infections exist.
Immunological indicators, blood glucose levels, oxygen levels and bilirubin levels may help identify future severe cases, and decision-support tools for diagnosing severe infections exist.
Immunological indicators, blood glucose levels, oxygen levels and bilirubin levels may help identify future severe cases, and decision-support tools for diagnosing severe infections exist.
Immunological indicators, blood glucose levels, oxygen levels and bilirubin levels may help identify future severe cases, and decision-support tools for diagnosing severe infections exist.
Immunological indicators, blood glucose levels, oxygen levels and bilirubin levels may help identify future severe cases, and decision-support tools for diagnosing severe infections exist.
Immunological indicators, blood glucose levels, oxygen levels and bilirubin levels may help identify future severe cases, and decision-support tools for diagnosing severe infections exist.
Immunological indicators, blood glucose levels, oxygen levels and bilirubin levels may help identify future severe cases, and decision-support tools for diagnosing severe infections exist.
Pooling samples and conducting RT-PCR tests may expand testing capability.
Pooling samples and conducting RT-PCR tests may expand testing capability.
Pooling samples and conducting RT-PCR tests may expand testing capability.
Pooling samples and conducting RT-PCR tests may expand testing capability.
Pooling samples and conducting RT-PCR tests may expand testing capability.
Pooling samples and conducting RT-PCR tests may expand testing capability.
Pooling samples and conducting RT-PCR tests may expand testing capability.
Pooling samples and conducting RT-PCR tests may expand testing capability.
Pooling samples and conducting RT-PCR tests may expand testing capability.
Pooling samples and conducting RT-PCR tests may expand testing capability.
Detection dogs are being used at airports to recommend individuals for subsequent SARS-CoV-2 PCR testing.
Detection dogs are being used at airports to recommend individuals for subsequent SARS-CoV-2 PCR testing.
Detection dogs are being used at airports to recommend individuals for subsequent SARS-CoV-2 PCR testing.
Detection dogs are being used at airports to recommend individuals for subsequent SARS-CoV-2 PCR testing.
Detection dogs are being used at airports to recommend individuals for subsequent SARS-CoV-2 PCR testing.
Detection dogs are being used at airports to recommend individuals for subsequent SARS-CoV-2 PCR testing.
Detection dogs are being used at airports to recommend individuals for subsequent SARS-CoV-2 PCR testing.
Detection dogs are being used at airports to recommend individuals for subsequent SARS-CoV-2 PCR testing.
Detection dogs are being used at airports to recommend individuals for subsequent SARS-CoV-2 PCR testing.
Detection dogs are being used at airports to recommend individuals for subsequent SARS-CoV-2 PCR testing.
High-throughput diagnostic are comparable in sensitivity and specificity to PCR, and may increase sampling speed.
High-throughput diagnostic are comparable in sensitivity and specificity to PCR, and may increase sampling speed.
High-throughput diagnostic are comparable in sensitivity and specificity to PCR, and may increase sampling speed.
High-throughput diagnostic are comparable in sensitivity and specificity to PCR, and may increase sampling speed.
High-throughput diagnostic are comparable in sensitivity and specificity to PCR, and may increase sampling speed.
High-throughput diagnostic are comparable in sensitivity and specificity to PCR, and may increase sampling speed.
High-throughput diagnostic are comparable in sensitivity and specificity to PCR, and may increase sampling speed.
High-throughput diagnostic are comparable in sensitivity and specificity to PCR, and may increase sampling speed.
High-throughput diagnostic are comparable in sensitivity and specificity to PCR, and may increase sampling speed.
High-throughput diagnostic are comparable in sensitivity and specificity to PCR, and may increase sampling speed.
A high-throughput diagnostic assay for screening asymptomatic individuals has received US Emergency Use Authorization.
A high-throughput diagnostic assay for screening asymptomatic individuals has received US Emergency Use Authorization.
A high-throughput diagnostic assay for screening asymptomatic individuals has received US Emergency Use Authorization.
A high-throughput diagnostic assay for screening asymptomatic individuals has received US Emergency Use Authorization.
A high-throughput diagnostic assay for screening asymptomatic individuals has received US Emergency Use Authorization.
A high-throughput diagnostic assay for screening asymptomatic individuals has received US Emergency Use Authorization.
A high-throughput diagnostic assay for screening asymptomatic individuals has received US Emergency Use Authorization.
A high-throughput diagnostic assay for screening asymptomatic individuals has received US Emergency Use Authorization.
A high-throughput diagnostic assay for screening asymptomatic individuals has received US Emergency Use Authorization.
A high-throughput diagnostic assay for screening asymptomatic individuals has received US Emergency Use Authorization.
Infrared temperature readings may be misleading when used at the entrance of buildings with low outdoor temperatures.
Infrared temperature readings may be misleading when used at the entrance of buildings with low outdoor temperatures.
Infrared temperature readings may be misleading when used at the entrance of buildings with low outdoor temperatures.
Infrared temperature readings may be misleading when used at the entrance of buildings with low outdoor temperatures.
Infrared temperature readings may be misleading when used at the entrance of buildings with low outdoor temperatures.
Infrared temperature readings may be misleading when used at the entrance of buildings with low outdoor temperatures.
Infrared temperature readings may be misleading when used at the entrance of buildings with low outdoor temperatures.
Infrared temperature readings may be misleading when used at the entrance of buildings with low outdoor temperatures.
Infrared temperature readings may be misleading when used at the entrance of buildings with low outdoor temperatures.
Infrared temperature readings may be misleading when used at the entrance of buildings with low outdoor temperatures.
Some skin manifestations of COVID-19 may be diagnostic, in particular those associated with inflammatory reactions.
Some skin manifestations of COVID-19 may be diagnostic, in particular those associated with inflammatory reactions.
Some skin manifestations of COVID-19 may be diagnostic, in particular those associated with inflammatory reactions.
Some skin manifestations of COVID-19 may be diagnostic, in particular those associated with inflammatory reactions.
Some skin manifestations of COVID-19 may be diagnostic, in particular those associated with inflammatory reactions.
Some skin manifestations of COVID-19 may be diagnostic, in particular those associated with inflammatory reactions.
Some skin manifestations of COVID-19 may be diagnostic, in particular those associated with inflammatory reactions.
Some skin manifestations of COVID-19 may be diagnostic, in particular those associated with inflammatory reactions.
Some skin manifestations of COVID-19 may be diagnostic, in particular those associated with inflammatory reactions.
Some skin manifestations of COVID-19 may be diagnostic, in particular those associated with inflammatory reactions.
Validated serological (antibody) assays are being used to help determine who has been exposed to SARS-CoV-2.
Validated serological (antibody) assays are being used to help determine who has been exposed to SARS-CoV-2.
Validated serological (antibody) assays are being used to help determine who has been exposed to SARS-CoV-2.
Validated serological (antibody) assays are being used to help determine who has been exposed to SARS-CoV-2.
Validated serological (antibody) assays are being used to help determine who has been exposed to SARS-CoV-2.
Validated serological (antibody) assays are being used to help determine who has been exposed to SARS-CoV-2.
Validated serological (antibody) assays are being used to help determine who has been exposed to SARS-CoV-2.
Validated serological (antibody) assays are being used to help determine who has been exposed to SARS-CoV-2.
Validated serological (antibody) assays are being used to help determine who has been exposed to SARS-CoV-2.
Validated serological (antibody) assays are being used to help determine who has been exposed to SARS-CoV-2.
Repeated serological testing is necessary to identify asymptomatic and other undetected patients.
Repeated serological testing is necessary to identify asymptomatic and other undetected patients.
Repeated serological testing is necessary to identify asymptomatic and other undetected patients.
Repeated serological testing is necessary to identify asymptomatic and other undetected patients.
Repeated serological testing is necessary to identify asymptomatic and other undetected patients.
Repeated serological testing is necessary to identify asymptomatic and other undetected patients.
Repeated serological testing is necessary to identify asymptomatic and other undetected patients.
Repeated serological testing is necessary to identify asymptomatic and other undetected patients.
Repeated serological testing is necessary to identify asymptomatic and other undetected patients.
Repeated serological testing is necessary to identify asymptomatic and other undetected patients.
Exclusively testing symptomatic healthcare workers is likely to exclude a large fraction of COVID-19 positive personnel.
Exclusively testing symptomatic healthcare workers is likely to exclude a large fraction of COVID-19 positive personnel.
Exclusively testing symptomatic healthcare workers is likely to exclude a large fraction of COVID-19 positive personnel.
Exclusively testing symptomatic healthcare workers is likely to exclude a large fraction of COVID-19 positive personnel.
Exclusively testing symptomatic healthcare workers is likely to exclude a large fraction of COVID-19 positive personnel.
Exclusively testing symptomatic healthcare workers is likely to exclude a large fraction of COVID-19 positive personnel.
Exclusively testing symptomatic healthcare workers is likely to exclude a large fraction of COVID-19 positive personnel.
Exclusively testing symptomatic healthcare workers is likely to exclude a large fraction of COVID-19 positive personnel.
Exclusively testing symptomatic healthcare workers is likely to exclude a large fraction of COVID-19 positive personnel.
Exclusively testing symptomatic healthcare workers is likely to exclude a large fraction of COVID-19 positive personnel.
Research has shown high variability in the ability of tests by different manufacturers to accurately detect positive and negative cases.
Research has shown high variability in the ability of tests by different manufacturers to accurately detect positive and negative cases.
Research has shown high variability in the ability of tests by different manufacturers to accurately detect positive and negative cases.
Research has shown high variability in the ability of tests by different manufacturers to accurately detect positive and negative cases.
Research has shown high variability in the ability of tests by different manufacturers to accurately detect positive and negative cases.
Research has shown high variability in the ability of tests by different manufacturers to accurately detect positive and negative cases.
Research has shown high variability in the ability of tests by different manufacturers to accurately detect positive and negative cases.
Research has shown high variability in the ability of tests by different manufacturers to accurately detect positive and negative cases.
Research has shown high variability in the ability of tests by different manufacturers to accurately detect positive and negative cases.
Research has shown high variability in the ability of tests by different manufacturers to accurately detect positive and negative cases.
Meta-analysis suggests that lateral flow assays (LFIA) are less accurate than ELISA or chemiluminescent methods (CLIA), but that the target of serological studies (e.g., IgG or IgM) does not affect accuracy.
Meta-analysis suggests that lateral flow assays (LFIA) are less accurate than ELISA or chemiluminescent methods (CLIA), but that the target of serological studies (e.g., IgG or IgM) does not affect accuracy.
Meta-analysis suggests that lateral flow assays (LFIA) are less accurate than ELISA or chemiluminescent methods (CLIA), but that the target of serological studies (e.g., IgG or IgM) does not affect accuracy.
Meta-analysis suggests that lateral flow assays (LFIA) are less accurate than ELISA or chemiluminescent methods (CLIA), but that the target of serological studies (e.g., IgG or IgM) does not affect accuracy.
Meta-analysis suggests that lateral flow assays (LFIA) are less accurate than ELISA or chemiluminescent methods (CLIA), but that the target of serological studies (e.g., IgG or IgM) does not affect accuracy.
Meta-analysis suggests that lateral flow assays (LFIA) are less accurate than ELISA or chemiluminescent methods (CLIA), but that the target of serological studies (e.g., IgG or IgM) does not affect accuracy.
Meta-analysis suggests that lateral flow assays (LFIA) are less accurate than ELISA or chemiluminescent methods (CLIA), but that the target of serological studies (e.g., IgG or IgM) does not affect accuracy.
Meta-analysis suggests that lateral flow assays (LFIA) are less accurate than ELISA or chemiluminescent methods (CLIA), but that the target of serological studies (e.g., IgG or IgM) does not affect accuracy.
Meta-analysis suggests that lateral flow assays (LFIA) are less accurate than ELISA or chemiluminescent methods (CLIA), but that the target of serological studies (e.g., IgG or IgM) does not affect accuracy.
Meta-analysis suggests that lateral flow assays (LFIA) are less accurate than ELISA or chemiluminescent methods (CLIA), but that the target of serological studies (e.g., IgG or IgM) does not affect accuracy.
The FDA has excluded several dozen serological diagnostic assays based on failure to conform to updated regulatory requirements.
The FDA has excluded several dozen serological diagnostic assays based on failure to conform to updated regulatory requirements.
The FDA has excluded several dozen serological diagnostic assays based on failure to conform to updated regulatory requirements.
The FDA has excluded several dozen serological diagnostic assays based on failure to conform to updated regulatory requirements.
The FDA has excluded several dozen serological diagnostic assays based on failure to conform to updated regulatory requirements.
The FDA has excluded several dozen serological diagnostic assays based on failure to conform to updated regulatory requirements.
The FDA has excluded several dozen serological diagnostic assays based on failure to conform to updated regulatory requirements.
The FDA has excluded several dozen serological diagnostic assays based on failure to conform to updated regulatory requirements.
The FDA has excluded several dozen serological diagnostic assays based on failure to conform to updated regulatory requirements.
The FDA has excluded several dozen serological diagnostic assays based on failure to conform to updated regulatory requirements.
In a study with pregnant women, rapid antibody (lateral flow assay) testing resulted in a 50% positive predictive value and 50% false positive rate, which are lower than the values touted for non-pregnant populations.
In a study with pregnant women, rapid antibody (lateral flow assay) testing resulted in a 50% positive predictive value and 50% false positive rate, which are lower than the values touted for non-pregnant populations.
In a study with pregnant women, rapid antibody (lateral flow assay) testing resulted in a 50% positive predictive value and 50% false positive rate, which are lower than the values touted for non-pregnant populations.
In a study with pregnant women, rapid antibody (lateral flow assay) testing resulted in a 50% positive predictive value and 50% false positive rate, which are lower than the values touted for non-pregnant populations.
In a study with pregnant women, rapid antibody (lateral flow assay) testing resulted in a 50% positive predictive value and 50% false positive rate, which are lower than the values touted for non-pregnant populations.
In a study with pregnant women, rapid antibody (lateral flow assay) testing resulted in a 50% positive predictive value and 50% false positive rate, which are lower than the values touted for non-pregnant populations.
In a study with pregnant women, rapid antibody (lateral flow assay) testing resulted in a 50% positive predictive value and 50% false positive rate, which are lower than the values touted for non-pregnant populations.
In a study with pregnant women, rapid antibody (lateral flow assay) testing resulted in a 50% positive predictive value and 50% false positive rate, which are lower than the values touted for non-pregnant populations.
In a study with pregnant women, rapid antibody (lateral flow assay) testing resulted in a 50% positive predictive value and 50% false positive rate, which are lower than the values touted for non-pregnant populations.
In a study with pregnant women, rapid antibody (lateral flow assay) testing resulted in a 50% positive predictive value and 50% false positive rate, which are lower than the values touted for non-pregnant populations.
SARS-CoV-2 RNA is likely to persist long enough in untreated wastewater to permit reliable detection for COVID-19 surveillance, and can warn of SARS-CoV-2 cases ahead of positive PCR tests and hospital admissions.
SARS-CoV-2 RNA is likely to persist long enough in untreated wastewater to permit reliable detection for COVID-19 surveillance, and can warn of SARS-CoV-2 cases ahead of positive PCR tests and hospital admissions.
SARS-CoV-2 RNA is likely to persist long enough in untreated wastewater to permit reliable detection for COVID-19 surveillance, and can warn of SARS-CoV-2 cases ahead of positive PCR tests and hospital admissions.
SARS-CoV-2 RNA is likely to persist long enough in untreated wastewater to permit reliable detection for COVID-19 surveillance, and can warn of SARS-CoV-2 cases ahead of positive PCR tests and hospital admissions.
SARS-CoV-2 RNA is likely to persist long enough in untreated wastewater to permit reliable detection for COVID-19 surveillance, and can warn of SARS-CoV-2 cases ahead of positive PCR tests and hospital admissions.
SARS-CoV-2 RNA is likely to persist long enough in untreated wastewater to permit reliable detection for COVID-19 surveillance, and can warn of SARS-CoV-2 cases ahead of positive PCR tests and hospital admissions.
SARS-CoV-2 RNA is likely to persist long enough in untreated wastewater to permit reliable detection for COVID-19 surveillance, and can warn of SARS-CoV-2 cases ahead of positive PCR tests and hospital admissions.
SARS-CoV-2 RNA is likely to persist long enough in untreated wastewater to permit reliable detection for COVID-19 surveillance, and can warn of SARS-CoV-2 cases ahead of positive PCR tests and hospital admissions.
SARS-CoV-2 RNA is likely to persist long enough in untreated wastewater to permit reliable detection for COVID-19 surveillance, and can warn of SARS-CoV-2 cases ahead of positive PCR tests and hospital admissions.
SARS-CoV-2 RNA is likely to persist long enough in untreated wastewater to permit reliable detection for COVID-19 surveillance, and can warn of SARS-CoV-2 cases ahead of positive PCR tests and hospital admissions.
There is no universally effective treatment for COVID-19, but some treatments reduce disease severity and mortality.
There is no universally effective treatment for COVID-19, but some treatments reduce disease severity and mortality.
There is no universally effective treatment for COVID-19, but some treatments reduce disease severity and mortality.
There is no universally effective treatment for COVID-19, but some treatments reduce disease severity and mortality.
There is no universally effective treatment for COVID-19, but some treatments reduce disease severity and mortality.
There is no universally effective treatment for COVID-19, but some treatments reduce disease severity and mortality.
There is no universally effective treatment for COVID-19, but some treatments reduce disease severity and mortality.
There is no universally effective treatment for COVID-19, but some treatments reduce disease severity and mortality.
There is no universally effective treatment for COVID-19, but some treatments reduce disease severity and mortality.
There is no universally effective treatment for COVID-19, but some treatments reduce disease severity and mortality.
Remdesivir may reduce symptom duration in hospitalized patients, and may reduce mortality when combined with other treatment regimens (e.g., baricitinab).
Remdesivir may reduce symptom duration in hospitalized patients, and may reduce mortality when combined with other treatment regimens (e.g., baricitinab).
Remdesivir may reduce symptom duration in hospitalized patients, and may reduce mortality when combined with other treatment regimens (e.g., baricitinab).
Remdesivir may reduce symptom duration in hospitalized patients, and may reduce mortality when combined with other treatment regimens (e.g., baricitinab).
Remdesivir may reduce symptom duration in hospitalized patients, and may reduce mortality when combined with other treatment regimens (e.g., baricitinab).
Remdesivir may reduce symptom duration in hospitalized patients, and may reduce mortality when combined with other treatment regimens (e.g., baricitinab).
Remdesivir may reduce symptom duration in hospitalized patients, and may reduce mortality when combined with other treatment regimens (e.g., baricitinab).
Remdesivir may reduce symptom duration in hospitalized patients, and may reduce mortality when combined with other treatment regimens (e.g., baricitinab).
Remdesivir may reduce symptom duration in hospitalized patients, and may reduce mortality when combined with other treatment regimens (e.g., baricitinab).
Remdesivir may reduce symptom duration in hospitalized patients, and may reduce mortality when combined with other treatment regimens (e.g., baricitinab).
The US FDA has approved the use of remdesivir in hospitalized patients 12 years and older, with an Emergency Use Authorization for other patient groups.
The US FDA has approved the use of remdesivir in hospitalized patients 12 years and older, with an Emergency Use Authorization for other patient groups.
The US FDA has approved the use of remdesivir in hospitalized patients 12 years and older, with an Emergency Use Authorization for other patient groups.
The US FDA has approved the use of remdesivir in hospitalized patients 12 years and older, with an Emergency Use Authorization for other patient groups.
The US FDA has approved the use of remdesivir in hospitalized patients 12 years and older, with an Emergency Use Authorization for other patient groups.
The US FDA has approved the use of remdesivir in hospitalized patients 12 years and older, with an Emergency Use Authorization for other patient groups.
The US FDA has approved the use of remdesivir in hospitalized patients 12 years and older, with an Emergency Use Authorization for other patient groups.
The US FDA has approved the use of remdesivir in hospitalized patients 12 years and older, with an Emergency Use Authorization for other patient groups.
The US FDA has approved the use of remdesivir in hospitalized patients 12 years and older, with an Emergency Use Authorization for other patient groups.
The US FDA has approved the use of remdesivir in hospitalized patients 12 years and older, with an Emergency Use Authorization for other patient groups.
An abbreviated clinical trial of remdesivir (n=237) found no significant benefits.
An abbreviated clinical trial of remdesivir (n=237) found no significant benefits.
An abbreviated clinical trial of remdesivir (n=237) found no significant benefits.
An abbreviated clinical trial of remdesivir (n=237) found no significant benefits.
An abbreviated clinical trial of remdesivir (n=237) found no significant benefits.
An abbreviated clinical trial of remdesivir (n=237) found no significant benefits.
An abbreviated clinical trial of remdesivir (n=237) found no significant benefits.
An abbreviated clinical trial of remdesivir (n=237) found no significant benefits.
An abbreviated clinical trial of remdesivir (n=237) found no significant benefits.
An abbreviated clinical trial of remdesivir (n=237) found no significant benefits.
The FDA revoked Hydroxychloroquines EUA on 6/15/20.
The FDA revoked Hydroxychloroquines EUA on 6/15/20.
Corticosteroids may significantly reduce mortality in severely ill and ventilated patients, especially if given early.
Corticosteroids may significantly reduce mortality in severely ill and ventilated patients, especially if given early.
Corticosteroids may significantly reduce mortality in severely ill and ventilated patients, especially if given early.
Corticosteroids may significantly reduce mortality in severely ill and ventilated patients, especially if given early.
Corticosteroids may significantly reduce mortality in severely ill and ventilated patients, especially if given early.
Corticosteroids may significantly reduce mortality in severely ill and ventilated patients, especially if given early.
Corticosteroids may significantly reduce mortality in severely ill and ventilated patients, especially if given early.
Corticosteroids may significantly reduce mortality in severely ill and ventilated patients, especially if given early.
Corticosteroids may significantly reduce mortality in severely ill and ventilated patients, especially if given early.
Corticosteroids may significantly reduce mortality in severely ill and ventilated patients, especially if given early.
The benefits of glucocorticoids may depend heavily on patient inflammation.
The benefits of glucocorticoids may depend heavily on patient inflammation.
The benefits of glucocorticoids may depend heavily on patient inflammation.
The benefits of glucocorticoids may depend heavily on patient inflammation.
The benefits of glucocorticoids may depend heavily on patient inflammation.
The benefits of glucocorticoids may depend heavily on patient inflammation.
The benefits of glucocorticoids may depend heavily on patient inflammation.
The benefits of glucocorticoids may depend heavily on patient inflammation.
The benefits of glucocorticoids may depend heavily on patient inflammation.
The benefits of glucocorticoids may depend heavily on patient inflammation.
Convalescent plasma treatment is safe and may be effective when administered early, though evidence is mixed.
Convalescent plasma treatment is safe and may be effective when administered early, though evidence is mixed.
Convalescent plasma treatment is safe and may be effective when administered early, though evidence is mixed.
Convalescent plasma treatment is safe and may be effective when administered early, though evidence is mixed.
Convalescent plasma treatment is safe and may be effective when administered early, though evidence is mixed.
Convalescent plasma treatment is safe and may be effective when administered early, though evidence is mixed.
Convalescent plasma treatment is safe and may be effective when administered early, though evidence is mixed.
Convalescent plasma treatment is safe and may be effective when administered early, though evidence is mixed.
Convalescent plasma treatment is safe and may be effective when administered early, though evidence is mixed.
Convalescent plasma treatment is safe and may be effective when administered early, though evidence is mixed.
A large trial of plasma therapy (>25,000 patients) shows that treatment is safe, with some evidence that it can reduce 7-day mortality.
A large trial of plasma therapy (>25,000 patients) shows that treatment is safe, with some evidence that it can reduce 7-day mortality.
A large trial of plasma therapy (>25,000 patients) shows that treatment is safe, with some evidence that it can reduce 7-day mortality.
A large trial of plasma therapy (>25,000 patients) shows that treatment is safe, with some evidence that it can reduce 7-day mortality.
A large trial of plasma therapy (>25,000 patients) shows that treatment is safe, with some evidence that it can reduce 7-day mortality.
A large trial of plasma therapy (>25,000 patients) shows that treatment is safe, with some evidence that it can reduce 7-day mortality.
A large trial of plasma therapy (>25,000 patients) shows that treatment is safe, with some evidence that it can reduce 7-day mortality.
A large trial of plasma therapy (>25,000 patients) shows that treatment is safe, with some evidence that it can reduce 7-day mortality.
A large trial of plasma therapy (>25,000 patients) shows that treatment is safe, with some evidence that it can reduce 7-day mortality.
A large trial of plasma therapy (>25,000 patients) shows that treatment is safe, with some evidence that it can reduce 7-day mortality.
Plasma therapy shows larger reductions in mortality when administered within 44 hours of hospital admission, and donor plasma with higher antibody levels appears more effective.
Plasma therapy shows larger reductions in mortality when administered within 44 hours of hospital admission, and donor plasma with higher antibody levels appears more effective.
Plasma therapy shows larger reductions in mortality when administered within 44 hours of hospital admission, and donor plasma with higher antibody levels appears more effective.
Plasma therapy shows larger reductions in mortality when administered within 44 hours of hospital admission, and donor plasma with higher antibody levels appears more effective.
Plasma therapy shows larger reductions in mortality when administered within 44 hours of hospital admission, and donor plasma with higher antibody levels appears more effective.
Plasma therapy shows larger reductions in mortality when administered within 44 hours of hospital admission, and donor plasma with higher antibody levels appears more effective.
Plasma therapy shows larger reductions in mortality when administered within 44 hours of hospital admission, and donor plasma with higher antibody levels appears more effective.
Plasma therapy shows larger reductions in mortality when administered within 44 hours of hospital admission, and donor plasma with higher antibody levels appears more effective.
Plasma therapy shows larger reductions in mortality when administered within 44 hours of hospital admission, and donor plasma with higher antibody levels appears more effective.
Plasma therapy shows larger reductions in mortality when administered within 44 hours of hospital admission, and donor plasma with higher antibody levels appears more effective.
Even high-titer donor plasma, however, did not substantially improve outcomes in a clinical trial with severe COVID-19 patients (n=228).
Even high-titer donor plasma, however, did not substantially improve outcomes in a clinical trial with severe COVID-19 patients (n=228).
Even high-titer donor plasma, however, did not substantially improve outcomes in a clinical trial with severe COVID-19 patients (n=228).
Even high-titer donor plasma, however, did not substantially improve outcomes in a clinical trial with severe COVID-19 patients (n=228).
Even high-titer donor plasma, however, did not substantially improve outcomes in a clinical trial with severe COVID-19 patients (n=228).
Even high-titer donor plasma, however, did not substantially improve outcomes in a clinical trial with severe COVID-19 patients (n=228).
Even high-titer donor plasma, however, did not substantially improve outcomes in a clinical trial with severe COVID-19 patients (n=228).
Even high-titer donor plasma, however, did not substantially improve outcomes in a clinical trial with severe COVID-19 patients (n=228).
Even high-titer donor plasma, however, did not substantially improve outcomes in a clinical trial with severe COVID-19 patients (n=228).
Even high-titer donor plasma, however, did not substantially improve outcomes in a clinical trial with severe COVID-19 patients (n=228).
On 8/24/2020, the US FDA approved an Emergency Use Authorization for convalescent plasma therapy.
On 8/24/2020, the US FDA approved an Emergency Use Authorization for convalescent plasma therapy.
On 8/24/2020, the US FDA approved an Emergency Use Authorization for convalescent plasma therapy.
On 8/24/2020, the US FDA approved an Emergency Use Authorization for convalescent plasma therapy.
On 8/24/2020, the US FDA approved an Emergency Use Authorization for convalescent plasma therapy.
On 8/24/2020, the US FDA approved an Emergency Use Authorization for convalescent plasma therapy.
On 8/24/2020, the US FDA approved an Emergency Use Authorization for convalescent plasma therapy.
On 8/24/2020, the US FDA approved an Emergency Use Authorization for convalescent plasma therapy.
On 8/24/2020, the US FDA approved an Emergency Use Authorization for convalescent plasma therapy.
On 8/24/2020, the US FDA approved an Emergency Use Authorization for convalescent plasma therapy.
Anticoagulants may reduce COVID-19 mortality in hospitalized patients.
Anticoagulants may reduce COVID-19 mortality in hospitalized patients.
Anticoagulants may reduce COVID-19 mortality in hospitalized patients.
Anticoagulants may reduce COVID-19 mortality in hospitalized patients.
Anticoagulants may reduce COVID-19 mortality in hospitalized patients.
Anticoagulants may reduce COVID-19 mortality in hospitalized patients.
Anticoagulants may reduce COVID-19 mortality in hospitalized patients.
Anticoagulants may reduce COVID-19 mortality in hospitalized patients.
Anticoagulants may reduce COVID-19 mortality in hospitalized patients.
Anticoagulants may reduce COVID-19 mortality in hospitalized patients.
Both therapeutic and prophylactic use of anticoagulants has been associated with significant (~50%) reduction in mortality in hospitalized COVID-19 patients.
Both therapeutic and prophylactic use of anticoagulants has been associated with significant (~50%) reduction in mortality in hospitalized COVID-19 patients.
Both therapeutic and prophylactic use of anticoagulants has been associated with significant (~50%) reduction in mortality in hospitalized COVID-19 patients.
Both therapeutic and prophylactic use of anticoagulants has been associated with significant (~50%) reduction in mortality in hospitalized COVID-19 patients.
Both therapeutic and prophylactic use of anticoagulants has been associated with significant (~50%) reduction in mortality in hospitalized COVID-19 patients.
Both therapeutic and prophylactic use of anticoagulants has been associated with significant (~50%) reduction in mortality in hospitalized COVID-19 patients.
Both therapeutic and prophylactic use of anticoagulants has been associated with significant (~50%) reduction in mortality in hospitalized COVID-19 patients.
Both therapeutic and prophylactic use of anticoagulants has been associated with significant (~50%) reduction in mortality in hospitalized COVID-19 patients.
Both therapeutic and prophylactic use of anticoagulants has been associated with significant (~50%) reduction in mortality in hospitalized COVID-19 patients.
Both therapeutic and prophylactic use of anticoagulants has been associated with significant (~50%) reduction in mortality in hospitalized COVID-19 patients.
Anticoagulant use was associated with lower mortality in the severely ill, but the correct dose is critical to avoid complications.
Anticoagulant use was associated with lower mortality in the severely ill, but the correct dose is critical to avoid complications.
Anticoagulant use was associated with lower mortality in the severely ill, but the correct dose is critical to avoid complications.
Anticoagulant use was associated with lower mortality in the severely ill, but the correct dose is critical to avoid complications.
Anticoagulant use was associated with lower mortality in the severely ill, but the correct dose is critical to avoid complications.
Anticoagulant use was associated with lower mortality in the severely ill, but the correct dose is critical to avoid complications.
Anticoagulant use was associated with lower mortality in the severely ill, but the correct dose is critical to avoid complications.
Anticoagulant use was associated with lower mortality in the severely ill, but the correct dose is critical to avoid complications.
Anticoagulant use was associated with lower mortality in the severely ill, but the correct dose is critical to avoid complications.
Anticoagulant use was associated with lower mortality in the severely ill, but the correct dose is critical to avoid complications.
High doses of anticoagulants may be effective in critically ill patients.
High doses of anticoagulants may be effective in critically ill patients.
High doses of anticoagulants may be effective in critically ill patients.
High doses of anticoagulants may be effective in critically ill patients.
High doses of anticoagulants may be effective in critically ill patients.
High doses of anticoagulants may be effective in critically ill patients.
High doses of anticoagulants may be effective in critically ill patients.
High doses of anticoagulants may be effective in critically ill patients.
High doses of anticoagulants may be effective in critically ill patients.
High doses of anticoagulants may be effective in critically ill patients.
Patients 65 years and up receiving chronic anticoagulant treatment showed higher survival than propensity-matched controls.
Patients 65 years and up receiving chronic anticoagulant treatment showed higher survival than propensity-matched controls.
Patients 65 years and up receiving chronic anticoagulant treatment showed higher survival than propensity-matched controls.
Patients 65 years and up receiving chronic anticoagulant treatment showed higher survival than propensity-matched controls.
Patients 65 years and up receiving chronic anticoagulant treatment showed higher survival than propensity-matched controls.
Patients 65 years and up receiving chronic anticoagulant treatment showed higher survival than propensity-matched controls.
Patients 65 years and up receiving chronic anticoagulant treatment showed higher survival than propensity-matched controls.
Patients 65 years and up receiving chronic anticoagulant treatment showed higher survival than propensity-matched controls.
Patients 65 years and up receiving chronic anticoagulant treatment showed higher survival than propensity-matched controls.
Patients 65 years and up receiving chronic anticoagulant treatment showed higher survival than propensity-matched controls.
The benefits of tocilizumab are unclear, and it can increase hospital stay time and the risk of secondary infection.
The benefits of tocilizumab are unclear, and it can increase hospital stay time and the risk of secondary infection.
The benefits of tocilizumab are unclear, and it can increase hospital stay time and the risk of secondary infection.
The benefits of tocilizumab are unclear, and it can increase hospital stay time and the risk of secondary infection.
The benefits of tocilizumab are unclear, and it can increase hospital stay time and the risk of secondary infection.
The benefits of tocilizumab are unclear, and it can increase hospital stay time and the risk of secondary infection.
The benefits of tocilizumab are unclear, and it can increase hospital stay time and the risk of secondary infection.
The benefits of tocilizumab are unclear, and it can increase hospital stay time and the risk of secondary infection.
The benefits of tocilizumab are unclear, and it can increase hospital stay time and the risk of secondary infection.
The benefits of tocilizumab are unclear, and it can increase hospital stay time and the risk of secondary infection.
While tocilizumab appears to show a 12% reduction in mortality in treated patients, a randomized clinical trial found no effects on mortality, and other evidence suggests that it may be beneficial only in certain circumstances.
While tocilizumab appears to show a 12% reduction in mortality in treated patients, a randomized clinical trial found no effects on mortality, and other evidence suggests that it may be beneficial only in certain circumstances.
While tocilizumab appears to show a 12% reduction in mortality in treated patients, a randomized clinical trial found no effects on mortality, and other evidence suggests that it may be beneficial only in certain circumstances.
While tocilizumab appears to show a 12% reduction in mortality in treated patients, a randomized clinical trial found no effects on mortality, and other evidence suggests that it may be beneficial only in certain circumstances.
While tocilizumab appears to show a 12% reduction in mortality in treated patients, a randomized clinical trial found no effects on mortality, and other evidence suggests that it may be beneficial only in certain circumstances.
While tocilizumab appears to show a 12% reduction in mortality in treated patients, a randomized clinical trial found no effects on mortality, and other evidence suggests that it may be beneficial only in certain circumstances.
While tocilizumab appears to show a 12% reduction in mortality in treated patients, a randomized clinical trial found no effects on mortality, and other evidence suggests that it may be beneficial only in certain circumstances.
While tocilizumab appears to show a 12% reduction in mortality in treated patients, a randomized clinical trial found no effects on mortality, and other evidence suggests that it may be beneficial only in certain circumstances.
While tocilizumab appears to show a 12% reduction in mortality in treated patients, a randomized clinical trial found no effects on mortality, and other evidence suggests that it may be beneficial only in certain circumstances.
While tocilizumab appears to show a 12% reduction in mortality in treated patients, a randomized clinical trial found no effects on mortality, and other evidence suggests that it may be beneficial only in certain circumstances.
Other pharmaceutical interventions are being investigated but results from large clinical trials are needed.
Other pharmaceutical interventions are being investigated but results from large clinical trials are needed.
Other pharmaceutical interventions are being investigated but results from large clinical trials are needed.
Other pharmaceutical interventions are being investigated but results from large clinical trials are needed.
Other pharmaceutical interventions are being investigated but results from large clinical trials are needed.
Other pharmaceutical interventions are being investigated but results from large clinical trials are needed.
Other pharmaceutical interventions are being investigated but results from large clinical trials are needed.
Other pharmaceutical interventions are being investigated but results from large clinical trials are needed.
Other pharmaceutical interventions are being investigated but results from large clinical trials are needed.
Other pharmaceutical interventions are being investigated but results from large clinical trials are needed.
Eli Lilly has received Emergency Use Authorization from the US FDA for its monoclonal antibody product, bamlanivimab, for use in recently diagnosed, mild to moderate COVID-19 patients.
Eli Lilly has received Emergency Use Authorization from the US FDA for its monoclonal antibody product, bamlanivimab, for use in recently diagnosed, mild to moderate COVID-19 patients.
Eli Lilly has received Emergency Use Authorization from the US FDA for its monoclonal antibody product, bamlanivimab, for use in recently diagnosed, mild to moderate COVID-19 patients.
Eli Lilly has received Emergency Use Authorization from the US FDA for its monoclonal antibody product, bamlanivimab, for use in recently diagnosed, mild to moderate COVID-19 patients.
Eli Lilly has received Emergency Use Authorization from the US FDA for its monoclonal antibody product, bamlanivimab, for use in recently diagnosed, mild to moderate COVID-19 patients.
Eli Lilly has received Emergency Use Authorization from the US FDA for its monoclonal antibody product, bamlanivimab, for use in recently diagnosed, mild to moderate COVID-19 patients.
Eli Lilly has received Emergency Use Authorization from the US FDA for its monoclonal antibody product, bamlanivimab, for use in recently diagnosed, mild to moderate COVID-19 patients.
Eli Lilly has received Emergency Use Authorization from the US FDA for its monoclonal antibody product, bamlanivimab, for use in recently diagnosed, mild to moderate COVID-19 patients.
Eli Lilly has received Emergency Use Authorization from the US FDA for its monoclonal antibody product, bamlanivimab, for use in recently diagnosed, mild to moderate COVID-19 patients.
Eli Lilly has received Emergency Use Authorization from the US FDA for its monoclonal antibody product, bamlanivimab, for use in recently diagnosed, mild to moderate COVID-19 patients.
Regeneron‚Äö√Ñ√∂‚àö√ë‚àö¬•s REGN-COV2 monoclonal antibody has been associated with reductions in symptom duration.
Regeneron‚Äö√Ñ√∂‚àö√ë‚àö¬•s REGN-COV2 monoclonal antibody has been associated with reductions in symptom duration.
Regeneron‚Äö√Ñ√∂‚àö√ë‚àö¬•s REGN-COV2 monoclonal antibody has been associated with reductions in symptom duration.
Regeneron‚Äö√Ñ√∂‚àö√ë‚àö¬•s REGN-COV2 monoclonal antibody has been associated with reductions in symptom duration.
Regeneron‚Äö√Ñ√∂‚àö√ë‚àö¬•s REGN-COV2 monoclonal antibody has been associated with reductions in symptom duration.
Regeneron‚Äö√Ñ√∂‚àö√ë‚àö¬•s REGN-COV2 monoclonal antibody has been associated with reductions in symptom duration.
Regeneron‚Äö√Ñ√∂‚àö√ë‚àö¬•s REGN-COV2 monoclonal antibody has been associated with reductions in symptom duration.
Regeneron‚Äö√Ñ√∂‚àö√ë‚àö¬•s REGN-COV2 monoclonal antibody has been associated with reductions in symptom duration.
Regeneron‚Äö√Ñ√∂‚àö√ë‚àö¬•s REGN-COV2 monoclonal antibody has been associated with reductions in symptom duration.
Regeneron‚Äö√Ñ√∂‚àö√ë‚àö¬•s REGN-COV2 monoclonal antibody has been associated with reductions in symptom duration.
However, data from both Eli Lilly and Regeneron suggest that their monoclonal antibody treatments may not work well for hospitalized patients or those with high oxygen requirements.
However, data from both Eli Lilly and Regeneron suggest that their monoclonal antibody treatments may not work well for hospitalized patients or those with high oxygen requirements.
However, data from both Eli Lilly and Regeneron suggest that their monoclonal antibody treatments may not work well for hospitalized patients or those with high oxygen requirements.
However, data from both Eli Lilly and Regeneron suggest that their monoclonal antibody treatments may not work well for hospitalized patients or those with high oxygen requirements.
However, data from both Eli Lilly and Regeneron suggest that their monoclonal antibody treatments may not work well for hospitalized patients or those with high oxygen requirements.
However, data from both Eli Lilly and Regeneron suggest that their monoclonal antibody treatments may not work well for hospitalized patients or those with high oxygen requirements.
However, data from both Eli Lilly and Regeneron suggest that their monoclonal antibody treatments may not work well for hospitalized patients or those with high oxygen requirements.
However, data from both Eli Lilly and Regeneron suggest that their monoclonal antibody treatments may not work well for hospitalized patients or those with high oxygen requirements.
However, data from both Eli Lilly and Regeneron suggest that their monoclonal antibody treatments may not work well for hospitalized patients or those with high oxygen requirements.
However, data from both Eli Lilly and Regeneron suggest that their monoclonal antibody treatments may not work well for hospitalized patients or those with high oxygen requirements.
Regeneron received Emergency Use Authorization for an antibody cocktail to treat mild/moderate COVID-19 patients.
Regeneron received Emergency Use Authorization for an antibody cocktail to treat mild/moderate COVID-19 patients.
Regeneron received Emergency Use Authorization for an antibody cocktail to treat mild/moderate COVID-19 patients.
Regeneron received Emergency Use Authorization for an antibody cocktail to treat mild/moderate COVID-19 patients.
Regeneron received Emergency Use Authorization for an antibody cocktail to treat mild/moderate COVID-19 patients.
Regeneron received Emergency Use Authorization for an antibody cocktail to treat mild/moderate COVID-19 patients.
Regeneron received Emergency Use Authorization for an antibody cocktail to treat mild/moderate COVID-19 patients.
Regeneron received Emergency Use Authorization for an antibody cocktail to treat mild/moderate COVID-19 patients.
Regeneron received Emergency Use Authorization for an antibody cocktail to treat mild/moderate COVID-19 patients.
Regeneron received Emergency Use Authorization for an antibody cocktail to treat mild/moderate COVID-19 patients.
A Phase II trial of inhaled interferon beta-1a showed benefits in terms of reduced disease severity, though results from the SOLIDARITY trial found no benefit of a separate interferon beta-1a formulation.
A Phase II trial of inhaled interferon beta-1a showed benefits in terms of reduced disease severity, though results from the SOLIDARITY trial found no benefit of a separate interferon beta-1a formulation.
A Phase II trial of inhaled interferon beta-1a showed benefits in terms of reduced disease severity, though results from the SOLIDARITY trial found no benefit of a separate interferon beta-1a formulation.
A Phase II trial of inhaled interferon beta-1a showed benefits in terms of reduced disease severity, though results from the SOLIDARITY trial found no benefit of a separate interferon beta-1a formulation.
A Phase II trial of inhaled interferon beta-1a showed benefits in terms of reduced disease severity, though results from the SOLIDARITY trial found no benefit of a separate interferon beta-1a formulation.
A Phase II trial of inhaled interferon beta-1a showed benefits in terms of reduced disease severity, though results from the SOLIDARITY trial found no benefit of a separate interferon beta-1a formulation.
A Phase II trial of inhaled interferon beta-1a showed benefits in terms of reduced disease severity, though results from the SOLIDARITY trial found no benefit of a separate interferon beta-1a formulation.
A Phase II trial of inhaled interferon beta-1a showed benefits in terms of reduced disease severity, though results from the SOLIDARITY trial found no benefit of a separate interferon beta-1a formulation.
A Phase II trial of inhaled interferon beta-1a showed benefits in terms of reduced disease severity, though results from the SOLIDARITY trial found no benefit of a separate interferon beta-1a formulation.
A Phase II trial of inhaled interferon beta-1a showed benefits in terms of reduced disease severity, though results from the SOLIDARITY trial found no benefit of a separate interferon beta-1a formulation.
Anakinra has shown clinical benefits in small observational studies, and may be effective with methylprednisolone.
Anakinra has shown clinical benefits in small observational studies, and may be effective with methylprednisolone.
Anakinra has shown clinical benefits in small observational studies, and may be effective with methylprednisolone.
Anakinra has shown clinical benefits in small observational studies, and may be effective with methylprednisolone.
Anakinra has shown clinical benefits in small observational studies, and may be effective with methylprednisolone.
Anakinra has shown clinical benefits in small observational studies, and may be effective with methylprednisolone.
Anakinra has shown clinical benefits in small observational studies, and may be effective with methylprednisolone.
Anakinra has shown clinical benefits in small observational studies, and may be effective with methylprednisolone.
Anakinra has shown clinical benefits in small observational studies, and may be effective with methylprednisolone.
Anakinra has shown clinical benefits in small observational studies, and may be effective with methylprednisolone.
Favipiravir may reduce the duration of clinical symptoms and reduce the time for viral clearance.
Favipiravir may reduce the duration of clinical symptoms and reduce the time for viral clearance.
Favipiravir may reduce the duration of clinical symptoms and reduce the time for viral clearance.
Favipiravir may reduce the duration of clinical symptoms and reduce the time for viral clearance.
Favipiravir may reduce the duration of clinical symptoms and reduce the time for viral clearance.
Favipiravir may reduce the duration of clinical symptoms and reduce the time for viral clearance.
Favipiravir may reduce the duration of clinical symptoms and reduce the time for viral clearance.
Favipiravir may reduce the duration of clinical symptoms and reduce the time for viral clearance.
Favipiravir may reduce the duration of clinical symptoms and reduce the time for viral clearance.
Favipiravir may reduce the duration of clinical symptoms and reduce the time for viral clearance.
Bradykinin inhibitors are being investigated as COVID-19 treatments, due to the potential role of bradykinins in disease.
Bradykinin inhibitors are being investigated as COVID-19 treatments, due to the potential role of bradykinins in disease.
Bradykinin inhibitors are being investigated as COVID-19 treatments, due to the potential role of bradykinins in disease.
Bradykinin inhibitors are being investigated as COVID-19 treatments, due to the potential role of bradykinins in disease.
Bradykinin inhibitors are being investigated as COVID-19 treatments, due to the potential role of bradykinins in disease.
Bradykinin inhibitors are being investigated as COVID-19 treatments, due to the potential role of bradykinins in disease.
Bradykinin inhibitors are being investigated as COVID-19 treatments, due to the potential role of bradykinins in disease.
Bradykinin inhibitors are being investigated as COVID-19 treatments, due to the potential role of bradykinins in disease.
Bradykinin inhibitors are being investigated as COVID-19 treatments, due to the potential role of bradykinins in disease.
Bradykinin inhibitors are being investigated as COVID-19 treatments, due to the potential role of bradykinins in disease.
Statins and RAAS inhibitors (for hypertension) do not appear to elevate COVID-19 risk and may protect against mortality in elderly patients who continue taking them.
Statins and RAAS inhibitors (for hypertension) do not appear to elevate COVID-19 risk and may protect against mortality in elderly patients who continue taking them.
Statins and RAAS inhibitors (for hypertension) do not appear to elevate COVID-19 risk and may protect against mortality in elderly patients who continue taking them.
Statins and RAAS inhibitors (for hypertension) do not appear to elevate COVID-19 risk and may protect against mortality in elderly patients who continue taking them.
Statins and RAAS inhibitors (for hypertension) do not appear to elevate COVID-19 risk and may protect against mortality in elderly patients who continue taking them.
Statins and RAAS inhibitors (for hypertension) do not appear to elevate COVID-19 risk and may protect against mortality in elderly patients who continue taking them.
Statins and RAAS inhibitors (for hypertension) do not appear to elevate COVID-19 risk and may protect against mortality in elderly patients who continue taking them.
Statins and RAAS inhibitors (for hypertension) do not appear to elevate COVID-19 risk and may protect against mortality in elderly patients who continue taking them.
Statins and RAAS inhibitors (for hypertension) do not appear to elevate COVID-19 risk and may protect against mortality in elderly patients who continue taking them.
Statins and RAAS inhibitors (for hypertension) do not appear to elevate COVID-19 risk and may protect against mortality in elderly patients who continue taking them.
Vitamin D (with vitamin B12 and magnesium) may reduce the need for ventilation in COVID-19 patients.
Vitamin D (with vitamin B12 and magnesium) may reduce the need for ventilation in COVID-19 patients.
Vitamin D (with vitamin B12 and magnesium) may reduce the need for ventilation in COVID-19 patients.
Vitamin D (with vitamin B12 and magnesium) may reduce the need for ventilation in COVID-19 patients.
Vitamin D (with vitamin B12 and magnesium) may reduce the need for ventilation in COVID-19 patients.
Vitamin D (with vitamin B12 and magnesium) may reduce the need for ventilation in COVID-19 patients.
Vitamin D (with vitamin B12 and magnesium) may reduce the need for ventilation in COVID-19 patients.
Vitamin D (with vitamin B12 and magnesium) may reduce the need for ventilation in COVID-19 patients.
Vitamin D (with vitamin B12 and magnesium) may reduce the need for ventilation in COVID-19 patients.
Vitamin D (with vitamin B12 and magnesium) may reduce the need for ventilation in COVID-19 patients.
Acalabrutinib may improve patient oxygenation, and is being included in large clinical trials (SOLIDARITY).
Acalabrutinib may improve patient oxygenation, and is being included in large clinical trials (SOLIDARITY).
Acalabrutinib may improve patient oxygenation, and is being included in large clinical trials (SOLIDARITY).
Acalabrutinib may improve patient oxygenation, and is being included in large clinical trials (SOLIDARITY).
Acalabrutinib may improve patient oxygenation, and is being included in large clinical trials (SOLIDARITY).
Acalabrutinib may improve patient oxygenation, and is being included in large clinical trials (SOLIDARITY).
Acalabrutinib may improve patient oxygenation, and is being included in large clinical trials (SOLIDARITY).
Acalabrutinib may improve patient oxygenation, and is being included in large clinical trials (SOLIDARITY).
Acalabrutinib may improve patient oxygenation, and is being included in large clinical trials (SOLIDARITY).
Acalabrutinib may improve patient oxygenation, and is being included in large clinical trials (SOLIDARITY).
Colchicine may reduce rates of intubation and mortality.
Colchicine may reduce rates of intubation and mortality.
Colchicine may reduce rates of intubation and mortality.
Colchicine may reduce rates of intubation and mortality.
Colchicine may reduce rates of intubation and mortality.
Colchicine may reduce rates of intubation and mortality.
Colchicine may reduce rates of intubation and mortality.
Colchicine may reduce rates of intubation and mortality.
Colchicine may reduce rates of intubation and mortality.
Colchicine may reduce rates of intubation and mortality.
Ivermectin reduced viral shedding duration in a small clinical trial (n=72).
Ivermectin reduced viral shedding duration in a small clinical trial (n=72).
Ivermectin reduced viral shedding duration in a small clinical trial (n=72).
Ivermectin reduced viral shedding duration in a small clinical trial (n=72).
Ivermectin reduced viral shedding duration in a small clinical trial (n=72).
Ivermectin reduced viral shedding duration in a small clinical trial (n=72).
Ivermectin reduced viral shedding duration in a small clinical trial (n=72).
Ivermectin reduced viral shedding duration in a small clinical trial (n=72).
Ivermectin reduced viral shedding duration in a small clinical trial (n=72).
Ivermectin reduced viral shedding duration in a small clinical trial (n=72).
IV immunoglobulin reduced the need for mechanical ventilation in a small trial (n=16).
IV immunoglobulin reduced the need for mechanical ventilation in a small trial (n=16).
IV immunoglobulin reduced the need for mechanical ventilation in a small trial (n=16).
IV immunoglobulin reduced the need for mechanical ventilation in a small trial (n=16).
IV immunoglobulin reduced the need for mechanical ventilation in a small trial (n=16).
IV immunoglobulin reduced the need for mechanical ventilation in a small trial (n=16).
IV immunoglobulin reduced the need for mechanical ventilation in a small trial (n=16).
IV immunoglobulin reduced the need for mechanical ventilation in a small trial (n=16).
IV immunoglobulin reduced the need for mechanical ventilation in a small trial (n=16).
IV immunoglobulin reduced the need for mechanical ventilation in a small trial (n=16).
Androgen has been suggested as a factor in disease severity in men, and treatment options are in trial.
Androgen has been suggested as a factor in disease severity in men, and treatment options are in trial.
Androgen has been suggested as a factor in disease severity in men, and treatment options are in trial.
Androgen has been suggested as a factor in disease severity in men, and treatment options are in trial.
Androgen has been suggested as a factor in disease severity in men, and treatment options are in trial.
Androgen has been suggested as a factor in disease severity in men, and treatment options are in trial.
Androgen has been suggested as a factor in disease severity in men, and treatment options are in trial.
Androgen has been suggested as a factor in disease severity in men, and treatment options are in trial.
Androgen has been suggested as a factor in disease severity in men, and treatment options are in trial.
Androgen has been suggested as a factor in disease severity in men, and treatment options are in trial.
Insulin use may increase mortality risk compared to other type 2 diabetes treatments such as metformin.
Insulin use may increase mortality risk compared to other type 2 diabetes treatments such as metformin.
Insulin use may increase mortality risk compared to other type 2 diabetes treatments such as metformin.
Insulin use may increase mortality risk compared to other type 2 diabetes treatments such as metformin.
Insulin use may increase mortality risk compared to other type 2 diabetes treatments such as metformin.
Insulin use may increase mortality risk compared to other type 2 diabetes treatments such as metformin.
Insulin use may increase mortality risk compared to other type 2 diabetes treatments such as metformin.
Insulin use may increase mortality risk compared to other type 2 diabetes treatments such as metformin.
Insulin use may increase mortality risk compared to other type 2 diabetes treatments such as metformin.
Insulin use may increase mortality risk compared to other type 2 diabetes treatments such as metformin.
Several vaccine candidates have shown promising Phase III trial results, and one is currently being administered under FDA Emergency Use Authorization.
Several vaccine candidates have shown promising Phase III trial results, and one is currently being administered under FDA Emergency Use Authorization.
Several vaccine candidates have shown promising Phase III trial results, and one is currently being administered under FDA Emergency Use Authorization.
Several vaccine candidates have shown promising Phase III trial results, and one is currently being administered under FDA Emergency Use Authorization.
Several vaccine candidates have shown promising Phase III trial results, and one is currently being administered under FDA Emergency Use Authorization.
Several vaccine candidates have shown promising Phase III trial results, and one is currently being administered under FDA Emergency Use Authorization.
Several vaccine candidates have shown promising Phase III trial results, and one is currently being administered under FDA Emergency Use Authorization.
Several vaccine candidates have shown promising Phase III trial results, and one is currently being administered under FDA Emergency Use Authorization.
Several vaccine candidates have shown promising Phase III trial results, and one is currently being administered under FDA Emergency Use Authorization.
Several vaccine candidates have shown promising Phase III trial results, and one is currently being administered under FDA Emergency Use Authorization.
In the US, vaccination priority is being given to healthcare workers and long-term care residents (1a), all individuals 75 and older and frontline essential workers (1b), and all people 65-75 and those 16-64 with high-risk medical conditions (1c).
In the US, vaccination priority is being given to healthcare workers and long-term care residents (1a), all individuals 75 and older and frontline essential workers (1b), and all people 65-75 and those 16-64 with high-risk medical conditions (1c).
In the US, vaccination priority is being given to healthcare workers and long-term care residents (1a), all individuals 75 and older and frontline essential workers (1b), and all people 65-75 and those 16-64 with high-risk medical conditions (1c).
In the US, vaccination priority is being given to healthcare workers and long-term care residents (1a), all individuals 75 and older and frontline essential workers (1b), and all people 65-75 and those 16-64 with high-risk medical conditions (1c).
In the US, vaccination priority is being given to healthcare workers and long-term care residents (1a), all individuals 75 and older and frontline essential workers (1b), and all people 65-75 and those 16-64 with high-risk medical conditions (1c).
In the US, vaccination priority is being given to healthcare workers and long-term care residents (1a), all individuals 75 and older and frontline essential workers (1b), and all people 65-75 and those 16-64 with high-risk medical conditions (1c).
In the US, vaccination priority is being given to healthcare workers and long-term care residents (1a), all individuals 75 and older and frontline essential workers (1b), and all people 65-75 and those 16-64 with high-risk medical conditions (1c).
In the US, vaccination priority is being given to healthcare workers and long-term care residents (1a), all individuals 75 and older and frontline essential workers (1b), and all people 65-75 and those 16-64 with high-risk medical conditions (1c).
In the US, vaccination priority is being given to healthcare workers and long-term care residents (1a), all individuals 75 and older and frontline essential workers (1b), and all people 65-75 and those 16-64 with high-risk medical conditions (1c).
In the US, vaccination priority is being given to healthcare workers and long-term care residents (1a), all individuals 75 and older and frontline essential workers (1b), and all people 65-75 and those 16-64 with high-risk medical conditions (1c).
There were study participants, with 162 cases (9 severe) in the placebo group and 8 cases (1 severe) in vaccine group.
There were study participants, with 162 cases (9 severe) in the placebo group and 8 cases (1 severe) in vaccine group.
There were study participants, with 162 cases (9 severe) in the placebo group and 8 cases (1 severe) in vaccine group.
There were study participants, with 162 cases (9 severe) in the placebo group and 8 cases (1 severe) in vaccine group.
There were study participants, with 162 cases (9 severe) in the placebo group and 8 cases (1 severe) in vaccine group.
There were study participants, with 162 cases (9 severe) in the placebo group and 8 cases (1 severe) in vaccine group.
There were study participants, with 162 cases (9 severe) in the placebo group and 8 cases (1 severe) in vaccine group.
There were study participants, with 162 cases (9 severe) in the placebo group and 8 cases (1 severe) in vaccine group.
There were study participants, with 162 cases (9 severe) in the placebo group and 8 cases (1 severe) in vaccine group.
There were study participants, with 162 cases (9 severe) in the placebo group and 8 cases (1 severe) in vaccine group.
Safety was assessed in children (n=100, 12-15 years old), racially and ethnically diverse patients (30-42% of trial pool), and individuals 56-85 years old (41-45% of participants).
Safety was assessed in children (n=100, 12-15 years old), racially and ethnically diverse patients (30-42% of trial pool), and individuals 56-85 years old (41-45% of participants).
Safety was assessed in children (n=100, 12-15 years old), racially and ethnically diverse patients (30-42% of trial pool), and individuals 56-85 years old (41-45% of participants).
Safety was assessed in children (n=100, 12-15 years old), racially and ethnically diverse patients (30-42% of trial pool), and individuals 56-85 years old (41-45% of participants).
Safety was assessed in children (n=100, 12-15 years old), racially and ethnically diverse patients (30-42% of trial pool), and individuals 56-85 years old (41-45% of participants).
Safety was assessed in children (n=100, 12-15 years old), racially and ethnically diverse patients (30-42% of trial pool), and individuals 56-85 years old (41-45% of participants).
Safety was assessed in children (n=100, 12-15 years old), racially and ethnically diverse patients (30-42% of trial pool), and individuals 56-85 years old (41-45% of participants).
Safety was assessed in children (n=100, 12-15 years old), racially and ethnically diverse patients (30-42% of trial pool), and individuals 56-85 years old (41-45% of participants).
Safety was assessed in children (n=100, 12-15 years old), racially and ethnically diverse patients (30-42% of trial pool), and individuals 56-85 years old (41-45% of participants).
Safety was assessed in children (n=100, 12-15 years old), racially and ethnically diverse patients (30-42% of trial pool), and individuals 56-85 years old (41-45% of participants).
No serious safety concerns were observed, and adverse events included fatigue (3.8%) and headache (2.0%).
No serious safety concerns were observed, and adverse events included fatigue (3.8%) and headache (2.0%).
No serious safety concerns were observed, and adverse events included fatigue (3.8%) and headache (2.0%).
No serious safety concerns were observed, and adverse events included fatigue (3.8%) and headache (2.0%).
No serious safety concerns were observed, and adverse events included fatigue (3.8%) and headache (2.0%).
No serious safety concerns were observed, and adverse events included fatigue (3.8%) and headache (2.0%).
No serious safety concerns were observed, and adverse events included fatigue (3.8%) and headache (2.0%).
No serious safety concerns were observed, and adverse events included fatigue (3.8%) and headache (2.0%).
No serious safety concerns were observed, and adverse events included fatigue (3.8%) and headache (2.0%).
No serious safety concerns were observed, and adverse events included fatigue (3.8%) and headache (2.0%).
Other common side effects included pain at the injection site and muscle pain.
Other common side effects included pain at the injection site and muscle pain.
Other common side effects included pain at the injection site and muscle pain.
Other common side effects included pain at the injection site and muscle pain.
Other common side effects included pain at the injection site and muscle pain.
Other common side effects included pain at the injection site and muscle pain.
Other common side effects included pain at the injection site and muscle pain.
Other common side effects included pain at the injection site and muscle pain.
Other common side effects included pain at the injection site and muscle pain.
Other common side effects included pain at the injection site and muscle pain.
After reports of two allergic reactions in UK healthcare workers, the US CDC concluded that individuals with known allergies to foods, latex, or pollen (for instance) do not have to take special precautions for the Pfizer/BioNTech vaccine, but should talk to their doctor and be observed for 30 minutes after vaccination.
After reports of two allergic reactions in UK healthcare workers, the US CDC concluded that individuals with known allergies to foods, latex, or pollen (for instance) do not have to take special precautions for the Pfizer/BioNTech vaccine, but should talk to their doctor and be observed for 30 minutes after vaccination.
After reports of two allergic reactions in UK healthcare workers, the US CDC concluded that individuals with known allergies to foods, latex, or pollen (for instance) do not have to take special precautions for the Pfizer/BioNTech vaccine, but should talk to their doctor and be observed for 30 minutes after vaccination.
After reports of two allergic reactions in UK healthcare workers, the US CDC concluded that individuals with known allergies to foods, latex, or pollen (for instance) do not have to take special precautions for the Pfizer/BioNTech vaccine, but should talk to their doctor and be observed for 30 minutes after vaccination.
After reports of two allergic reactions in UK healthcare workers, the US CDC concluded that individuals with known allergies to foods, latex, or pollen (for instance) do not have to take special precautions for the Pfizer/BioNTech vaccine, but should talk to their doctor and be observed for 30 minutes after vaccination.
After reports of two allergic reactions in UK healthcare workers, the US CDC concluded that individuals with known allergies to foods, latex, or pollen (for instance) do not have to take special precautions for the Pfizer/BioNTech vaccine, but should talk to their doctor and be observed for 30 minutes after vaccination.
After reports of two allergic reactions in UK healthcare workers, the US CDC concluded that individuals with known allergies to foods, latex, or pollen (for instance) do not have to take special precautions for the Pfizer/BioNTech vaccine, but should talk to their doctor and be observed for 30 minutes after vaccination.
After reports of two allergic reactions in UK healthcare workers, the US CDC concluded that individuals with known allergies to foods, latex, or pollen (for instance) do not have to take special precautions for the Pfizer/BioNTech vaccine, but should talk to their doctor and be observed for 30 minutes after vaccination.
After reports of two allergic reactions in UK healthcare workers, the US CDC concluded that individuals with known allergies to foods, latex, or pollen (for instance) do not have to take special precautions for the Pfizer/BioNTech vaccine, but should talk to their doctor and be observed for 30 minutes after vaccination.
After reports of two allergic reactions in UK healthcare workers, the US CDC concluded that individuals with known allergies to foods, latex, or pollen (for instance) do not have to take special precautions for the Pfizer/BioNTech vaccine, but should talk to their doctor and be observed for 30 minutes after vaccination.
Storage and shipping requirements are -70¬¨¬®‚Äö√†√ªC; once thawed, the vaccine vial can be stored for up to 5 days at refrigerated (2‚Äö√Ñ√∂‚àö√ë‚àö¬®8¬¨¬®‚Äö√†√ªC) conditions.
Storage and shipping requirements are -70¬¨¬®‚Äö√†√ªC; once thawed, the vaccine vial can be stored for up to 5 days at refrigerated (2‚Äö√Ñ√∂‚àö√ë‚àö¬®8¬¨¬®‚Äö√†√ªC) conditions.
Storage and shipping requirements are -70¬¨¬®‚Äö√†√ªC; once thawed, the vaccine vial can be stored for up to 5 days at refrigerated (2‚Äö√Ñ√∂‚àö√ë‚àö¬®8¬¨¬®‚Äö√†√ªC) conditions.
Storage and shipping requirements are -70¬¨¬®‚Äö√†√ªC; once thawed, the vaccine vial can be stored for up to 5 days at refrigerated (2‚Äö√Ñ√∂‚àö√ë‚àö¬®8¬¨¬®‚Äö√†√ªC) conditions.
Storage and shipping requirements are -70¬¨¬®‚Äö√†√ªC; once thawed, the vaccine vial can be stored for up to 5 days at refrigerated (2‚Äö√Ñ√∂‚àö√ë‚àö¬®8¬¨¬®‚Äö√†√ªC) conditions.
Storage and shipping requirements are -70¬¨¬®‚Äö√†√ªC; once thawed, the vaccine vial can be stored for up to 5 days at refrigerated (2‚Äö√Ñ√∂‚àö√ë‚àö¬®8¬¨¬®‚Äö√†√ªC) conditions.
Storage and shipping requirements are -70¬¨¬®‚Äö√†√ªC; once thawed, the vaccine vial can be stored for up to 5 days at refrigerated (2‚Äö√Ñ√∂‚àö√ë‚àö¬®8¬¨¬®‚Äö√†√ªC) conditions.
Storage and shipping requirements are -70¬¨¬®‚Äö√†√ªC; once thawed, the vaccine vial can be stored for up to 5 days at refrigerated (2‚Äö√Ñ√∂‚àö√ë‚àö¬®8¬¨¬®‚Äö√†√ªC) conditions.
Storage and shipping requirements are -70¬¨¬®‚Äö√†√ªC; once thawed, the vaccine vial can be stored for up to 5 days at refrigerated (2‚Äö√Ñ√∂‚àö√ë‚àö¬®8¬¨¬®‚Äö√†√ªC) conditions.
Storage and shipping requirements are -70¬¨¬®‚Äö√†√ªC; once thawed, the vaccine vial can be stored for up to 5 days at refrigerated (2‚Äö√Ñ√∂‚àö√ë‚àö¬®8¬¨¬®‚Äö√†√ªC) conditions.
Pfizer and BioNTech received Emergency Use Authorization from the USFDA for individuals 16 and older.
Pfizer and BioNTech received Emergency Use Authorization from the USFDA for individuals 16 and older.
Pfizer and BioNTech received Emergency Use Authorization from the USFDA for individuals 16 and older.
Pfizer and BioNTech received Emergency Use Authorization from the USFDA for individuals 16 and older.
Pfizer and BioNTech received Emergency Use Authorization from the USFDA for individuals 16 and older.
Pfizer and BioNTech received Emergency Use Authorization from the USFDA for individuals 16 and older.
Pfizer and BioNTech received Emergency Use Authorization from the USFDA for individuals 16 and older.
Pfizer and BioNTech received Emergency Use Authorization from the USFDA for individuals 16 and older.
Pfizer and BioNTech received Emergency Use Authorization from the USFDA for individuals 16 and older.
Pfizer and BioNTech received Emergency Use Authorization from the USFDA for individuals 16 and older.
The vaccine is given as 2 shots, 28 days apart.
The vaccine is given as 2 shots, 28 days apart.
The vaccine is given as 2 shots, 28 days apart.
The vaccine is given as 2 shots, 28 days apart.
At the conclusion of the Phase III clinical trial, the vaccine showed 94.1% efficacy, 14 days after the second dose.
At the conclusion of the Phase III clinical trial, the vaccine showed 94.1% efficacy, 14 days after the second dose.
At the conclusion of the Phase III clinical trial, the vaccine showed 94.1% efficacy, 14 days after the second dose.
At the conclusion of the Phase III clinical trial, the vaccine showed 94.1% efficacy, 14 days after the second dose.
At the conclusion of the Phase III clinical trial, the vaccine showed 94.1% efficacy, 14 days after the second dose.
At the conclusion of the Phase III clinical trial, the vaccine showed 94.1% efficacy, 14 days after the second dose.
At the conclusion of the Phase III clinical trial, the vaccine showed 94.1% efficacy, 14 days after the second dose.
At the conclusion of the Phase III clinical trial, the vaccine showed 94.1% efficacy, 14 days after the second dose.
At the conclusion of the Phase III clinical trial, the vaccine showed 94.1% efficacy, 14 days after the second dose.
At the conclusion of the Phase III clinical trial, the vaccine showed 94.1% efficacy, 14 days after the second dose.
Efficacy was consistent across age, race, ethnicity, and sex.456 Vaccine-induced antibodies persisted for at least 119 days.
Efficacy was consistent across age, race, ethnicity, and sex.456 Vaccine-induced antibodies persisted for at least 119 days.
Efficacy was consistent across age, race, ethnicity, and sex.456 Vaccine-induced antibodies persisted for at least 119 days.
Efficacy was consistent across age, race, ethnicity, and sex.456 Vaccine-induced antibodies persisted for at least 119 days.
Efficacy was consistent across age, race, ethnicity, and sex.456 Vaccine-induced antibodies persisted for at least 119 days.
Efficacy was consistent across age, race, ethnicity, and sex.456 Vaccine-induced antibodies persisted for at least 119 days.
Efficacy was consistent across age, race, ethnicity, and sex.456 Vaccine-induced antibodies persisted for at least 119 days.
Efficacy was consistent across age, race, ethnicity, and sex.456 Vaccine-induced antibodies persisted for at least 119 days.
Efficacy was consistent across age, race, ethnicity, and sex.456 Vaccine-induced antibodies persisted for at least 119 days.
Efficacy was consistent across age, race, ethnicity, and sex.456 Vaccine-induced antibodies persisted for at least 119 days.
Side effects included fatigue (10%), muscle aches (9%), joint paint (5%), and headaches (5%).
Side effects included fatigue (10%), muscle aches (9%), joint paint (5%), and headaches (5%).
Side effects included fatigue (10%), muscle aches (9%), joint paint (5%), and headaches (5%).
Side effects included fatigue (10%), muscle aches (9%), joint paint (5%), and headaches (5%).
Side effects included fatigue (10%), muscle aches (9%), joint paint (5%), and headaches (5%).
Side effects included fatigue (10%), muscle aches (9%), joint paint (5%), and headaches (5%).
Side effects included fatigue (10%), muscle aches (9%), joint paint (5%), and headaches (5%).
Side effects included fatigue (10%), muscle aches (9%), joint paint (5%), and headaches (5%).
Side effects included fatigue (10%), muscle aches (9%), joint paint (5%), and headaches (5%).
Side effects included fatigue (10%), muscle aches (9%), joint paint (5%), and headaches (5%).
Pain and redness at the injection site were also noted; adverse events increased in frequency after the second dose.
Pain and redness at the injection site were also noted; adverse events increased in frequency after the second dose.
Pain and redness at the injection site were also noted; adverse events increased in frequency after the second dose.
Pain and redness at the injection site were also noted; adverse events increased in frequency after the second dose.
Pain and redness at the injection site were also noted; adverse events increased in frequency after the second dose.
Pain and redness at the injection site were also noted; adverse events increased in frequency after the second dose.
Pain and redness at the injection site were also noted; adverse events increased in frequency after the second dose.
Pain and redness at the injection site were also noted; adverse events increased in frequency after the second dose.
Pain and redness at the injection site were also noted; adverse events increased in frequency after the second dose.
Pain and redness at the injection site were also noted; adverse events increased in frequency after the second dose.
The vaccine can be shipped and stored at standard freezer temperatures (-20¬¨¬®‚Äö√†√ªC) for 6 months, and is expected to be stable under refrigeration (2-8¬¨¬®‚Äö√†√ªC) for 30 days and at room temperature for 12 hours.
The vaccine can be shipped and stored at standard freezer temperatures (-20¬¨¬®‚Äö√†√ªC) for 6 months, and is expected to be stable under refrigeration (2-8¬¨¬®‚Äö√†√ªC) for 30 days and at room temperature for 12 hours.
The vaccine can be shipped and stored at standard freezer temperatures (-20¬¨¬®‚Äö√†√ªC) for 6 months, and is expected to be stable under refrigeration (2-8¬¨¬®‚Äö√†√ªC) for 30 days and at room temperature for 12 hours.
The vaccine can be shipped and stored at standard freezer temperatures (-20¬¨¬®‚Äö√†√ªC) for 6 months, and is expected to be stable under refrigeration (2-8¬¨¬®‚Äö√†√ªC) for 30 days and at room temperature for 12 hours.
The vaccine can be shipped and stored at standard freezer temperatures (-20¬¨¬®‚Äö√†√ªC) for 6 months, and is expected to be stable under refrigeration (2-8¬¨¬®‚Äö√†√ªC) for 30 days and at room temperature for 12 hours.
The vaccine can be shipped and stored at standard freezer temperatures (-20¬¨¬®‚Äö√†√ªC) for 6 months, and is expected to be stable under refrigeration (2-8¬¨¬®‚Äö√†√ªC) for 30 days and at room temperature for 12 hours.
The vaccine can be shipped and stored at standard freezer temperatures (-20¬¨¬®‚Äö√†√ªC) for 6 months, and is expected to be stable under refrigeration (2-8¬¨¬®‚Äö√†√ªC) for 30 days and at room temperature for 12 hours.
The vaccine can be shipped and stored at standard freezer temperatures (-20¬¨¬®‚Äö√†√ªC) for 6 months, and is expected to be stable under refrigeration (2-8¬¨¬®‚Äö√†√ªC) for 30 days and at room temperature for 12 hours.
The vaccine can be shipped and stored at standard freezer temperatures (-20¬¨¬®‚Äö√†√ªC) for 6 months, and is expected to be stable under refrigeration (2-8¬¨¬®‚Äö√†√ªC) for 30 days and at room temperature for 12 hours.
The vaccine can be shipped and stored at standard freezer temperatures (-20¬¨¬®‚Äö√†√ªC) for 6 months, and is expected to be stable under refrigeration (2-8¬¨¬®‚Äö√†√ªC) for 30 days and at room temperature for 12 hours.
Moderna was granted an EUA from the USFDA for individuals 18 and older.
Moderna was granted an EUA from the USFDA for individuals 18 and older.
Moderna was granted an EUA from the USFDA for individuals 18 and older.
The adenovirus vaccine candidate AZD1222 (from University of Oxford and AstraZeneca) showed 62% efficacy in individuals given two full doses, and 90% efficacy in an accidental subset of individuals given a half dose followed by a full dose.
The adenovirus vaccine candidate AZD1222 (from University of Oxford and AstraZeneca) showed 62% efficacy in individuals given two full doses, and 90% efficacy in an accidental subset of individuals given a half dose followed by a full dose.
The adenovirus vaccine candidate AZD1222 (from University of Oxford and AstraZeneca) showed 62% efficacy in individuals given two full doses, and 90% efficacy in an accidental subset of individuals given a half dose followed by a full dose.
The adenovirus vaccine candidate AZD1222 (from University of Oxford and AstraZeneca) showed 62% efficacy in individuals given two full doses, and 90% efficacy in an accidental subset of individuals given a half dose followed by a full dose.
The adenovirus vaccine candidate AZD1222 (from University of Oxford and AstraZeneca) showed 62% efficacy in individuals given two full doses, and 90% efficacy in an accidental subset of individuals given a half dose followed by a full dose.
The adenovirus vaccine candidate AZD1222 (from University of Oxford and AstraZeneca) showed 62% efficacy in individuals given two full doses, and 90% efficacy in an accidental subset of individuals given a half dose followed by a full dose.
The adenovirus vaccine candidate AZD1222 (from University of Oxford and AstraZeneca) showed 62% efficacy in individuals given two full doses, and 90% efficacy in an accidental subset of individuals given a half dose followed by a full dose.
The adenovirus vaccine candidate AZD1222 (from University of Oxford and AstraZeneca) showed 62% efficacy in individuals given two full doses, and 90% efficacy in an accidental subset of individuals given a half dose followed by a full dose.
The adenovirus vaccine candidate AZD1222 (from University of Oxford and AstraZeneca) showed 62% efficacy in individuals given two full doses, and 90% efficacy in an accidental subset of individuals given a half dose followed by a full dose.
The adenovirus vaccine candidate AZD1222 (from University of Oxford and AstraZeneca) showed 62% efficacy in individuals given two full doses, and 90% efficacy in an accidental subset of individuals given a half dose followed by a full dose.
None of the individuals in the accidental dosing cohort were over 55, potentially explaining discrepancies in efficacy results.
None of the individuals in the accidental dosing cohort were over 55, potentially explaining discrepancies in efficacy results.
None of the individuals in the accidental dosing cohort were over 55, potentially explaining discrepancies in efficacy results.
None of the individuals in the accidental dosing cohort were over 55, potentially explaining discrepancies in efficacy results.
None of the individuals in the accidental dosing cohort were over 55, potentially explaining discrepancies in efficacy results.
None of the individuals in the accidental dosing cohort were over 55, potentially explaining discrepancies in efficacy results.
None of the individuals in the accidental dosing cohort were over 55, potentially explaining discrepancies in efficacy results.
None of the individuals in the accidental dosing cohort were over 55, potentially explaining discrepancies in efficacy results.
None of the individuals in the accidental dosing cohort were over 55, potentially explaining discrepancies in efficacy results.
None of the individuals in the accidental dosing cohort were over 55, potentially explaining discrepancies in efficacy results.
The vaccine appears safe, and instills a robust immune response across age groups.
The vaccine appears safe, and instills a robust immune response across age groups.
The vaccine appears safe, and instills a robust immune response across age groups.
The vaccine appears safe, and instills a robust immune response across age groups.
The vaccine appears safe, and instills a robust immune response across age groups.
The vaccine appears safe, and instills a robust immune response across age groups.
The vaccine appears safe, and instills a robust immune response across age groups.
The vaccine appears safe, and instills a robust immune response across age groups.
The vaccine appears safe, and instills a robust immune response across age groups.
The vaccine appears safe, and instills a robust immune response across age groups.
The vaccine is given in two doses, 1 month apart.
The vaccine is given in two doses, 1 month apart.
The vaccine is given in two doses, 1 month apart.
The vaccine is given in two doses, 1 month apart.
The vaccine is given in two doses, 1 month apart.
The vaccine is given in two doses, 1 month apart.
The vaccine is given in two doses, 1 month apart.
The vaccine is given in two doses, 1 month apart.
The vaccine is given in two doses, 1 month apart.
The vaccine is given in two doses, 1 month apart.
The Phase III trial included 23,000 participants, all over 18.
The Phase III trial included 23,000 participants, all over 18.
The Phase III trial included 23,000 participants, all over 18.
The Phase III trial included 23,000 participants, all over 18.
The Phase III trial included 23,000 participants, all over 18.
The Phase III trial included 23,000 participants, all over 18.
The Phase III trial included 23,000 participants, all over 18.
The Phase III trial included 23,000 participants, all over 18.
The Phase III trial included 23,000 participants, all over 18.
The Phase III trial included 23,000 participants, all over 18.
The vaccine is stable at 2-8¬¨¬®‚Äö√†√ªC for up to 6 months.
The vaccine is stable at 2-8¬¨¬®‚Äö√†√ªC for up to 6 months.
The vaccine is stable at 2-8¬¨¬®‚Äö√†√ªC for up to 6 months.
The vaccine is stable at 2-8¬¨¬®‚Äö√†√ªC for up to 6 months.
The vaccine is stable at 2-8¬¨¬®‚Äö√†√ªC for up to 6 months.
The vaccine is stable at 2-8¬¨¬®‚Äö√†√ªC for up to 6 months.
The vaccine is stable at 2-8¬¨¬®‚Äö√†√ªC for up to 6 months.
The vaccine is stable at 2-8¬¨¬®‚Äö√†√ªC for up to 6 months.
The vaccine is stable at 2-8¬¨¬®‚Äö√†√ªC for up to 6 months.
The vaccine is stable at 2-8¬¨¬®‚Äö√†√ªC for up to 6 months.
Sinovac has begun Phase III trials of its CoronaVac inactivated vaccine candidate in healthcare professionals.
Sinovac has begun Phase III trials of its CoronaVac inactivated vaccine candidate in healthcare professionals.
Sinovac has begun Phase III trials of its CoronaVac inactivated vaccine candidate in healthcare professionals.
Sinovac has begun Phase III trials of its CoronaVac inactivated vaccine candidate in healthcare professionals.
Sinovac has begun Phase III trials of its CoronaVac inactivated vaccine candidate in healthcare professionals.
Sinovac has begun Phase III trials of its CoronaVac inactivated vaccine candidate in healthcare professionals.
Sinovac has begun Phase III trials of its CoronaVac inactivated vaccine candidate in healthcare professionals.
Sinovac has begun Phase III trials of its CoronaVac inactivated vaccine candidate in healthcare professionals.
Sinovac has begun Phase III trials of its CoronaVac inactivated vaccine candidate in healthcare professionals.
Sinovac has begun Phase III trials of its CoronaVac inactivated vaccine candidate in healthcare professionals.
Sinopharm has begun Phase III trials of two of its inactivated SARS-CoV-2 vaccine candidates.
Sinopharm has begun Phase III trials of two of its inactivated SARS-CoV-2 vaccine candidates.
Sinopharm has begun Phase III trials of two of its inactivated SARS-CoV-2 vaccine candidates.
Sinopharm has begun Phase III trials of two of its inactivated SARS-CoV-2 vaccine candidates.
Sinopharm has begun Phase III trials of two of its inactivated SARS-CoV-2 vaccine candidates.
Sinopharm has begun Phase III trials of two of its inactivated SARS-CoV-2 vaccine candidates.
Sinopharm has begun Phase III trials of two of its inactivated SARS-CoV-2 vaccine candidates.
Sinopharm has begun Phase III trials of two of its inactivated SARS-CoV-2 vaccine candidates.
Sinopharm has begun Phase III trials of two of its inactivated SARS-CoV-2 vaccine candidates.
Sinopharm has begun Phase III trials of two of its inactivated SARS-CoV-2 vaccine candidates.
Janssen, with Johnson and Johnson, has begun a Phase III trial with 60,000 participants for their adenovirus candidate.
Janssen, with Johnson and Johnson, has begun a Phase III trial with 60,000 participants for their adenovirus candidate.
Janssen, with Johnson and Johnson, has begun a Phase III trial with 60,000 participants for their adenovirus candidate.
Janssen, with Johnson and Johnson, has begun a Phase III trial with 60,000 participants for their adenovirus candidate.
Janssen, with Johnson and Johnson, has begun a Phase III trial with 60,000 participants for their adenovirus candidate.
Janssen, with Johnson and Johnson, has begun a Phase III trial with 60,000 participants for their adenovirus candidate.
Janssen, with Johnson and Johnson, has begun a Phase III trial with 60,000 participants for their adenovirus candidate.
Janssen, with Johnson and Johnson, has begun a Phase III trial with 60,000 participants for their adenovirus candidate.
Janssen, with Johnson and Johnson, has begun a Phase III trial with 60,000 participants for their adenovirus candidate.
Janssen, with Johnson and Johnson, has begun a Phase III trial with 60,000 participants for their adenovirus candidate.
CanSino‚Äö√Ñ√∂‚àö√ë‚àö¬•s Ad5-nCoV adenovirus vaccine is undergoing Phase III clinical trials.
CanSino‚Äö√Ñ√∂‚àö√ë‚àö¬•s Ad5-nCoV adenovirus vaccine is undergoing Phase III clinical trials.
CanSino‚Äö√Ñ√∂‚àö√ë‚àö¬•s Ad5-nCoV adenovirus vaccine is undergoing Phase III clinical trials.
CanSino‚Äö√Ñ√∂‚àö√ë‚àö¬•s Ad5-nCoV adenovirus vaccine is undergoing Phase III clinical trials.
CanSino‚Äö√Ñ√∂‚àö√ë‚àö¬•s Ad5-nCoV adenovirus vaccine is undergoing Phase III clinical trials.
CanSino‚Äö√Ñ√∂‚àö√ë‚àö¬•s Ad5-nCoV adenovirus vaccine is undergoing Phase III clinical trials.
CanSino‚Äö√Ñ√∂‚àö√ë‚àö¬•s Ad5-nCoV adenovirus vaccine is undergoing Phase III clinical trials.
CanSino‚Äö√Ñ√∂‚àö√ë‚àö¬•s Ad5-nCoV adenovirus vaccine is undergoing Phase III clinical trials.
CanSino‚Äö√Ñ√∂‚àö√ë‚àö¬•s Ad5-nCoV adenovirus vaccine is undergoing Phase III clinical trials.
CanSino‚Äö√Ñ√∂‚àö√ë‚àö¬•s Ad5-nCoV adenovirus vaccine is undergoing Phase III clinical trials.
Novavax has begun a Phase III trial of its subunit vaccine candidate NVX-CoV2373.
Novavax has begun a Phase III trial of its subunit vaccine candidate NVX-CoV2373.
Novavax has begun a Phase III trial of its subunit vaccine candidate NVX-CoV2373.
Novavax has begun a Phase III trial of its subunit vaccine candidate NVX-CoV2373.
Novavax has begun a Phase III trial of its subunit vaccine candidate NVX-CoV2373.
Novavax has begun a Phase III trial of its subunit vaccine candidate NVX-CoV2373.
Novavax has begun a Phase III trial of its subunit vaccine candidate NVX-CoV2373.
Novavax has begun a Phase III trial of its subunit vaccine candidate NVX-CoV2373.
Novavax has begun a Phase III trial of its subunit vaccine candidate NVX-CoV2373.
Novavax has begun a Phase III trial of its subunit vaccine candidate NVX-CoV2373.
Baharat has begun a Phase III trial of its inactivated rabies virus platform (Covaxin) on 28,500 people in India.
Baharat has begun a Phase III trial of its inactivated rabies virus platform (Covaxin) on 28,500 people in India.
Baharat has begun a Phase III trial of its inactivated rabies virus platform (Covaxin) on 28,500 people in India.
Baharat has begun a Phase III trial of its inactivated rabies virus platform (Covaxin) on 28,500 people in India.
Baharat has begun a Phase III trial of its inactivated rabies virus platform (Covaxin) on 28,500 people in India.
Baharat has begun a Phase III trial of its inactivated rabies virus platform (Covaxin) on 28,500 people in India.
Baharat has begun a Phase III trial of its inactivated rabies virus platform (Covaxin) on 28,500 people in India.
Baharat has begun a Phase III trial of its inactivated rabies virus platform (Covaxin) on 28,500 people in India.
Baharat has begun a Phase III trial of its inactivated rabies virus platform (Covaxin) on 28,500 people in India.
Baharat has begun a Phase III trial of its inactivated rabies virus platform (Covaxin) on 28,500 people in India.
Medicago, with GlaxoSmithKline, has announced a Phase II/III trial of their tobacco plant vaccine candidate (CoVLP).
Medicago, with GlaxoSmithKline, has announced a Phase II/III trial of their tobacco plant vaccine candidate (CoVLP).
Medicago, with GlaxoSmithKline, has announced a Phase II/III trial of their tobacco plant vaccine candidate (CoVLP).
Medicago, with GlaxoSmithKline, has announced a Phase II/III trial of their tobacco plant vaccine candidate (CoVLP).
Medicago, with GlaxoSmithKline, has announced a Phase II/III trial of their tobacco plant vaccine candidate (CoVLP).
Medicago, with GlaxoSmithKline, has announced a Phase II/III trial of their tobacco plant vaccine candidate (CoVLP).
Medicago, with GlaxoSmithKline, has announced a Phase II/III trial of their tobacco plant vaccine candidate (CoVLP).
Medicago, with GlaxoSmithKline, has announced a Phase II/III trial of their tobacco plant vaccine candidate (CoVLP).
Medicago, with GlaxoSmithKline, has announced a Phase II/III trial of their tobacco plant vaccine candidate (CoVLP).
Medicago, with GlaxoSmithKline, has announced a Phase II/III trial of their tobacco plant vaccine candidate (CoVLP).
Anhui Zhifei Longcom (with the China Academy of Medical Sciences) has begun Phase III trials for their RBD-dimer vaccine.
Anhui Zhifei Longcom (with the China Academy of Medical Sciences) has begun Phase III trials for their RBD-dimer vaccine.
Anhui Zhifei Longcom (with the China Academy of Medical Sciences) has begun Phase III trials for their RBD-dimer vaccine.
Anhui Zhifei Longcom (with the China Academy of Medical Sciences) has begun Phase III trials for their RBD-dimer vaccine.
Anhui Zhifei Longcom (with the China Academy of Medical Sciences) has begun Phase III trials for their RBD-dimer vaccine.
Anhui Zhifei Longcom (with the China Academy of Medical Sciences) has begun Phase III trials for their RBD-dimer vaccine.
Anhui Zhifei Longcom (with the China Academy of Medical Sciences) has begun Phase III trials for their RBD-dimer vaccine.
Anhui Zhifei Longcom (with the China Academy of Medical Sciences) has begun Phase III trials for their RBD-dimer vaccine.
Anhui Zhifei Longcom (with the China Academy of Medical Sciences) has begun Phase III trials for their RBD-dimer vaccine.
Anhui Zhifei Longcom (with the China Academy of Medical Sciences) has begun Phase III trials for their RBD-dimer vaccine.
CureVac has begun a Phase III trial of their mRNA vaccine candidate CVnCoV in 36,500 participants.
CureVac has begun a Phase III trial of their mRNA vaccine candidate CVnCoV in 36,500 participants.
CureVac has begun a Phase III trial of their mRNA vaccine candidate CVnCoV in 36,500 participants.
CureVac has begun a Phase III trial of their mRNA vaccine candidate CVnCoV in 36,500 participants.
CureVac has begun a Phase III trial of their mRNA vaccine candidate CVnCoV in 36,500 participants.
CureVac has begun a Phase III trial of their mRNA vaccine candidate CVnCoV in 36,500 participants.
CureVac has begun a Phase III trial of their mRNA vaccine candidate CVnCoV in 36,500 participants.
CureVac has begun a Phase III trial of their mRNA vaccine candidate CVnCoV in 36,500 participants.
CureVac has begun a Phase III trial of their mRNA vaccine candidate CVnCoV in 36,500 participants.
CureVac has begun a Phase III trial of their mRNA vaccine candidate CVnCoV in 36,500 participants.
The Institute of Medical Biology has begun a Phase III clinical trial of their inactivated vaccine on 34,020 people.
The Institute of Medical Biology has begun a Phase III clinical trial of their inactivated vaccine on 34,020 people.
The Institute of Medical Biology has begun a Phase III clinical trial of their inactivated vaccine on 34,020 people.
The Institute of Medical Biology has begun a Phase III clinical trial of their inactivated vaccine on 34,020 people.
The Institute of Medical Biology has begun a Phase III clinical trial of their inactivated vaccine on 34,020 people.
The Institute of Medical Biology has begun a Phase III clinical trial of their inactivated vaccine on 34,020 people.
The Institute of Medical Biology has begun a Phase III clinical trial of their inactivated vaccine on 34,020 people.
The Institute of Medical Biology has begun a Phase III clinical trial of their inactivated vaccine on 34,020 people.
The Institute of Medical Biology has begun a Phase III clinical trial of their inactivated vaccine on 34,020 people.
The Institute of Medical Biology has begun a Phase III clinical trial of their inactivated vaccine on 34,020 people.
Clover Biopharmaceuticals registered a Phase II/III clinical trial for their candidate, targeting 34,000 participants.
Clover Biopharmaceuticals registered a Phase II/III clinical trial for their candidate, targeting 34,000 participants.
Clover Biopharmaceuticals registered a Phase II/III clinical trial for their candidate, targeting 34,000 participants.
Clover Biopharmaceuticals registered a Phase II/III clinical trial for their candidate, targeting 34,000 participants.
Clover Biopharmaceuticals registered a Phase II/III clinical trial for their candidate, targeting 34,000 participants.
Clover Biopharmaceuticals registered a Phase II/III clinical trial for their candidate, targeting 34,000 participants.
Clover Biopharmaceuticals registered a Phase II/III clinical trial for their candidate, targeting 34,000 participants.
Clover Biopharmaceuticals registered a Phase II/III clinical trial for their candidate, targeting 34,000 participants.
Clover Biopharmaceuticals registered a Phase II/III clinical trial for their candidate, targeting 34,000 participants.
Clover Biopharmaceuticals registered a Phase II/III clinical trial for their candidate, targeting 34,000 participants.
Broad-scale control measures such as stay-at-home orders and widespread face mask use effectively reduce transmission and are more impactful when implemented simultaneously.
Broad-scale control measures such as stay-at-home orders and widespread face mask use effectively reduce transmission and are more impactful when implemented simultaneously.
Broad-scale control measures such as stay-at-home orders and widespread face mask use effectively reduce transmission and are more impactful when implemented simultaneously.
Broad-scale control measures such as stay-at-home orders and widespread face mask use effectively reduce transmission and are more impactful when implemented simultaneously.
Broad-scale control measures such as stay-at-home orders and widespread face mask use effectively reduce transmission and are more impactful when implemented simultaneously.
Broad-scale control measures such as stay-at-home orders and widespread face mask use effectively reduce transmission and are more impactful when implemented simultaneously.
Broad-scale control measures such as stay-at-home orders and widespread face mask use effectively reduce transmission and are more impactful when implemented simultaneously.
Broad-scale control measures such as stay-at-home orders and widespread face mask use effectively reduce transmission and are more impactful when implemented simultaneously.
Broad-scale control measures such as stay-at-home orders and widespread face mask use effectively reduce transmission and are more impactful when implemented simultaneously.
Broad-scale control measures such as stay-at-home orders and widespread face mask use effectively reduce transmission and are more impactful when implemented simultaneously.
Public health notifications increase adherence to policies.
Public health notifications increase adherence to policies.
Public health notifications increase adherence to policies.
Public health notifications increase adherence to policies.
Public health notifications increase adherence to policies.
Public health notifications increase adherence to policies.
Public health notifications increase adherence to policies.
Public health notifications increase adherence to policies.
Public health notifications increase adherence to policies.
Public health notifications increase adherence to policies.
Social distancing and other policies quickly reduced spread throughout China, Europe, and the US.
Social distancing and other policies quickly reduced spread throughout China, Europe, and the US.
Social distancing and other policies quickly reduced spread throughout China, Europe, and the US.
Social distancing and other policies quickly reduced spread throughout China, Europe, and the US.
Social distancing and other policies quickly reduced spread throughout China, Europe, and the US.
Social distancing and other policies quickly reduced spread throughout China, Europe, and the US.
Social distancing and other policies quickly reduced spread throughout China, Europe, and the US.
Social distancing and other policies quickly reduced spread throughout China, Europe, and the US.
Social distancing and other policies quickly reduced spread throughout China, Europe, and the US.
Social distancing and other policies quickly reduced spread throughout China, Europe, and the US.
In China, modeling suggests that a one-day delay in implementing control measures increased the time needed to curtail an outbreak by 2.4 days.
In China, modeling suggests that a one-day delay in implementing control measures increased the time needed to curtail an outbreak by 2.4 days.
In China, modeling suggests that a one-day delay in implementing control measures increased the time needed to curtail an outbreak by 2.4 days.
In China, modeling suggests that a one-day delay in implementing control measures increased the time needed to curtail an outbreak by 2.4 days.
In China, modeling suggests that a one-day delay in implementing control measures increased the time needed to curtail an outbreak by 2.4 days.
In China, modeling suggests that a one-day delay in implementing control measures increased the time needed to curtail an outbreak by 2.4 days.
In China, modeling suggests that a one-day delay in implementing control measures increased the time needed to curtail an outbreak by 2.4 days.
In China, modeling suggests that a one-day delay in implementing control measures increased the time needed to curtail an outbreak by 2.4 days.
In China, modeling suggests that a one-day delay in implementing control measures increased the time needed to curtail an outbreak by 2.4 days.
In China, modeling suggests that a one-day delay in implementing control measures increased the time needed to curtail an outbreak by 2.4 days.
Reductions in transmission are generally visible 6-9 days after the implementation of NPIs, and increased transmission is generally visible 14-20 days after NPIs are lifted.
Reductions in transmission are generally visible 6-9 days after the implementation of NPIs, and increased transmission is generally visible 14-20 days after NPIs are lifted.
Reductions in transmission are generally visible 6-9 days after the implementation of NPIs, and increased transmission is generally visible 14-20 days after NPIs are lifted.
Reductions in transmission are generally visible 6-9 days after the implementation of NPIs, and increased transmission is generally visible 14-20 days after NPIs are lifted.
Reductions in transmission are generally visible 6-9 days after the implementation of NPIs, and increased transmission is generally visible 14-20 days after NPIs are lifted.
Reductions in transmission are generally visible 6-9 days after the implementation of NPIs, and increased transmission is generally visible 14-20 days after NPIs are lifted.
Reductions in transmission are generally visible 6-9 days after the implementation of NPIs, and increased transmission is generally visible 14-20 days after NPIs are lifted.
Reductions in transmission are generally visible 6-9 days after the implementation of NPIs, and increased transmission is generally visible 14-20 days after NPIs are lifted.
Reductions in transmission are generally visible 6-9 days after the implementation of NPIs, and increased transmission is generally visible 14-20 days after NPIs are lifted.
Reductions in transmission are generally visible 6-9 days after the implementation of NPIs, and increased transmission is generally visible 14-20 days after NPIs are lifted.
US counties with mask mandates have lower case growth rates than neighboring counties lacking mask mandates.
US counties with mask mandates have lower case growth rates than neighboring counties lacking mask mandates.
US counties with mask mandates have lower case growth rates than neighboring counties lacking mask mandates.
US counties with mask mandates have lower case growth rates than neighboring counties lacking mask mandates.
US counties with mask mandates have lower case growth rates than neighboring counties lacking mask mandates.
US counties with mask mandates have lower case growth rates than neighboring counties lacking mask mandates.
US counties with mask mandates have lower case growth rates than neighboring counties lacking mask mandates.
US counties with mask mandates have lower case growth rates than neighboring counties lacking mask mandates.
US counties with mask mandates have lower case growth rates than neighboring counties lacking mask mandates.
US counties with mask mandates have lower case growth rates than neighboring counties lacking mask mandates.
Modeling suggests that widespread use of facemasks is effective at reducing transmission even when individual mask efficiency is low, though their benefits are maximized when most of the population wears masks.
Modeling suggests that widespread use of facemasks is effective at reducing transmission even when individual mask efficiency is low, though their benefits are maximized when most of the population wears masks.
Modeling suggests that widespread use of facemasks is effective at reducing transmission even when individual mask efficiency is low, though their benefits are maximized when most of the population wears masks.
Modeling suggests that widespread use of facemasks is effective at reducing transmission even when individual mask efficiency is low, though their benefits are maximized when most of the population wears masks.
Modeling suggests that widespread use of facemasks is effective at reducing transmission even when individual mask efficiency is low, though their benefits are maximized when most of the population wears masks.
Modeling suggests that widespread use of facemasks is effective at reducing transmission even when individual mask efficiency is low, though their benefits are maximized when most of the population wears masks.
Modeling suggests that widespread use of facemasks is effective at reducing transmission even when individual mask efficiency is low, though their benefits are maximized when most of the population wears masks.
Modeling suggests that widespread use of facemasks is effective at reducing transmission even when individual mask efficiency is low, though their benefits are maximized when most of the population wears masks.
Modeling suggests that widespread use of facemasks is effective at reducing transmission even when individual mask efficiency is low, though their benefits are maximized when most of the population wears masks.
Modeling suggests that widespread use of facemasks is effective at reducing transmission even when individual mask efficiency is low, though their benefits are maximized when most of the population wears masks.
School closures and cancellation of large gatherings had smaller effects.
School closures and cancellation of large gatherings had smaller effects.
School closures and cancellation of large gatherings had smaller effects.
School closures and cancellation of large gatherings had smaller effects.
School closures and cancellation of large gatherings had smaller effects.
School closures and cancellation of large gatherings had smaller effects.
School closures and cancellation of large gatherings had smaller effects.
School closures and cancellation of large gatherings had smaller effects.
School closures and cancellation of large gatherings had smaller effects.
School closures and cancellation of large gatherings had smaller effects.
Similarly, more public health interventions in a given week was strongly associated with lower COVID-19 growth rates in the next week.
Similarly, more public health interventions in a given week was strongly associated with lower COVID-19 growth rates in the next week.
Similarly, more public health interventions in a given week was strongly associated with lower COVID-19 growth rates in the next week.
Similarly, more public health interventions in a given week was strongly associated with lower COVID-19 growth rates in the next week.
Similarly, more public health interventions in a given week was strongly associated with lower COVID-19 growth rates in the next week.
Similarly, more public health interventions in a given week was strongly associated with lower COVID-19 growth rates in the next week.
Similarly, more public health interventions in a given week was strongly associated with lower COVID-19 growth rates in the next week.
Similarly, more public health interventions in a given week was strongly associated with lower COVID-19 growth rates in the next week.
Similarly, more public health interventions in a given week was strongly associated with lower COVID-19 growth rates in the next week.
Similarly, more public health interventions in a given week was strongly associated with lower COVID-19 growth rates in the next week.
Adherence to social distancing policies depends on income.
Adherence to social distancing policies depends on income.
Adherence to social distancing policies depends on income.
Adherence to social distancing policies depends on income.
Adherence to social distancing policies depends on income.
Adherence to social distancing policies depends on income.
Adherence to social distancing policies depends on income.
Adherence to social distancing policies depends on income.
Adherence to social distancing policies depends on income.
Adherence to social distancing policies depends on income.
Mobility and physical contact rates decline after public health control measures are implemented.
Mobility and physical contact rates decline after public health control measures are implemented.
Mobility and physical contact rates decline after public health control measures are implemented.
Mobility and physical contact rates decline after public health control measures are implemented.
Mobility and physical contact rates decline after public health control measures are implemented.
Mobility and physical contact rates decline after public health control measures are implemented.
Mobility and physical contact rates decline after public health control measures are implemented.
Mobility and physical contact rates decline after public health control measures are implemented.
Mobility and physical contact rates decline after public health control measures are implemented.
Mobility and physical contact rates decline after public health control measures are implemented.
Mobility reductions in the US have been associated with significant reductions in COVID-19 case growth.
Mobility reductions in the US have been associated with significant reductions in COVID-19 case growth.
Mobility reductions in the US have been associated with significant reductions in COVID-19 case growth.
Mobility reductions in the US have been associated with significant reductions in COVID-19 case growth.
Mobility reductions in the US have been associated with significant reductions in COVID-19 case growth.
Mobility reductions in the US have been associated with significant reductions in COVID-19 case growth.
Mobility reductions in the US have been associated with significant reductions in COVID-19 case growth.
Mobility reductions in the US have been associated with significant reductions in COVID-19 case growth.
Mobility reductions in the US have been associated with significant reductions in COVID-19 case growth.
Mobility reductions in the US have been associated with significant reductions in COVID-19 case growth.
Social distancing and reductions in both non-essential visits to stores and overall movement distance led to lower transmission rates.
Social distancing and reductions in both non-essential visits to stores and overall movement distance led to lower transmission rates.
Social distancing and reductions in both non-essential visits to stores and overall movement distance led to lower transmission rates.
Social distancing and reductions in both non-essential visits to stores and overall movement distance led to lower transmission rates.
Social distancing and reductions in both non-essential visits to stores and overall movement distance led to lower transmission rates.
Social distancing and reductions in both non-essential visits to stores and overall movement distance led to lower transmission rates.
Social distancing and reductions in both non-essential visits to stores and overall movement distance led to lower transmission rates.
Social distancing and reductions in both non-essential visits to stores and overall movement distance led to lower transmission rates.
Social distancing and reductions in both non-essential visits to stores and overall movement distance led to lower transmission rates.
Social distancing and reductions in both non-essential visits to stores and overall movement distance led to lower transmission rates.
A combination of school closures, work restrictions, and other measures are likely required to effectively limit transmission.
A combination of school closures, work restrictions, and other measures are likely required to effectively limit transmission.
A combination of school closures, work restrictions, and other measures are likely required to effectively limit transmission.
A combination of school closures, work restrictions, and other measures are likely required to effectively limit transmission.
A combination of school closures, work restrictions, and other measures are likely required to effectively limit transmission.
A combination of school closures, work restrictions, and other measures are likely required to effectively limit transmission.
A combination of school closures, work restrictions, and other measures are likely required to effectively limit transmission.
A combination of school closures, work restrictions, and other measures are likely required to effectively limit transmission.
A combination of school closures, work restrictions, and other measures are likely required to effectively limit transmission.
A combination of school closures, work restrictions, and other measures are likely required to effectively limit transmission.
School closures alone appear insufficient, though likely reduced mortality in the UK and the US.
School closures alone appear insufficient, though likely reduced mortality in the UK and the US.
School closures alone appear insufficient, though likely reduced mortality in the UK and the US.
School closures alone appear insufficient, though likely reduced mortality in the UK and the US.
School closures alone appear insufficient, though likely reduced mortality in the UK and the US.
School closures alone appear insufficient, though likely reduced mortality in the UK and the US.
School closures alone appear insufficient, though likely reduced mortality in the UK and the US.
School closures alone appear insufficient, though likely reduced mortality in the UK and the US.
School closures alone appear insufficient, though likely reduced mortality in the UK and the US.
School closures alone appear insufficient, though likely reduced mortality in the UK and the US.
Reducing capacity at crowded indoor locations such as restaurants, gyms, hotels, cafes, and religious organizations may be an effective way to reduce COVID-19 transmission without more substantial lockdowns.
Reducing capacity at crowded indoor locations such as restaurants, gyms, hotels, cafes, and religious organizations may be an effective way to reduce COVID-19 transmission without more substantial lockdowns.
Reducing capacity at crowded indoor locations such as restaurants, gyms, hotels, cafes, and religious organizations may be an effective way to reduce COVID-19 transmission without more substantial lockdowns.
Reducing capacity at crowded indoor locations such as restaurants, gyms, hotels, cafes, and religious organizations may be an effective way to reduce COVID-19 transmission without more substantial lockdowns.
Reducing capacity at crowded indoor locations such as restaurants, gyms, hotels, cafes, and religious organizations may be an effective way to reduce COVID-19 transmission without more substantial lockdowns.
Reducing capacity at crowded indoor locations such as restaurants, gyms, hotels, cafes, and religious organizations may be an effective way to reduce COVID-19 transmission without more substantial lockdowns.
Reducing capacity at crowded indoor locations such as restaurants, gyms, hotels, cafes, and religious organizations may be an effective way to reduce COVID-19 transmission without more substantial lockdowns.
Reducing capacity at crowded indoor locations such as restaurants, gyms, hotels, cafes, and religious organizations may be an effective way to reduce COVID-19 transmission without more substantial lockdowns.
Reducing capacity at crowded indoor locations such as restaurants, gyms, hotels, cafes, and religious organizations may be an effective way to reduce COVID-19 transmission without more substantial lockdowns.
Reducing capacity at crowded indoor locations such as restaurants, gyms, hotels, cafes, and religious organizations may be an effective way to reduce COVID-19 transmission without more substantial lockdowns.
Increasing air flow rates in indoor environments, improving mechanical filtration efficiency, and wearing masks may also reduce indoor transmission rates.
Increasing air flow rates in indoor environments, improving mechanical filtration efficiency, and wearing masks may also reduce indoor transmission rates.
Increasing air flow rates in indoor environments, improving mechanical filtration efficiency, and wearing masks may also reduce indoor transmission rates.
Increasing air flow rates in indoor environments, improving mechanical filtration efficiency, and wearing masks may also reduce indoor transmission rates.
Increasing air flow rates in indoor environments, improving mechanical filtration efficiency, and wearing masks may also reduce indoor transmission rates.
Increasing air flow rates in indoor environments, improving mechanical filtration efficiency, and wearing masks may also reduce indoor transmission rates.
Increasing air flow rates in indoor environments, improving mechanical filtration efficiency, and wearing masks may also reduce indoor transmission rates.
Increasing air flow rates in indoor environments, improving mechanical filtration efficiency, and wearing masks may also reduce indoor transmission rates.
Increasing air flow rates in indoor environments, improving mechanical filtration efficiency, and wearing masks may also reduce indoor transmission rates.
Increasing air flow rates in indoor environments, improving mechanical filtration efficiency, and wearing masks may also reduce indoor transmission rates.
Adolescents and young adults (15-24) may require different messaging to improve adherence to NPIs and public health policies, and self-reported adherence to NPI policies (e.g., mask use) is consistently low in 18- to 29-year-olds.
Adolescents and young adults (15-24) may require different messaging to improve adherence to NPIs and public health policies, and self-reported adherence to NPI policies (e.g., mask use) is consistently low in 18- to 29-year-olds.
Adolescents and young adults (15-24) may require different messaging to improve adherence to NPIs and public health policies, and self-reported adherence to NPI policies (e.g., mask use) is consistently low in 18- to 29-year-olds.
Adolescents and young adults (15-24) may require different messaging to improve adherence to NPIs and public health policies, and self-reported adherence to NPI policies (e.g., mask use) is consistently low in 18- to 29-year-olds.
Adolescents and young adults (15-24) may require different messaging to improve adherence to NPIs and public health policies, and self-reported adherence to NPI policies (e.g., mask use) is consistently low in 18- to 29-year-olds.
Adolescents and young adults (15-24) may require different messaging to improve adherence to NPIs and public health policies, and self-reported adherence to NPI policies (e.g., mask use) is consistently low in 18- to 29-year-olds.
Adolescents and young adults (15-24) may require different messaging to improve adherence to NPIs and public health policies, and self-reported adherence to NPI policies (e.g., mask use) is consistently low in 18- to 29-year-olds.
Adolescents and young adults (15-24) may require different messaging to improve adherence to NPIs and public health policies, and self-reported adherence to NPI policies (e.g., mask use) is consistently low in 18- to 29-year-olds.
Adolescents and young adults (15-24) may require different messaging to improve adherence to NPIs and public health policies, and self-reported adherence to NPI policies (e.g., mask use) is consistently low in 18- to 29-year-olds.
Adolescents and young adults (15-24) may require different messaging to improve adherence to NPIs and public health policies, and self-reported adherence to NPI policies (e.g., mask use) is consistently low in 18- to 29-year-olds.
In the US, limiting transmission in younger populations is crucial for reducing hospitalizations and mortality in older cohorts.
In the US, limiting transmission in younger populations is crucial for reducing hospitalizations and mortality in older cohorts.
In the US, limiting transmission in younger populations is crucial for reducing hospitalizations and mortality in older cohorts.
In the US, limiting transmission in younger populations is crucial for reducing hospitalizations and mortality in older cohorts.
In the US, limiting transmission in younger populations is crucial for reducing hospitalizations and mortality in older cohorts.
In the US, limiting transmission in younger populations is crucial for reducing hospitalizations and mortality in older cohorts.
In the US, limiting transmission in younger populations is crucial for reducing hospitalizations and mortality in older cohorts.
In the US, limiting transmission in younger populations is crucial for reducing hospitalizations and mortality in older cohorts.
In the US, limiting transmission in younger populations is crucial for reducing hospitalizations and mortality in older cohorts.
In the US, limiting transmission in younger populations is crucial for reducing hospitalizations and mortality in older cohorts.
Individual behaviors (e.g., face masks, social distancing) have been associated with reduced risk of COVID-19 infection.
Individual behaviors (e.g., face masks, social distancing) have been associated with reduced risk of COVID-19 infection.
Individual behaviors (e.g., face masks, social distancing) have been associated with reduced risk of COVID-19 infection.
Individual behaviors (e.g., face masks, social distancing) have been associated with reduced risk of COVID-19 infection.
Individual behaviors (e.g., face masks, social distancing) have been associated with reduced risk of COVID-19 infection.
Individual behaviors (e.g., face masks, social distancing) have been associated with reduced risk of COVID-19 infection.
Individual behaviors (e.g., face masks, social distancing) have been associated with reduced risk of COVID-19 infection.
Individual behaviors (e.g., face masks, social distancing) have been associated with reduced risk of COVID-19 infection.
Individual behaviors (e.g., face masks, social distancing) have been associated with reduced risk of COVID-19 infection.
Individual behaviors (e.g., face masks, social distancing) have been associated with reduced risk of COVID-19 infection.
The US CDC recommends universal masking when indoors to inhibit the spread of COVID-19, alongside physical distancing, avoiding nonessential indoor and crowded outdoor spaces, postponing travel, and increasing ventilation and disinfection.
The US CDC recommends universal masking when indoors to inhibit the spread of COVID-19, alongside physical distancing, avoiding nonessential indoor and crowded outdoor spaces, postponing travel, and increasing ventilation and disinfection.
The US CDC recommends universal masking when indoors to inhibit the spread of COVID-19, alongside physical distancing, avoiding nonessential indoor and crowded outdoor spaces, postponing travel, and increasing ventilation and disinfection.
The US CDC recommends universal masking when indoors to inhibit the spread of COVID-19, alongside physical distancing, avoiding nonessential indoor and crowded outdoor spaces, postponing travel, and increasing ventilation and disinfection.
The US CDC recommends universal masking when indoors to inhibit the spread of COVID-19, alongside physical distancing, avoiding nonessential indoor and crowded outdoor spaces, postponing travel, and increasing ventilation and disinfection.
The US CDC recommends universal masking when indoors to inhibit the spread of COVID-19, alongside physical distancing, avoiding nonessential indoor and crowded outdoor spaces, postponing travel, and increasing ventilation and disinfection.
The US CDC recommends universal masking when indoors to inhibit the spread of COVID-19, alongside physical distancing, avoiding nonessential indoor and crowded outdoor spaces, postponing travel, and increasing ventilation and disinfection.
The US CDC recommends universal masking when indoors to inhibit the spread of COVID-19, alongside physical distancing, avoiding nonessential indoor and crowded outdoor spaces, postponing travel, and increasing ventilation and disinfection.
The US CDC recommends universal masking when indoors to inhibit the spread of COVID-19, alongside physical distancing, avoiding nonessential indoor and crowded outdoor spaces, postponing travel, and increasing ventilation and disinfection.
The US CDC recommends universal masking when indoors to inhibit the spread of COVID-19, alongside physical distancing, avoiding nonessential indoor and crowded outdoor spaces, postponing travel, and increasing ventilation and disinfection.
Particle physics modeling suggests that 2m physical distancing is generally sufficient for reduction of SARS-CoV-2 aerosols expressed during coughs, though smaller particles can travel farther, and wind direction and speed may play a role.
Particle physics modeling suggests that 2m physical distancing is generally sufficient for reduction of SARS-CoV-2 aerosols expressed during coughs, though smaller particles can travel farther, and wind direction and speed may play a role.
Particle physics modeling suggests that 2m physical distancing is generally sufficient for reduction of SARS-CoV-2 aerosols expressed during coughs, though smaller particles can travel farther, and wind direction and speed may play a role.
Particle physics modeling suggests that 2m physical distancing is generally sufficient for reduction of SARS-CoV-2 aerosols expressed during coughs, though smaller particles can travel farther, and wind direction and speed may play a role.
Particle physics modeling suggests that 2m physical distancing is generally sufficient for reduction of SARS-CoV-2 aerosols expressed during coughs, though smaller particles can travel farther, and wind direction and speed may play a role.
Particle physics modeling suggests that 2m physical distancing is generally sufficient for reduction of SARS-CoV-2 aerosols expressed during coughs, though smaller particles can travel farther, and wind direction and speed may play a role.
Particle physics modeling suggests that 2m physical distancing is generally sufficient for reduction of SARS-CoV-2 aerosols expressed during coughs, though smaller particles can travel farther, and wind direction and speed may play a role.
Particle physics modeling suggests that 2m physical distancing is generally sufficient for reduction of SARS-CoV-2 aerosols expressed during coughs, though smaller particles can travel farther, and wind direction and speed may play a role.
Particle physics modeling suggests that 2m physical distancing is generally sufficient for reduction of SARS-CoV-2 aerosols expressed during coughs, though smaller particles can travel farther, and wind direction and speed may play a role.
Particle physics modeling suggests that 2m physical distancing is generally sufficient for reduction of SARS-CoV-2 aerosols expressed during coughs, though smaller particles can travel farther, and wind direction and speed may play a role.
A Danish study found that mask use was not associated with protection from COVID-19 infection, but suffered from limitations in timing (i.e., low COVID-19 prevalence) and self-reporting, and did not assess reductions in emission rates.
A Danish study found that mask use was not associated with protection from COVID-19 infection, but suffered from limitations in timing (i.e., low COVID-19 prevalence) and self-reporting, and did not assess reductions in emission rates.
A Danish study found that mask use was not associated with protection from COVID-19 infection, but suffered from limitations in timing (i.e., low COVID-19 prevalence) and self-reporting, and did not assess reductions in emission rates.
A Danish study found that mask use was not associated with protection from COVID-19 infection, but suffered from limitations in timing (i.e., low COVID-19 prevalence) and self-reporting, and did not assess reductions in emission rates.
A Danish study found that mask use was not associated with protection from COVID-19 infection, but suffered from limitations in timing (i.e., low COVID-19 prevalence) and self-reporting, and did not assess reductions in emission rates.
A Danish study found that mask use was not associated with protection from COVID-19 infection, but suffered from limitations in timing (i.e., low COVID-19 prevalence) and self-reporting, and did not assess reductions in emission rates.
A Danish study found that mask use was not associated with protection from COVID-19 infection, but suffered from limitations in timing (i.e., low COVID-19 prevalence) and self-reporting, and did not assess reductions in emission rates.
A Danish study found that mask use was not associated with protection from COVID-19 infection, but suffered from limitations in timing (i.e., low COVID-19 prevalence) and self-reporting, and did not assess reductions in emission rates.
A Danish study found that mask use was not associated with protection from COVID-19 infection, but suffered from limitations in timing (i.e., low COVID-19 prevalence) and self-reporting, and did not assess reductions in emission rates.
A Danish study found that mask use was not associated with protection from COVID-19 infection, but suffered from limitations in timing (i.e., low COVID-19 prevalence) and self-reporting, and did not assess reductions in emission rates.
Particular focus should be placed on minimizing large gatherings where superspreading events are more likely.
Particular focus should be placed on minimizing large gatherings where superspreading events are more likely.
Particular focus should be placed on minimizing large gatherings where superspreading events are more likely.
Particular focus should be placed on minimizing large gatherings where superspreading events are more likely.
Particular focus should be placed on minimizing large gatherings where superspreading events are more likely.
Particular focus should be placed on minimizing large gatherings where superspreading events are more likely.
Particular focus should be placed on minimizing large gatherings where superspreading events are more likely.
Particular focus should be placed on minimizing large gatherings where superspreading events are more likely.
Particular focus should be placed on minimizing large gatherings where superspreading events are more likely.
Particular focus should be placed on minimizing large gatherings where superspreading events are more likely.
Retrospective contact tracing may help identify the source of large clusters of cases, and should be implemented due to the overdispersion or heterogeneity in secondary transmission arising from each primary COVID-19 case.
Retrospective contact tracing may help identify the source of large clusters of cases, and should be implemented due to the overdispersion or heterogeneity in secondary transmission arising from each primary COVID-19 case.
Retrospective contact tracing may help identify the source of large clusters of cases, and should be implemented due to the overdispersion or heterogeneity in secondary transmission arising from each primary COVID-19 case.
Retrospective contact tracing may help identify the source of large clusters of cases, and should be implemented due to the overdispersion or heterogeneity in secondary transmission arising from each primary COVID-19 case.
Retrospective contact tracing may help identify the source of large clusters of cases, and should be implemented due to the overdispersion or heterogeneity in secondary transmission arising from each primary COVID-19 case.
Retrospective contact tracing may help identify the source of large clusters of cases, and should be implemented due to the overdispersion or heterogeneity in secondary transmission arising from each primary COVID-19 case.
Retrospective contact tracing may help identify the source of large clusters of cases, and should be implemented due to the overdispersion or heterogeneity in secondary transmission arising from each primary COVID-19 case.
Retrospective contact tracing may help identify the source of large clusters of cases, and should be implemented due to the overdispersion or heterogeneity in secondary transmission arising from each primary COVID-19 case.
Retrospective contact tracing may help identify the source of large clusters of cases, and should be implemented due to the overdispersion or heterogeneity in secondary transmission arising from each primary COVID-19 case.
Retrospective contact tracing may help identify the source of large clusters of cases, and should be implemented due to the overdispersion or heterogeneity in secondary transmission arising from each primary COVID-19 case.
There are multiple types of superspreading events, and different policies are required to mitigate risks from each.
There are multiple types of superspreading events, and different policies are required to mitigate risks from each.
There are multiple types of superspreading events, and different policies are required to mitigate risks from each.
There are multiple types of superspreading events, and different policies are required to mitigate risks from each.
There are multiple types of superspreading events, and different policies are required to mitigate risks from each.
There are multiple types of superspreading events, and different policies are required to mitigate risks from each.
There are multiple types of superspreading events, and different policies are required to mitigate risks from each.
There are multiple types of superspreading events, and different policies are required to mitigate risks from each.
There are multiple types of superspreading events, and different policies are required to mitigate risks from each.
There are multiple types of superspreading events, and different policies are required to mitigate risks from each.
Research is needed to plan the path to SARS-CoV-2 elimination via pharmaceutical and non-pharmaceutical interventions.
Research is needed to plan the path to SARS-CoV-2 elimination via pharmaceutical and non-pharmaceutical interventions.
Research is needed to plan the path to SARS-CoV-2 elimination via pharmaceutical and non-pharmaceutical interventions.
Research is needed to plan the path to SARS-CoV-2 elimination via pharmaceutical and non-pharmaceutical interventions.
Research is needed to plan the path to SARS-CoV-2 elimination via pharmaceutical and non-pharmaceutical interventions.
Research is needed to plan the path to SARS-CoV-2 elimination via pharmaceutical and non-pharmaceutical interventions.
Research is needed to plan the path to SARS-CoV-2 elimination via pharmaceutical and non-pharmaceutical interventions.
Research is needed to plan the path to SARS-CoV-2 elimination via pharmaceutical and non-pharmaceutical interventions.
Research is needed to plan the path to SARS-CoV-2 elimination via pharmaceutical and non-pharmaceutical interventions.
Research is needed to plan the path to SARS-CoV-2 elimination via pharmaceutical and non-pharmaceutical interventions.
In South Korea, early implementation of rapid contact tracing, testing, and quarantine was able to reduce the transmission rate of COVID-19.
In South Korea, early implementation of rapid contact tracing, testing, and quarantine was able to reduce the transmission rate of COVID-19.
In South Korea, early implementation of rapid contact tracing, testing, and quarantine was able to reduce the transmission rate of COVID-19.
In South Korea, early implementation of rapid contact tracing, testing, and quarantine was able to reduce the transmission rate of COVID-19.
In South Korea, early implementation of rapid contact tracing, testing, and quarantine was able to reduce the transmission rate of COVID-19.
In South Korea, early implementation of rapid contact tracing, testing, and quarantine was able to reduce the transmission rate of COVID-19.
In South Korea, early implementation of rapid contact tracing, testing, and quarantine was able to reduce the transmission rate of COVID-19.
In South Korea, early implementation of rapid contact tracing, testing, and quarantine was able to reduce the transmission rate of COVID-19.
In South Korea, early implementation of rapid contact tracing, testing, and quarantine was able to reduce the transmission rate of COVID-19.
In South Korea, early implementation of rapid contact tracing, testing, and quarantine was able to reduce the transmission rate of COVID-19.
Contact tracing and high levels of testing and physical distancing352 may limit COVID-19 resurgence.
Contact tracing and high levels of testing and physical distancing352 may limit COVID-19 resurgence.
Contact tracing and high levels of testing and physical distancing352 may limit COVID-19 resurgence.
Contact tracing and high levels of testing and physical distancing352 may limit COVID-19 resurgence.
Contact tracing and high levels of testing and physical distancing352 may limit COVID-19 resurgence.
Contact tracing and high levels of testing and physical distancing352 may limit COVID-19 resurgence.
Contact tracing and high levels of testing and physical distancing352 may limit COVID-19 resurgence.
Contact tracing and high levels of testing and physical distancing352 may limit COVID-19 resurgence.
Contact tracing and high levels of testing and physical distancing352 may limit COVID-19 resurgence.
Contact tracing and high levels of testing and physical distancing352 may limit COVID-19 resurgence.
Premature relaxation of public health control measures may facilitate rapid increases in prevalence at the state level.
Premature relaxation of public health control measures may facilitate rapid increases in prevalence at the state level.
Premature relaxation of public health control measures may facilitate rapid increases in prevalence at the state level.
Premature relaxation of public health control measures may facilitate rapid increases in prevalence at the state level.
Premature relaxation of public health control measures may facilitate rapid increases in prevalence at the state level.
Premature relaxation of public health control measures may facilitate rapid increases in prevalence at the state level.
Premature relaxation of public health control measures may facilitate rapid increases in prevalence at the state level.
Premature relaxation of public health control measures may facilitate rapid increases in prevalence at the state level.
Premature relaxation of public health control measures may facilitate rapid increases in prevalence at the state level.
Premature relaxation of public health control measures may facilitate rapid increases in prevalence at the state level.
Modeling suggests that periods of social distancing or lock-down may be effective in reducing exposure from asymptomatic cases.
Modeling suggests that periods of social distancing or lock-down may be effective in reducing exposure from asymptomatic cases.
Modeling suggests that periods of social distancing or lock-down may be effective in reducing exposure from asymptomatic cases.
Modeling suggests that periods of social distancing or lock-down may be effective in reducing exposure from asymptomatic cases.
Modeling suggests that periods of social distancing or lock-down may be effective in reducing exposure from asymptomatic cases.
Modeling suggests that periods of social distancing or lock-down may be effective in reducing exposure from asymptomatic cases.
Modeling suggests that periods of social distancing or lock-down may be effective in reducing exposure from asymptomatic cases.
Modeling suggests that periods of social distancing or lock-down may be effective in reducing exposure from asymptomatic cases.
Modeling suggests that periods of social distancing or lock-down may be effective in reducing exposure from asymptomatic cases.
Modeling suggests that periods of social distancing or lock-down may be effective in reducing exposure from asymptomatic cases.
Testing is critical to balancing public health and economic costs.
Testing is critical to balancing public health and economic costs.
Testing is critical to balancing public health and economic costs.
Testing is critical to balancing public health and economic costs.
Testing is critical to balancing public health and economic costs.
Testing is critical to balancing public health and economic costs.
Testing is critical to balancing public health and economic costs.
Testing is critical to balancing public health and economic costs.
Testing is critical to balancing public health and economic costs.
Testing is critical to balancing public health and economic costs.
Undetected cases can lead to elevated risk of re-emergence after restrictions are lifted.
Undetected cases can lead to elevated risk of re-emergence after restrictions are lifted.
Undetected cases can lead to elevated risk of re-emergence after restrictions are lifted.
Undetected cases can lead to elevated risk of re-emergence after restrictions are lifted.
Undetected cases can lead to elevated risk of re-emergence after restrictions are lifted.
Undetected cases can lead to elevated risk of re-emergence after restrictions are lifted.
Undetected cases can lead to elevated risk of re-emergence after restrictions are lifted.
Undetected cases can lead to elevated risk of re-emergence after restrictions are lifted.
Undetected cases can lead to elevated risk of re-emergence after restrictions are lifted.
Undetected cases can lead to elevated risk of re-emergence after restrictions are lifted.
Synchronizing public health interventions across US state lines may reduce the total number of required interventions.
Synchronizing public health interventions across US state lines may reduce the total number of required interventions.
Synchronizing public health interventions across US state lines may reduce the total number of required interventions.
Synchronizing public health interventions across US state lines may reduce the total number of required interventions.
Synchronizing public health interventions across US state lines may reduce the total number of required interventions.
Synchronizing public health interventions across US state lines may reduce the total number of required interventions.
Synchronizing public health interventions across US state lines may reduce the total number of required interventions.
Synchronizing public health interventions across US state lines may reduce the total number of required interventions.
Synchronizing public health interventions across US state lines may reduce the total number of required interventions.
Synchronizing public health interventions across US state lines may reduce the total number of required interventions.
Modeling shows that travel restrictions are likely to have the greatest impact at reducing SARS-CoV-2 transmission in countries that are highly connected to those with high incidence, and also in countries with low incidence.
Modeling shows that travel restrictions are likely to have the greatest impact at reducing SARS-CoV-2 transmission in countries that are highly connected to those with high incidence, and also in countries with low incidence.
Modeling shows that travel restrictions are likely to have the greatest impact at reducing SARS-CoV-2 transmission in countries that are highly connected to those with high incidence, and also in countries with low incidence.
Modeling shows that travel restrictions are likely to have the greatest impact at reducing SARS-CoV-2 transmission in countries that are highly connected to those with high incidence, and also in countries with low incidence.
Modeling shows that travel restrictions are likely to have the greatest impact at reducing SARS-CoV-2 transmission in countries that are highly connected to those with high incidence, and also in countries with low incidence.
Modeling shows that travel restrictions are likely to have the greatest impact at reducing SARS-CoV-2 transmission in countries that are highly connected to those with high incidence, and also in countries with low incidence.
Modeling shows that travel restrictions are likely to have the greatest impact at reducing SARS-CoV-2 transmission in countries that are highly connected to those with high incidence, and also in countries with low incidence.
Modeling shows that travel restrictions are likely to have the greatest impact at reducing SARS-CoV-2 transmission in countries that are highly connected to those with high incidence, and also in countries with low incidence.
Modeling shows that travel restrictions are likely to have the greatest impact at reducing SARS-CoV-2 transmission in countries that are highly connected to those with high incidence, and also in countries with low incidence.
Modeling shows that travel restrictions are likely to have the greatest impact at reducing SARS-CoV-2 transmission in countries that are highly connected to those with high incidence, and also in countries with low incidence.
SARS-CoV-2 can survive on surfaces from hours to days and is stable in air for at least several hours, depending on the presence of UV light, temperature, and humidity.
SARS-CoV-2 can survive on surfaces from hours to days and is stable in air for at least several hours, depending on the presence of UV light, temperature, and humidity.
SARS-CoV-2 can survive on surfaces from hours to days and is stable in air for at least several hours, depending on the presence of UV light, temperature, and humidity.
SARS-CoV-2 can survive on surfaces from hours to days and is stable in air for at least several hours, depending on the presence of UV light, temperature, and humidity.
SARS-CoV-2 can survive on surfaces from hours to days and is stable in air for at least several hours, depending on the presence of UV light, temperature, and humidity.
SARS-CoV-2 can survive on surfaces from hours to days and is stable in air for at least several hours, depending on the presence of UV light, temperature, and humidity.
SARS-CoV-2 can survive on surfaces from hours to days and is stable in air for at least several hours, depending on the presence of UV light, temperature, and humidity.
SARS-CoV-2 can survive on surfaces from hours to days and is stable in air for at least several hours, depending on the presence of UV light, temperature, and humidity.
SARS-CoV-2 can survive on surfaces from hours to days and is stable in air for at least several hours, depending on the presence of UV light, temperature, and humidity.
SARS-CoV-2 can survive on surfaces from hours to days and is stable in air for at least several hours, depending on the presence of UV light, temperature, and humidity.
Viable SARS-CoV-2 and/or RNA can be recovered from contaminated surfaces; however, survivability varies.
Viable SARS-CoV-2 and/or RNA can be recovered from contaminated surfaces; however, survivability varies.
Viable SARS-CoV-2 and/or RNA can be recovered from contaminated surfaces; however, survivability varies.
Viable SARS-CoV-2 and/or RNA can be recovered from contaminated surfaces; however, survivability varies.
Viable SARS-CoV-2 and/or RNA can be recovered from contaminated surfaces; however, survivability varies.
Viable SARS-CoV-2 and/or RNA can be recovered from contaminated surfaces; however, survivability varies.
Viable SARS-CoV-2 and/or RNA can be recovered from contaminated surfaces; however, survivability varies.
Viable SARS-CoV-2 and/or RNA can be recovered from contaminated surfaces; however, survivability varies.
Viable SARS-CoV-2 and/or RNA can be recovered from contaminated surfaces; however, survivability varies.
Viable SARS-CoV-2 and/or RNA can be recovered from contaminated surfaces; however, survivability varies.
Both temperature and humidity contribute to SARS-CoV-2 survival on nonporous surfaces, with cooler, less humid environments facilitating survival (stainless steel, ABS plastic, and nitrile rubber; indoors only; simulated saliva matrix).
Both temperature and humidity contribute to SARS-CoV-2 survival on nonporous surfaces, with cooler, less humid environments facilitating survival (stainless steel, ABS plastic, and nitrile rubber; indoors only; simulated saliva matrix).
Both temperature and humidity contribute to SARS-CoV-2 survival on nonporous surfaces, with cooler, less humid environments facilitating survival (stainless steel, ABS plastic, and nitrile rubber; indoors only; simulated saliva matrix).
Both temperature and humidity contribute to SARS-CoV-2 survival on nonporous surfaces, with cooler, less humid environments facilitating survival (stainless steel, ABS plastic, and nitrile rubber; indoors only; simulated saliva matrix).
Both temperature and humidity contribute to SARS-CoV-2 survival on nonporous surfaces, with cooler, less humid environments facilitating survival (stainless steel, ABS plastic, and nitrile rubber; indoors only; simulated saliva matrix).
Both temperature and humidity contribute to SARS-CoV-2 survival on nonporous surfaces, with cooler, less humid environments facilitating survival (stainless steel, ABS plastic, and nitrile rubber; indoors only; simulated saliva matrix).
Both temperature and humidity contribute to SARS-CoV-2 survival on nonporous surfaces, with cooler, less humid environments facilitating survival (stainless steel, ABS plastic, and nitrile rubber; indoors only; simulated saliva matrix).
Both temperature and humidity contribute to SARS-CoV-2 survival on nonporous surfaces, with cooler, less humid environments facilitating survival (stainless steel, ABS plastic, and nitrile rubber; indoors only; simulated saliva matrix).
Both temperature and humidity contribute to SARS-CoV-2 survival on nonporous surfaces, with cooler, less humid environments facilitating survival (stainless steel, ABS plastic, and nitrile rubber; indoors only; simulated saliva matrix).
Both temperature and humidity contribute to SARS-CoV-2 survival on nonporous surfaces, with cooler, less humid environments facilitating survival (stainless steel, ABS plastic, and nitrile rubber; indoors only; simulated saliva matrix).
Persistence is reduced with warmer temperatures (37¬¨¬®‚Äö√†√ªC), and enhanced at colder temperatures (4¬¨¬®‚Äö√†√ªC).
Persistence is reduced with warmer temperatures (37¬¨¬®‚Äö√†√ªC), and enhanced at colder temperatures (4¬¨¬®‚Äö√†√ªC).
Persistence is reduced with warmer temperatures (37¬¨¬®‚Äö√†√ªC), and enhanced at colder temperatures (4¬¨¬®‚Äö√†√ªC).
Persistence is reduced with warmer temperatures (37¬¨¬®‚Äö√†√ªC), and enhanced at colder temperatures (4¬¨¬®‚Äö√†√ªC).
Persistence is reduced with warmer temperatures (37¬¨¬®‚Äö√†√ªC), and enhanced at colder temperatures (4¬¨¬®‚Äö√†√ªC).
Persistence is reduced with warmer temperatures (37¬¨¬®‚Äö√†√ªC), and enhanced at colder temperatures (4¬¨¬®‚Äö√†√ªC).
Persistence is reduced with warmer temperatures (37¬¨¬®‚Äö√†√ªC), and enhanced at colder temperatures (4¬¨¬®‚Äö√†√ªC).
SARS-CoV-2 was shown to be stable up to 7 days (25-27¬¨¬®‚Äö√†√ªC; 35% RH) on smooth surfaces, to include plastic, stainless steel, glass, ceramics, wood, latex gloves, and surgical masks.
SARS-CoV-2 was shown to be stable up to 7 days (25-27¬¨¬®‚Äö√†√ªC; 35% RH) on smooth surfaces, to include plastic, stainless steel, glass, ceramics, wood, latex gloves, and surgical masks.
SARS-CoV-2 was shown to be stable up to 7 days (25-27¬¨¬®‚Äö√†√ªC; 35% RH) on smooth surfaces, to include plastic, stainless steel, glass, ceramics, wood, latex gloves, and surgical masks.
SARS-CoV-2 was shown to be stable up to 7 days (25-27¬¨¬®‚Äö√†√ªC; 35% RH) on smooth surfaces, to include plastic, stainless steel, glass, ceramics, wood, latex gloves, and surgical masks.
SARS-CoV-2 was shown to be stable up to 7 days (25-27¬¨¬®‚Äö√†√ªC; 35% RH) on smooth surfaces, to include plastic, stainless steel, glass, ceramics, wood, latex gloves, and surgical masks.
SARS-CoV-2 was shown to be stable up to 7 days (25-27¬¨¬®‚Äö√†√ªC; 35% RH) on smooth surfaces, to include plastic, stainless steel, glass, ceramics, wood, latex gloves, and surgical masks.
SARS-CoV-2 was shown to be stable up to 7 days (25-27¬¨¬®‚Äö√†√ªC; 35% RH) on smooth surfaces, to include plastic, stainless steel, glass, ceramics, wood, latex gloves, and surgical masks.
SARS-CoV-2 was shown to be stable up to 7 days (25-27¬¨¬®‚Äö√†√ªC; 35% RH) on smooth surfaces, to include plastic, stainless steel, glass, ceramics, wood, latex gloves, and surgical masks.
SARS-CoV-2 was shown to be stable up to 7 days (25-27¬¨¬®‚Äö√†√ªC; 35% RH) on smooth surfaces, to include plastic, stainless steel, glass, ceramics, wood, latex gloves, and surgical masks.
SARS-CoV-2 was shown to be stable up to 7 days (25-27¬¨¬®‚Äö√†√ªC; 35% RH) on smooth surfaces, to include plastic, stainless steel, glass, ceramics, wood, latex gloves, and surgical masks.
At 22¬¨¬®‚Äö√†√ªC, SARS-CoV-2 was shown to be detectable (via plaque assay) on paper currency for up to 24 hours, on clothing for up to 4 hours, and on skin for up to 96 hours.
At 22¬¨¬®‚Äö√†√ªC, SARS-CoV-2 was shown to be detectable (via plaque assay) on paper currency for up to 24 hours, on clothing for up to 4 hours, and on skin for up to 96 hours.
At 22¬¨¬®‚Äö√†√ªC, SARS-CoV-2 was shown to be detectable (via plaque assay) on paper currency for up to 24 hours, on clothing for up to 4 hours, and on skin for up to 96 hours.
At 22¬¨¬®‚Äö√†√ªC, SARS-CoV-2 was shown to be detectable (via plaque assay) on paper currency for up to 24 hours, on clothing for up to 4 hours, and on skin for up to 96 hours.
At 22¬¨¬®‚Äö√†√ªC, SARS-CoV-2 was shown to be detectable (via plaque assay) on paper currency for up to 24 hours, on clothing for up to 4 hours, and on skin for up to 96 hours.
At 22¬¨¬®‚Äö√†√ªC, SARS-CoV-2 was shown to be detectable (via plaque assay) on paper currency for up to 24 hours, on clothing for up to 4 hours, and on skin for up to 96 hours.
At 22¬¨¬®‚Äö√†√ªC, SARS-CoV-2 was shown to be detectable (via plaque assay) on paper currency for up to 24 hours, on clothing for up to 4 hours, and on skin for up to 96 hours.
At 22¬¨¬®‚Äö√†√ªC, SARS-CoV-2 was shown to be detectable (via plaque assay) on paper currency for up to 24 hours, on clothing for up to 4 hours, and on skin for up to 96 hours.
At 22¬¨¬®‚Äö√†√ªC, SARS-CoV-2 was shown to be detectable (via plaque assay) on paper currency for up to 24 hours, on clothing for up to 4 hours, and on skin for up to 96 hours.
At 22¬¨¬®‚Äö√†√ªC, SARS-CoV-2 was shown to be detectable (via plaque assay) on paper currency for up to 24 hours, on clothing for up to 4 hours, and on skin for up to 96 hours.
SARS-CoV-2 was found to be stable across pH 3-10 on several surfaces at 22¬¨¬®‚Äö√†√ªC.
SARS-CoV-2 was found to be stable across pH 3-10 on several surfaces at 22¬¨¬®‚Äö√†√ªC.
SARS-CoV-2 was found to be stable across pH 3-10 on several surfaces at 22¬¨¬®‚Äö√†√ªC.
SARS-CoV-2 was found to be stable across pH 3-10 on several surfaces at 22¬¨¬®‚Äö√†√ªC.
SARS-CoV-2 was found to be stable across pH 3-10 on several surfaces at 22¬¨¬®‚Äö√†√ªC.
SARS-CoV-2 was found to be stable across pH 3-10 on several surfaces at 22¬¨¬®‚Äö√†√ªC.
SARS-CoV-2 was found to be stable across pH 3-10 on several surfaces at 22¬¨¬®‚Äö√†√ªC.
SARS-CoV-2 was found to be stable across pH 3-10 on several surfaces at 22¬¨¬®‚Äö√†√ªC.
SARS-CoV-2 was found to be stable across pH 3-10 on several surfaces at 22¬¨¬®‚Äö√†√ªC.
SARS-CoV-2 was found to be stable across pH 3-10 on several surfaces at 22¬¨¬®‚Äö√†√ªC.
At standard room temperature and humidity, SARS-CoV-2 becomes undetectable on common library items after 2 to 8 days of quarantine depending on the material (e.g., book cover vs leather) and conditions (e.g., stacked vs unstacked).
At standard room temperature and humidity, SARS-CoV-2 becomes undetectable on common library items after 2 to 8 days of quarantine depending on the material (e.g., book cover vs leather) and conditions (e.g., stacked vs unstacked).
At standard room temperature and humidity, SARS-CoV-2 becomes undetectable on common library items after 2 to 8 days of quarantine depending on the material (e.g., book cover vs leather) and conditions (e.g., stacked vs unstacked).
At standard room temperature and humidity, SARS-CoV-2 becomes undetectable on common library items after 2 to 8 days of quarantine depending on the material (e.g., book cover vs leather) and conditions (e.g., stacked vs unstacked).
At standard room temperature and humidity, SARS-CoV-2 becomes undetectable on common library items after 2 to 8 days of quarantine depending on the material (e.g., book cover vs leather) and conditions (e.g., stacked vs unstacked).
At standard room temperature and humidity, SARS-CoV-2 becomes undetectable on common library items after 2 to 8 days of quarantine depending on the material (e.g., book cover vs leather) and conditions (e.g., stacked vs unstacked).
At standard room temperature and humidity, SARS-CoV-2 becomes undetectable on common library items after 2 to 8 days of quarantine depending on the material (e.g., book cover vs leather) and conditions (e.g., stacked vs unstacked).
At standard room temperature and humidity, SARS-CoV-2 becomes undetectable on common library items after 2 to 8 days of quarantine depending on the material (e.g., book cover vs leather) and conditions (e.g., stacked vs unstacked).
At standard room temperature and humidity, SARS-CoV-2 becomes undetectable on common library items after 2 to 8 days of quarantine depending on the material (e.g., book cover vs leather) and conditions (e.g., stacked vs unstacked).
At standard room temperature and humidity, SARS-CoV-2 becomes undetectable on common library items after 2 to 8 days of quarantine depending on the material (e.g., book cover vs leather) and conditions (e.g., stacked vs unstacked).
SARS-CoV-2 can persist on plastic and metal surfaces for up to 3 days (21-23¬¨¬®‚Äö√†√ªC, 40% RH) and infectious virus can be recovered from a surgical mask after 7 days (22¬¨¬®‚Äö√†√ªC, 65% RH).
SARS-CoV-2 can persist on plastic and metal surfaces for up to 3 days (21-23¬¨¬®‚Äö√†√ªC, 40% RH) and infectious virus can be recovered from a surgical mask after 7 days (22¬¨¬®‚Äö√†√ªC, 65% RH).
SARS-CoV-2 can persist on plastic and metal surfaces for up to 3 days (21-23¬¨¬®‚Äö√†√ªC, 40% RH) and infectious virus can be recovered from a surgical mask after 7 days (22¬¨¬®‚Äö√†√ªC, 65% RH).
SARS-CoV-2 can persist on plastic and metal surfaces for up to 3 days (21-23¬¨¬®‚Äö√†√ªC, 40% RH) and infectious virus can be recovered from a surgical mask after 7 days (22¬¨¬®‚Äö√†√ªC, 65% RH).
SARS-CoV-2 can persist on plastic and metal surfaces for up to 3 days (21-23¬¨¬®‚Äö√†√ªC, 40% RH) and infectious virus can be recovered from a surgical mask after 7 days (22¬¨¬®‚Äö√†√ªC, 65% RH).
SARS-CoV-2 can persist on plastic and metal surfaces for up to 3 days (21-23¬¨¬®‚Äö√†√ªC, 40% RH) and infectious virus can be recovered from a surgical mask after 7 days (22¬¨¬®‚Äö√†√ªC, 65% RH).
SARS-CoV-2 can persist on plastic and metal surfaces for up to 3 days (21-23¬¨¬®‚Äö√†√ªC, 40% RH) and infectious virus can be recovered from a surgical mask after 7 days (22¬¨¬®‚Äö√†√ªC, 65% RH).
SARS-CoV-2 can persist on plastic and metal surfaces for up to 3 days (21-23¬¨¬®‚Äö√†√ªC, 40% RH) and infectious virus can be recovered from a surgical mask after 7 days (22¬¨¬®‚Äö√†√ªC, 65% RH).
SARS-CoV-2 can persist on plastic and metal surfaces for up to 3 days (21-23¬¨¬®‚Äö√†√ªC, 40% RH) and infectious virus can be recovered from a surgical mask after 7 days (22¬¨¬®‚Äö√†√ªC, 65% RH).
SARS-CoV-2 can persist on plastic and metal surfaces for up to 3 days (21-23¬¨¬®‚Äö√†√ªC, 40% RH) and infectious virus can be recovered from a surgical mask after 7 days (22¬¨¬®‚Äö√†√ªC, 65% RH).
SARS-CoV-2 RNA was detected in symptomatic and asymptomatic cruise ship passenger rooms up to 17 days.
SARS-CoV-2 RNA was detected in symptomatic and asymptomatic cruise ship passenger rooms up to 17 days.
SARS-CoV-2 RNA was detected in symptomatic and asymptomatic cruise ship passenger rooms up to 17 days.
SARS-CoV-2 RNA was detected in symptomatic and asymptomatic cruise ship passenger rooms up to 17 days.
SARS-CoV-2 RNA was detected in symptomatic and asymptomatic cruise ship passenger rooms up to 17 days.
SARS-CoV-2 RNA was detected in symptomatic and asymptomatic cruise ship passenger rooms up to 17 days.
SARS-CoV-2 RNA was detected in symptomatic and asymptomatic cruise ship passenger rooms up to 17 days.
SARS-CoV-2 RNA was detected in symptomatic and asymptomatic cruise ship passenger rooms up to 17 days.
SARS-CoV-2 RNA was detected in symptomatic and asymptomatic cruise ship passenger rooms up to 17 days.
SARS-CoV-2 RNA was detected in symptomatic and asymptomatic cruise ship passenger rooms up to 17 days.
It is estimated that at least 1,000 viral particles per 25 cm2 are needed to detect SARS-CoV-2 RNA on surfaces.
It is estimated that at least 1,000 viral particles per 25 cm2 are needed to detect SARS-CoV-2 RNA on surfaces.
It is estimated that at least 1,000 viral particles per 25 cm2 are needed to detect SARS-CoV-2 RNA on surfaces.
It is estimated that at least 1,000 viral particles per 25 cm2 are needed to detect SARS-CoV-2 RNA on surfaces.
It is estimated that at least 1,000 viral particles per 25 cm2 are needed to detect SARS-CoV-2 RNA on surfaces.
It is estimated that at least 1,000 viral particles per 25 cm2 are needed to detect SARS-CoV-2 RNA on surfaces.
It is estimated that at least 1,000 viral particles per 25 cm2 are needed to detect SARS-CoV-2 RNA on surfaces.
It is estimated that at least 1,000 viral particles per 25 cm2 are needed to detect SARS-CoV-2 RNA on surfaces.
It is estimated that at least 1,000 viral particles per 25 cm2 are needed to detect SARS-CoV-2 RNA on surfaces.
It is estimated that at least 1,000 viral particles per 25 cm2 are needed to detect SARS-CoV-2 RNA on surfaces.
In the absence of sunlight, infectious SARS-CoV-2 can remain on non-porous (e.g., glass, vinyl) surfaces for at least 28 days at 20¬¨¬®‚Äö√†√ªC and 50% RH; higher temperatures greatly reduce the environmental stability of SARS-CoV-2.
In the absence of sunlight, infectious SARS-CoV-2 can remain on non-porous (e.g., glass, vinyl) surfaces for at least 28 days at 20¬¨¬®‚Äö√†√ªC and 50% RH; higher temperatures greatly reduce the environmental stability of SARS-CoV-2.
In the absence of sunlight, infectious SARS-CoV-2 can remain on non-porous (e.g., glass, vinyl) surfaces for at least 28 days at 20¬¨¬®‚Äö√†√ªC and 50% RH; higher temperatures greatly reduce the environmental stability of SARS-CoV-2.
In the absence of sunlight, infectious SARS-CoV-2 can remain on non-porous (e.g., glass, vinyl) surfaces for at least 28 days at 20¬¨¬®‚Äö√†√ªC and 50% RH; higher temperatures greatly reduce the environmental stability of SARS-CoV-2.
In the absence of sunlight, infectious SARS-CoV-2 can remain on non-porous (e.g., glass, vinyl) surfaces for at least 28 days at 20¬¨¬®‚Äö√†√ªC and 50% RH; higher temperatures greatly reduce the environmental stability of SARS-CoV-2.
In the absence of sunlight, infectious SARS-CoV-2 can remain on non-porous (e.g., glass, vinyl) surfaces for at least 28 days at 20¬¨¬®‚Äö√†√ªC and 50% RH; higher temperatures greatly reduce the environmental stability of SARS-CoV-2.
In the absence of sunlight, infectious SARS-CoV-2 can remain on non-porous (e.g., glass, vinyl) surfaces for at least 28 days at 20¬¨¬®‚Äö√†√ªC and 50% RH; higher temperatures greatly reduce the environmental stability of SARS-CoV-2.
In the absence of sunlight, infectious SARS-CoV-2 can remain on non-porous (e.g., glass, vinyl) surfaces for at least 28 days at 20¬¨¬®‚Äö√†√ªC and 50% RH; higher temperatures greatly reduce the environmental stability of SARS-CoV-2.
In the absence of sunlight, infectious SARS-CoV-2 can remain on non-porous (e.g., glass, vinyl) surfaces for at least 28 days at 20¬¨¬®‚Äö√†√ªC and 50% RH; higher temperatures greatly reduce the environmental stability of SARS-CoV-2.
In the absence of sunlight, infectious SARS-CoV-2 can remain on non-porous (e.g., glass, vinyl) surfaces for at least 28 days at 20¬¨¬®‚Äö√†√ªC and 50% RH; higher temperatures greatly reduce the environmental stability of SARS-CoV-2.
This value is longer than other stability estimates, potentially due to a fluid matrix with more protein to simulate human respiratory fluid and a higher inoculation dose.
This value is longer than other stability estimates, potentially due to a fluid matrix with more protein to simulate human respiratory fluid and a higher inoculation dose.
This value is longer than other stability estimates, potentially due to a fluid matrix with more protein to simulate human respiratory fluid and a higher inoculation dose.
This value is longer than other stability estimates, potentially due to a fluid matrix with more protein to simulate human respiratory fluid and a higher inoculation dose.
This value is longer than other stability estimates, potentially due to a fluid matrix with more protein to simulate human respiratory fluid and a higher inoculation dose.
This value is longer than other stability estimates, potentially due to a fluid matrix with more protein to simulate human respiratory fluid and a higher inoculation dose.
This value is longer than other stability estimates, potentially due to a fluid matrix with more protein to simulate human respiratory fluid and a higher inoculation dose.
This value is longer than other stability estimates, potentially due to a fluid matrix with more protein to simulate human respiratory fluid and a higher inoculation dose.
This value is longer than other stability estimates, potentially due to a fluid matrix with more protein to simulate human respiratory fluid and a higher inoculation dose.
This value is longer than other stability estimates, potentially due to a fluid matrix with more protein to simulate human respiratory fluid and a higher inoculation dose.
In simulated saliva on stainless steel surfaces, SARS-CoV-2 shows negligible decay over 60 minutes in darkness, but loses 90% of infectivity every 6.8-12.8 minutes, depending on simulated UVB radiation.
In simulated saliva on stainless steel surfaces, SARS-CoV-2 shows negligible decay over 60 minutes in darkness, but loses 90% of infectivity every 6.8-12.8 minutes, depending on simulated UVB radiation.
In simulated saliva on stainless steel surfaces, SARS-CoV-2 shows negligible decay over 60 minutes in darkness, but loses 90% of infectivity every 6.8-12.8 minutes, depending on simulated UVB radiation.
In simulated saliva on stainless steel surfaces, SARS-CoV-2 shows negligible decay over 60 minutes in darkness, but loses 90% of infectivity every 6.8-12.8 minutes, depending on simulated UVB radiation.
In simulated saliva on stainless steel surfaces, SARS-CoV-2 shows negligible decay over 60 minutes in darkness, but loses 90% of infectivity every 6.8-12.8 minutes, depending on simulated UVB radiation.
In simulated saliva on stainless steel surfaces, SARS-CoV-2 shows negligible decay over 60 minutes in darkness, but loses 90% of infectivity every 6.8-12.8 minutes, depending on simulated UVB radiation.
In simulated saliva on stainless steel surfaces, SARS-CoV-2 shows negligible decay over 60 minutes in darkness, but loses 90% of infectivity every 6.8-12.8 minutes, depending on simulated UVB radiation.
In simulated saliva on stainless steel surfaces, SARS-CoV-2 shows negligible decay over 60 minutes in darkness, but loses 90% of infectivity every 6.8-12.8 minutes, depending on simulated UVB radiation.
In simulated saliva on stainless steel surfaces, SARS-CoV-2 shows negligible decay over 60 minutes in darkness, but loses 90% of infectivity every 6.8-12.8 minutes, depending on simulated UVB radiation.
In simulated saliva on stainless steel surfaces, SARS-CoV-2 shows negligible decay over 60 minutes in darkness, but loses 90% of infectivity every 6.8-12.8 minutes, depending on simulated UVB radiation.
The Department of Homeland Security (DHS) developed a data-based model for SARS-CoV-2 decay on inert surfaces (stainless steel, ABS plastic and nitrile rubber) at varying temperature and relative humidity without sunlight.
The Department of Homeland Security (DHS) developed a data-based model for SARS-CoV-2 decay on inert surfaces (stainless steel, ABS plastic and nitrile rubber) at varying temperature and relative humidity without sunlight.
The Department of Homeland Security (DHS) developed a data-based model for SARS-CoV-2 decay on inert surfaces (stainless steel, ABS plastic and nitrile rubber) at varying temperature and relative humidity without sunlight.
The Department of Homeland Security (DHS) developed a data-based model for SARS-CoV-2 decay on inert surfaces (stainless steel, ABS plastic and nitrile rubber) at varying temperature and relative humidity without sunlight.
The Department of Homeland Security (DHS) developed a data-based model for SARS-CoV-2 decay on inert surfaces (stainless steel, ABS plastic and nitrile rubber) at varying temperature and relative humidity without sunlight.
The Department of Homeland Security (DHS) developed a data-based model for SARS-CoV-2 decay on inert surfaces (stainless steel, ABS plastic and nitrile rubber) at varying temperature and relative humidity without sunlight.
The Department of Homeland Security (DHS) developed a data-based model for SARS-CoV-2 decay on inert surfaces (stainless steel, ABS plastic and nitrile rubber) at varying temperature and relative humidity without sunlight.
The Department of Homeland Security (DHS) developed a data-based model for SARS-CoV-2 decay on inert surfaces (stainless steel, ABS plastic and nitrile rubber) at varying temperature and relative humidity without sunlight.
The Department of Homeland Security (DHS) developed a data-based model for SARS-CoV-2 decay on inert surfaces (stainless steel, ABS plastic and nitrile rubber) at varying temperature and relative humidity without sunlight.
The Department of Homeland Security (DHS) developed a data-based model for SARS-CoV-2 decay on inert surfaces (stainless steel, ABS plastic and nitrile rubber) at varying temperature and relative humidity without sunlight.
Particulate matter (PM) does not appear to be a viable transmission model of SARS-CoV-2.
Particulate matter (PM) does not appear to be a viable transmission model of SARS-CoV-2.
Particulate matter (PM) does not appear to be a viable transmission model of SARS-CoV-2.
Particulate matter (PM) does not appear to be a viable transmission model of SARS-CoV-2.
Particulate matter (PM) does not appear to be a viable transmission model of SARS-CoV-2.
Particulate matter (PM) does not appear to be a viable transmission model of SARS-CoV-2.
Particulate matter (PM) does not appear to be a viable transmission model of SARS-CoV-2.
Particulate matter (PM) does not appear to be a viable transmission model of SARS-CoV-2.
Particulate matter (PM) does not appear to be a viable transmission model of SARS-CoV-2.
Particulate matter (PM) does not appear to be a viable transmission model of SARS-CoV-2.
It does not appear that pollen or air particulates are carriers of SARS-CoV-2, despite some country-level associations.
SARS-CoV-2 survival in the air is highly dependent on the presence of UV light and temperature.
SARS-CoV-2 survival in the air is highly dependent on the presence of UV light and temperature.
SARS-CoV-2 survival in the air is highly dependent on the presence of UV light and temperature.
SARS-CoV-2 survival in the air is highly dependent on the presence of UV light and temperature.
SARS-CoV-2 survival in the air is highly dependent on the presence of UV light and temperature.
SARS-CoV-2 survival in the air is highly dependent on the presence of UV light and temperature.
SARS-CoV-2 survival in the air is highly dependent on the presence of UV light and temperature.
SARS-CoV-2 survival in the air is highly dependent on the presence of UV light and temperature.
SARS-CoV-2 survival in the air is highly dependent on the presence of UV light and temperature.
SARS-CoV-2 survival in the air is highly dependent on the presence of UV light and temperature.
Due to the effects of evaporation, modeling suggests that hot, dry conditions increase the aerosol risk of SARS-CoV-2, though cold, humid conditions facilitate transmission by droplet spread.
Due to the effects of evaporation, modeling suggests that hot, dry conditions increase the aerosol risk of SARS-CoV-2, though cold, humid conditions facilitate transmission by droplet spread.
Due to the effects of evaporation, modeling suggests that hot, dry conditions increase the aerosol risk of SARS-CoV-2, though cold, humid conditions facilitate transmission by droplet spread.
Due to the effects of evaporation, modeling suggests that hot, dry conditions increase the aerosol risk of SARS-CoV-2, though cold, humid conditions facilitate transmission by droplet spread.
Due to the effects of evaporation, modeling suggests that hot, dry conditions increase the aerosol risk of SARS-CoV-2, though cold, humid conditions facilitate transmission by droplet spread.
Due to the effects of evaporation, modeling suggests that hot, dry conditions increase the aerosol risk of SARS-CoV-2, though cold, humid conditions facilitate transmission by droplet spread.
Due to the effects of evaporation, modeling suggests that hot, dry conditions increase the aerosol risk of SARS-CoV-2, though cold, humid conditions facilitate transmission by droplet spread.
Due to the effects of evaporation, modeling suggests that hot, dry conditions increase the aerosol risk of SARS-CoV-2, though cold, humid conditions facilitate transmission by droplet spread.
Due to the effects of evaporation, modeling suggests that hot, dry conditions increase the aerosol risk of SARS-CoV-2, though cold, humid conditions facilitate transmission by droplet spread.
Due to the effects of evaporation, modeling suggests that hot, dry conditions increase the aerosol risk of SARS-CoV-2, though cold, humid conditions facilitate transmission by droplet spread.
Experimental studies using SARS-CoV-2 aerosols (1.78-1.96 ‚âà√≠¬¨‚à´m mass median aerodynamic diameter in artificial saliva matrix) found that simulated sunlight rapidly inactivates the virus, with 90% reductions in infectious concentration after 6 minutes in high-intensity sunlight (similar to mid-June) and 19 minutes in low-intensity sunlight (similar to early March or October).
Experimental studies using SARS-CoV-2 aerosols (1.78-1.96 ‚âà√≠¬¨‚à´m mass median aerodynamic diameter in artificial saliva matrix) found that simulated sunlight rapidly inactivates the virus, with 90% reductions in infectious concentration after 6 minutes in high-intensity sunlight (similar to mid-June) and 19 minutes in low-intensity sunlight (similar to early March or October).
Experimental studies using SARS-CoV-2 aerosols (1.78-1.96 ‚âà√≠¬¨‚à´m mass median aerodynamic diameter in artificial saliva matrix) found that simulated sunlight rapidly inactivates the virus, with 90% reductions in infectious concentration after 6 minutes in high-intensity sunlight (similar to mid-June) and 19 minutes in low-intensity sunlight (similar to early March or October).
Experimental studies using SARS-CoV-2 aerosols (1.78-1.96 ‚âà√≠¬¨‚à´m mass median aerodynamic diameter in artificial saliva matrix) found that simulated sunlight rapidly inactivates the virus, with 90% reductions in infectious concentration after 6 minutes in high-intensity sunlight (similar to mid-June) and 19 minutes in low-intensity sunlight (similar to early March or October).
Experimental studies using SARS-CoV-2 aerosols (1.78-1.96 ‚âà√≠¬¨‚à´m mass median aerodynamic diameter in artificial saliva matrix) found that simulated sunlight rapidly inactivates the virus, with 90% reductions in infectious concentration after 6 minutes in high-intensity sunlight (similar to mid-June) and 19 minutes in low-intensity sunlight (similar to early March or October).
Experimental studies using SARS-CoV-2 aerosols (1.78-1.96 ‚âà√≠¬¨‚à´m mass median aerodynamic diameter in artificial saliva matrix) found that simulated sunlight rapidly inactivates the virus, with 90% reductions in infectious concentration after 6 minutes in high-intensity sunlight (similar to mid-June) and 19 minutes in low-intensity sunlight (similar to early March or October).
Experimental studies using SARS-CoV-2 aerosols (1.78-1.96 ‚âà√≠¬¨‚à´m mass median aerodynamic diameter in artificial saliva matrix) found that simulated sunlight rapidly inactivates the virus, with 90% reductions in infectious concentration after 6 minutes in high-intensity sunlight (similar to mid-June) and 19 minutes in low-intensity sunlight (similar to early March or October).
Experimental studies using SARS-CoV-2 aerosols (1.78-1.96 ‚âà√≠¬¨‚à´m mass median aerodynamic diameter in artificial saliva matrix) found that simulated sunlight rapidly inactivates the virus, with 90% reductions in infectious concentration after 6 minutes in high-intensity sunlight (similar to mid-June) and 19 minutes in low-intensity sunlight (similar to early March or October).
Experimental studies using SARS-CoV-2 aerosols (1.78-1.96 ‚âà√≠¬¨‚à´m mass median aerodynamic diameter in artificial saliva matrix) found that simulated sunlight rapidly inactivates the virus, with 90% reductions in infectious concentration after 6 minutes in high-intensity sunlight (similar to mid-June) and 19 minutes in low-intensity sunlight (similar to early March or October).
Experimental studies using SARS-CoV-2 aerosols (1.78-1.96 ‚âà√≠¬¨‚à´m mass median aerodynamic diameter in artificial saliva matrix) found that simulated sunlight rapidly inactivates the virus, with 90% reductions in infectious concentration after 6 minutes in high-intensity sunlight (similar to mid-June) and 19 minutes in low-intensity sunlight (similar to early March or October).
In dark conditions, the half-life of aerosolized SARS-CoV-2 is approximately 86 minutes in simulated saliva matrix.
In dark conditions, the half-life of aerosolized SARS-CoV-2 is approximately 86 minutes in simulated saliva matrix.
In dark conditions, the half-life of aerosolized SARS-CoV-2 is approximately 86 minutes in simulated saliva matrix.
In dark conditions, the half-life of aerosolized SARS-CoV-2 is approximately 86 minutes in simulated saliva matrix.
In dark conditions, the half-life of aerosolized SARS-CoV-2 is approximately 86 minutes in simulated saliva matrix.
Humidity alone had no significant impact on aerosolized virus survival.
Humidity alone had no significant impact on aerosolized virus survival.
Humidity alone had no significant impact on aerosolized virus survival.
Humidity alone had no significant impact on aerosolized virus survival.
Humidity alone had no significant impact on aerosolized virus survival.
Humidity alone had no significant impact on aerosolized virus survival.
Humidity alone had no significant impact on aerosolized virus survival.
Humidity alone had no significant impact on aerosolized virus survival.
Humidity alone had no significant impact on aerosolized virus survival.
Humidity alone had no significant impact on aerosolized virus survival.
SARS-CoV-2 was shown to have an aerosol half-life of 2.7 hours (without sunlight, particles <5 ‚âà√≠¬¨‚à´m, tested at 21-23¬¨¬®‚Äö√†√ªC and 65% RH),673 retaining infectivity for up to 16 hours in appropriate conditions (23¬¨¬®‚Äö√†√ªC, 53% RH, no sunlight).
SARS-CoV-2 was shown to have an aerosol half-life of 2.7 hours (without sunlight, particles <5 ‚âà√≠¬¨‚à´m, tested at 21-23¬¨¬®‚Äö√†√ªC and 65% RH),673 retaining infectivity for up to 16 hours in appropriate conditions (23¬¨¬®‚Äö√†√ªC, 53% RH, no sunlight).
SARS-CoV-2 was shown to have an aerosol half-life of 2.7 hours (without sunlight, particles <5 ‚âà√≠¬¨‚à´m, tested at 21-23¬¨¬®‚Äö√†√ªC and 65% RH),673 retaining infectivity for up to 16 hours in appropriate conditions (23¬¨¬®‚Äö√†√ªC, 53% RH, no sunlight).
SARS-CoV-2 was shown to have an aerosol half-life of 2.7 hours (without sunlight, particles <5 ‚âà√≠¬¨‚à´m, tested at 21-23¬¨¬®‚Äö√†√ªC and 65% RH),673 retaining infectivity for up to 16 hours in appropriate conditions (23¬¨¬®‚Äö√†√ªC, 53% RH, no sunlight).
SARS-CoV-2 was shown to have an aerosol half-life of 2.7 hours (without sunlight, particles <5 ‚âà√≠¬¨‚à´m, tested at 21-23¬¨¬®‚Äö√†√ªC and 65% RH),673 retaining infectivity for up to 16 hours in appropriate conditions (23¬¨¬®‚Äö√†√ªC, 53% RH, no sunlight).
SARS-CoV-2 was shown to have an aerosol half-life of 2.7 hours (without sunlight, particles <5 ‚âà√≠¬¨‚à´m, tested at 21-23¬¨¬®‚Äö√†√ªC and 65% RH),673 retaining infectivity for up to 16 hours in appropriate conditions (23¬¨¬®‚Äö√†√ªC, 53% RH, no sunlight).
SARS-CoV-2 was shown to have an aerosol half-life of 2.7 hours (without sunlight, particles <5 ‚âà√≠¬¨‚à´m, tested at 21-23¬¨¬®‚Äö√†√ªC and 65% RH),673 retaining infectivity for up to 16 hours in appropriate conditions (23¬¨¬®‚Äö√†√ªC, 53% RH, no sunlight).
SARS-CoV-2 was shown to have an aerosol half-life of 2.7 hours (without sunlight, particles <5 ‚âà√≠¬¨‚à´m, tested at 21-23¬¨¬®‚Äö√†√ªC and 65% RH),673 retaining infectivity for up to 16 hours in appropriate conditions (23¬¨¬®‚Äö√†√ªC, 53% RH, no sunlight).
SARS-CoV-2 was shown to have an aerosol half-life of 2.7 hours (without sunlight, particles <5 ‚âà√≠¬¨‚à´m, tested at 21-23¬¨¬®‚Äö√†√ªC and 65% RH),673 retaining infectivity for up to 16 hours in appropriate conditions (23¬¨¬®‚Äö√†√ªC, 53% RH, no sunlight).
SARS-CoV-2 was shown to have an aerosol half-life of 2.7 hours (without sunlight, particles <5 ‚âà√≠¬¨‚à´m, tested at 21-23¬¨¬®‚Äö√†√ªC and 65% RH),673 retaining infectivity for up to 16 hours in appropriate conditions (23¬¨¬®‚Äö√†√ªC, 53% RH, no sunlight).
Stability of SARS-CoV-2 RNA in clinical samples depends on temperature and transport medium.
Stability of SARS-CoV-2 RNA in clinical samples depends on temperature and transport medium.
Stability of SARS-CoV-2 RNA in clinical samples depends on temperature and transport medium.
Stability of SARS-CoV-2 RNA in clinical samples depends on temperature and transport medium.
Stability of SARS-CoV-2 RNA in clinical samples depends on temperature and transport medium.
Stability of SARS-CoV-2 RNA in clinical samples depends on temperature and transport medium.
Stability of SARS-CoV-2 RNA in clinical samples depends on temperature and transport medium.
Stability of SARS-CoV-2 RNA in clinical samples depends on temperature and transport medium.
Stability of SARS-CoV-2 RNA in clinical samples depends on temperature and transport medium.
Stability of SARS-CoV-2 RNA in clinical samples depends on temperature and transport medium.
RNA in clinical samples collected in viral transport medium is stable at 18-25¬¨¬®‚Äö√†√ªC or 2-8¬¨¬®‚Äö√†√ªC for up to 21 days without impacting real-time RT-PCR results.
RNA in clinical samples collected in viral transport medium is stable at 18-25¬¨¬®‚Äö√†√ªC or 2-8¬¨¬®‚Äö√†√ªC for up to 21 days without impacting real-time RT-PCR results.
RNA in clinical samples collected in viral transport medium is stable at 18-25¬¨¬®‚Äö√†√ªC or 2-8¬¨¬®‚Äö√†√ªC for up to 21 days without impacting real-time RT-PCR results.
RNA in clinical samples collected in viral transport medium is stable at 18-25¬¨¬®‚Äö√†√ªC or 2-8¬¨¬®‚Äö√†√ªC for up to 21 days without impacting real-time RT-PCR results.
RNA in clinical samples collected in viral transport medium is stable at 18-25¬¨¬®‚Äö√†√ªC or 2-8¬¨¬®‚Äö√†√ªC for up to 21 days without impacting real-time RT-PCR results.
RNA in clinical samples collected in viral transport medium is stable at 18-25¬¨¬®‚Äö√†√ªC or 2-8¬¨¬®‚Äö√†√ªC for up to 21 days without impacting real-time RT-PCR results.
RNA in clinical samples collected in viral transport medium is stable at 18-25¬¨¬®‚Äö√†√ªC or 2-8¬¨¬®‚Äö√†√ªC for up to 21 days without impacting real-time RT-PCR results.
RNA in clinical samples collected in viral transport medium is stable at 18-25¬¨¬®‚Äö√†√ªC or 2-8¬¨¬®‚Äö√†√ªC for up to 21 days without impacting real-time RT-PCR results.
RNA in clinical samples collected in viral transport medium is stable at 18-25¬¨¬®‚Äö√†√ªC or 2-8¬¨¬®‚Äö√†√ªC for up to 21 days without impacting real-time RT-PCR results.
RNA in clinical samples collected in viral transport medium is stable at 18-25¬¨¬®‚Äö√†√ªC or 2-8¬¨¬®‚Äö√†√ªC for up to 21 days without impacting real-time RT-PCR results.
RNA in clinical samples is also stable at 4¬¨¬®‚Äö√†√ªC for up for 4 weeks with regard to quantitative RT-PCR testing (given that the sample contains 5,000 copies/mL).
RNA in clinical samples is also stable at 4¬¨¬®‚Äö√†√ªC for up for 4 weeks with regard to quantitative RT-PCR testing (given that the sample contains 5,000 copies/mL).
RNA in clinical samples is also stable at 4¬¨¬®‚Äö√†√ªC for up for 4 weeks with regard to quantitative RT-PCR testing (given that the sample contains 5,000 copies/mL).
RNA in clinical samples is also stable at 4¬¨¬®‚Äö√†√ªC for up for 4 weeks with regard to quantitative RT-PCR testing (given that the sample contains 5,000 copies/mL).
RNA in clinical samples is also stable at 4¬¨¬®‚Äö√†√ªC for up for 4 weeks with regard to quantitative RT-PCR testing (given that the sample contains 5,000 copies/mL).
RNA in clinical samples is also stable at 4¬¨¬®‚Äö√†√ªC for up for 4 weeks with regard to quantitative RT-PCR testing (given that the sample contains 5,000 copies/mL).
RNA in clinical samples is also stable at 4¬¨¬®‚Äö√†√ªC for up for 4 weeks with regard to quantitative RT-PCR testing (given that the sample contains 5,000 copies/mL).
RNA in clinical samples is also stable at 4¬¨¬®‚Äö√†√ªC for up for 4 weeks with regard to quantitative RT-PCR testing (given that the sample contains 5,000 copies/mL).
RNA in clinical samples is also stable at 4¬¨¬®‚Äö√†√ªC for up for 4 weeks with regard to quantitative RT-PCR testing (given that the sample contains 5,000 copies/mL).
RNA in clinical samples is also stable at 4¬¨¬®‚Äö√†√ªC for up for 4 weeks with regard to quantitative RT-PCR testing (given that the sample contains 5,000 copies/mL).
Separately, storage of RNA in phosphate buffered saline (PBS) at room temperature (18-25¬¨¬®‚Äö√†√ªC) resulted in unstable sample concentrations.
Separately, storage of RNA in phosphate buffered saline (PBS) at room temperature (18-25¬¨¬®‚Äö√†√ªC) resulted in unstable sample concentrations.
Separately, storage of RNA in phosphate buffered saline (PBS) at room temperature (18-25¬¨¬®‚Äö√†√ªC) resulted in unstable sample concentrations.
Separately, storage of RNA in phosphate buffered saline (PBS) at room temperature (18-25¬¨¬®‚Äö√†√ªC) resulted in unstable sample concentrations.
Separately, storage of RNA in phosphate buffered saline (PBS) at room temperature (18-25¬¨¬®‚Äö√†√ªC) resulted in unstable sample concentrations.
Separately, storage of RNA in phosphate buffered saline (PBS) at room temperature (18-25¬¨¬®‚Äö√†√ªC) resulted in unstable sample concentrations.
Separately, storage of RNA in phosphate buffered saline (PBS) at room temperature (18-25¬¨¬®‚Äö√†√ªC) resulted in unstable sample concentrations.
Separately, storage of RNA in phosphate buffered saline (PBS) at room temperature (18-25¬¨¬®‚Äö√†√ªC) resulted in unstable sample concentrations.
Separately, storage of RNA in phosphate buffered saline (PBS) at room temperature (18-25¬¨¬®‚Äö√†√ªC) resulted in unstable sample concentrations.
Separately, storage of RNA in phosphate buffered saline (PBS) at room temperature (18-25¬¨¬®‚Äö√†√ªC) resulted in unstable sample concentrations.
There is currently no evidence that SARS-CoV-2 is transmitted to people through food.
There is currently no evidence that SARS-CoV-2 is transmitted to people through food.
There is currently no evidence that SARS-CoV-2 is transmitted to people through food.
There is currently no evidence that SARS-CoV-2 is transmitted to people through food.
There is currently no evidence that SARS-CoV-2 is transmitted to people through food.
There is currently no evidence that SARS-CoV-2 is transmitted to people through food.
There is currently no evidence that SARS-CoV-2 is transmitted to people through food.
There is currently no evidence that SARS-CoV-2 is transmitted to people through food.
There is currently no evidence that SARS-CoV-2 is transmitted to people through food.
There is currently no evidence that SARS-CoV-2 is transmitted to people through food.
There is no documented evidence that food, food packaging, or food handling is a significant source of COVID-19 infections, though several outbreaks have a hypothesized food origin.
There is no documented evidence that food, food packaging, or food handling is a significant source of COVID-19 infections, though several outbreaks have a hypothesized food origin.
There is no documented evidence that food, food packaging, or food handling is a significant source of COVID-19 infections, though several outbreaks have a hypothesized food origin.
There is no documented evidence that food, food packaging, or food handling is a significant source of COVID-19 infections, though several outbreaks have a hypothesized food origin.
There is no documented evidence that food, food packaging, or food handling is a significant source of COVID-19 infections, though several outbreaks have a hypothesized food origin.
There is no documented evidence that food, food packaging, or food handling is a significant source of COVID-19 infections, though several outbreaks have a hypothesized food origin.
There is no documented evidence that food, food packaging, or food handling is a significant source of COVID-19 infections, though several outbreaks have a hypothesized food origin.
There is no documented evidence that food, food packaging, or food handling is a significant source of COVID-19 infections, though several outbreaks have a hypothesized food origin.
There is no documented evidence that food, food packaging, or food handling is a significant source of COVID-19 infections, though several outbreaks have a hypothesized food origin.
There is no documented evidence that food, food packaging, or food handling is a significant source of COVID-19 infections, though several outbreaks have a hypothesized food origin.
Infectious SARS-CoV-2 has been found on frozen food packaging, but has not been linked to actual infections.
Infectious SARS-CoV-2 has been found on frozen food packaging, but has not been linked to actual infections.
Infectious SARS-CoV-2 has been found on frozen food packaging, but has not been linked to actual infections.
Infectious SARS-CoV-2 has been found on frozen food packaging, but has not been linked to actual infections.
Infectious SARS-CoV-2 has been found on frozen food packaging, but has not been linked to actual infections.
Infectious SARS-CoV-2 has been found on frozen food packaging, but has not been linked to actual infections.
Infectious SARS-CoV-2 has been found on frozen food packaging, but has not been linked to actual infections.
Infectious SARS-CoV-2 has been found on frozen food packaging, but has not been linked to actual infections.
Infectious SARS-CoV-2 has been found on frozen food packaging, but has not been linked to actual infections.
Infectious SARS-CoV-2 has been found on frozen food packaging, but has not been linked to actual infections.
SARS-CoV-2 is susceptible to heat treatment (70¬¨¬®‚Äö√†√ªC) but can persist for at least two weeks at refrigerated temperatures (4¬¨¬®‚Äö√†√ªC).
SARS-CoV-2 is susceptible to heat treatment (70¬¨¬®‚Äö√†√ªC) but can persist for at least two weeks at refrigerated temperatures (4¬¨¬®‚Äö√†√ªC).
SARS-CoV-2 is susceptible to heat treatment (70¬¨¬®‚Äö√†√ªC) but can persist for at least two weeks at refrigerated temperatures (4¬¨¬®‚Äö√†√ªC).
SARS-CoV-2 is susceptible to heat treatment (70¬¨¬®‚Äö√†√ªC) but can persist for at least two weeks at refrigerated temperatures (4¬¨¬®‚Äö√†√ªC).
SARS-CoV-2 is susceptible to heat treatment (70¬¨¬®‚Äö√†√ªC) but can persist for at least two weeks at refrigerated temperatures (4¬¨¬®‚Äö√†√ªC).
SARS-CoV-2 is susceptible to heat treatment (70¬¨¬®‚Äö√†√ªC) but can persist for at least two weeks at refrigerated temperatures (4¬¨¬®‚Äö√†√ªC).
SARS-CoV-2 is susceptible to heat treatment (70¬¨¬®‚Äö√†√ªC) but can persist for at least two weeks at refrigerated temperatures (4¬¨¬®‚Äö√†√ªC).
SARS-CoV-2 is susceptible to heat treatment (70¬¨¬®‚Äö√†√ªC) but can persist for at least two weeks at refrigerated temperatures (4¬¨¬®‚Äö√†√ªC).
SARS-CoV-2 is susceptible to heat treatment (70¬¨¬®‚Äö√†√ªC) but can persist for at least two weeks at refrigerated temperatures (4¬¨¬®‚Äö√†√ªC).
SARS-CoV-2 is susceptible to heat treatment (70¬¨¬®‚Äö√†√ªC) but can persist for at least two weeks at refrigerated temperatures (4¬¨¬®‚Äö√†√ªC).
SARS-CoV-2 maintains infectivity for at least 21 days when inoculated on frozen foods and stored below -20¬¨¬®‚Äö√†√ªC.
SARS-CoV-2 maintains infectivity for at least 21 days when inoculated on frozen foods and stored below -20¬¨¬®‚Äö√†√ªC.
SARS-CoV-2 maintains infectivity for at least 21 days when inoculated on frozen foods and stored below -20¬¨¬®‚Äö√†√ªC.
SARS-CoV-2 maintains infectivity for at least 21 days when inoculated on frozen foods and stored below -20¬¨¬®‚Äö√†√ªC.
SARS-CoV-2 maintains infectivity for at least 21 days when inoculated on frozen foods and stored below -20¬¨¬®‚Äö√†√ªC.
SARS-CoV-2 maintains infectivity for at least 21 days when inoculated on frozen foods and stored below -20¬¨¬®‚Äö√†√ªC.
SARS-CoV-2 maintains infectivity for at least 21 days when inoculated on frozen foods and stored below -20¬¨¬®‚Äö√†√ªC.
SARS-CoV-2 maintains infectivity for at least 21 days when inoculated on frozen foods and stored below -20¬¨¬®‚Äö√†√ªC.
SARS-CoV-2 maintains infectivity for at least 21 days when inoculated on frozen foods and stored below -20¬¨¬®‚Äö√†√ªC.
SARS-CoV-2 maintains infectivity for at least 21 days when inoculated on frozen foods and stored below -20¬¨¬®‚Äö√†√ªC.
Soap and water, as well as common alcohol and chlorine-based cleaners, hand sanitizers, and disinfectants are effective at inactivating SARS-CoV-2 on hands and surfaces.
Soap and water, as well as common alcohol and chlorine-based cleaners, hand sanitizers, and disinfectants are effective at inactivating SARS-CoV-2 on hands and surfaces.
Soap and water, as well as common alcohol and chlorine-based cleaners, hand sanitizers, and disinfectants are effective at inactivating SARS-CoV-2 on hands and surfaces.
Soap and water, as well as common alcohol and chlorine-based cleaners, hand sanitizers, and disinfectants are effective at inactivating SARS-CoV-2 on hands and surfaces.
Soap and water, as well as common alcohol and chlorine-based cleaners, hand sanitizers, and disinfectants are effective at inactivating SARS-CoV-2 on hands and surfaces.
Soap and water, as well as common alcohol and chlorine-based cleaners, hand sanitizers, and disinfectants are effective at inactivating SARS-CoV-2 on hands and surfaces.
Soap and water, as well as common alcohol and chlorine-based cleaners, hand sanitizers, and disinfectants are effective at inactivating SARS-CoV-2 on hands and surfaces.
Soap and water, as well as common alcohol and chlorine-based cleaners, hand sanitizers, and disinfectants are effective at inactivating SARS-CoV-2 on hands and surfaces.
Soap and water, as well as common alcohol and chlorine-based cleaners, hand sanitizers, and disinfectants are effective at inactivating SARS-CoV-2 on hands and surfaces.
Soap and water, as well as common alcohol and chlorine-based cleaners, hand sanitizers, and disinfectants are effective at inactivating SARS-CoV-2 on hands and surfaces.
A systematic review identified sunlight, UV light, ethanol, hydrogen peroxide, and hypochlorite as methods to reduce surface contamination.
A systematic review identified sunlight, UV light, ethanol, hydrogen peroxide, and hypochlorite as methods to reduce surface contamination.
A systematic review identified sunlight, UV light, ethanol, hydrogen peroxide, and hypochlorite as methods to reduce surface contamination.
A systematic review identified sunlight, UV light, ethanol, hydrogen peroxide, and hypochlorite as methods to reduce surface contamination.
A systematic review identified sunlight, UV light, ethanol, hydrogen peroxide, and hypochlorite as methods to reduce surface contamination.
A systematic review identified sunlight, UV light, ethanol, hydrogen peroxide, and hypochlorite as methods to reduce surface contamination.
A systematic review identified sunlight, UV light, ethanol, hydrogen peroxide, and hypochlorite as methods to reduce surface contamination.
A systematic review identified sunlight, UV light, ethanol, hydrogen peroxide, and hypochlorite as methods to reduce surface contamination.
A systematic review identified sunlight, UV light, ethanol, hydrogen peroxide, and hypochlorite as methods to reduce surface contamination.
A systematic review identified sunlight, UV light, ethanol, hydrogen peroxide, and hypochlorite as methods to reduce surface contamination.
However, the levels of decontamination necessary to affect transmission per se are still unknown.
However, the levels of decontamination necessary to affect transmission per se are still unknown.
Alcohol-based hand rubs are effective at inactivating SARS-CoV-2.
Alcohol-based hand rubs are effective at inactivating SARS-CoV-2.
Alcohol-based hand rubs are effective at inactivating SARS-CoV-2.
Alcohol-based hand rubs are effective at inactivating SARS-CoV-2.
Alcohol-based hand rubs are effective at inactivating SARS-CoV-2.
Alcohol-based hand rubs are effective at inactivating SARS-CoV-2.
Alcohol-based hand rubs are effective at inactivating SARS-CoV-2.
Alcohol-based hand rubs are effective at inactivating SARS-CoV-2.
Alcohol-based hand rubs are effective at inactivating SARS-CoV-2.
Alcohol-based hand rubs are effective at inactivating SARS-CoV-2.
Chlorine bleach (1%, 2%), 70% ethanol and 0.05% chlorhexidine are effective against live virus in lab tests.
Chlorine bleach (1%, 2%), 70% ethanol and 0.05% chlorhexidine are effective against live virus in lab tests.
Chlorine bleach (1%, 2%), 70% ethanol and 0.05% chlorhexidine are effective against live virus in lab tests.
Chlorine bleach (1%, 2%), 70% ethanol and 0.05% chlorhexidine are effective against live virus in lab tests.
Chlorine bleach (1%, 2%), 70% ethanol and 0.05% chlorhexidine are effective against live virus in lab tests.
Chlorine bleach (1%, 2%), 70% ethanol and 0.05% chlorhexidine are effective against live virus in lab tests.
Chlorine bleach (1%, 2%), 70% ethanol and 0.05% chlorhexidine are effective against live virus in lab tests.
Chlorine bleach (1%, 2%), 70% ethanol and 0.05% chlorhexidine are effective against live virus in lab tests.
Chlorine bleach (1%, 2%), 70% ethanol and 0.05% chlorhexidine are effective against live virus in lab tests.
Chlorine bleach (1%, 2%), 70% ethanol and 0.05% chlorhexidine are effective against live virus in lab tests.
Twice-daily cleaning with sodium dichloroisocyanurate decontaminated surfaces in COVID-19 patient hospital rooms.
Twice-daily cleaning with sodium dichloroisocyanurate decontaminated surfaces in COVID-19 patient hospital rooms.
Twice-daily cleaning with sodium dichloroisocyanurate decontaminated surfaces in COVID-19 patient hospital rooms.
Twice-daily cleaning with sodium dichloroisocyanurate decontaminated surfaces in COVID-19 patient hospital rooms.
Twice-daily cleaning with sodium dichloroisocyanurate decontaminated surfaces in COVID-19 patient hospital rooms.
Twice-daily cleaning with sodium dichloroisocyanurate decontaminated surfaces in COVID-19 patient hospital rooms.
Twice-daily cleaning with sodium dichloroisocyanurate decontaminated surfaces in COVID-19 patient hospital rooms.
Twice-daily cleaning with sodium dichloroisocyanurate decontaminated surfaces in COVID-19 patient hospital rooms.
Regular disinfection of hospital rooms (with benzalkonium wipes) can reduce the presence of SARS-CoV-2 on surfaces, though contamination is widespread without regular cleaning.
Regular disinfection of hospital rooms (with benzalkonium wipes) can reduce the presence of SARS-CoV-2 on surfaces, though contamination is widespread without regular cleaning.
Regular disinfection of hospital rooms (with benzalkonium wipes) can reduce the presence of SARS-CoV-2 on surfaces, though contamination is widespread without regular cleaning.
Regular disinfection of hospital rooms (with benzalkonium wipes) can reduce the presence of SARS-CoV-2 on surfaces, though contamination is widespread without regular cleaning.
Regular disinfection of hospital rooms (with benzalkonium wipes) can reduce the presence of SARS-CoV-2 on surfaces, though contamination is widespread without regular cleaning.
Regular disinfection of hospital rooms (with benzalkonium wipes) can reduce the presence of SARS-CoV-2 on surfaces, though contamination is widespread without regular cleaning.
Regular disinfection of hospital rooms (with benzalkonium wipes) can reduce the presence of SARS-CoV-2 on surfaces, though contamination is widespread without regular cleaning.
Regular disinfection of hospital rooms (with benzalkonium wipes) can reduce the presence of SARS-CoV-2 on surfaces, though contamination is widespread without regular cleaning.
Regular disinfection of hospital rooms (with benzalkonium wipes) can reduce the presence of SARS-CoV-2 on surfaces, though contamination is widespread without regular cleaning.
Regular disinfection of hospital rooms (with benzalkonium wipes) can reduce the presence of SARS-CoV-2 on surfaces, though contamination is widespread without regular cleaning.
Chlorhexidine digluconate may be ineffective.
Chlorhexidine digluconate may be ineffective.
Chlorhexidine digluconate may be ineffective.
Iodine-based antiseptics may be able to decontaminate nasal passages, though any influence on transmission is unknown.
Iodine-based antiseptics may be able to decontaminate nasal passages, though any influence on transmission is unknown.
Iodine-based antiseptics may be able to decontaminate nasal passages, though any influence on transmission is unknown.
Iodine-based antiseptics may be able to decontaminate nasal passages, though any influence on transmission is unknown.
Iodine-based antiseptics may be able to decontaminate nasal passages, though any influence on transmission is unknown.
Iodine-based antiseptics may be able to decontaminate nasal passages, though any influence on transmission is unknown.
A mouth-spray previously investigated for the cold-causing coronavirus 229E (ColdZyme¬¨¬®‚àö√ú) effectively inactivated SARS-CoV-2 in vitro; additional tests are necessary to determine any clinical benefit.
A mouth-spray previously investigated for the cold-causing coronavirus 229E (ColdZyme¬¨¬®‚àö√ú) effectively inactivated SARS-CoV-2 in vitro; additional tests are necessary to determine any clinical benefit.
A mouth-spray previously investigated for the cold-causing coronavirus 229E (ColdZyme¬¨¬®‚àö√ú) effectively inactivated SARS-CoV-2 in vitro; additional tests are necessary to determine any clinical benefit.
A mouth-spray previously investigated for the cold-causing coronavirus 229E (ColdZyme¬¨¬®‚àö√ú) effectively inactivated SARS-CoV-2 in vitro; additional tests are necessary to determine any clinical benefit.
A mouth-spray previously investigated for the cold-causing coronavirus 229E (ColdZyme¬¨¬®‚àö√ú) effectively inactivated SARS-CoV-2 in vitro; additional tests are necessary to determine any clinical benefit.
A mouth-spray previously investigated for the cold-causing coronavirus 229E (ColdZyme¬¨¬®‚àö√ú) effectively inactivated SARS-CoV-2 in vitro; additional tests are necessary to determine any clinical benefit.
A mouth-spray previously investigated for the cold-causing coronavirus 229E (ColdZyme¬¨¬®‚àö√ú) effectively inactivated SARS-CoV-2 in vitro; additional tests are necessary to determine any clinical benefit.
A mouth-spray previously investigated for the cold-causing coronavirus 229E (ColdZyme¬¨¬®‚àö√ú) effectively inactivated SARS-CoV-2 in vitro; additional tests are necessary to determine any clinical benefit.
A mouth-spray previously investigated for the cold-causing coronavirus 229E (ColdZyme¬¨¬®‚àö√ú) effectively inactivated SARS-CoV-2 in vitro; additional tests are necessary to determine any clinical benefit.
A mouth-spray previously investigated for the cold-causing coronavirus 229E (ColdZyme¬¨¬®‚àö√ú) effectively inactivated SARS-CoV-2 in vitro; additional tests are necessary to determine any clinical benefit.
Indoor air filters based on non-thermal plasma or reactive oxygen species may be effective at reducing circulating SARS-CoV-2 concentrations, estimated by reductions in surrogate virus, though additional testing on live SARS-CoV-2 virus is needed.
Indoor air filters based on non-thermal plasma or reactive oxygen species may be effective at reducing circulating SARS-CoV-2 concentrations, estimated by reductions in surrogate virus, though additional testing on live SARS-CoV-2 virus is needed.
Indoor air filters based on non-thermal plasma or reactive oxygen species may be effective at reducing circulating SARS-CoV-2 concentrations, estimated by reductions in surrogate virus, though additional testing on live SARS-CoV-2 virus is needed.
Indoor air filters based on non-thermal plasma or reactive oxygen species may be effective at reducing circulating SARS-CoV-2 concentrations, estimated by reductions in surrogate virus, though additional testing on live SARS-CoV-2 virus is needed.
Indoor air filters based on non-thermal plasma or reactive oxygen species may be effective at reducing circulating SARS-CoV-2 concentrations, estimated by reductions in surrogate virus, though additional testing on live SARS-CoV-2 virus is needed.
Indoor air filters based on non-thermal plasma or reactive oxygen species may be effective at reducing circulating SARS-CoV-2 concentrations, estimated by reductions in surrogate virus, though additional testing on live SARS-CoV-2 virus is needed.
Indoor air filters based on non-thermal plasma or reactive oxygen species may be effective at reducing circulating SARS-CoV-2 concentrations, estimated by reductions in surrogate virus, though additional testing on live SARS-CoV-2 virus is needed.
Indoor air filters based on non-thermal plasma or reactive oxygen species may be effective at reducing circulating SARS-CoV-2 concentrations, estimated by reductions in surrogate virus, though additional testing on live SARS-CoV-2 virus is needed.
Indoor air filters based on non-thermal plasma or reactive oxygen species may be effective at reducing circulating SARS-CoV-2 concentrations, estimated by reductions in surrogate virus, though additional testing on live SARS-CoV-2 virus is needed.
Indoor air filters based on non-thermal plasma or reactive oxygen species may be effective at reducing circulating SARS-CoV-2 concentrations, estimated by reductions in surrogate virus, though additional testing on live SARS-CoV-2 virus is needed.
Indoor air filtration devices based on hydroxyl radical cascades, which do not emit ozone, are being trialed at 4 UK hospitals due to their efficacy in reducing concentrations of a surrogate virus (M2 phage).
Indoor air filtration devices based on hydroxyl radical cascades, which do not emit ozone, are being trialed at 4 UK hospitals due to their efficacy in reducing concentrations of a surrogate virus (M2 phage).
Indoor air filtration devices based on hydroxyl radical cascades, which do not emit ozone, are being trialed at 4 UK hospitals due to their efficacy in reducing concentrations of a surrogate virus (M2 phage).
Indoor air filtration devices based on hydroxyl radical cascades, which do not emit ozone, are being trialed at 4 UK hospitals due to their efficacy in reducing concentrations of a surrogate virus (M2 phage).
Indoor air filtration devices based on hydroxyl radical cascades, which do not emit ozone, are being trialed at 4 UK hospitals due to their efficacy in reducing concentrations of a surrogate virus (M2 phage).
Indoor air filtration devices based on hydroxyl radical cascades, which do not emit ozone, are being trialed at 4 UK hospitals due to their efficacy in reducing concentrations of a surrogate virus (M2 phage).
Indoor air filtration devices based on hydroxyl radical cascades, which do not emit ozone, are being trialed at 4 UK hospitals due to their efficacy in reducing concentrations of a surrogate virus (M2 phage).
Indoor air filtration devices based on hydroxyl radical cascades, which do not emit ozone, are being trialed at 4 UK hospitals due to their efficacy in reducing concentrations of a surrogate virus (M2 phage).
Indoor air filtration devices based on hydroxyl radical cascades, which do not emit ozone, are being trialed at 4 UK hospitals due to their efficacy in reducing concentrations of a surrogate virus (M2 phage).
Indoor air filtration devices based on hydroxyl radical cascades, which do not emit ozone, are being trialed at 4 UK hospitals due to their efficacy in reducing concentrations of a surrogate virus (M2 phage).
In tests with a surrogate virus (Phi6 phage), a modified version of the Joint Biological Agent Decontamination System (JBADS) was effective at decontaminating military aircraft in approximately three hours using high heat and humidity; Phi6, however, may be less stable than SARS-CoV-2 on surfaces, and therefore may not be the best surrogate.
In tests with a surrogate virus (Phi6 phage), a modified version of the Joint Biological Agent Decontamination System (JBADS) was effective at decontaminating military aircraft in approximately three hours using high heat and humidity; Phi6, however, may be less stable than SARS-CoV-2 on surfaces, and therefore may not be the best surrogate.
In tests with a surrogate virus (Phi6 phage), a modified version of the Joint Biological Agent Decontamination System (JBADS) was effective at decontaminating military aircraft in approximately three hours using high heat and humidity; Phi6, however, may be less stable than SARS-CoV-2 on surfaces, and therefore may not be the best surrogate.
In tests with a surrogate virus (Phi6 phage), a modified version of the Joint Biological Agent Decontamination System (JBADS) was effective at decontaminating military aircraft in approximately three hours using high heat and humidity; Phi6, however, may be less stable than SARS-CoV-2 on surfaces, and therefore may not be the best surrogate.
In tests with a surrogate virus (Phi6 phage), a modified version of the Joint Biological Agent Decontamination System (JBADS) was effective at decontaminating military aircraft in approximately three hours using high heat and humidity; Phi6, however, may be less stable than SARS-CoV-2 on surfaces, and therefore may not be the best surrogate.
In tests with a surrogate virus (Phi6 phage), a modified version of the Joint Biological Agent Decontamination System (JBADS) was effective at decontaminating military aircraft in approximately three hours using high heat and humidity; Phi6, however, may be less stable than SARS-CoV-2 on surfaces, and therefore may not be the best surrogate.
In tests with a surrogate virus (Phi6 phage), a modified version of the Joint Biological Agent Decontamination System (JBADS) was effective at decontaminating military aircraft in approximately three hours using high heat and humidity; Phi6, however, may be less stable than SARS-CoV-2 on surfaces, and therefore may not be the best surrogate.
In tests with a surrogate virus (Phi6 phage), a modified version of the Joint Biological Agent Decontamination System (JBADS) was effective at decontaminating military aircraft in approximately three hours using high heat and humidity; Phi6, however, may be less stable than SARS-CoV-2 on surfaces, and therefore may not be the best surrogate.
In tests with a surrogate virus (Phi6 phage), a modified version of the Joint Biological Agent Decontamination System (JBADS) was effective at decontaminating military aircraft in approximately three hours using high heat and humidity; Phi6, however, may be less stable than SARS-CoV-2 on surfaces, and therefore may not be the best surrogate.
In tests with a surrogate virus (Phi6 phage), a modified version of the Joint Biological Agent Decontamination System (JBADS) was effective at decontaminating military aircraft in approximately three hours using high heat and humidity; Phi6, however, may be less stable than SARS-CoV-2 on surfaces, and therefore may not be the best surrogate.
Aquila Bioscience has developed a spray decontamination technique to pair with its existing alcohol- and chemical-free wipe; these products may be used to capture SARS-CoV-2 on skin, surfaces, and washable masks via high-affinity binding.
Aquila Bioscience has developed a spray decontamination technique to pair with its existing alcohol- and chemical-free wipe; these products may be used to capture SARS-CoV-2 on skin, surfaces, and washable masks via high-affinity binding.
Aquila Bioscience has developed a spray decontamination technique to pair with its existing alcohol- and chemical-free wipe; these products may be used to capture SARS-CoV-2 on skin, surfaces, and washable masks via high-affinity binding.
Aquila Bioscience has developed a spray decontamination technique to pair with its existing alcohol- and chemical-free wipe; these products may be used to capture SARS-CoV-2 on skin, surfaces, and washable masks via high-affinity binding.
Aquila Bioscience has developed a spray decontamination technique to pair with its existing alcohol- and chemical-free wipe; these products may be used to capture SARS-CoV-2 on skin, surfaces, and washable masks via high-affinity binding.
Aquila Bioscience has developed a spray decontamination technique to pair with its existing alcohol- and chemical-free wipe; these products may be used to capture SARS-CoV-2 on skin, surfaces, and washable masks via high-affinity binding.
Aquila Bioscience has developed a spray decontamination technique to pair with its existing alcohol- and chemical-free wipe; these products may be used to capture SARS-CoV-2 on skin, surfaces, and washable masks via high-affinity binding.
Aquila Bioscience has developed a spray decontamination technique to pair with its existing alcohol- and chemical-free wipe; these products may be used to capture SARS-CoV-2 on skin, surfaces, and washable masks via high-affinity binding.
Aquila Bioscience has developed a spray decontamination technique to pair with its existing alcohol- and chemical-free wipe; these products may be used to capture SARS-CoV-2 on skin, surfaces, and washable masks via high-affinity binding.
Aquila Bioscience has developed a spray decontamination technique to pair with its existing alcohol- and chemical-free wipe; these products may be used to capture SARS-CoV-2 on skin, surfaces, and washable masks via high-affinity binding.
Masks with laser-induced graphene have previously shown antibacterial properties, and may facilitate mask decontamination, particularly when masks are exposed to sunlight.
Masks with laser-induced graphene have previously shown antibacterial properties, and may facilitate mask decontamination, particularly when masks are exposed to sunlight.
Masks with laser-induced graphene have previously shown antibacterial properties, and may facilitate mask decontamination, particularly when masks are exposed to sunlight.
Masks with laser-induced graphene have previously shown antibacterial properties, and may facilitate mask decontamination, particularly when masks are exposed to sunlight.
Masks with laser-induced graphene have previously shown antibacterial properties, and may facilitate mask decontamination, particularly when masks are exposed to sunlight.
Masks with laser-induced graphene have previously shown antibacterial properties, and may facilitate mask decontamination, particularly when masks are exposed to sunlight.
Masks with laser-induced graphene have previously shown antibacterial properties, and may facilitate mask decontamination, particularly when masks are exposed to sunlight.
Masks with laser-induced graphene have previously shown antibacterial properties, and may facilitate mask decontamination, particularly when masks are exposed to sunlight.
Masks with laser-induced graphene have previously shown antibacterial properties, and may facilitate mask decontamination, particularly when masks are exposed to sunlight.
Masks with laser-induced graphene have previously shown antibacterial properties, and may facilitate mask decontamination, particularly when masks are exposed to sunlight.
Peracetic acid dry fogging was shown to be effective at inactivating SARS-CoV-2 on stainless steel coupons, simulating whole-room fumigation.
Peracetic acid dry fogging was shown to be effective at inactivating SARS-CoV-2 on stainless steel coupons, simulating whole-room fumigation.
Peracetic acid dry fogging was shown to be effective at inactivating SARS-CoV-2 on stainless steel coupons, simulating whole-room fumigation.
Peracetic acid dry fogging was shown to be effective at inactivating SARS-CoV-2 on stainless steel coupons, simulating whole-room fumigation.
Peracetic acid dry fogging was shown to be effective at inactivating SARS-CoV-2 on stainless steel coupons, simulating whole-room fumigation.
Peracetic acid dry fogging was shown to be effective at inactivating SARS-CoV-2 on stainless steel coupons, simulating whole-room fumigation.
Peracetic acid dry fogging was shown to be effective at inactivating SARS-CoV-2 on stainless steel coupons, simulating whole-room fumigation.
Peracetic acid dry fogging was shown to be effective at inactivating SARS-CoV-2 on stainless steel coupons, simulating whole-room fumigation.
Peracetic acid dry fogging was shown to be effective at inactivating SARS-CoV-2 on stainless steel coupons, simulating whole-room fumigation.
Peracetic acid dry fogging was shown to be effective at inactivating SARS-CoV-2 on stainless steel coupons, simulating whole-room fumigation.
Several methods exist for decontaminating N95 respirators and other PPE.
Several methods exist for decontaminating N95 respirators and other PPE.
Several methods exist for decontaminating N95 respirators and other PPE.
Several methods exist for decontaminating N95 respirators and other PPE.
Several methods exist for decontaminating N95 respirators and other PPE.
Several methods exist for decontaminating N95 respirators and other PPE.
Several methods exist for decontaminating N95 respirators and other PPE.
Several methods exist for decontaminating N95 respirators and other PPE.
Several methods exist for decontaminating N95 respirators and other PPE.
Several methods exist for decontaminating N95 respirators and other PPE.
Researchers have identified four methods capable of decontaminating N95 respirators while maintaining physical integrity (fit factor) UV radiation, heating to 70¬¨¬®‚Äö√†√ªC, and vaporized hydrogen peroxide (VHP).
Researchers have identified four methods capable of decontaminating N95 respirators while maintaining physical integrity (fit factor) UV radiation, heating to 70¬¨¬®‚Äö√†√ªC, and vaporized hydrogen peroxide (VHP).
Researchers have identified four methods capable of decontaminating N95 respirators while maintaining physical integrity (fit factor) UV radiation, heating to 70¬¨¬®‚Äö√†√ªC, and vaporized hydrogen peroxide (VHP).
Researchers have identified four methods capable of decontaminating N95 respirators while maintaining physical integrity (fit factor) UV radiation, heating to 70¬¨¬®‚Äö√†√ªC, and vaporized hydrogen peroxide (VHP).
Researchers have identified four methods capable of decontaminating N95 respirators while maintaining physical integrity (fit factor) UV radiation, heating to 70¬¨¬®‚Äö√†√ªC, and vaporized hydrogen peroxide (VHP).
Researchers have identified four methods capable of decontaminating N95 respirators while maintaining physical integrity (fit factor) UV radiation, heating to 70¬¨¬®‚Äö√†√ªC, and vaporized hydrogen peroxide (VHP).
Researchers have identified four methods capable of decontaminating N95 respirators while maintaining physical integrity (fit factor) UV radiation, heating to 70¬¨¬®‚Äö√†√ªC, and vaporized hydrogen peroxide (VHP).
Researchers have identified four methods capable of decontaminating N95 respirators while maintaining physical integrity (fit factor) UV radiation, heating to 70¬¨¬®‚Äö√†√ªC, and vaporized hydrogen peroxide (VHP).
Researchers have identified four methods capable of decontaminating N95 respirators while maintaining physical integrity (fit factor) UV radiation, heating to 70¬¨¬®‚Äö√†√ªC, and vaporized hydrogen peroxide (VHP).
Researchers have identified four methods capable of decontaminating N95 respirators while maintaining physical integrity (fit factor) UV radiation, heating to 70¬¨¬®‚Äö√†√ªC, and vaporized hydrogen peroxide (VHP).
Ethanol (70%) decontamination of N95 respirators was associated with loss of physical integrity.
Ethanol (70%) decontamination of N95 respirators was associated with loss of physical integrity.
Ethanol (70%) decontamination of N95 respirators was associated with loss of physical integrity.
Ethanol (70%) decontamination of N95 respirators was associated with loss of physical integrity.
Ethanol (70%) decontamination of N95 respirators was associated with loss of physical integrity.
Ethanol (70%) decontamination of N95 respirators was associated with loss of physical integrity.
Ethanol (70%) decontamination of N95 respirators was associated with loss of physical integrity.
Ethanol (70%) decontamination of N95 respirators was associated with loss of physical integrity.
Ethanol (70%) decontamination of N95 respirators was associated with loss of physical integrity.
Ethanol (70%) decontamination of N95 respirators was associated with loss of physical integrity.
Dry heat and UV decontaminating N95 respirators can also be used under certain conditions.
Dry heat and UV decontaminating N95 respirators can also be used under certain conditions.
Dry heat and UV decontaminating N95 respirators can also be used under certain conditions.
Dry heat and UV decontaminating N95 respirators can also be used under certain conditions.
Dry heat and UV decontaminating N95 respirators can also be used under certain conditions.
Dry heat and UV decontaminating N95 respirators can also be used under certain conditions.
Dry heat and UV decontaminating N95 respirators can also be used under certain conditions.
Dry heat and UV decontaminating N95 respirators can also be used under certain conditions.
Dry heat and UV decontaminating N95 respirators can also be used under certain conditions.
Dry heat and UV decontaminating N95 respirators can also be used under certain conditions.
Additional methods showing efficacy against SARS-CoV-2 on respirators include pulsed xenon ultraviolet light, wet heat (using a multicooker), and methylene blue plus light.
Additional methods showing efficacy against SARS-CoV-2 on respirators include pulsed xenon ultraviolet light, wet heat (using a multicooker), and methylene blue plus light.
Additional methods showing efficacy against SARS-CoV-2 on respirators include pulsed xenon ultraviolet light, wet heat (using a multicooker), and methylene blue plus light.
Additional methods showing efficacy against SARS-CoV-2 on respirators include pulsed xenon ultraviolet light, wet heat (using a multicooker), and methylene blue plus light.
Additional methods showing efficacy against SARS-CoV-2 on respirators include pulsed xenon ultraviolet light, wet heat (using a multicooker), and methylene blue plus light.
Additional methods showing efficacy against SARS-CoV-2 on respirators include pulsed xenon ultraviolet light, wet heat (using a multicooker), and methylene blue plus light.
Additional methods showing efficacy against SARS-CoV-2 on respirators include pulsed xenon ultraviolet light, wet heat (using a multicooker), and methylene blue plus light.
Additional methods showing efficacy against SARS-CoV-2 on respirators include pulsed xenon ultraviolet light, wet heat (using a multicooker), and methylene blue plus light.
Additional methods showing efficacy against SARS-CoV-2 on respirators include pulsed xenon ultraviolet light, wet heat (using a multicooker), and methylene blue plus light.
Additional methods showing efficacy against SARS-CoV-2 on respirators include pulsed xenon ultraviolet light, wet heat (using a multicooker), and methylene blue plus light.
Hydrogen peroxide vapor (VHP) can repeatedly decontaminate N95 respirators.
Hydrogen peroxide vapor (VHP) can repeatedly decontaminate N95 respirators.
Hydrogen peroxide vapor (VHP) can repeatedly decontaminate N95 respirators.
Hydrogen peroxide vapor (VHP) can repeatedly decontaminate N95 respirators.
Hydrogen peroxide vapor (VHP) can repeatedly decontaminate N95 respirators.
Hydrogen peroxide vapor (VHP) can repeatedly decontaminate N95 respirators.
Hydrogen peroxide vapor (VHP) can repeatedly decontaminate N95 respirators.
Hydrogen peroxide vapor (VHP) can repeatedly decontaminate N95 respirators.
Hydrogen peroxide vapor (VHP) can repeatedly decontaminate N95 respirators.
Hydrogen peroxide vapor (VHP) can repeatedly decontaminate N95 respirators.
Devices capable of decontaminating 80,000 masks per day have been granted Emergency Use Authorization from the FDA.
Devices capable of decontaminating 80,000 masks per day have been granted Emergency Use Authorization from the FDA.
Devices capable of decontaminating 80,000 masks per day have been granted Emergency Use Authorization from the FDA.
Devices capable of decontaminating 80,000 masks per day have been granted Emergency Use Authorization from the FDA.
Devices capable of decontaminating 80,000 masks per day have been granted Emergency Use Authorization from the FDA.
Devices capable of decontaminating 80,000 masks per day have been granted Emergency Use Authorization from the FDA.
Devices capable of decontaminating 80,000 masks per day have been granted Emergency Use Authorization from the FDA.
Devices capable of decontaminating 80,000 masks per day have been granted Emergency Use Authorization from the FDA.
Devices capable of decontaminating 80,000 masks per day have been granted Emergency Use Authorization from the FDA.
Devices capable of decontaminating 80,000 masks per day have been granted Emergency Use Authorization from the FDA.
The FDA has issued an Emergency Use Authorization for a system capable of decontaminating ten N95 masks at a time using devices already present in many US hospitals, though fit failure after reuse remains a concern.
The FDA has issued an Emergency Use Authorization for a system capable of decontaminating ten N95 masks at a time using devices already present in many US hospitals, though fit failure after reuse remains a concern.
The FDA has issued an Emergency Use Authorization for a system capable of decontaminating ten N95 masks at a time using devices already present in many US hospitals, though fit failure after reuse remains a concern.
The FDA has issued an Emergency Use Authorization for a system capable of decontaminating ten N95 masks at a time using devices already present in many US hospitals, though fit failure after reuse remains a concern.
The FDA has issued an Emergency Use Authorization for a system capable of decontaminating ten N95 masks at a time using devices already present in many US hospitals, though fit failure after reuse remains a concern.
The FDA has issued an Emergency Use Authorization for a system capable of decontaminating ten N95 masks at a time using devices already present in many US hospitals, though fit failure after reuse remains a concern.
The FDA has issued an Emergency Use Authorization for a system capable of decontaminating ten N95 masks at a time using devices already present in many US hospitals, though fit failure after reuse remains a concern.
The FDA has issued an Emergency Use Authorization for a system capable of decontaminating ten N95 masks at a time using devices already present in many US hospitals, though fit failure after reuse remains a concern.
The FDA has issued an Emergency Use Authorization for a system capable of decontaminating ten N95 masks at a time using devices already present in many US hospitals, though fit failure after reuse remains a concern.
The FDA has issued an Emergency Use Authorization for a system capable of decontaminating ten N95 masks at a time using devices already present in many US hospitals, though fit failure after reuse remains a concern.
Respirator decontamination methods such as VHP appear to maintain filtration efficiency after repeated decontamination cycles.
Respirator decontamination methods such as VHP appear to maintain filtration efficiency after repeated decontamination cycles.
Respirator decontamination methods such as VHP appear to maintain filtration efficiency after repeated decontamination cycles.
Respirator decontamination methods such as VHP appear to maintain filtration efficiency after repeated decontamination cycles.
Respirator decontamination methods such as VHP appear to maintain filtration efficiency after repeated decontamination cycles.
Respirator decontamination methods such as VHP appear to maintain filtration efficiency after repeated decontamination cycles.
Respirator decontamination methods such as VHP appear to maintain filtration efficiency after repeated decontamination cycles.
Respirator decontamination methods such as VHP appear to maintain filtration efficiency after repeated decontamination cycles.
Respirator decontamination methods such as VHP appear to maintain filtration efficiency after repeated decontamination cycles.
Respirator decontamination methods such as VHP appear to maintain filtration efficiency after repeated decontamination cycles.
Several decontamination methods, including VHP, moist heat, and UVC, are capable of decontaminating N95 respirators for 10-20 cycles without loss of fit or filtration efficiency.
Several decontamination methods, including VHP, moist heat, and UVC, are capable of decontaminating N95 respirators for 10-20 cycles without loss of fit or filtration efficiency.
Several decontamination methods, including VHP, moist heat, and UVC, are capable of decontaminating N95 respirators for 10-20 cycles without loss of fit or filtration efficiency.
Several decontamination methods, including VHP, moist heat, and UVC, are capable of decontaminating N95 respirators for 10-20 cycles without loss of fit or filtration efficiency.
Several decontamination methods, including VHP, moist heat, and UVC, are capable of decontaminating N95 respirators for 10-20 cycles without loss of fit or filtration efficiency.
Several decontamination methods, including VHP, moist heat, and UVC, are capable of decontaminating N95 respirators for 10-20 cycles without loss of fit or filtration efficiency.
Several decontamination methods, including VHP, moist heat, and UVC, are capable of decontaminating N95 respirators for 10-20 cycles without loss of fit or filtration efficiency.
Several decontamination methods, including VHP, moist heat, and UVC, are capable of decontaminating N95 respirators for 10-20 cycles without loss of fit or filtration efficiency.
Several decontamination methods, including VHP, moist heat, and UVC, are capable of decontaminating N95 respirators for 10-20 cycles without loss of fit or filtration efficiency.
Several decontamination methods, including VHP, moist heat, and UVC, are capable of decontaminating N95 respirators for 10-20 cycles without loss of fit or filtration efficiency.
Stacking respirators may increase decontamination rates without compromising efficiency.
Stacking respirators may increase decontamination rates without compromising efficiency.
Stacking respirators may increase decontamination rates without compromising efficiency.
Stacking respirators may increase decontamination rates without compromising efficiency.
Stacking respirators may increase decontamination rates without compromising efficiency.
Stacking respirators may increase decontamination rates without compromising efficiency.
Stacking respirators may increase decontamination rates without compromising efficiency.
Stacking respirators may increase decontamination rates without compromising efficiency.
Stacking respirators may increase decontamination rates without compromising efficiency.
Stacking respirators may increase decontamination rates without compromising efficiency.
Peracetic acid may be effective in combination with VHP for respirator decontamination.
Peracetic acid may be effective in combination with VHP for respirator decontamination.
Peracetic acid may be effective in combination with VHP for respirator decontamination.
Peracetic acid may be effective in combination with VHP for respirator decontamination.
Peracetic acid may be effective in combination with VHP for respirator decontamination.
Peracetic acid may be effective in combination with VHP for respirator decontamination.
Peracetic acid may be effective in combination with VHP for respirator decontamination.
Peracetic acid may be effective in combination with VHP for respirator decontamination.
Peracetic acid may be effective in combination with VHP for respirator decontamination.
Peracetic acid may be effective in combination with VHP for respirator decontamination.
The US FDA has issued guidance for bioburden reduction systems using dry heat to decontaminate certain respirators.
The US FDA has issued guidance for bioburden reduction systems using dry heat to decontaminate certain respirators.
The US FDA has issued guidance for bioburden reduction systems using dry heat to decontaminate certain respirators.
The US FDA has issued guidance for bioburden reduction systems using dry heat to decontaminate certain respirators.
The US FDA has issued guidance for bioburden reduction systems using dry heat to decontaminate certain respirators.
The US FDA has issued guidance for bioburden reduction systems using dry heat to decontaminate certain respirators.
The US FDA has issued guidance for bioburden reduction systems using dry heat to decontaminate certain respirators.
The US FDA has issued guidance for bioburden reduction systems using dry heat to decontaminate certain respirators.
The US FDA has issued guidance for bioburden reduction systems using dry heat to decontaminate certain respirators.
The US FDA has issued guidance for bioburden reduction systems using dry heat to decontaminate certain respirators.
A Canadian technology (‚Äö√Ñ√∂‚àö√ë‚àö‚à´D-Pod‚Äö√Ñ√∂‚àö√ë‚àöœÄ) using heat and UVC for PPE is being manufactured for North American distribution.
A Canadian technology (‚Äö√Ñ√∂‚àö√ë‚àö‚à´D-Pod‚Äö√Ñ√∂‚àö√ë‚àöœÄ) using heat and UVC for PPE is being manufactured for North American distribution.
A Canadian technology (‚Äö√Ñ√∂‚àö√ë‚àö‚à´D-Pod‚Äö√Ñ√∂‚àö√ë‚àöœÄ) using heat and UVC for PPE is being manufactured for North American distribution.
A Canadian technology (‚Äö√Ñ√∂‚àö√ë‚àö‚à´D-Pod‚Äö√Ñ√∂‚àö√ë‚àöœÄ) using heat and UVC for PPE is being manufactured for North American distribution.
A Canadian technology (‚Äö√Ñ√∂‚àö√ë‚àö‚à´D-Pod‚Äö√Ñ√∂‚àö√ë‚àöœÄ) using heat and UVC for PPE is being manufactured for North American distribution.
A Canadian technology (‚Äö√Ñ√∂‚àö√ë‚àö‚à´D-Pod‚Äö√Ñ√∂‚àö√ë‚àöœÄ) using heat and UVC for PPE is being manufactured for North American distribution.
A Canadian technology (‚Äö√Ñ√∂‚àö√ë‚àö‚à´D-Pod‚Äö√Ñ√∂‚àö√ë‚àöœÄ) using heat and UVC for PPE is being manufactured for North American distribution.
A Canadian technology (‚Äö√Ñ√∂‚àö√ë‚àö‚à´D-Pod‚Äö√Ñ√∂‚àö√ë‚àöœÄ) using heat and UVC for PPE is being manufactured for North American distribution.
A Canadian technology (‚Äö√Ñ√∂‚àö√ë‚àö‚à´D-Pod‚Äö√Ñ√∂‚àö√ë‚àöœÄ) using heat and UVC for PPE is being manufactured for North American distribution.
A Canadian technology (‚Äö√Ñ√∂‚àö√ë‚àö‚à´D-Pod‚Äö√Ñ√∂‚àö√ë‚àöœÄ) using heat and UVC for PPE is being manufactured for North American distribution.
Researchers have developed a thermal inactivation model for SARS-CoV-2, providing estimates of infectivity reduction based on time and temperature in the environment and under decontamination strategies.
Researchers have developed a thermal inactivation model for SARS-CoV-2, providing estimates of infectivity reduction based on time and temperature in the environment and under decontamination strategies.
Researchers have developed a thermal inactivation model for SARS-CoV-2, providing estimates of infectivity reduction based on time and temperature in the environment and under decontamination strategies.
Researchers have developed a thermal inactivation model for SARS-CoV-2, providing estimates of infectivity reduction based on time and temperature in the environment and under decontamination strategies.
Researchers have developed a thermal inactivation model for SARS-CoV-2, providing estimates of infectivity reduction based on time and temperature in the environment and under decontamination strategies.
Researchers have developed a thermal inactivation model for SARS-CoV-2, providing estimates of infectivity reduction based on time and temperature in the environment and under decontamination strategies.
Researchers have developed a thermal inactivation model for SARS-CoV-2, providing estimates of infectivity reduction based on time and temperature in the environment and under decontamination strategies.
Researchers have developed a thermal inactivation model for SARS-CoV-2, providing estimates of infectivity reduction based on time and temperature in the environment and under decontamination strategies.
Researchers have developed a thermal inactivation model for SARS-CoV-2, providing estimates of infectivity reduction based on time and temperature in the environment and under decontamination strategies.
Researchers have developed a thermal inactivation model for SARS-CoV-2, providing estimates of infectivity reduction based on time and temperature in the environment and under decontamination strategies.
Forced air ozone reactors may be able to decontaminate surgical gowns, though SARS-CoV-2 tests are needed.
Forced air ozone reactors may be able to decontaminate surgical gowns, though SARS-CoV-2 tests are needed.
Forced air ozone reactors may be able to decontaminate surgical gowns, though SARS-CoV-2 tests are needed.
Forced air ozone reactors may be able to decontaminate surgical gowns, though SARS-CoV-2 tests are needed.
Oral antiseptic rinses used in pre-procedural rinses for dentistry containing povidone-iodine (PVP-I) are effective decontaminants of SARS-CoV-2, completely inactivating SARS-CoV-2 at concentrations above 0.5% in lab tests (for 15-30 s).
Oral antiseptic rinses used in pre-procedural rinses for dentistry containing povidone-iodine (PVP-I) are effective decontaminants of SARS-CoV-2, completely inactivating SARS-CoV-2 at concentrations above 0.5% in lab tests (for 15-30 s).
Oral antiseptic rinses used in pre-procedural rinses for dentistry containing povidone-iodine (PVP-I) are effective decontaminants of SARS-CoV-2, completely inactivating SARS-CoV-2 at concentrations above 0.5% in lab tests (for 15-30 s).
Oral antiseptic rinses used in pre-procedural rinses for dentistry containing povidone-iodine (PVP-I) are effective decontaminants of SARS-CoV-2, completely inactivating SARS-CoV-2 at concentrations above 0.5% in lab tests (for 15-30 s).
Oral antiseptic rinses used in pre-procedural rinses for dentistry containing povidone-iodine (PVP-I) are effective decontaminants of SARS-CoV-2, completely inactivating SARS-CoV-2 at concentrations above 0.5% in lab tests (for 15-30 s).
Oral antiseptic rinses used in pre-procedural rinses for dentistry containing povidone-iodine (PVP-I) are effective decontaminants of SARS-CoV-2, completely inactivating SARS-CoV-2 at concentrations above 0.5% in lab tests (for 15-30 s).
Oral antiseptic rinses used in pre-procedural rinses for dentistry containing povidone-iodine (PVP-I) are effective decontaminants of SARS-CoV-2, completely inactivating SARS-CoV-2 at concentrations above 0.5% in lab tests (for 15-30 s).
Oral antiseptic rinses used in pre-procedural rinses for dentistry containing povidone-iodine (PVP-I) are effective decontaminants of SARS-CoV-2, completely inactivating SARS-CoV-2 at concentrations above 0.5% in lab tests (for 15-30 s).
Oral antiseptic rinses used in pre-procedural rinses for dentistry containing povidone-iodine (PVP-I) are effective decontaminants of SARS-CoV-2, completely inactivating SARS-CoV-2 at concentrations above 0.5% in lab tests (for 15-30 s).
Oral antiseptic rinses used in pre-procedural rinses for dentistry containing povidone-iodine (PVP-I) are effective decontaminants of SARS-CoV-2, completely inactivating SARS-CoV-2 at concentrations above 0.5% in lab tests (for 15-30 s).
Face masks appear effective at reducing infections from SARS-CoV-2.
Face masks appear effective at reducing infections from SARS-CoV-2.
Face masks appear effective at reducing infections from SARS-CoV-2.
Face masks appear effective at reducing infections from SARS-CoV-2.
Face masks appear effective at reducing infections from SARS-CoV-2.
Face masks appear effective at reducing infections from SARS-CoV-2.
Face masks appear effective at reducing infections from SARS-CoV-2.
Face masks appear effective at reducing infections from SARS-CoV-2.
Face masks appear effective at reducing infections from SARS-CoV-2.
Face masks appear effective at reducing infections from SARS-CoV-2.
Healthcare workers are at high risk of acquiring COVID-19, even with recommended PPE.
Healthcare workers are at high risk of acquiring COVID-19, even with recommended PPE.
Healthcare workers are at high risk of acquiring COVID-19, even with recommended PPE.
Healthcare workers are at high risk of acquiring COVID-19, even with recommended PPE.
Healthcare workers are at high risk of acquiring COVID-19, even with recommended PPE.
Healthcare workers are at high risk of acquiring COVID-19, even with recommended PPE.
Healthcare workers are at high risk of acquiring COVID-19, even with recommended PPE.
Healthcare workers are at high risk of acquiring COVID-19, even with recommended PPE.
Healthcare workers are at high risk of acquiring COVID-19, even with recommended PPE.
Healthcare workers are at high risk of acquiring COVID-19, even with recommended PPE.
Healthcare worker illnesses650 demonstrates human-to-human transmission despite isolation, PPE, and infection control.
Healthcare worker illnesses650 demonstrates human-to-human transmission despite isolation, PPE, and infection control.
Healthcare worker illnesses650 demonstrates human-to-human transmission despite isolation, PPE, and infection control.
Healthcare worker illnesses650 demonstrates human-to-human transmission despite isolation, PPE, and infection control.
Healthcare worker illnesses650 demonstrates human-to-human transmission despite isolation, PPE, and infection control.
Healthcare worker illnesses650 demonstrates human-to-human transmission despite isolation, PPE, and infection control.
Healthcare worker illnesses650 demonstrates human-to-human transmission despite isolation, PPE, and infection control.
Healthcare worker illnesses650 demonstrates human-to-human transmission despite isolation, PPE, and infection control.
Healthcare worker illnesses650 demonstrates human-to-human transmission despite isolation, PPE, and infection control.
Healthcare worker illnesses650 demonstrates human-to-human transmission despite isolation, PPE, and infection control.
Risk of transmission to healthcare workers is high.
Risk of transmission to healthcare workers is high.
Risk of transmission to healthcare workers is high.
Risk of transmission to healthcare workers is high.
Risk of transmission to healthcare workers is high.
Risk of transmission to healthcare workers is high.
Risk of transmission to healthcare workers is high.
Risk of transmission to healthcare workers is high.
Risk of transmission to healthcare workers is high.
Risk of transmission to healthcare workers is high.
Contacts with healthcare workers tend to transmit COVID-19 more often than other casual contacts.
Contacts with healthcare workers tend to transmit COVID-19 more often than other casual contacts.
Contacts with healthcare workers tend to transmit COVID-19 more often than other casual contacts.
Contacts with healthcare workers tend to transmit COVID-19 more often than other casual contacts.
Contacts with healthcare workers tend to transmit COVID-19 more often than other casual contacts.
Contacts with healthcare workers tend to transmit COVID-19 more often than other casual contacts.
Contacts with healthcare workers tend to transmit COVID-19 more often than other casual contacts.
Contacts with healthcare workers tend to transmit COVID-19 more often than other casual contacts.
Contacts with healthcare workers tend to transmit COVID-19 more often than other casual contacts.
Contacts with healthcare workers tend to transmit COVID-19 more often than other casual contacts.
Hospital-acquired infection rates fell after introduction of comprehensive infection control measures, including expanded testing and use of PPE for all patient contacts.
Hospital-acquired infection rates fell after introduction of comprehensive infection control measures, including expanded testing and use of PPE for all patient contacts.
Hospital-acquired infection rates fell after introduction of comprehensive infection control measures, including expanded testing and use of PPE for all patient contacts.
Hospital-acquired infection rates fell after introduction of comprehensive infection control measures, including expanded testing and use of PPE for all patient contacts.
Hospital-acquired infection rates fell after introduction of comprehensive infection control measures, including expanded testing and use of PPE for all patient contacts.
Hospital-acquired infection rates fell after introduction of comprehensive infection control measures, including expanded testing and use of PPE for all patient contacts.
Hospital-acquired infection rates fell after introduction of comprehensive infection control measures, including expanded testing and use of PPE for all patient contacts.
Hospital-acquired infection rates fell after introduction of comprehensive infection control measures, including expanded testing and use of PPE for all patient contacts.
Hospital-acquired infection rates fell after introduction of comprehensive infection control measures, including expanded testing and use of PPE for all patient contacts.
Hospital-acquired infection rates fell after introduction of comprehensive infection control measures, including expanded testing and use of PPE for all patient contacts.
Universal masking policies also reduced the rate of new healthcare worker infections.
Universal masking policies also reduced the rate of new healthcare worker infections.
Universal masking policies also reduced the rate of new healthcare worker infections.
Universal masking policies also reduced the rate of new healthcare worker infections.
Universal masking policies also reduced the rate of new healthcare worker infections.
Universal masking policies also reduced the rate of new healthcare worker infections.
Universal masking policies also reduced the rate of new healthcare worker infections.
Universal masking policies also reduced the rate of new healthcare worker infections.
Universal masking policies also reduced the rate of new healthcare worker infections.
Universal masking policies also reduced the rate of new healthcare worker infections.
Even among healthcare personnel reporting adequate PPE early in the pandemic (March-April), rates of infection were 3.4 times higher than the general population.
Even among healthcare personnel reporting adequate PPE early in the pandemic (March-April), rates of infection were 3.4 times higher than the general population.
Even among healthcare personnel reporting adequate PPE early in the pandemic (March-April), rates of infection were 3.4 times higher than the general population.
Even among healthcare personnel reporting adequate PPE early in the pandemic (March-April), rates of infection were 3.4 times higher than the general population.
Even among healthcare personnel reporting adequate PPE early in the pandemic (March-April), rates of infection were 3.4 times higher than the general population.
Even among healthcare personnel reporting adequate PPE early in the pandemic (March-April), rates of infection were 3.4 times higher than the general population.
Even among healthcare personnel reporting adequate PPE early in the pandemic (March-April), rates of infection were 3.4 times higher than the general population.
Even among healthcare personnel reporting adequate PPE early in the pandemic (March-April), rates of infection were 3.4 times higher than the general population.
Even among healthcare personnel reporting adequate PPE early in the pandemic (March-April), rates of infection were 3.4 times higher than the general population.
Even among healthcare personnel reporting adequate PPE early in the pandemic (March-April), rates of infection were 3.4 times higher than the general population.
The WHO considers face shields as inferior to masks and respirators for control of droplet transmission.
The WHO considers face shields as inferior to masks and respirators for control of droplet transmission.
The WHO considers face shields as inferior to masks and respirators for control of droplet transmission.
The WHO considers face shields as inferior to masks and respirators for control of droplet transmission.
The WHO considers face shields as inferior to masks and respirators for control of droplet transmission.
The WHO considers face shields as inferior to masks and respirators for control of droplet transmission.
The WHO considers face shields as inferior to masks and respirators for control of droplet transmission.
The WHO considers face shields as inferior to masks and respirators for control of droplet transmission.
The WHO considers face shields as inferior to masks and respirators for control of droplet transmission.
The WHO considers face shields as inferior to masks and respirators for control of droplet transmission.
Healthcare personnel entering the room [of SARS-CoV-2 patients] should use standard precautions, contact precautions, airborne precautions, and use eye protection (e.g., goggles or a face shield).
Healthcare personnel entering the room [of SARS-CoV-2 patients] should use standard precautions, contact precautions, airborne precautions, and use eye protection (e.g., goggles or a face shield).
Healthcare personnel entering the room [of SARS-CoV-2 patients] should use standard precautions, contact precautions, airborne precautions, and use eye protection (e.g., goggles or a face shield).
Healthcare personnel entering the room [of SARS-CoV-2 patients] should use standard precautions, contact precautions, airborne precautions, and use eye protection (e.g., goggles or a face shield).
Healthcare personnel entering the room [of SARS-CoV-2 patients] should use standard precautions, contact precautions, airborne precautions, and use eye protection (e.g., goggles or a face shield).
Healthcare personnel entering the room [of SARS-CoV-2 patients] should use standard precautions, contact precautions, airborne precautions, and use eye protection (e.g., goggles or a face shield).
Healthcare personnel entering the room [of SARS-CoV-2 patients] should use standard precautions, contact precautions, airborne precautions, and use eye protection (e.g., goggles or a face shield).
Healthcare personnel entering the room [of SARS-CoV-2 patients] should use standard precautions, contact precautions, airborne precautions, and use eye protection (e.g., goggles or a face shield).
Healthcare personnel entering the room [of SARS-CoV-2 patients] should use standard precautions, contact precautions, airborne precautions, and use eye protection (e.g., goggles or a face shield).
Healthcare personnel entering the room [of SARS-CoV-2 patients] should use standard precautions, contact precautions, airborne precautions, and use eye protection (e.g., goggles or a face shield).
WHO indicates healthcare workers should wear clean long-sleeve gowns as well as gloves.
WHO indicates healthcare workers should wear clean long-sleeve gowns as well as gloves.
WHO indicates healthcare workers should wear clean long-sleeve gowns as well as gloves.
WHO indicates healthcare workers should wear clean long-sleeve gowns as well as gloves.
WHO indicates healthcare workers should wear clean long-sleeve gowns as well as gloves.
WHO indicates healthcare workers should wear clean long-sleeve gowns as well as gloves.
WHO indicates healthcare workers should wear clean long-sleeve gowns as well as gloves.
WHO indicates healthcare workers should wear clean long-sleeve gowns as well as gloves.
WHO indicates healthcare workers should wear clean long-sleeve gowns as well as gloves.
WHO indicates healthcare workers should wear clean long-sleeve gowns as well as gloves.
PPE that covers all skin may reduce exposure to pathogens.
PPE that covers all skin may reduce exposure to pathogens.
PPE that covers all skin may reduce exposure to pathogens.
PPE that covers all skin may reduce exposure to pathogens.
PPE that covers all skin may reduce exposure to pathogens.
PPE that covers all skin may reduce exposure to pathogens.
PPE that covers all skin may reduce exposure to pathogens.
PPE that covers all skin may reduce exposure to pathogens.
PPE that covers all skin may reduce exposure to pathogens.
PPE that covers all skin may reduce exposure to pathogens.
Respirators (NIOSH-certified N95, EUFFP2 or equivalent) are recommended for those working with potential aerosols.
Respirators (NIOSH-certified N95, EUFFP2 or equivalent) are recommended for those working with potential aerosols.
Respirators (NIOSH-certified N95, EUFFP2 or equivalent) are recommended for those working with potential aerosols.
Respirators (NIOSH-certified N95, EUFFP2 or equivalent) are recommended for those working with potential aerosols.
Respirators (NIOSH-certified N95, EUFFP2 or equivalent) are recommended for those working with potential aerosols.
Respirators (NIOSH-certified N95, EUFFP2 or equivalent) are recommended for those working with potential aerosols.
Respirators (NIOSH-certified N95, EUFFP2 or equivalent) are recommended for those working with potential aerosols.
Respirators (NIOSH-certified N95, EUFFP2 or equivalent) are recommended for those working with potential aerosols.
Respirators (NIOSH-certified N95, EUFFP2 or equivalent) are recommended for those working with potential aerosols.
Respirators (NIOSH-certified N95, EUFFP2 or equivalent) are recommended for those working with potential aerosols.
Additional protection (Powered Air Purifying Respirator (PAPR) with hood), should be considered for high-risk procedures.
Additional protection (Powered Air Purifying Respirator (PAPR) with hood), should be considered for high-risk procedures.
Additional protection (Powered Air Purifying Respirator (PAPR) with hood), should be considered for high-risk procedures.
Additional protection (Powered Air Purifying Respirator (PAPR) with hood), should be considered for high-risk procedures.
Additional protection (Powered Air Purifying Respirator (PAPR) with hood), should be considered for high-risk procedures.
Additional protection (Powered Air Purifying Respirator (PAPR) with hood), should be considered for high-risk procedures.
Additional protection (Powered Air Purifying Respirator (PAPR) with hood), should be considered for high-risk procedures.
Additional protection (Powered Air Purifying Respirator (PAPR) with hood), should be considered for high-risk procedures.
Additional protection (Powered Air Purifying Respirator (PAPR) with hood), should be considered for high-risk procedures.
Additional protection (Powered Air Purifying Respirator (PAPR) with hood), should be considered for high-risk procedures.
KN95 respirators are, under certain conditions, approved for use under FDA Emergency Use Authorization.
KN95 respirators are, under certain conditions, approved for use under FDA Emergency Use Authorization.
KN95 respirators are, under certain conditions, approved for use under FDA Emergency Use Authorization.
KN95 respirators are, under certain conditions, approved for use under FDA Emergency Use Authorization.
KN95 respirators are, under certain conditions, approved for use under FDA Emergency Use Authorization.
KN95 respirators are, under certain conditions, approved for use under FDA Emergency Use Authorization.
KN95 respirators are, under certain conditions, approved for use under FDA Emergency Use Authorization.
KN95 respirators are, under certain conditions, approved for use under FDA Emergency Use Authorization.
KN95 respirators are, under certain conditions, approved for use under FDA Emergency Use Authorization.
KN95 respirators are, under certain conditions, approved for use under FDA Emergency Use Authorization.
On May 7, the FDA rescinded a number of KN95 models that no longer meet the EUA criteria and are no longer authorized.
On May 7, the FDA rescinded a number of KN95 models that no longer meet the EUA criteria and are no longer authorized.
On May 7, the FDA rescinded a number of KN95 models that no longer meet the EUA criteria and are no longer authorized.
On May 7, the FDA rescinded a number of KN95 models that no longer meet the EUA criteria and are no longer authorized.
On May 7, the FDA rescinded a number of KN95 models that no longer meet the EUA criteria and are no longer authorized.
On May 7, the FDA rescinded a number of KN95 models that no longer meet the EUA criteria and are no longer authorized.
On May 7, the FDA rescinded a number of KN95 models that no longer meet the EUA criteria and are no longer authorized.
On May 7, the FDA rescinded a number of KN95 models that no longer meet the EUA criteria and are no longer authorized.
On May 7, the FDA rescinded a number of KN95 models that no longer meet the EUA criteria and are no longer authorized.
On May 7, the FDA rescinded a number of KN95 models that no longer meet the EUA criteria and are no longer authorized.
A study suggests that P100 respirators with removable filter cartridges have similar filtration efficiency compared to N95 respirators and could plausibly be used if N95 respirators were in short supply.
A study suggests that P100 respirators with removable filter cartridges have similar filtration efficiency compared to N95 respirators and could plausibly be used if N95 respirators were in short supply.
A study suggests that P100 respirators with removable filter cartridges have similar filtration efficiency compared to N95 respirators and could plausibly be used if N95 respirators were in short supply.
A study suggests that P100 respirators with removable filter cartridges have similar filtration efficiency compared to N95 respirators and could plausibly be used if N95 respirators were in short supply.
A study suggests that P100 respirators with removable filter cartridges have similar filtration efficiency compared to N95 respirators and could plausibly be used if N95 respirators were in short supply.
A study suggests that P100 respirators with removable filter cartridges have similar filtration efficiency compared to N95 respirators and could plausibly be used if N95 respirators were in short supply.
A study suggests that P100 respirators with removable filter cartridges have similar filtration efficiency compared to N95 respirators and could plausibly be used if N95 respirators were in short supply.
A study suggests that P100 respirators with removable filter cartridges have similar filtration efficiency compared to N95 respirators and could plausibly be used if N95 respirators were in short supply.
A study suggests that P100 respirators with removable filter cartridges have similar filtration efficiency compared to N95 respirators and could plausibly be used if N95 respirators were in short supply.
A study suggests that P100 respirators with removable filter cartridges have similar filtration efficiency compared to N95 respirators and could plausibly be used if N95 respirators were in short supply.
Particular care should be taken with ‚Äö√Ñ√∂‚àö√ë‚àö‚à´duckbill‚Äö√Ñ√∂‚àö√ë‚àöœÄ N95 respirators, which may fail fit tests after repeated doffing.
Particular care should be taken with ‚Äö√Ñ√∂‚àö√ë‚àö‚à´duckbill‚Äö√Ñ√∂‚àö√ë‚àöœÄ N95 respirators, which may fail fit tests after repeated doffing.
Particular care should be taken with ‚Äö√Ñ√∂‚àö√ë‚àö‚à´duckbill‚Äö√Ñ√∂‚àö√ë‚àöœÄ N95 respirators, which may fail fit tests after repeated doffing.
Particular care should be taken with ‚Äö√Ñ√∂‚àö√ë‚àö‚à´duckbill‚Äö√Ñ√∂‚àö√ë‚àöœÄ N95 respirators, which may fail fit tests after repeated doffing.
Particular care should be taken with ‚Äö√Ñ√∂‚àö√ë‚àö‚à´duckbill‚Äö√Ñ√∂‚àö√ë‚àöœÄ N95 respirators, which may fail fit tests after repeated doffing.
Particular care should be taken with ‚Äö√Ñ√∂‚àö√ë‚àö‚à´duckbill‚Äö√Ñ√∂‚àö√ë‚àöœÄ N95 respirators, which may fail fit tests after repeated doffing.
Particular care should be taken with ‚Äö√Ñ√∂‚àö√ë‚àö‚à´duckbill‚Äö√Ñ√∂‚àö√ë‚àöœÄ N95 respirators, which may fail fit tests after repeated doffing.
Particular care should be taken with ‚Äö√Ñ√∂‚àö√ë‚àö‚à´duckbill‚Äö√Ñ√∂‚àö√ë‚àöœÄ N95 respirators, which may fail fit tests after repeated doffing.
Particular care should be taken with ‚Äö√Ñ√∂‚àö√ë‚àö‚à´duckbill‚Äö√Ñ√∂‚àö√ë‚àöœÄ N95 respirators, which may fail fit tests after repeated doffing.
Particular care should be taken with ‚Äö√Ñ√∂‚àö√ë‚àö‚à´duckbill‚Äö√Ñ√∂‚àö√ë‚àöœÄ N95 respirators, which may fail fit tests after repeated doffing.
The US FDA cautions healthcare facilities using passive protective barrier enclosures without negative pressure, and has withdrawn a prior Emergency Use Authorization for the devices.
The US FDA cautions healthcare facilities using passive protective barrier enclosures without negative pressure, and has withdrawn a prior Emergency Use Authorization for the devices.
The US FDA cautions healthcare facilities using passive protective barrier enclosures without negative pressure, and has withdrawn a prior Emergency Use Authorization for the devices.
The US FDA cautions healthcare facilities using passive protective barrier enclosures without negative pressure, and has withdrawn a prior Emergency Use Authorization for the devices.
The US FDA cautions healthcare facilities using passive protective barrier enclosures without negative pressure, and has withdrawn a prior Emergency Use Authorization for the devices.
The US FDA cautions healthcare facilities using passive protective barrier enclosures without negative pressure, and has withdrawn a prior Emergency Use Authorization for the devices.
The US FDA cautions healthcare facilities using passive protective barrier enclosures without negative pressure, and has withdrawn a prior Emergency Use Authorization for the devices.
The US FDA cautions healthcare facilities using passive protective barrier enclosures without negative pressure, and has withdrawn a prior Emergency Use Authorization for the devices.
The US FDA cautions healthcare facilities using passive protective barrier enclosures without negative pressure, and has withdrawn a prior Emergency Use Authorization for the devices.
The US FDA cautions healthcare facilities using passive protective barrier enclosures without negative pressure, and has withdrawn a prior Emergency Use Authorization for the devices.
Experiments with mannequins show that face masks reduce potential spread of SARS-CoV-2 when worn by an infectious individual, but also that face masks by non-infected recipients can reduce the number of inhaled particles; the protective effect was maximized when both infected and uninfected individuals (mannequins) wore masks.
Experiments with mannequins show that face masks reduce potential spread of SARS-CoV-2 when worn by an infectious individual, but also that face masks by non-infected recipients can reduce the number of inhaled particles; the protective effect was maximized when both infected and uninfected individuals (mannequins) wore masks.
Experiments with mannequins show that face masks reduce potential spread of SARS-CoV-2 when worn by an infectious individual, but also that face masks by non-infected recipients can reduce the number of inhaled particles; the protective effect was maximized when both infected and uninfected individuals (mannequins) wore masks.
Experiments with mannequins show that face masks reduce potential spread of SARS-CoV-2 when worn by an infectious individual, but also that face masks by non-infected recipients can reduce the number of inhaled particles; the protective effect was maximized when both infected and uninfected individuals (mannequins) wore masks.
Experiments with mannequins show that face masks reduce potential spread of SARS-CoV-2 when worn by an infectious individual, but also that face masks by non-infected recipients can reduce the number of inhaled particles; the protective effect was maximized when both infected and uninfected individuals (mannequins) wore masks.
Experiments with mannequins show that face masks reduce potential spread of SARS-CoV-2 when worn by an infectious individual, but also that face masks by non-infected recipients can reduce the number of inhaled particles; the protective effect was maximized when both infected and uninfected individuals (mannequins) wore masks.
Experiments with mannequins show that face masks reduce potential spread of SARS-CoV-2 when worn by an infectious individual, but also that face masks by non-infected recipients can reduce the number of inhaled particles; the protective effect was maximized when both infected and uninfected individuals (mannequins) wore masks.
Experiments with mannequins show that face masks reduce potential spread of SARS-CoV-2 when worn by an infectious individual, but also that face masks by non-infected recipients can reduce the number of inhaled particles; the protective effect was maximized when both infected and uninfected individuals (mannequins) wore masks.
Experiments with mannequins show that face masks reduce potential spread of SARS-CoV-2 when worn by an infectious individual, but also that face masks by non-infected recipients can reduce the number of inhaled particles; the protective effect was maximized when both infected and uninfected individuals (mannequins) wore masks.
Experiments with mannequins show that face masks reduce potential spread of SARS-CoV-2 when worn by an infectious individual, but also that face masks by non-infected recipients can reduce the number of inhaled particles; the protective effect was maximized when both infected and uninfected individuals (mannequins) wore masks.
Researchers have developed a lipopeptide fusion inhibitor that prevents SARS-CoV-2 transmission in ferrets given the peptide prophylactically via the intranasal route; human studies have yet to be conducted.
Researchers have developed a lipopeptide fusion inhibitor that prevents SARS-CoV-2 transmission in ferrets given the peptide prophylactically via the intranasal route; human studies have yet to be conducted.
Researchers have developed a lipopeptide fusion inhibitor that prevents SARS-CoV-2 transmission in ferrets given the peptide prophylactically via the intranasal route; human studies have yet to be conducted.
Researchers have developed a lipopeptide fusion inhibitor that prevents SARS-CoV-2 transmission in ferrets given the peptide prophylactically via the intranasal route; human studies have yet to be conducted.
Researchers have developed a lipopeptide fusion inhibitor that prevents SARS-CoV-2 transmission in ferrets given the peptide prophylactically via the intranasal route; human studies have yet to be conducted.
Researchers have developed a lipopeptide fusion inhibitor that prevents SARS-CoV-2 transmission in ferrets given the peptide prophylactically via the intranasal route; human studies have yet to be conducted.
Researchers have developed a lipopeptide fusion inhibitor that prevents SARS-CoV-2 transmission in ferrets given the peptide prophylactically via the intranasal route; human studies have yet to be conducted.
Researchers have developed a lipopeptide fusion inhibitor that prevents SARS-CoV-2 transmission in ferrets given the peptide prophylactically via the intranasal route; human studies have yet to be conducted.
Researchers have developed a lipopeptide fusion inhibitor that prevents SARS-CoV-2 transmission in ferrets given the peptide prophylactically via the intranasal route; human studies have yet to be conducted.
Researchers have developed a lipopeptide fusion inhibitor that prevents SARS-CoV-2 transmission in ferrets given the peptide prophylactically via the intranasal route; human studies have yet to be conducted.
Non-medical masks may be effective at slowing transmission, though data specific to SARS-CoV-2 are sparse.
Non-medical masks may be effective at slowing transmission, though data specific to SARS-CoV-2 are sparse.
Non-medical masks may be effective at slowing transmission, though data specific to SARS-CoV-2 are sparse.
Non-medical masks may be effective at slowing transmission, though data specific to SARS-CoV-2 are sparse.
Non-medical masks may be effective at slowing transmission, though data specific to SARS-CoV-2 are sparse.
Non-medical masks may be effective at slowing transmission, though data specific to SARS-CoV-2 are sparse.
Non-medical masks may be effective at slowing transmission, though data specific to SARS-CoV-2 are sparse.
Non-medical masks may be effective at slowing transmission, though data specific to SARS-CoV-2 are sparse.
Non-medical masks may be effective at slowing transmission, though data specific to SARS-CoV-2 are sparse.
Non-medical masks may be effective at slowing transmission, though data specific to SARS-CoV-2 are sparse.
On 4/3/2020, the US CDC recommended wearing cloth face masks in public where social distancing measures are difficult to maintain.
On 4/3/2020, the US CDC recommended wearing cloth face masks in public where social distancing measures are difficult to maintain.
On 4/3/2020, the US CDC recommended wearing cloth face masks in public where social distancing measures are difficult to maintain.
On 4/3/2020, the US CDC recommended wearing cloth face masks in public where social distancing measures are difficult to maintain.
On 4/3/2020, the US CDC recommended wearing cloth face masks in public where social distancing measures are difficult to maintain.
On 4/3/2020, the US CDC recommended wearing cloth face masks in public where social distancing measures are difficult to maintain.
On 4/3/2020, the US CDC recommended wearing cloth face masks in public where social distancing measures are difficult to maintain.
On 4/3/2020, the US CDC recommended wearing cloth face masks in public where social distancing measures are difficult to maintain.
On 4/3/2020, the US CDC recommended wearing cloth face masks in public where social distancing measures are difficult to maintain.
On 4/3/2020, the US CDC recommended wearing cloth face masks in public where social distancing measures are difficult to maintain.
The CDC recommends masks without exhalation vents or valves, as masks with valves can allow particles to pass through unfiltered.
The CDC recommends masks without exhalation vents or valves, as masks with valves can allow particles to pass through unfiltered.
The CDC recommends masks without exhalation vents or valves, as masks with valves can allow particles to pass through unfiltered.
The CDC recommends masks without exhalation vents or valves, as masks with valves can allow particles to pass through unfiltered.
The CDC recommends masks without exhalation vents or valves, as masks with valves can allow particles to pass through unfiltered.
The CDC recommends masks without exhalation vents or valves, as masks with valves can allow particles to pass through unfiltered.
The CDC recommends masks without exhalation vents or valves, as masks with valves can allow particles to pass through unfiltered.
The CDC recommends masks without exhalation vents or valves, as masks with valves can allow particles to pass through unfiltered.
The CDC recommends masks without exhalation vents or valves, as masks with valves can allow particles to pass through unfiltered.
The CDC recommends masks without exhalation vents or valves, as masks with valves can allow particles to pass through unfiltered.
The WHO recommends that the general population wear non-medical masks when in public settings and when physical distancing is difficult, and that vulnerable populations (e.g., elderly) wear medical masks when close contact is likely.
The WHO recommends that the general population wear non-medical masks when in public settings and when physical distancing is difficult, and that vulnerable populations (e.g., elderly) wear medical masks when close contact is likely.
The WHO recommends that the general population wear non-medical masks when in public settings and when physical distancing is difficult, and that vulnerable populations (e.g., elderly) wear medical masks when close contact is likely.
The WHO recommends that the general population wear non-medical masks when in public settings and when physical distancing is difficult, and that vulnerable populations (e.g., elderly) wear medical masks when close contact is likely.
The WHO recommends that the general population wear non-medical masks when in public settings and when physical distancing is difficult, and that vulnerable populations (e.g., elderly) wear medical masks when close contact is likely.
The WHO recommends that the general population wear non-medical masks when in public settings and when physical distancing is difficult, and that vulnerable populations (e.g., elderly) wear medical masks when close contact is likely.
The WHO recommends that the general population wear non-medical masks when in public settings and when physical distancing is difficult, and that vulnerable populations (e.g., elderly) wear medical masks when close contact is likely.
The WHO recommends that the general population wear non-medical masks when in public settings and when physical distancing is difficult, and that vulnerable populations (e.g., elderly) wear medical masks when close contact is likely.
The WHO recommends that the general population wear non-medical masks when in public settings and when physical distancing is difficult, and that vulnerable populations (e.g., elderly) wear medical masks when close contact is likely.
The WHO recommends that the general population wear non-medical masks when in public settings and when physical distancing is difficult, and that vulnerable populations (e.g., elderly) wear medical masks when close contact is likely.
Infected individuals wearing facemasks in the home before the onset of symptoms was associated with a reduction in household transmission.
Infected individuals wearing facemasks in the home before the onset of symptoms was associated with a reduction in household transmission.
Infected individuals wearing facemasks in the home before the onset of symptoms was associated with a reduction in household transmission.
Infected individuals wearing facemasks in the home before the onset of symptoms was associated with a reduction in household transmission.
Infected individuals wearing facemasks in the home before the onset of symptoms was associated with a reduction in household transmission.
Infected individuals wearing facemasks in the home before the onset of symptoms was associated with a reduction in household transmission.
Infected individuals wearing facemasks in the home before the onset of symptoms was associated with a reduction in household transmission.
Infected individuals wearing facemasks in the home before the onset of symptoms was associated with a reduction in household transmission.
Infected individuals wearing facemasks in the home before the onset of symptoms was associated with a reduction in household transmission.
Infected individuals wearing facemasks in the home before the onset of symptoms was associated with a reduction in household transmission.
A meta-analysis of SARS-CoV-1, MERS, and COVID-19 transmission events found evidence that wearing face masks and eye protection were each associated with lower risk of transmission, with N95 respirators more effective than surgical masks.
A meta-analysis of SARS-CoV-1, MERS, and COVID-19 transmission events found evidence that wearing face masks and eye protection were each associated with lower risk of transmission, with N95 respirators more effective than surgical masks.
A meta-analysis of SARS-CoV-1, MERS, and COVID-19 transmission events found evidence that wearing face masks and eye protection were each associated with lower risk of transmission, with N95 respirators more effective than surgical masks.
A meta-analysis of SARS-CoV-1, MERS, and COVID-19 transmission events found evidence that wearing face masks and eye protection were each associated with lower risk of transmission, with N95 respirators more effective than surgical masks.
A meta-analysis of SARS-CoV-1, MERS, and COVID-19 transmission events found evidence that wearing face masks and eye protection were each associated with lower risk of transmission, with N95 respirators more effective than surgical masks.
A meta-analysis of SARS-CoV-1, MERS, and COVID-19 transmission events found evidence that wearing face masks and eye protection were each associated with lower risk of transmission, with N95 respirators more effective than surgical masks.
A meta-analysis of SARS-CoV-1, MERS, and COVID-19 transmission events found evidence that wearing face masks and eye protection were each associated with lower risk of transmission, with N95 respirators more effective than surgical masks.
A meta-analysis of SARS-CoV-1, MERS, and COVID-19 transmission events found evidence that wearing face masks and eye protection were each associated with lower risk of transmission, with N95 respirators more effective than surgical masks.
A meta-analysis of SARS-CoV-1, MERS, and COVID-19 transmission events found evidence that wearing face masks and eye protection were each associated with lower risk of transmission, with N95 respirators more effective than surgical masks.
A meta-analysis of SARS-CoV-1, MERS, and COVID-19 transmission events found evidence that wearing face masks and eye protection were each associated with lower risk of transmission, with N95 respirators more effective than surgical masks.
In a separate meta-analysis, N95 respirators were found to be beneficial for reducing the occurrence of respiratory illness in health care professionals including influenza, though surgical masks were similarly effective for influenza.
In a separate meta-analysis, N95 respirators were found to be beneficial for reducing the occurrence of respiratory illness in health care professionals including influenza, though surgical masks were similarly effective for influenza.
In a separate meta-analysis, N95 respirators were found to be beneficial for reducing the occurrence of respiratory illness in health care professionals including influenza, though surgical masks were similarly effective for influenza.
In a separate meta-analysis, N95 respirators were found to be beneficial for reducing the occurrence of respiratory illness in health care professionals including influenza, though surgical masks were similarly effective for influenza.
In a separate meta-analysis, N95 respirators were found to be beneficial for reducing the occurrence of respiratory illness in health care professionals including influenza, though surgical masks were similarly effective for influenza.
In a separate meta-analysis, N95 respirators were found to be beneficial for reducing the occurrence of respiratory illness in health care professionals including influenza, though surgical masks were similarly effective for influenza.
In a separate meta-analysis, N95 respirators were found to be beneficial for reducing the occurrence of respiratory illness in health care professionals including influenza, though surgical masks were similarly effective for influenza.
In a separate meta-analysis, N95 respirators were found to be beneficial for reducing the occurrence of respiratory illness in health care professionals including influenza, though surgical masks were similarly effective for influenza.
In a separate meta-analysis, N95 respirators were found to be beneficial for reducing the occurrence of respiratory illness in health care professionals including influenza, though surgical masks were similarly effective for influenza.
In a separate meta-analysis, N95 respirators were found to be beneficial for reducing the occurrence of respiratory illness in health care professionals including influenza, though surgical masks were similarly effective for influenza.
N95 respirators were associated with up to 80% reductions in SARS-CoV-1 infections.
N95 respirators were associated with up to 80% reductions in SARS-CoV-1 infections.
N95 respirators were associated with up to 80% reductions in SARS-CoV-1 infections.
N95 respirators were associated with up to 80% reductions in SARS-CoV-1 infections.
N95 respirators were associated with up to 80% reductions in SARS-CoV-1 infections.
N95 respirators were associated with up to 80% reductions in SARS-CoV-1 infections.
N95 respirators were associated with up to 80% reductions in SARS-CoV-1 infections.
N95 respirators were associated with up to 80% reductions in SARS-CoV-1 infections.
N95 respirators were associated with up to 80% reductions in SARS-CoV-1 infections.
N95 respirators were associated with up to 80% reductions in SARS-CoV-1 infections.
Surgical face masks, respirators, and homemade face masks may prevent transmission of coronaviruses from infectious individuals to other individuals.
Surgical face masks, respirators, and homemade face masks may prevent transmission of coronaviruses from infectious individuals to other individuals.
Surgical face masks, respirators, and homemade face masks may prevent transmission of coronaviruses from infectious individuals to other individuals.
Surgical face masks, respirators, and homemade face masks may prevent transmission of coronaviruses from infectious individuals to other individuals.
Surgical face masks, respirators, and homemade face masks may prevent transmission of coronaviruses from infectious individuals to other individuals.
Surgical face masks, respirators, and homemade face masks may prevent transmission of coronaviruses from infectious individuals to other individuals.
Surgical face masks, respirators, and homemade face masks may prevent transmission of coronaviruses from infectious individuals to other individuals.
Surgical face masks, respirators, and homemade face masks may prevent transmission of coronaviruses from infectious individuals to other individuals.
Surgical face masks, respirators, and homemade face masks may prevent transmission of coronaviruses from infectious individuals to other individuals.
Surgical face masks, respirators, and homemade face masks may prevent transmission of coronaviruses from infectious individuals to other individuals.
Surgical masks were associated with a significant reduction in the amount of seasonal coronavirus expressed as aerosol particles (<5 ‚âà√≠¬¨‚à´m).
Surgical masks were associated with a significant reduction in the amount of seasonal coronavirus expressed as aerosol particles (<5 ‚âà√≠¬¨‚à´m).
Surgical masks were associated with a significant reduction in the amount of seasonal coronavirus expressed as aerosol particles (<5 ‚âà√≠¬¨‚à´m).
Surgical masks were associated with a significant reduction in the amount of seasonal coronavirus expressed as aerosol particles (<5 ‚âà√≠¬¨‚à´m).
Surgical masks were associated with a significant reduction in the amount of seasonal coronavirus expressed as aerosol particles (<5 ‚âà√≠¬¨‚à´m).
Surgical masks were associated with a significant reduction in the amount of seasonal coronavirus expressed as aerosol particles (<5 ‚âà√≠¬¨‚à´m).
Surgical masks were associated with a significant reduction in the amount of seasonal coronavirus expressed as aerosol particles (<5 ‚âà√≠¬¨‚à´m).
Surgical masks were associated with a significant reduction in the amount of seasonal coronavirus expressed as aerosol particles (<5 ‚âà√≠¬¨‚à´m).
Surgical masks were associated with a significant reduction in the amount of seasonal coronavirus expressed as aerosol particles (<5 ‚âà√≠¬¨‚à´m).
Surgical masks were associated with a significant reduction in the amount of seasonal coronavirus expressed as aerosol particles (<5 ‚âà√≠¬¨‚à´m).
Homemade masks reduce overall flow from breathing and coughing (63-86% reduction) but also generate leakage jets facing downward and backward from the wearer‚Äö√Ñ√∂‚àö√ë‚àö¬•s face.
Homemade masks reduce overall flow from breathing and coughing (63-86% reduction) but also generate leakage jets facing downward and backward from the wearer‚Äö√Ñ√∂‚àö√ë‚àö¬•s face.
Homemade masks reduce overall flow from breathing and coughing (63-86% reduction) but also generate leakage jets facing downward and backward from the wearer‚Äö√Ñ√∂‚àö√ë‚àö¬•s face.
Homemade masks reduce overall flow from breathing and coughing (63-86% reduction) but also generate leakage jets facing downward and backward from the wearer‚Äö√Ñ√∂‚àö√ë‚àö¬•s face.
Homemade masks reduce overall flow from breathing and coughing (63-86% reduction) but also generate leakage jets facing downward and backward from the wearer‚Äö√Ñ√∂‚àö√ë‚àö¬•s face.
Homemade masks reduce overall flow from breathing and coughing (63-86% reduction) but also generate leakage jets facing downward and backward from the wearer‚Äö√Ñ√∂‚àö√ë‚àö¬•s face.
Homemade masks reduce overall flow from breathing and coughing (63-86% reduction) but also generate leakage jets facing downward and backward from the wearer‚Äö√Ñ√∂‚àö√ë‚àö¬•s face.
Homemade masks reduce overall flow from breathing and coughing (63-86% reduction) but also generate leakage jets facing downward and backward from the wearer‚Äö√Ñ√∂‚àö√ë‚àö¬•s face.
Homemade masks reduce overall flow from breathing and coughing (63-86% reduction) but also generate leakage jets facing downward and backward from the wearer‚Äö√Ñ√∂‚àö√ë‚àö¬•s face.
Homemade masks reduce overall flow from breathing and coughing (63-86% reduction) but also generate leakage jets facing downward and backward from the wearer‚Äö√Ñ√∂‚àö√ë‚àö¬•s face.
Some non-standard materials (e.g., cotton, cotton hybrids) may be able to filter out >90% of simulant particles >0.3‚âà√≠¬¨‚à´m, while other materials (e.g., T-shirt, vacuum cleaner bag, towels) appear to have lower filtration efficacy (~35-62%).
Some non-standard materials (e.g., cotton, cotton hybrids) may be able to filter out >90% of simulant particles >0.3‚âà√≠¬¨‚à´m, while other materials (e.g., T-shirt, vacuum cleaner bag, towels) appear to have lower filtration efficacy (~35-62%).
Some non-standard materials (e.g., cotton, cotton hybrids) may be able to filter out >90% of simulant particles >0.3‚âà√≠¬¨‚à´m, while other materials (e.g., T-shirt, vacuum cleaner bag, towels) appear to have lower filtration efficacy (~35-62%).
Some non-standard materials (e.g., cotton, cotton hybrids) may be able to filter out >90% of simulant particles >0.3‚âà√≠¬¨‚à´m, while other materials (e.g., T-shirt, vacuum cleaner bag, towels) appear to have lower filtration efficacy (~35-62%).
Some non-standard materials (e.g., cotton, cotton hybrids) may be able to filter out >90% of simulant particles >0.3‚âà√≠¬¨‚à´m, while other materials (e.g., T-shirt, vacuum cleaner bag, towels) appear to have lower filtration efficacy (~35-62%).
Some non-standard materials (e.g., cotton, cotton hybrids) may be able to filter out >90% of simulant particles >0.3‚âà√≠¬¨‚à´m, while other materials (e.g., T-shirt, vacuum cleaner bag, towels) appear to have lower filtration efficacy (~35-62%).
Some non-standard materials (e.g., cotton, cotton hybrids) may be able to filter out >90% of simulant particles >0.3‚âà√≠¬¨‚à´m, while other materials (e.g., T-shirt, vacuum cleaner bag, towels) appear to have lower filtration efficacy (~35-62%).
Some non-standard materials (e.g., cotton, cotton hybrids) may be able to filter out >90% of simulant particles >0.3‚âà√≠¬¨‚à´m, while other materials (e.g., T-shirt, vacuum cleaner bag, towels) appear to have lower filtration efficacy (~35-62%).
Some non-standard materials (e.g., cotton, cotton hybrids) may be able to filter out >90% of simulant particles >0.3‚âà√≠¬¨‚à´m, while other materials (e.g., T-shirt, vacuum cleaner bag, towels) appear to have lower filtration efficacy (~35-62%).
Some non-standard materials (e.g., cotton, cotton hybrids) may be able to filter out >90% of simulant particles >0.3‚âà√≠¬¨‚à´m, while other materials (e.g., T-shirt, vacuum cleaner bag, towels) appear to have lower filtration efficacy (~35-62%).
Of 42 homemade materials tested, the three with the greatest filtration efficiencies were layered cotton with raised visible fibers.
Of 42 homemade materials tested, the three with the greatest filtration efficiencies were layered cotton with raised visible fibers.
Of 42 homemade materials tested, the three with the greatest filtration efficiencies were layered cotton with raised visible fibers.
Of 42 homemade materials tested, the three with the greatest filtration efficiencies were layered cotton with raised visible fibers.
Of 42 homemade materials tested, the three with the greatest filtration efficiencies were layered cotton with raised visible fibers.
Of 42 homemade materials tested, the three with the greatest filtration efficiencies were layered cotton with raised visible fibers.
Of 42 homemade materials tested, the three with the greatest filtration efficiencies were layered cotton with raised visible fibers.
Of 42 homemade materials tested, the three with the greatest filtration efficiencies were layered cotton with raised visible fibers.
Of 42 homemade materials tested, the three with the greatest filtration efficiencies were layered cotton with raised visible fibers.
Of 42 homemade materials tested, the three with the greatest filtration efficiencies were layered cotton with raised visible fibers.
Neck fleeces commonly worn by runners may increase the frequency of small aerosol particles, compared to wearing no mask at all.
Neck fleeces commonly worn by runners may increase the frequency of small aerosol particles, compared to wearing no mask at all.
Neck fleeces commonly worn by runners may increase the frequency of small aerosol particles, compared to wearing no mask at all.
Neck fleeces commonly worn by runners may increase the frequency of small aerosol particles, compared to wearing no mask at all.
Neck fleeces commonly worn by runners may increase the frequency of small aerosol particles, compared to wearing no mask at all.
Neck fleeces commonly worn by runners may increase the frequency of small aerosol particles, compared to wearing no mask at all.
Neck fleeces commonly worn by runners may increase the frequency of small aerosol particles, compared to wearing no mask at all.
Neck fleeces commonly worn by runners may increase the frequency of small aerosol particles, compared to wearing no mask at all.
Neck fleeces commonly worn by runners may increase the frequency of small aerosol particles, compared to wearing no mask at all.
Neck fleeces commonly worn by runners may increase the frequency of small aerosol particles, compared to wearing no mask at all.
Cotton T-shirt masks appear ineffective at reducing emitted particles when individuals talk, breathe, sneeze, or cough, with those made of single layers increasing emitted particles during these activities.
Cotton T-shirt masks appear ineffective at reducing emitted particles when individuals talk, breathe, sneeze, or cough, with those made of single layers increasing emitted particles during these activities.
Cotton T-shirt masks appear ineffective at reducing emitted particles when individuals talk, breathe, sneeze, or cough, with those made of single layers increasing emitted particles during these activities.
Cotton T-shirt masks appear ineffective at reducing emitted particles when individuals talk, breathe, sneeze, or cough, with those made of single layers increasing emitted particles during these activities.
Cotton T-shirt masks appear ineffective at reducing emitted particles when individuals talk, breathe, sneeze, or cough, with those made of single layers increasing emitted particles during these activities.
Cotton T-shirt masks appear ineffective at reducing emitted particles when individuals talk, breathe, sneeze, or cough, with those made of single layers increasing emitted particles during these activities.
Cotton T-shirt masks appear ineffective at reducing emitted particles when individuals talk, breathe, sneeze, or cough, with those made of single layers increasing emitted particles during these activities.
Cotton T-shirt masks appear ineffective at reducing emitted particles when individuals talk, breathe, sneeze, or cough, with those made of single layers increasing emitted particles during these activities.
Cotton T-shirt masks appear ineffective at reducing emitted particles when individuals talk, breathe, sneeze, or cough, with those made of single layers increasing emitted particles during these activities.
Cotton T-shirt masks appear ineffective at reducing emitted particles when individuals talk, breathe, sneeze, or cough, with those made of single layers increasing emitted particles during these activities.
Smaller aerosol particles (e.g., <0.1‚âà√≠¬¨‚à´m) are more difficult to filter for most respirators and face masks.
Smaller aerosol particles (e.g., <0.1‚âà√≠¬¨‚à´m) are more difficult to filter for most respirators and face masks.
Smaller aerosol particles (e.g., <0.1‚âà√≠¬¨‚à´m) are more difficult to filter for most respirators and face masks.
Smaller aerosol particles (e.g., <0.1‚âà√≠¬¨‚à´m) are more difficult to filter for most respirators and face masks.
Smaller aerosol particles (e.g., <0.1‚âà√≠¬¨‚à´m) are more difficult to filter for most respirators and face masks.
Smaller aerosol particles (e.g., <0.1‚âà√≠¬¨‚à´m) are more difficult to filter for most respirators and face masks.
Smaller aerosol particles (e.g., <0.1‚âà√≠¬¨‚à´m) are more difficult to filter for most respirators and face masks.
Smaller aerosol particles (e.g., <0.1‚âà√≠¬¨‚à´m) are more difficult to filter for most respirators and face masks.
Smaller aerosol particles (e.g., <0.1‚âà√≠¬¨‚à´m) are more difficult to filter for most respirators and face masks.
Smaller aerosol particles (e.g., <0.1‚âà√≠¬¨‚à´m) are more difficult to filter for most respirators and face masks.
All current evidence supports the natural emergence of SARS-CoV-2 via a bat and possible intermediate mammal species.
All current evidence supports the natural emergence of SARS-CoV-2 via a bat and possible intermediate mammal species.
All current evidence supports the natural emergence of SARS-CoV-2 via a bat and possible intermediate mammal species.
All current evidence supports the natural emergence of SARS-CoV-2 via a bat and possible intermediate mammal species.
All current evidence supports the natural emergence of SARS-CoV-2 via a bat and possible intermediate mammal species.
All current evidence supports the natural emergence of SARS-CoV-2 via a bat and possible intermediate mammal species.
All current evidence supports the natural emergence of SARS-CoV-2 via a bat and possible intermediate mammal species.
All current evidence supports the natural emergence of SARS-CoV-2 via a bat and possible intermediate mammal species.
All current evidence supports the natural emergence of SARS-CoV-2 via a bat and possible intermediate mammal species.
All current evidence supports the natural emergence of SARS-CoV-2 via a bat and possible intermediate mammal species.
New analysis of SARS-CoV-2 and related SARS-like coronaviruses suggests that SARS-CoV-2 jumped directly from bats to humans, without the influence of an intermediate mixing host.
New analysis of SARS-CoV-2 and related SARS-like coronaviruses suggests that SARS-CoV-2 jumped directly from bats to humans, without the influence of an intermediate mixing host.
New analysis of SARS-CoV-2 and related SARS-like coronaviruses suggests that SARS-CoV-2 jumped directly from bats to humans, without the influence of an intermediate mixing host.
New analysis of SARS-CoV-2 and related SARS-like coronaviruses suggests that SARS-CoV-2 jumped directly from bats to humans, without the influence of an intermediate mixing host.
New analysis of SARS-CoV-2 and related SARS-like coronaviruses suggests that SARS-CoV-2 jumped directly from bats to humans, without the influence of an intermediate mixing host.
New analysis of SARS-CoV-2 and related SARS-like coronaviruses suggests that SARS-CoV-2 jumped directly from bats to humans, without the influence of an intermediate mixing host.
New analysis of SARS-CoV-2 and related SARS-like coronaviruses suggests that SARS-CoV-2 jumped directly from bats to humans, without the influence of an intermediate mixing host.
New analysis of SARS-CoV-2 and related SARS-like coronaviruses suggests that SARS-CoV-2 jumped directly from bats to humans, without the influence of an intermediate mixing host.
New analysis of SARS-CoV-2 and related SARS-like coronaviruses suggests that SARS-CoV-2 jumped directly from bats to humans, without the influence of an intermediate mixing host.
New analysis of SARS-CoV-2 and related SARS-like coronaviruses suggests that SARS-CoV-2 jumped directly from bats to humans, without the influence of an intermediate mixing host.
Pangolin coronaviruses were shown to be more divergent and split off from bat coronaviruses earlier than SARS-CoV-2.
Pangolin coronaviruses were shown to be more divergent and split off from bat coronaviruses earlier than SARS-CoV-2.
Pangolin coronaviruses were shown to be more divergent and split off from bat coronaviruses earlier than SARS-CoV-2.
Pangolin coronaviruses were shown to be more divergent and split off from bat coronaviruses earlier than SARS-CoV-2.
Pangolin coronaviruses were shown to be more divergent and split off from bat coronaviruses earlier than SARS-CoV-2.
Pangolin coronaviruses were shown to be more divergent and split off from bat coronaviruses earlier than SARS-CoV-2.
Pangolin coronaviruses were shown to be more divergent and split off from bat coronaviruses earlier than SARS-CoV-2.
Pangolin coronaviruses were shown to be more divergent and split off from bat coronaviruses earlier than SARS-CoV-2.
Pangolin coronaviruses were shown to be more divergent and split off from bat coronaviruses earlier than SARS-CoV-2.
Pangolin coronaviruses were shown to be more divergent and split off from bat coronaviruses earlier than SARS-CoV-2.
These data suggest SARS-CoV-2 emerged from circulating bat coronaviruses in SE China/SE Asia and additional zoonotic emergence of novel coronaviruses could occur.
These data suggest SARS-CoV-2 emerged from circulating bat coronaviruses in SE China/SE Asia and additional zoonotic emergence of novel coronaviruses could occur.
These data suggest SARS-CoV-2 emerged from circulating bat coronaviruses in SE China/SE Asia and additional zoonotic emergence of novel coronaviruses could occur.
These data suggest SARS-CoV-2 emerged from circulating bat coronaviruses in SE China/SE Asia and additional zoonotic emergence of novel coronaviruses could occur.
These data suggest SARS-CoV-2 emerged from circulating bat coronaviruses in SE China/SE Asia and additional zoonotic emergence of novel coronaviruses could occur.
These data suggest SARS-CoV-2 emerged from circulating bat coronaviruses in SE China/SE Asia and additional zoonotic emergence of novel coronaviruses could occur.
These data suggest SARS-CoV-2 emerged from circulating bat coronaviruses in SE China/SE Asia and additional zoonotic emergence of novel coronaviruses could occur.
These data suggest SARS-CoV-2 emerged from circulating bat coronaviruses in SE China/SE Asia and additional zoonotic emergence of novel coronaviruses could occur.
These data suggest SARS-CoV-2 emerged from circulating bat coronaviruses in SE China/SE Asia and additional zoonotic emergence of novel coronaviruses could occur.
These data suggest SARS-CoV-2 emerged from circulating bat coronaviruses in SE China/SE Asia and additional zoonotic emergence of novel coronaviruses could occur.
Based on phylogenetic analysis, SARS-CoV-2 most likely emerged from Rhinolophus (horseshoe) bats living in China, Laos, Myanmar, Vietnam, or another Southeast Asian country, though historical recombination with pangolin coronaviruses may explain some features of the SARS-CoV-2 genome.
Based on phylogenetic analysis, SARS-CoV-2 most likely emerged from Rhinolophus (horseshoe) bats living in China, Laos, Myanmar, Vietnam, or another Southeast Asian country, though historical recombination with pangolin coronaviruses may explain some features of the SARS-CoV-2 genome.
Based on phylogenetic analysis, SARS-CoV-2 most likely emerged from Rhinolophus (horseshoe) bats living in China, Laos, Myanmar, Vietnam, or another Southeast Asian country, though historical recombination with pangolin coronaviruses may explain some features of the SARS-CoV-2 genome.
Based on phylogenetic analysis, SARS-CoV-2 most likely emerged from Rhinolophus (horseshoe) bats living in China, Laos, Myanmar, Vietnam, or another Southeast Asian country, though historical recombination with pangolin coronaviruses may explain some features of the SARS-CoV-2 genome.
Based on phylogenetic analysis, SARS-CoV-2 most likely emerged from Rhinolophus (horseshoe) bats living in China, Laos, Myanmar, Vietnam, or another Southeast Asian country, though historical recombination with pangolin coronaviruses may explain some features of the SARS-CoV-2 genome.
Based on phylogenetic analysis, SARS-CoV-2 most likely emerged from Rhinolophus (horseshoe) bats living in China, Laos, Myanmar, Vietnam, or another Southeast Asian country, though historical recombination with pangolin coronaviruses may explain some features of the SARS-CoV-2 genome.
Based on phylogenetic analysis, SARS-CoV-2 most likely emerged from Rhinolophus (horseshoe) bats living in China, Laos, Myanmar, Vietnam, or another Southeast Asian country, though historical recombination with pangolin coronaviruses may explain some features of the SARS-CoV-2 genome.
Based on phylogenetic analysis, SARS-CoV-2 most likely emerged from Rhinolophus (horseshoe) bats living in China, Laos, Myanmar, Vietnam, or another Southeast Asian country, though historical recombination with pangolin coronaviruses may explain some features of the SARS-CoV-2 genome.
Based on phylogenetic analysis, SARS-CoV-2 most likely emerged from Rhinolophus (horseshoe) bats living in China, Laos, Myanmar, Vietnam, or another Southeast Asian country, though historical recombination with pangolin coronaviruses may explain some features of the SARS-CoV-2 genome.
Based on phylogenetic analysis, SARS-CoV-2 most likely emerged from Rhinolophus (horseshoe) bats living in China, Laos, Myanmar, Vietnam, or another Southeast Asian country, though historical recombination with pangolin coronaviruses may explain some features of the SARS-CoV-2 genome.
Genomic analysis suggests that SARS-CoV-2 is a natural variant and is unlikely to be human-derived or otherwise created by ‚Äö√Ñ√∂‚àö√ë‚àö‚à´recombination‚Äö√Ñ√∂‚àö√ë‚àöœÄ with other circulating strains of coronavirus.
Genomic analysis suggests that SARS-CoV-2 is a natural variant and is unlikely to be human-derived or otherwise created by ‚Äö√Ñ√∂‚àö√ë‚àö‚à´recombination‚Äö√Ñ√∂‚àö√ë‚àöœÄ with other circulating strains of coronavirus.
Genomic analysis suggests that SARS-CoV-2 is a natural variant and is unlikely to be human-derived or otherwise created by ‚Äö√Ñ√∂‚àö√ë‚àö‚à´recombination‚Äö√Ñ√∂‚àö√ë‚àöœÄ with other circulating strains of coronavirus.
Genomic analysis suggests that SARS-CoV-2 is a natural variant and is unlikely to be human-derived or otherwise created by ‚Äö√Ñ√∂‚àö√ë‚àö‚à´recombination‚Äö√Ñ√∂‚àö√ë‚àöœÄ with other circulating strains of coronavirus.
Genomic analysis suggests that SARS-CoV-2 is a natural variant and is unlikely to be human-derived or otherwise created by ‚Äö√Ñ√∂‚àö√ë‚àö‚à´recombination‚Äö√Ñ√∂‚àö√ë‚àöœÄ with other circulating strains of coronavirus.
Genomic analysis suggests that SARS-CoV-2 is a natural variant and is unlikely to be human-derived or otherwise created by ‚Äö√Ñ√∂‚àö√ë‚àö‚à´recombination‚Äö√Ñ√∂‚àö√ë‚àöœÄ with other circulating strains of coronavirus.
Genomic analysis suggests that SARS-CoV-2 is a natural variant and is unlikely to be human-derived or otherwise created by ‚Äö√Ñ√∂‚àö√ë‚àö‚à´recombination‚Äö√Ñ√∂‚àö√ë‚àöœÄ with other circulating strains of coronavirus.
Genomic analysis suggests that SARS-CoV-2 is a natural variant and is unlikely to be human-derived or otherwise created by ‚Äö√Ñ√∂‚àö√ë‚àö‚à´recombination‚Äö√Ñ√∂‚àö√ë‚àöœÄ with other circulating strains of coronavirus.
Genomic analysis suggests that SARS-CoV-2 is a natural variant and is unlikely to be human-derived or otherwise created by ‚Äö√Ñ√∂‚àö√ë‚àö‚à´recombination‚Äö√Ñ√∂‚àö√ë‚àöœÄ with other circulating strains of coronavirus.
Genomic analysis suggests that SARS-CoV-2 is a natural variant and is unlikely to be human-derived or otherwise created by ‚Äö√Ñ√∂‚àö√ë‚àö‚à´recombination‚Äö√Ñ√∂‚àö√ë‚àöœÄ with other circulating strains of coronavirus.
Phylogenetics suggest that SARS-CoV-2 is of bat origin, but is closely related to coronaviruses found in pangolins.
Phylogenetics suggest that SARS-CoV-2 is of bat origin, but is closely related to coronaviruses found in pangolins.
Phylogenetics suggest that SARS-CoV-2 is of bat origin, but is closely related to coronaviruses found in pangolins.
Phylogenetics suggest that SARS-CoV-2 is of bat origin, but is closely related to coronaviruses found in pangolins.
Phylogenetics suggest that SARS-CoV-2 is of bat origin, but is closely related to coronaviruses found in pangolins.
Phylogenetics suggest that SARS-CoV-2 is of bat origin, but is closely related to coronaviruses found in pangolins.
Phylogenetics suggest that SARS-CoV-2 is of bat origin, but is closely related to coronaviruses found in pangolins.
Phylogenetics suggest that SARS-CoV-2 is of bat origin, but is closely related to coronaviruses found in pangolins.
Phylogenetics suggest that SARS-CoV-2 is of bat origin, but is closely related to coronaviruses found in pangolins.
Phylogenetics suggest that SARS-CoV-2 is of bat origin, but is closely related to coronaviruses found in pangolins.
The SARS-CoV-2 Spike protein, which mediates entry into host cells and is a major determinant of host range, is very similar to the SARS-CoV-1 Spike protein.
The SARS-CoV-2 Spike protein, which mediates entry into host cells and is a major determinant of host range, is very similar to the SARS-CoV-1 Spike protein.
The SARS-CoV-2 Spike protein, which mediates entry into host cells and is a major determinant of host range, is very similar to the SARS-CoV-1 Spike protein.
The SARS-CoV-2 Spike protein, which mediates entry into host cells and is a major determinant of host range, is very similar to the SARS-CoV-1 Spike protein.
The SARS-CoV-2 Spike protein, which mediates entry into host cells and is a major determinant of host range, is very similar to the SARS-CoV-1 Spike protein.
The SARS-CoV-2 Spike protein, which mediates entry into host cells and is a major determinant of host range, is very similar to the SARS-CoV-1 Spike protein.
The SARS-CoV-2 Spike protein, which mediates entry into host cells and is a major determinant of host range, is very similar to the SARS-CoV-1 Spike protein.
The SARS-CoV-2 Spike protein, which mediates entry into host cells and is a major determinant of host range, is very similar to the SARS-CoV-1 Spike protein.
The SARS-CoV-2 Spike protein, which mediates entry into host cells and is a major determinant of host range, is very similar to the SARS-CoV-1 Spike protein.
The SARS-CoV-2 Spike protein, which mediates entry into host cells and is a major determinant of host range, is very similar to the SARS-CoV-1 Spike protein.
The rest of the genome is more closely related to two separate bat coronaviruses and coronaviruses found in pangolins.
The rest of the genome is more closely related to two separate bat coronaviruses and coronaviruses found in pangolins.
The rest of the genome is more closely related to two separate bat coronaviruses and coronaviruses found in pangolins.
The rest of the genome is more closely related to two separate bat coronaviruses and coronaviruses found in pangolins.
The rest of the genome is more closely related to two separate bat coronaviruses and coronaviruses found in pangolins.
The rest of the genome is more closely related to two separate bat coronaviruses and coronaviruses found in pangolins.
The rest of the genome is more closely related to two separate bat coronaviruses and coronaviruses found in pangolins.
The rest of the genome is more closely related to two separate bat coronaviruses and coronaviruses found in pangolins.
The rest of the genome is more closely related to two separate bat coronaviruses and coronaviruses found in pangolins.
The rest of the genome is more closely related to two separate bat coronaviruses and coronaviruses found in pangolins.
Deletion mutants were identified at low levels in human clinical samples, suggesting that the PRRA furin cleavage site alone is not fully responsible for human infection, but does confer a fitness advantage in the human host.
Deletion mutants were identified at low levels in human clinical samples, suggesting that the PRRA furin cleavage site alone is not fully responsible for human infection, but does confer a fitness advantage in the human host.
Deletion mutants were identified at low levels in human clinical samples, suggesting that the PRRA furin cleavage site alone is not fully responsible for human infection, but does confer a fitness advantage in the human host.
Deletion mutants were identified at low levels in human clinical samples, suggesting that the PRRA furin cleavage site alone is not fully responsible for human infection, but does confer a fitness advantage in the human host.
Deletion mutants were identified at low levels in human clinical samples, suggesting that the PRRA furin cleavage site alone is not fully responsible for human infection, but does confer a fitness advantage in the human host.
Deletion mutants were identified at low levels in human clinical samples, suggesting that the PRRA furin cleavage site alone is not fully responsible for human infection, but does confer a fitness advantage in the human host.
Deletion mutants were identified at low levels in human clinical samples, suggesting that the PRRA furin cleavage site alone is not fully responsible for human infection, but does confer a fitness advantage in the human host.
Deletion mutants were identified at low levels in human clinical samples, suggesting that the PRRA furin cleavage site alone is not fully responsible for human infection, but does confer a fitness advantage in the human host.
Deletion mutants were identified at low levels in human clinical samples, suggesting that the PRRA furin cleavage site alone is not fully responsible for human infection, but does confer a fitness advantage in the human host.
Deletion mutants were identified at low levels in human clinical samples, suggesting that the PRRA furin cleavage site alone is not fully responsible for human infection, but does confer a fitness advantage in the human host.
Additional whole- genome sequencing in humans would help to confirm this finding.
Additional whole- genome sequencing in humans would help to confirm this finding.
Additional whole- genome sequencing in humans would help to confirm this finding.
Additional whole- genome sequencing in humans would help to confirm this finding.
Additional whole- genome sequencing in humans would help to confirm this finding.
Additional whole- genome sequencing in humans would help to confirm this finding.
Additional whole- genome sequencing in humans would help to confirm this finding.
Additional whole- genome sequencing in humans would help to confirm this finding.
Additional whole- genome sequencing in humans would help to confirm this finding.
Additional whole- genome sequencing in humans would help to confirm this finding.
Genomic data support at least two plausible origins of SARS-CoV-2 ‚Äö√Ñ√∂‚àö√ë‚àö‚à´(i) natural selection in a non-human animal host prior to zoonotic transfer, and (ii) natural selection in humans following zoonotic transfer.‚Äö√Ñ√∂‚àö√ë‚àöœÄ
Genomic data support at least two plausible origins of SARS-CoV-2 ‚Äö√Ñ√∂‚àö√ë‚àö‚à´(i) natural selection in a non-human animal host prior to zoonotic transfer, and (ii) natural selection in humans following zoonotic transfer.‚Äö√Ñ√∂‚àö√ë‚àöœÄ
Genomic data support at least two plausible origins of SARS-CoV-2 ‚Äö√Ñ√∂‚àö√ë‚àö‚à´(i) natural selection in a non-human animal host prior to zoonotic transfer, and (ii) natural selection in humans following zoonotic transfer.‚Äö√Ñ√∂‚àö√ë‚àöœÄ
Genomic data support at least two plausible origins of SARS-CoV-2 ‚Äö√Ñ√∂‚àö√ë‚àö‚à´(i) natural selection in a non-human animal host prior to zoonotic transfer, and (ii) natural selection in humans following zoonotic transfer.‚Äö√Ñ√∂‚àö√ë‚àöœÄ
Genomic data support at least two plausible origins of SARS-CoV-2 ‚Äö√Ñ√∂‚àö√ë‚àö‚à´(i) natural selection in a non-human animal host prior to zoonotic transfer, and (ii) natural selection in humans following zoonotic transfer.‚Äö√Ñ√∂‚àö√ë‚àöœÄ
Genomic data support at least two plausible origins of SARS-CoV-2 ‚Äö√Ñ√∂‚àö√ë‚àö‚à´(i) natural selection in a non-human animal host prior to zoonotic transfer, and (ii) natural selection in humans following zoonotic transfer.‚Äö√Ñ√∂‚àö√ë‚àöœÄ
Genomic data support at least two plausible origins of SARS-CoV-2 ‚Äö√Ñ√∂‚àö√ë‚àö‚à´(i) natural selection in a non-human animal host prior to zoonotic transfer, and (ii) natural selection in humans following zoonotic transfer.‚Äö√Ñ√∂‚àö√ë‚àöœÄ
Genomic data support at least two plausible origins of SARS-CoV-2 ‚Äö√Ñ√∂‚àö√ë‚àö‚à´(i) natural selection in a non-human animal host prior to zoonotic transfer, and (ii) natural selection in humans following zoonotic transfer.‚Äö√Ñ√∂‚àö√ë‚àöœÄ
Genomic data support at least two plausible origins of SARS-CoV-2 ‚Äö√Ñ√∂‚àö√ë‚àö‚à´(i) natural selection in a non-human animal host prior to zoonotic transfer, and (ii) natural selection in humans following zoonotic transfer.‚Äö√Ñ√∂‚àö√ë‚àöœÄ
Genomic data support at least two plausible origins of SARS-CoV-2 ‚Äö√Ñ√∂‚àö√ë‚àö‚à´(i) natural selection in a non-human animal host prior to zoonotic transfer, and (ii) natural selection in humans following zoonotic transfer.‚Äö√Ñ√∂‚àö√ë‚àöœÄ
Both scenarios are consistent with the observed genetic changes found in all known SARS-CoV-2 isolates.
Both scenarios are consistent with the observed genetic changes found in all known SARS-CoV-2 isolates.
Both scenarios are consistent with the observed genetic changes found in all known SARS-CoV-2 isolates.
Both scenarios are consistent with the observed genetic changes found in all known SARS-CoV-2 isolates.
Both scenarios are consistent with the observed genetic changes found in all known SARS-CoV-2 isolates.
Both scenarios are consistent with the observed genetic changes found in all known SARS-CoV-2 isolates.
Both scenarios are consistent with the observed genetic changes found in all known SARS-CoV-2 isolates.
Both scenarios are consistent with the observed genetic changes found in all known SARS-CoV-2 isolates.
Both scenarios are consistent with the observed genetic changes found in all known SARS-CoV-2 isolates.
Both scenarios are consistent with the observed genetic changes found in all known SARS-CoV-2 isolates.
Some SARS-CoV-2 genomic evidence indicates a close relationship with pangolin coronaviruses, and data suggest that pangolins may be a natural host for beta-coronaviruses.
Some SARS-CoV-2 genomic evidence indicates a close relationship with pangolin coronaviruses, and data suggest that pangolins may be a natural host for beta-coronaviruses.
Some SARS-CoV-2 genomic evidence indicates a close relationship with pangolin coronaviruses, and data suggest that pangolins may be a natural host for beta-coronaviruses.
Some SARS-CoV-2 genomic evidence indicates a close relationship with pangolin coronaviruses, and data suggest that pangolins may be a natural host for beta-coronaviruses.
Some SARS-CoV-2 genomic evidence indicates a close relationship with pangolin coronaviruses, and data suggest that pangolins may be a natural host for beta-coronaviruses.
Some SARS-CoV-2 genomic evidence indicates a close relationship with pangolin coronaviruses, and data suggest that pangolins may be a natural host for beta-coronaviruses.
Some SARS-CoV-2 genomic evidence indicates a close relationship with pangolin coronaviruses, and data suggest that pangolins may be a natural host for beta-coronaviruses.
Some SARS-CoV-2 genomic evidence indicates a close relationship with pangolin coronaviruses, and data suggest that pangolins may be a natural host for beta-coronaviruses.
Some SARS-CoV-2 genomic evidence indicates a close relationship with pangolin coronaviruses, and data suggest that pangolins may be a natural host for beta-coronaviruses.
Some SARS-CoV-2 genomic evidence indicates a close relationship with pangolin coronaviruses, and data suggest that pangolins may be a natural host for beta-coronaviruses.
Genomic evidence suggests a plausible recombination event between a circulating coronavirus in pangolins and bats could be the source of SARS-CoV-2.
Genomic evidence suggests a plausible recombination event between a circulating coronavirus in pangolins and bats could be the source of SARS-CoV-2.
Genomic evidence suggests a plausible recombination event between a circulating coronavirus in pangolins and bats could be the source of SARS-CoV-2.
Genomic evidence suggests a plausible recombination event between a circulating coronavirus in pangolins and bats could be the source of SARS-CoV-2.
Genomic evidence suggests a plausible recombination event between a circulating coronavirus in pangolins and bats could be the source of SARS-CoV-2.
Genomic evidence suggests a plausible recombination event between a circulating coronavirus in pangolins and bats could be the source of SARS-CoV-2.
Genomic evidence suggests a plausible recombination event between a circulating coronavirus in pangolins and bats could be the source of SARS-CoV-2.
Genomic evidence suggests a plausible recombination event between a circulating coronavirus in pangolins and bats could be the source of SARS-CoV-2.
Genomic evidence suggests a plausible recombination event between a circulating coronavirus in pangolins and bats could be the source of SARS-CoV-2.
Genomic evidence suggests a plausible recombination event between a circulating coronavirus in pangolins and bats could be the source of SARS-CoV-2.
Emerging studies are showing that bats are not the only reservoir of SARS-like coronaviruses.
Emerging studies are showing that bats are not the only reservoir of SARS-like coronaviruses.
Emerging studies are showing that bats are not the only reservoir of SARS-like coronaviruses.
Emerging studies are showing that bats are not the only reservoir of SARS-like coronaviruses.
Emerging studies are showing that bats are not the only reservoir of SARS-like coronaviruses.
Emerging studies are showing that bats are not the only reservoir of SARS-like coronaviruses.
Emerging studies are showing that bats are not the only reservoir of SARS-like coronaviruses.
Emerging studies are showing that bats are not the only reservoir of SARS-like coronaviruses.
Emerging studies are showing that bats are not the only reservoir of SARS-like coronaviruses.
Emerging studies are showing that bats are not the only reservoir of SARS-like coronaviruses.
There are multiple studies showing that the SARS-CoV-2 S protein receptor binding domain, the portion of the protein responsible for binding the human receptor ACE2, was acquired through recombination between coronaviruses from pangolins and bats.
There are multiple studies showing that the SARS-CoV-2 S protein receptor binding domain, the portion of the protein responsible for binding the human receptor ACE2, was acquired through recombination between coronaviruses from pangolins and bats.
There are multiple studies showing that the SARS-CoV-2 S protein receptor binding domain, the portion of the protein responsible for binding the human receptor ACE2, was acquired through recombination between coronaviruses from pangolins and bats.
There are multiple studies showing that the SARS-CoV-2 S protein receptor binding domain, the portion of the protein responsible for binding the human receptor ACE2, was acquired through recombination between coronaviruses from pangolins and bats.
There are multiple studies showing that the SARS-CoV-2 S protein receptor binding domain, the portion of the protein responsible for binding the human receptor ACE2, was acquired through recombination between coronaviruses from pangolins and bats.
There are multiple studies showing that the SARS-CoV-2 S protein receptor binding domain, the portion of the protein responsible for binding the human receptor ACE2, was acquired through recombination between coronaviruses from pangolins and bats.
There are multiple studies showing that the SARS-CoV-2 S protein receptor binding domain, the portion of the protein responsible for binding the human receptor ACE2, was acquired through recombination between coronaviruses from pangolins and bats.
There are multiple studies showing that the SARS-CoV-2 S protein receptor binding domain, the portion of the protein responsible for binding the human receptor ACE2, was acquired through recombination between coronaviruses from pangolins and bats.
There are multiple studies showing that the SARS-CoV-2 S protein receptor binding domain, the portion of the protein responsible for binding the human receptor ACE2, was acquired through recombination between coronaviruses from pangolins and bats.
There are multiple studies showing that the SARS-CoV-2 S protein receptor binding domain, the portion of the protein responsible for binding the human receptor ACE2, was acquired through recombination between coronaviruses from pangolins and bats.
These studies suggest that pangolins may have played an intermediate role in the adaptation of SARS-CoV-2 to be able to bind to the human ACE2 receptor.
These studies suggest that pangolins may have played an intermediate role in the adaptation of SARS-CoV-2 to be able to bind to the human ACE2 receptor.
These studies suggest that pangolins may have played an intermediate role in the adaptation of SARS-CoV-2 to be able to bind to the human ACE2 receptor.
These studies suggest that pangolins may have played an intermediate role in the adaptation of SARS-CoV-2 to be able to bind to the human ACE2 receptor.
These studies suggest that pangolins may have played an intermediate role in the adaptation of SARS-CoV-2 to be able to bind to the human ACE2 receptor.
These studies suggest that pangolins may have played an intermediate role in the adaptation of SARS-CoV-2 to be able to bind to the human ACE2 receptor.
These studies suggest that pangolins may have played an intermediate role in the adaptation of SARS-CoV-2 to be able to bind to the human ACE2 receptor.
These studies suggest that pangolins may have played an intermediate role in the adaptation of SARS-CoV-2 to be able to bind to the human ACE2 receptor.
These studies suggest that pangolins may have played an intermediate role in the adaptation of SARS-CoV-2 to be able to bind to the human ACE2 receptor.
These studies suggest that pangolins may have played an intermediate role in the adaptation of SARS-CoV-2 to be able to bind to the human ACE2 receptor.
A key difference between SARS-CoV-2 and other beta-coronaviruses is the presence of a polybasic furin cleavage site in the Spike protein (insertion of a PRRA amino acid sequence between S1 and S2).
A key difference between SARS-CoV-2 and other beta-coronaviruses is the presence of a polybasic furin cleavage site in the Spike protein (insertion of a PRRA amino acid sequence between S1 and S2).
A key difference between SARS-CoV-2 and other beta-coronaviruses is the presence of a polybasic furin cleavage site in the Spike protein (insertion of a PRRA amino acid sequence between S1 and S2).
A key difference between SARS-CoV-2 and other beta-coronaviruses is the presence of a polybasic furin cleavage site in the Spike protein (insertion of a PRRA amino acid sequence between S1 and S2).
A key difference between SARS-CoV-2 and other beta-coronaviruses is the presence of a polybasic furin cleavage site in the Spike protein (insertion of a PRRA amino acid sequence between S1 and S2).
A key difference between SARS-CoV-2 and other beta-coronaviruses is the presence of a polybasic furin cleavage site in the Spike protein (insertion of a PRRA amino acid sequence between S1 and S2).
A key difference between SARS-CoV-2 and other beta-coronaviruses is the presence of a polybasic furin cleavage site in the Spike protein (insertion of a PRRA amino acid sequence between S1 and S2).
A key difference between SARS-CoV-2 and other beta-coronaviruses is the presence of a polybasic furin cleavage site in the Spike protein (insertion of a PRRA amino acid sequence between S1 and S2).
A key difference between SARS-CoV-2 and other beta-coronaviruses is the presence of a polybasic furin cleavage site in the Spike protein (insertion of a PRRA amino acid sequence between S1 and S2).
A key difference between SARS-CoV-2 and other beta-coronaviruses is the presence of a polybasic furin cleavage site in the Spike protein (insertion of a PRRA amino acid sequence between S1 and S2).
A novel bat coronavirus (RmYN02) has been identified in China with an insertion between the S1/S2 cleavage site of the Spike protein.
A novel bat coronavirus (RmYN02) has been identified in China with an insertion between the S1/S2 cleavage site of the Spike protein.
A novel bat coronavirus (RmYN02) has been identified in China with an insertion between the S1/S2 cleavage site of the Spike protein.
A novel bat coronavirus (RmYN02) has been identified in China with an insertion between the S1/S2 cleavage site of the Spike protein.
A novel bat coronavirus (RmYN02) has been identified in China with an insertion between the S1/S2 cleavage site of the Spike protein.
A novel bat coronavirus (RmYN02) has been identified in China with an insertion between the S1/S2 cleavage site of the Spike protein.
A novel bat coronavirus (RmYN02) has been identified in China with an insertion between the S1/S2 cleavage site of the Spike protein.
A novel bat coronavirus (RmYN02) has been identified in China with an insertion between the S1/S2 cleavage site of the Spike protein.
A novel bat coronavirus (RmYN02) has been identified in China with an insertion between the S1/S2 cleavage site of the Spike protein.
A novel bat coronavirus (RmYN02) has been identified in China with an insertion between the S1/S2 cleavage site of the Spike protein.
While distinct from the furin cleavage site insertion in SARS-CoV-2, this evidence shows that such insertions can occur naturally.
While distinct from the furin cleavage site insertion in SARS-CoV-2, this evidence shows that such insertions can occur naturally.
While distinct from the furin cleavage site insertion in SARS-CoV-2, this evidence shows that such insertions can occur naturally.
While distinct from the furin cleavage site insertion in SARS-CoV-2, this evidence shows that such insertions can occur naturally.
While distinct from the furin cleavage site insertion in SARS-CoV-2, this evidence shows that such insertions can occur naturally.
While distinct from the furin cleavage site insertion in SARS-CoV-2, this evidence shows that such insertions can occur naturally.
While distinct from the furin cleavage site insertion in SARS-CoV-2, this evidence shows that such insertions can occur naturally.
While distinct from the furin cleavage site insertion in SARS-CoV-2, this evidence shows that such insertions can occur naturally.
While distinct from the furin cleavage site insertion in SARS-CoV-2, this evidence shows that such insertions can occur naturally.
While distinct from the furin cleavage site insertion in SARS-CoV-2, this evidence shows that such insertions can occur naturally.
Additionally, ‚Äö√Ñ√∂‚àö√ë‚àö‚à´[...] SARS-CoV-2 is not derived from any previously used virus backbone,‚Äö√Ñ√∂‚àö√ë‚àöœÄ reducing the likelihood of laboratory origination, and ‚Äö√Ñ√∂‚àö√ë‚àö‚à´[...] genomic evidence does not support the idea that SARS-CoV-2 is a laboratory construct, [though] it is currently impossible to prove or disprove the other theories of its origin.‚Äö√Ñ√∂‚àö√ë‚àöœÄ
Additionally, ‚Äö√Ñ√∂‚àö√ë‚àö‚à´[...] SARS-CoV-2 is not derived from any previously used virus backbone,‚Äö√Ñ√∂‚àö√ë‚àöœÄ reducing the likelihood of laboratory origination, and ‚Äö√Ñ√∂‚àö√ë‚àö‚à´[...] genomic evidence does not support the idea that SARS-CoV-2 is a laboratory construct, [though] it is currently impossible to prove or disprove the other theories of its origin.‚Äö√Ñ√∂‚àö√ë‚àöœÄ
Additionally, ‚Äö√Ñ√∂‚àö√ë‚àö‚à´[...] SARS-CoV-2 is not derived from any previously used virus backbone,‚Äö√Ñ√∂‚àö√ë‚àöœÄ reducing the likelihood of laboratory origination, and ‚Äö√Ñ√∂‚àö√ë‚àö‚à´[...] genomic evidence does not support the idea that SARS-CoV-2 is a laboratory construct, [though] it is currently impossible to prove or disprove the other theories of its origin.‚Äö√Ñ√∂‚àö√ë‚àöœÄ
Additionally, ‚Äö√Ñ√∂‚àö√ë‚àö‚à´[...] SARS-CoV-2 is not derived from any previously used virus backbone,‚Äö√Ñ√∂‚àö√ë‚àöœÄ reducing the likelihood of laboratory origination, and ‚Äö√Ñ√∂‚àö√ë‚àö‚à´[...] genomic evidence does not support the idea that SARS-CoV-2 is a laboratory construct, [though] it is currently impossible to prove or disprove the other theories of its origin.‚Äö√Ñ√∂‚àö√ë‚àöœÄ
Additionally, ‚Äö√Ñ√∂‚àö√ë‚àö‚à´[...] SARS-CoV-2 is not derived from any previously used virus backbone,‚Äö√Ñ√∂‚àö√ë‚àöœÄ reducing the likelihood of laboratory origination, and ‚Äö√Ñ√∂‚àö√ë‚àö‚à´[...] genomic evidence does not support the idea that SARS-CoV-2 is a laboratory construct, [though] it is currently impossible to prove or disprove the other theories of its origin.‚Äö√Ñ√∂‚àö√ë‚àöœÄ
Additionally, ‚Äö√Ñ√∂‚àö√ë‚àö‚à´[...] SARS-CoV-2 is not derived from any previously used virus backbone,‚Äö√Ñ√∂‚àö√ë‚àöœÄ reducing the likelihood of laboratory origination, and ‚Äö√Ñ√∂‚àö√ë‚àö‚à´[...] genomic evidence does not support the idea that SARS-CoV-2 is a laboratory construct, [though] it is currently impossible to prove or disprove the other theories of its origin.‚Äö√Ñ√∂‚àö√ë‚àöœÄ
Additionally, ‚Äö√Ñ√∂‚àö√ë‚àö‚à´[...] SARS-CoV-2 is not derived from any previously used virus backbone,‚Äö√Ñ√∂‚àö√ë‚àöœÄ reducing the likelihood of laboratory origination, and ‚Äö√Ñ√∂‚àö√ë‚àö‚à´[...] genomic evidence does not support the idea that SARS-CoV-2 is a laboratory construct, [though] it is currently impossible to prove or disprove the other theories of its origin.‚Äö√Ñ√∂‚àö√ë‚àöœÄ
Additionally, ‚Äö√Ñ√∂‚àö√ë‚àö‚à´[...] SARS-CoV-2 is not derived from any previously used virus backbone,‚Äö√Ñ√∂‚àö√ë‚àöœÄ reducing the likelihood of laboratory origination, and ‚Äö√Ñ√∂‚àö√ë‚àö‚à´[...] genomic evidence does not support the idea that SARS-CoV-2 is a laboratory construct, [though] it is currently impossible to prove or disprove the other theories of its origin.‚Äö√Ñ√∂‚àö√ë‚àöœÄ
Additionally, ‚Äö√Ñ√∂‚àö√ë‚àö‚à´[...] SARS-CoV-2 is not derived from any previously used virus backbone,‚Äö√Ñ√∂‚àö√ë‚àöœÄ reducing the likelihood of laboratory origination, and ‚Äö√Ñ√∂‚àö√ë‚àö‚à´[...] genomic evidence does not support the idea that SARS-CoV-2 is a laboratory construct, [though] it is currently impossible to prove or disprove the other theories of its origin.‚Äö√Ñ√∂‚àö√ë‚àöœÄ
Additionally, ‚Äö√Ñ√∂‚àö√ë‚àö‚à´[...] SARS-CoV-2 is not derived from any previously used virus backbone,‚Äö√Ñ√∂‚àö√ë‚àöœÄ reducing the likelihood of laboratory origination, and ‚Äö√Ñ√∂‚àö√ë‚àö‚à´[...] genomic evidence does not support the idea that SARS-CoV-2 is a laboratory construct, [though] it is currently impossible to prove or disprove the other theories of its origin.‚Äö√Ñ√∂‚àö√ë‚àöœÄ
Work with other coronaviruses has indicated that heparan sulfate dependence can be an indicator of prior cell passage, due to a mutation in the previous furin enzyme recognition motif.
Work with other coronaviruses has indicated that heparan sulfate dependence can be an indicator of prior cell passage, due to a mutation in the previous furin enzyme recognition motif.
Work with other coronaviruses has indicated that heparan sulfate dependence can be an indicator of prior cell passage, due to a mutation in the previous furin enzyme recognition motif.
Work with other coronaviruses has indicated that heparan sulfate dependence can be an indicator of prior cell passage, due to a mutation in the previous furin enzyme recognition motif.
Work with other coronaviruses has indicated that heparan sulfate dependence can be an indicator of prior cell passage, due to a mutation in the previous furin enzyme recognition motif.
Work with other coronaviruses has indicated that heparan sulfate dependence can be an indicator of prior cell passage, due to a mutation in the previous furin enzyme recognition motif.
Work with other coronaviruses has indicated that heparan sulfate dependence can be an indicator of prior cell passage, due to a mutation in the previous furin enzyme recognition motif.
Work with other coronaviruses has indicated that heparan sulfate dependence can be an indicator of prior cell passage, due to a mutation in the previous furin enzyme recognition motif.
Work with other coronaviruses has indicated that heparan sulfate dependence can be an indicator of prior cell passage, due to a mutation in the previous furin enzyme recognition motif.
Work with other coronaviruses has indicated that heparan sulfate dependence can be an indicator of prior cell passage, due to a mutation in the previous furin enzyme recognition motif.
A report claiming a laboratory origin of SARS-CoV-2 has been heavily disputed by scientists at Johns Hopkins University.
A report claiming a laboratory origin of SARS-CoV-2 has been heavily disputed by scientists at Johns Hopkins University.
A report claiming a laboratory origin of SARS-CoV-2 has been heavily disputed by scientists at Johns Hopkins University.
A report claiming a laboratory origin of SARS-CoV-2 has been heavily disputed by scientists at Johns Hopkins University.
A report claiming a laboratory origin of SARS-CoV-2 has been heavily disputed by scientists at Johns Hopkins University.
A report claiming a laboratory origin of SARS-CoV-2 has been heavily disputed by scientists at Johns Hopkins University.
A report claiming a laboratory origin of SARS-CoV-2 has been heavily disputed by scientists at Johns Hopkins University.
A report claiming a laboratory origin of SARS-CoV-2 has been heavily disputed by scientists at Johns Hopkins University.
A report claiming a laboratory origin of SARS-CoV-2 has been heavily disputed by scientists at Johns Hopkins University.
A report claiming a laboratory origin of SARS-CoV-2 has been heavily disputed by scientists at Johns Hopkins University.
Comparing genomes of multiple coronaviruses using machine-learning has identified key genomic signatures shared among high case fatality rate coronaviruses (SARS-CoV-1, SARS-CoV-2, MERS) and animal counterparts.
Comparing genomes of multiple coronaviruses using machine-learning has identified key genomic signatures shared among high case fatality rate coronaviruses (SARS-CoV-1, SARS-CoV-2, MERS) and animal counterparts.
Comparing genomes of multiple coronaviruses using machine-learning has identified key genomic signatures shared among high case fatality rate coronaviruses (SARS-CoV-1, SARS-CoV-2, MERS) and animal counterparts.
Comparing genomes of multiple coronaviruses using machine-learning has identified key genomic signatures shared among high case fatality rate coronaviruses (SARS-CoV-1, SARS-CoV-2, MERS) and animal counterparts.
Comparing genomes of multiple coronaviruses using machine-learning has identified key genomic signatures shared among high case fatality rate coronaviruses (SARS-CoV-1, SARS-CoV-2, MERS) and animal counterparts.
Comparing genomes of multiple coronaviruses using machine-learning has identified key genomic signatures shared among high case fatality rate coronaviruses (SARS-CoV-1, SARS-CoV-2, MERS) and animal counterparts.
Comparing genomes of multiple coronaviruses using machine-learning has identified key genomic signatures shared among high case fatality rate coronaviruses (SARS-CoV-1, SARS-CoV-2, MERS) and animal counterparts.
Comparing genomes of multiple coronaviruses using machine-learning has identified key genomic signatures shared among high case fatality rate coronaviruses (SARS-CoV-1, SARS-CoV-2, MERS) and animal counterparts.
Comparing genomes of multiple coronaviruses using machine-learning has identified key genomic signatures shared among high case fatality rate coronaviruses (SARS-CoV-1, SARS-CoV-2, MERS) and animal counterparts.
Comparing genomes of multiple coronaviruses using machine-learning has identified key genomic signatures shared among high case fatality rate coronaviruses (SARS-CoV-1, SARS-CoV-2, MERS) and animal counterparts.
These data further suggest that SARS-CoV-2 emergence is the result of natural emergence and that there is a potential for future zoonotic transmission of additional pathogenic strains to humans.
These data further suggest that SARS-CoV-2 emergence is the result of natural emergence and that there is a potential for future zoonotic transmission of additional pathogenic strains to humans.
These data further suggest that SARS-CoV-2 emergence is the result of natural emergence and that there is a potential for future zoonotic transmission of additional pathogenic strains to humans.
These data further suggest that SARS-CoV-2 emergence is the result of natural emergence and that there is a potential for future zoonotic transmission of additional pathogenic strains to humans.
These data further suggest that SARS-CoV-2 emergence is the result of natural emergence and that there is a potential for future zoonotic transmission of additional pathogenic strains to humans.
These data further suggest that SARS-CoV-2 emergence is the result of natural emergence and that there is a potential for future zoonotic transmission of additional pathogenic strains to humans.
These data further suggest that SARS-CoV-2 emergence is the result of natural emergence and that there is a potential for future zoonotic transmission of additional pathogenic strains to humans.
These data further suggest that SARS-CoV-2 emergence is the result of natural emergence and that there is a potential for future zoonotic transmission of additional pathogenic strains to humans.
These data further suggest that SARS-CoV-2 emergence is the result of natural emergence and that there is a potential for future zoonotic transmission of additional pathogenic strains to humans.
These data further suggest that SARS-CoV-2 emergence is the result of natural emergence and that there is a potential for future zoonotic transmission of additional pathogenic strains to humans.
Current evidence suggests that SARS-CoV-2 accumulates mutations at a similar rate as other coronaviruses.
Current evidence suggests that SARS-CoV-2 accumulates mutations at a similar rate as other coronaviruses.
Current evidence suggests that SARS-CoV-2 accumulates mutations at a similar rate as other coronaviruses.
Current evidence suggests that SARS-CoV-2 accumulates mutations at a similar rate as other coronaviruses.
Current evidence suggests that SARS-CoV-2 accumulates mutations at a similar rate as other coronaviruses.
Current evidence suggests that SARS-CoV-2 accumulates mutations at a similar rate as other coronaviruses.
Current evidence suggests that SARS-CoV-2 accumulates mutations at a similar rate as other coronaviruses.
Current evidence suggests that SARS-CoV-2 accumulates mutations at a similar rate as other coronaviruses.
Current evidence suggests that SARS-CoV-2 accumulates mutations at a similar rate as other coronaviruses.
Current evidence suggests that SARS-CoV-2 accumulates mutations at a similar rate as other coronaviruses.
The estimated mutation rate for SARS-CoV-2 is 6x10-4 nucleotides per genome per year.
The estimated mutation rate for SARS-CoV-2 is 6x10-4 nucleotides per genome per year.
The estimated mutation rate for SARS-CoV-2 is 6x10-4 nucleotides per genome per year.
The estimated mutation rate for SARS-CoV-2 is 6x10-4 nucleotides per genome per year.
The estimated mutation rate for SARS-CoV-2 is 6x10-4 nucleotides per genome per year.
The estimated mutation rate for SARS-CoV-2 is 6x10-4 nucleotides per genome per year.
The estimated mutation rate for SARS-CoV-2 is 6x10-4 nucleotides per genome per year.
The estimated mutation rate for SARS-CoV-2 is 6x10-4 nucleotides per genome per year.
The estimated mutation rate for SARS-CoV-2 is 6x10-4 nucleotides per genome per year.
The estimated mutation rate for SARS-CoV-2 is 6x10-4 nucleotides per genome per year.
SARS-CoV-2 is acquiring nucleotide changes at a rate that suggests the virus is undergoing purifying selection (that the genome is stabilizing toward a common genome).
SARS-CoV-2 is acquiring nucleotide changes at a rate that suggests the virus is undergoing purifying selection (that the genome is stabilizing toward a common genome).
SARS-CoV-2 is acquiring nucleotide changes at a rate that suggests the virus is undergoing purifying selection (that the genome is stabilizing toward a common genome).
SARS-CoV-2 is acquiring nucleotide changes at a rate that suggests the virus is undergoing purifying selection (that the genome is stabilizing toward a common genome).
SARS-CoV-2 is acquiring nucleotide changes at a rate that suggests the virus is undergoing purifying selection (that the genome is stabilizing toward a common genome).
SARS-CoV-2 is acquiring nucleotide changes at a rate that suggests the virus is undergoing purifying selection (that the genome is stabilizing toward a common genome).
SARS-CoV-2 is acquiring nucleotide changes at a rate that suggests the virus is undergoing purifying selection (that the genome is stabilizing toward a common genome).
SARS-CoV-2 is acquiring nucleotide changes at a rate that suggests the virus is undergoing purifying selection (that the genome is stabilizing toward a common genome).
SARS-CoV-2 is acquiring nucleotide changes at a rate that suggests the virus is undergoing purifying selection (that the genome is stabilizing toward a common genome).
SARS-CoV-2 is acquiring nucleotide changes at a rate that suggests the virus is undergoing purifying selection (that the genome is stabilizing toward a common genome).
The variants were not rare overall, suggesting use as a screening tool, though a single variant alone is not necessarily responsible for virulence.
The variants were not rare overall, suggesting use as a screening tool, though a single variant alone is not necessarily responsible for virulence.
The variants were not rare overall, suggesting use as a screening tool, though a single variant alone is not necessarily responsible for virulence.
The variants were not rare overall, suggesting use as a screening tool, though a single variant alone is not necessarily responsible for virulence.
The variants were not rare overall, suggesting use as a screening tool, though a single variant alone is not necessarily responsible for virulence.
The variants were not rare overall, suggesting use as a screening tool, though a single variant alone is not necessarily responsible for virulence.
The variants were not rare overall, suggesting use as a screening tool, though a single variant alone is not necessarily responsible for virulence.
The variants were not rare overall, suggesting use as a screening tool, though a single variant alone is not necessarily responsible for virulence.
The variants were not rare overall, suggesting use as a screening tool, though a single variant alone is not necessarily responsible for virulence.
The variants were not rare overall, suggesting use as a screening tool, though a single variant alone is not necessarily responsible for virulence.
Variants leading to the most severe illness were located in the C-terminal end of the Spike protein.
Variants leading to the most severe illness were located in the C-terminal end of the Spike protein.
Variants leading to the most severe illness were located in the C-terminal end of the Spike protein.
Variants leading to the most severe illness were located in the C-terminal end of the Spike protein.
Variants leading to the most severe illness were located in the C-terminal end of the Spike protein.
Variants leading to the most severe illness were located in the C-terminal end of the Spike protein.
Variants leading to the most severe illness were located in the C-terminal end of the Spike protein.
Variants leading to the most severe illness were located in the C-terminal end of the Spike protein.
Variants leading to the most severe illness were located in the C-terminal end of the Spike protein.
Variants leading to the most severe illness were located in the C-terminal end of the Spike protein.
Several viral variants, representing unique collections of mutations, are being investigated for their effects on transmission and/or virulence.
Several viral variants, representing unique collections of mutations, are being investigated for their effects on transmission and/or virulence.
Several viral variants, representing unique collections of mutations, are being investigated for their effects on transmission and/or virulence.
Several viral variants, representing unique collections of mutations, are being investigated for their effects on transmission and/or virulence.
Several viral variants, representing unique collections of mutations, are being investigated for their effects on transmission and/or virulence.
Several viral variants, representing unique collections of mutations, are being investigated for their effects on transmission and/or virulence.
Several viral variants, representing unique collections of mutations, are being investigated for their effects on transmission and/or virulence.
Several viral variants, representing unique collections of mutations, are being investigated for their effects on transmission and/or virulence.
Several viral variants, representing unique collections of mutations, are being investigated for their effects on transmission and/or virulence.
Several viral variants, representing unique collections of mutations, are being investigated for their effects on transmission and/or virulence.
Phylogenetic and clinical analysis suggests the D614G mutation in the Spike protein is associated with higher rates of SARS-CoV-2 transmission, but no change in clinical severity in infected patients.
Phylogenetic and clinical analysis suggests the D614G mutation in the Spike protein is associated with higher rates of SARS-CoV-2 transmission, but no change in clinical severity in infected patients.
Phylogenetic and clinical analysis suggests the D614G mutation in the Spike protein is associated with higher rates of SARS-CoV-2 transmission, but no change in clinical severity in infected patients.
Phylogenetic and clinical analysis suggests the D614G mutation in the Spike protein is associated with higher rates of SARS-CoV-2 transmission, but no change in clinical severity in infected patients.
Phylogenetic and clinical analysis suggests the D614G mutation in the Spike protein is associated with higher rates of SARS-CoV-2 transmission, but no change in clinical severity in infected patients.
Phylogenetic and clinical analysis suggests the D614G mutation in the Spike protein is associated with higher rates of SARS-CoV-2 transmission, but no change in clinical severity in infected patients.
Phylogenetic and clinical analysis suggests the D614G mutation in the Spike protein is associated with higher rates of SARS-CoV-2 transmission, but no change in clinical severity in infected patients.
Phylogenetic and clinical analysis suggests the D614G mutation in the Spike protein is associated with higher rates of SARS-CoV-2 transmission, but no change in clinical severity in infected patients.
Phylogenetic and clinical analysis suggests the D614G mutation in the Spike protein is associated with higher rates of SARS-CoV-2 transmission, but no change in clinical severity in infected patients.
Phylogenetic and clinical analysis suggests the D614G mutation in the Spike protein is associated with higher rates of SARS-CoV-2 transmission, but no change in clinical severity in infected patients.
An ongoing study of SARS-CoV-2 sequences reveals the continued spread and increased presence of sequences with the D614G mutation, though it is possible that founder effects contributed to its prevalence.
An ongoing study of SARS-CoV-2 sequences reveals the continued spread and increased presence of sequences with the D614G mutation, though it is possible that founder effects contributed to its prevalence.
An ongoing study of SARS-CoV-2 sequences reveals the continued spread and increased presence of sequences with the D614G mutation, though it is possible that founder effects contributed to its prevalence.
An ongoing study of SARS-CoV-2 sequences reveals the continued spread and increased presence of sequences with the D614G mutation, though it is possible that founder effects contributed to its prevalence.
An ongoing study of SARS-CoV-2 sequences reveals the continued spread and increased presence of sequences with the D614G mutation, though it is possible that founder effects contributed to its prevalence.
An ongoing study of SARS-CoV-2 sequences reveals the continued spread and increased presence of sequences with the D614G mutation, though it is possible that founder effects contributed to its prevalence.
An ongoing study of SARS-CoV-2 sequences reveals the continued spread and increased presence of sequences with the D614G mutation, though it is possible that founder effects contributed to its prevalence.
An ongoing study of SARS-CoV-2 sequences reveals the continued spread and increased presence of sequences with the D614G mutation, though it is possible that founder effects contributed to its prevalence.
An ongoing study of SARS-CoV-2 sequences reveals the continued spread and increased presence of sequences with the D614G mutation, though it is possible that founder effects contributed to its prevalence.
An ongoing study of SARS-CoV-2 sequences reveals the continued spread and increased presence of sequences with the D614G mutation, though it is possible that founder effects contributed to its prevalence.
Limited animal model results support the possibility of increased transmissibility, and the mutation slightly increased viral replication in human cell lines.
Limited animal model results support the possibility of increased transmissibility, and the mutation slightly increased viral replication in human cell lines.
Limited animal model results support the possibility of increased transmissibility, and the mutation slightly increased viral replication in human cell lines.
Limited animal model results support the possibility of increased transmissibility, and the mutation slightly increased viral replication in human cell lines.
Limited animal model results support the possibility of increased transmissibility, and the mutation slightly increased viral replication in human cell lines.
Limited animal model results support the possibility of increased transmissibility, and the mutation slightly increased viral replication in human cell lines.
Limited animal model results support the possibility of increased transmissibility, and the mutation slightly increased viral replication in human cell lines.
Limited animal model results support the possibility of increased transmissibility, and the mutation slightly increased viral replication in human cell lines.
Limited animal model results support the possibility of increased transmissibility, and the mutation slightly increased viral replication in human cell lines.
Limited animal model results support the possibility of increased transmissibility, and the mutation slightly increased viral replication in human cell lines.
Broad phylogenetic analysis, however, suggests that no current, recurring SARS-CoV-2 mutations (including D614G) are associated with higher rates of transmission in human populations.
Broad phylogenetic analysis, however, suggests that no current, recurring SARS-CoV-2 mutations (including D614G) are associated with higher rates of transmission in human populations.
Broad phylogenetic analysis, however, suggests that no current, recurring SARS-CoV-2 mutations (including D614G) are associated with higher rates of transmission in human populations.
Broad phylogenetic analysis, however, suggests that no current, recurring SARS-CoV-2 mutations (including D614G) are associated with higher rates of transmission in human populations.
Broad phylogenetic analysis, however, suggests that no current, recurring SARS-CoV-2 mutations (including D614G) are associated with higher rates of transmission in human populations.
Broad phylogenetic analysis, however, suggests that no current, recurring SARS-CoV-2 mutations (including D614G) are associated with higher rates of transmission in human populations.
Broad phylogenetic analysis, however, suggests that no current, recurring SARS-CoV-2 mutations (including D614G) are associated with higher rates of transmission in human populations.
Broad phylogenetic analysis, however, suggests that no current, recurring SARS-CoV-2 mutations (including D614G) are associated with higher rates of transmission in human populations.
Broad phylogenetic analysis, however, suggests that no current, recurring SARS-CoV-2 mutations (including D614G) are associated with higher rates of transmission in human populations.
Broad phylogenetic analysis, however, suggests that no current, recurring SARS-CoV-2 mutations (including D614G) are associated with higher rates of transmission in human populations.
The D614G mutation appears to make the virus more susceptible to neutralization by monoclonal antibodies or by convalescent plasma.
The D614G mutation appears to make the virus more susceptible to neutralization by monoclonal antibodies or by convalescent plasma.
The D614G mutation appears to make the virus more susceptible to neutralization by monoclonal antibodies or by convalescent plasma.
The D614G mutation appears to make the virus more susceptible to neutralization by monoclonal antibodies or by convalescent plasma.
The D614G mutation appears to make the virus more susceptible to neutralization by monoclonal antibodies or by convalescent plasma.
The D614G mutation appears to make the virus more susceptible to neutralization by monoclonal antibodies or by convalescent plasma.
The D614G mutation appears to make the virus more susceptible to neutralization by monoclonal antibodies or by convalescent plasma.
The D614G mutation appears to make the virus more susceptible to neutralization by monoclonal antibodies or by convalescent plasma.
The D614G mutation appears to make the virus more susceptible to neutralization by monoclonal antibodies or by convalescent plasma.
The D614G mutation appears to make the virus more susceptible to neutralization by monoclonal antibodies or by convalescent plasma.
Antibodies induced by the D614G mutation or wild-type virus are able to neutralize each other.
Antibodies induced by the D614G mutation or wild-type virus are able to neutralize each other.
Antibodies induced by the D614G mutation or wild-type virus are able to neutralize each other.
Antibodies induced by the D614G mutation or wild-type virus are able to neutralize each other.
Antibodies induced by the D614G mutation or wild-type virus are able to neutralize each other.
Antibodies induced by the D614G mutation or wild-type virus are able to neutralize each other.
Antibodies induced by the D614G mutation or wild-type virus are able to neutralize each other.
Antibodies induced by the D614G mutation or wild-type virus are able to neutralize each other.
Antibodies induced by the D614G mutation or wild-type virus are able to neutralize each other.
Antibodies induced by the D614G mutation or wild-type virus are able to neutralize each other.
A separate Spike protein receptor binding motif variant (called N493K) results in similar clinical disease; importantly, it shows evidence of immune escape from polyclonal sera and neutralizing antibodies.
A separate Spike protein receptor binding motif variant (called N493K) results in similar clinical disease; importantly, it shows evidence of immune escape from polyclonal sera and neutralizing antibodies.
A separate Spike protein receptor binding motif variant (called N493K) results in similar clinical disease; importantly, it shows evidence of immune escape from polyclonal sera and neutralizing antibodies.
A separate Spike protein receptor binding motif variant (called N493K) results in similar clinical disease; importantly, it shows evidence of immune escape from polyclonal sera and neutralizing antibodies.
A separate Spike protein receptor binding motif variant (called N493K) results in similar clinical disease; importantly, it shows evidence of immune escape from polyclonal sera and neutralizing antibodies.
A separate Spike protein receptor binding motif variant (called N493K) results in similar clinical disease; importantly, it shows evidence of immune escape from polyclonal sera and neutralizing antibodies.
A separate Spike protein receptor binding motif variant (called N493K) results in similar clinical disease; importantly, it shows evidence of immune escape from polyclonal sera and neutralizing antibodies.
A separate Spike protein receptor binding motif variant (called N493K) results in similar clinical disease; importantly, it shows evidence of immune escape from polyclonal sera and neutralizing antibodies.
A separate Spike protein receptor binding motif variant (called N493K) results in similar clinical disease; importantly, it shows evidence of immune escape from polyclonal sera and neutralizing antibodies.
A separate Spike protein receptor binding motif variant (called N493K) results in similar clinical disease; importantly, it shows evidence of immune escape from polyclonal sera and neutralizing antibodies.
This may affect the ability of vaccines and therapeutics that target this region.
This may affect the ability of vaccines and therapeutics that target this region.
This may affect the ability of vaccines and therapeutics that target this region.
This may affect the ability of vaccines and therapeutics that target this region.
This may affect the ability of vaccines and therapeutics that target this region.
This may affect the ability of vaccines and therapeutics that target this region.
This may affect the ability of vaccines and therapeutics that target this region.
This may affect the ability of vaccines and therapeutics that target this region.
This may affect the ability of vaccines and therapeutics that target this region.
This may affect the ability of vaccines and therapeutics that target this region.
As of October 2020, this is the second most common receptor binding domain variant worldwide, and has been found in 12 countries.
As of October 2020, this is the second most common receptor binding domain variant worldwide, and has been found in 12 countries.
As of October 2020, this is the second most common receptor binding domain variant worldwide, and has been found in 12 countries.
As of October 2020, this is the second most common receptor binding domain variant worldwide, and has been found in 12 countries.
As of October 2020, this is the second most common receptor binding domain variant worldwide, and has been found in 12 countries.
As of October 2020, this is the second most common receptor binding domain variant worldwide, and has been found in 12 countries.
As of October 2020, this is the second most common receptor binding domain variant worldwide, and has been found in 12 countries.
As of October 2020, this is the second most common receptor binding domain variant worldwide, and has been found in 12 countries.
As of October 2020, this is the second most common receptor binding domain variant worldwide, and has been found in 12 countries.
As of October 2020, this is the second most common receptor binding domain variant worldwide, and has been found in 12 countries.
An existing variant (VUI 202012/01) that is increasing in prevalence in some areas of the UK has been associated with higher transmission rates, though confirmation in human or animal studies is needed.
An existing variant (VUI 202012/01) that is increasing in prevalence in some areas of the UK has been associated with higher transmission rates, though confirmation in human or animal studies is needed.
An existing variant (VUI 202012/01) that is increasing in prevalence in some areas of the UK has been associated with higher transmission rates, though confirmation in human or animal studies is needed.
An existing variant (VUI 202012/01) that is increasing in prevalence in some areas of the UK has been associated with higher transmission rates, though confirmation in human or animal studies is needed.
An existing variant (VUI 202012/01) that is increasing in prevalence in some areas of the UK has been associated with higher transmission rates, though confirmation in human or animal studies is needed.
An existing variant (VUI 202012/01) that is increasing in prevalence in some areas of the UK has been associated with higher transmission rates, though confirmation in human or animal studies is needed.
An existing variant (VUI 202012/01) that is increasing in prevalence in some areas of the UK has been associated with higher transmission rates, though confirmation in human or animal studies is needed.
An existing variant (VUI 202012/01) that is increasing in prevalence in some areas of the UK has been associated with higher transmission rates, though confirmation in human or animal studies is needed.
An existing variant (VUI 202012/01) that is increasing in prevalence in some areas of the UK has been associated with higher transmission rates, though confirmation in human or animal studies is needed.
An existing variant (VUI 202012/01) that is increasing in prevalence in some areas of the UK has been associated with higher transmission rates, though confirmation in human or animal studies is needed.
There have been no links between this variant (VUI 202012/01) and enhanced virulence.
There have been no links between this variant (VUI 202012/01) and enhanced virulence.
There have been no links between this variant (VUI 202012/01) and enhanced virulence.
There have been no links between this variant (VUI 202012/01) and enhanced virulence.
There have been no links between this variant (VUI 202012/01) and enhanced virulence.
There have been no links between this variant (VUI 202012/01) and enhanced virulence.
There have been no links between this variant (VUI 202012/01) and enhanced virulence.
There have been no links between this variant (VUI 202012/01) and enhanced virulence.
There have been no links between this variant (VUI 202012/01) and enhanced virulence.
The variant (VUI 202012/01) consists of several mutations linked to the viral Spike protein and receptor-binding domain.
The variant (VUI 202012/01) consists of several mutations linked to the viral Spike protein and receptor-binding domain.
The variant (VUI 202012/01) consists of several mutations linked to the viral Spike protein and receptor-binding domain.
The variant (VUI 202012/01) consists of several mutations linked to the viral Spike protein and receptor-binding domain.
The variant (VUI 202012/01) consists of several mutations linked to the viral Spike protein and receptor-binding domain.
The variant (VUI 202012/01) consists of several mutations linked to the viral Spike protein and receptor-binding domain.
The variant (VUI 202012/01) consists of several mutations linked to the viral Spike protein and receptor-binding domain.
The variant (VUI 202012/01) consists of several mutations linked to the viral Spike protein and receptor-binding domain.
The variant (VUI 202012/01) consists of several mutations linked to the viral Spike protein and receptor-binding domain.
The variant (VUI 202012/01) consists of several mutations linked to the viral Spike protein and receptor-binding domain.
Several human genomic regions, including those determining blood type, affect COVID-19 prevalence and/or severity.
Several human genomic regions, including those determining blood type, affect COVID-19 prevalence and/or severity.
Several human genomic regions, including those determining blood type, affect COVID-19 prevalence and/or severity.
Several human genomic regions, including those determining blood type, affect COVID-19 prevalence and/or severity.
Several human genomic regions, including those determining blood type, affect COVID-19 prevalence and/or severity.
Several human genomic regions, including those determining blood type, affect COVID-19 prevalence and/or severity.
Several human genomic regions, including those determining blood type, affect COVID-19 prevalence and/or severity.
Several human genomic regions, including those determining blood type, affect COVID-19 prevalence and/or severity.
Several human genomic regions, including those determining blood type, affect COVID-19 prevalence and/or severity.
Several human genomic regions, including those determining blood type, affect COVID-19 prevalence and/or severity.
Blood type may affect COVID-19, with evidence of slightly increased prevalence and moderately increased severity in those with type A blood (though evidence is mixed).
Blood type may affect COVID-19, with evidence of slightly increased prevalence and moderately increased severity in those with type A blood (though evidence is mixed).
Blood type may affect COVID-19, with evidence of slightly increased prevalence and moderately increased severity in those with type A blood (though evidence is mixed).
Blood type may affect COVID-19, with evidence of slightly increased prevalence and moderately increased severity in those with type A blood (though evidence is mixed).
Blood type may affect COVID-19, with evidence of slightly increased prevalence and moderately increased severity in those with type A blood (though evidence is mixed).
Blood type may affect COVID-19, with evidence of slightly increased prevalence and moderately increased severity in those with type A blood (though evidence is mixed).
Blood type may affect COVID-19, with evidence of slightly increased prevalence and moderately increased severity in those with type A blood (though evidence is mixed).
Blood type may affect COVID-19, with evidence of slightly increased prevalence and moderately increased severity in those with type A blood (though evidence is mixed).
Blood type may affect COVID-19, with evidence of slightly increased prevalence and moderately increased severity in those with type A blood (though evidence is mixed).
Blood type may affect COVID-19, with evidence of slightly increased prevalence and moderately increased severity in those with type A blood (though evidence is mixed).
A large study (n=225,556) found that individuals with type O blood had less severe disease and lower risk of death from COVID-19 than individuals with other blood types, and that Rh-negative status showed lower COVID-19 prevalence.
A large study (n=225,556) found that individuals with type O blood had less severe disease and lower risk of death from COVID-19 than individuals with other blood types, and that Rh-negative status showed lower COVID-19 prevalence.
A large study (n=225,556) found that individuals with type O blood had less severe disease and lower risk of death from COVID-19 than individuals with other blood types, and that Rh-negative status showed lower COVID-19 prevalence.
A large study (n=225,556) found that individuals with type O blood had less severe disease and lower risk of death from COVID-19 than individuals with other blood types, and that Rh-negative status showed lower COVID-19 prevalence.
A large study (n=225,556) found that individuals with type O blood had less severe disease and lower risk of death from COVID-19 than individuals with other blood types, and that Rh-negative status showed lower COVID-19 prevalence.
A large study (n=225,556) found that individuals with type O blood had less severe disease and lower risk of death from COVID-19 than individuals with other blood types, and that Rh-negative status showed lower COVID-19 prevalence.
A large study (n=225,556) found that individuals with type O blood had less severe disease and lower risk of death from COVID-19 than individuals with other blood types, and that Rh-negative status showed lower COVID-19 prevalence.
A large study (n=225,556) found that individuals with type O blood had less severe disease and lower risk of death from COVID-19 than individuals with other blood types, and that Rh-negative status showed lower COVID-19 prevalence.
A large study (n=225,556) found that individuals with type O blood had less severe disease and lower risk of death from COVID-19 than individuals with other blood types, and that Rh-negative status showed lower COVID-19 prevalence.
A large study (n=225,556) found that individuals with type O blood had less severe disease and lower risk of death from COVID-19 than individuals with other blood types, and that Rh-negative status showed lower COVID-19 prevalence.
Individuals with defective androgen signaling (long polyQ allelic repeats in the androgen receptor gene) were more likely to have severe COVID-19, possibly due to increased inflammatory responses; this may influence treatment decisions.
Individuals with defective androgen signaling (long polyQ allelic repeats in the androgen receptor gene) were more likely to have severe COVID-19, possibly due to increased inflammatory responses; this may influence treatment decisions.
Individuals with defective androgen signaling (long polyQ allelic repeats in the androgen receptor gene) were more likely to have severe COVID-19, possibly due to increased inflammatory responses; this may influence treatment decisions.
Individuals with defective androgen signaling (long polyQ allelic repeats in the androgen receptor gene) were more likely to have severe COVID-19, possibly due to increased inflammatory responses; this may influence treatment decisions.
Individuals with defective androgen signaling (long polyQ allelic repeats in the androgen receptor gene) were more likely to have severe COVID-19, possibly due to increased inflammatory responses; this may influence treatment decisions.
Individuals with defective androgen signaling (long polyQ allelic repeats in the androgen receptor gene) were more likely to have severe COVID-19, possibly due to increased inflammatory responses; this may influence treatment decisions.
Individuals with defective androgen signaling (long polyQ allelic repeats in the androgen receptor gene) were more likely to have severe COVID-19, possibly due to increased inflammatory responses; this may influence treatment decisions.
Individuals with defective androgen signaling (long polyQ allelic repeats in the androgen receptor gene) were more likely to have severe COVID-19, possibly due to increased inflammatory responses; this may influence treatment decisions.
Individuals with defective androgen signaling (long polyQ allelic repeats in the androgen receptor gene) were more likely to have severe COVID-19, possibly due to increased inflammatory responses; this may influence treatment decisions.
Individuals with defective androgen signaling (long polyQ allelic repeats in the androgen receptor gene) were more likely to have severe COVID-19, possibly due to increased inflammatory responses; this may influence treatment decisions.
In a study of 2,244 critically ill COVID-19 patients, researchers identified novel associations between several genes involved in innate antiviral defenses (IFNAR2 and OAS) and host-driven inflammatory lung injury (DPP9, TYK2, and CCR2).
In a study of 2,244 critically ill COVID-19 patients, researchers identified novel associations between several genes involved in innate antiviral defenses (IFNAR2 and OAS) and host-driven inflammatory lung injury (DPP9, TYK2, and CCR2).
In a study of 2,244 critically ill COVID-19 patients, researchers identified novel associations between several genes involved in innate antiviral defenses (IFNAR2 and OAS) and host-driven inflammatory lung injury (DPP9, TYK2, and CCR2).
In a study of 2,244 critically ill COVID-19 patients, researchers identified novel associations between several genes involved in innate antiviral defenses (IFNAR2 and OAS) and host-driven inflammatory lung injury (DPP9, TYK2, and CCR2).
In a study of 2,244 critically ill COVID-19 patients, researchers identified novel associations between several genes involved in innate antiviral defenses (IFNAR2 and OAS) and host-driven inflammatory lung injury (DPP9, TYK2, and CCR2).
In a study of 2,244 critically ill COVID-19 patients, researchers identified novel associations between several genes involved in innate antiviral defenses (IFNAR2 and OAS) and host-driven inflammatory lung injury (DPP9, TYK2, and CCR2).
In a study of 2,244 critically ill COVID-19 patients, researchers identified novel associations between several genes involved in innate antiviral defenses (IFNAR2 and OAS) and host-driven inflammatory lung injury (DPP9, TYK2, and CCR2).
In a study of 2,244 critically ill COVID-19 patients, researchers identified novel associations between several genes involved in innate antiviral defenses (IFNAR2 and OAS) and host-driven inflammatory lung injury (DPP9, TYK2, and CCR2).
In a study of 2,244 critically ill COVID-19 patients, researchers identified novel associations between several genes involved in innate antiviral defenses (IFNAR2 and OAS) and host-driven inflammatory lung injury (DPP9, TYK2, and CCR2).
In a study of 2,244 critically ill COVID-19 patients, researchers identified novel associations between several genes involved in innate antiviral defenses (IFNAR2 and OAS) and host-driven inflammatory lung injury (DPP9, TYK2, and CCR2).
Understanding the involvement of these genes could lead to targeted therapeutics; for instance, the development of baricitinab (or other Janus kinase inhibitors) to reduce inflammation caused by TYK2.
Understanding the involvement of these genes could lead to targeted therapeutics; for instance, the development of baricitinab (or other Janus kinase inhibitors) to reduce inflammation caused by TYK2.
Understanding the involvement of these genes could lead to targeted therapeutics; for instance, the development of baricitinab (or other Janus kinase inhibitors) to reduce inflammation caused by TYK2.
Understanding the involvement of these genes could lead to targeted therapeutics; for instance, the development of baricitinab (or other Janus kinase inhibitors) to reduce inflammation caused by TYK2.
Understanding the involvement of these genes could lead to targeted therapeutics; for instance, the development of baricitinab (or other Janus kinase inhibitors) to reduce inflammation caused by TYK2.
Understanding the involvement of these genes could lead to targeted therapeutics; for instance, the development of baricitinab (or other Janus kinase inhibitors) to reduce inflammation caused by TYK2.
Understanding the involvement of these genes could lead to targeted therapeutics; for instance, the development of baricitinab (or other Janus kinase inhibitors) to reduce inflammation caused by TYK2.
Understanding the involvement of these genes could lead to targeted therapeutics; for instance, the development of baricitinab (or other Janus kinase inhibitors) to reduce inflammation caused by TYK2.
Understanding the involvement of these genes could lead to targeted therapeutics; for instance, the development of baricitinab (or other Janus kinase inhibitors) to reduce inflammation caused by TYK2.
Understanding the involvement of these genes could lead to targeted therapeutics; for instance, the development of baricitinab (or other Janus kinase inhibitors) to reduce inflammation caused by TYK2.
There is some concern regarding SARS-CoV-2 strains involved in continued human and mink transmission.
There is some concern regarding SARS-CoV-2 strains involved in continued human and mink transmission.
There is some concern regarding SARS-CoV-2 strains involved in continued human and mink transmission.
There is some concern regarding SARS-CoV-2 strains involved in continued human and mink transmission.
There is some concern regarding SARS-CoV-2 strains involved in continued human and mink transmission.
There is some concern regarding SARS-CoV-2 strains involved in continued human and mink transmission.
There is some concern regarding SARS-CoV-2 strains involved in continued human and mink transmission.
There is some concern regarding SARS-CoV-2 strains involved in continued human and mink transmission.
There is some concern regarding SARS-CoV-2 strains involved in continued human and mink transmission.
There is some concern regarding SARS-CoV-2 strains involved in continued human and mink transmission.
Repeated outbreaks of COVID-19 on mink farms, and the detection of mink-adapted SARS-CoV-2 in humans, has led to the mass culling of all mink in Denmark.
Repeated outbreaks of COVID-19 on mink farms, and the detection of mink-adapted SARS-CoV-2 in humans, has led to the mass culling of all mink in Denmark.
Repeated outbreaks of COVID-19 on mink farms, and the detection of mink-adapted SARS-CoV-2 in humans, has led to the mass culling of all mink in Denmark.
Repeated outbreaks of COVID-19 on mink farms, and the detection of mink-adapted SARS-CoV-2 in humans, has led to the mass culling of all mink in Denmark.
Repeated outbreaks of COVID-19 on mink farms, and the detection of mink-adapted SARS-CoV-2 in humans, has led to the mass culling of all mink in Denmark.
Repeated outbreaks of COVID-19 on mink farms, and the detection of mink-adapted SARS-CoV-2 in humans, has led to the mass culling of all mink in Denmark.
Repeated outbreaks of COVID-19 on mink farms, and the detection of mink-adapted SARS-CoV-2 in humans, has led to the mass culling of all mink in Denmark.
Repeated outbreaks of COVID-19 on mink farms, and the detection of mink-adapted SARS-CoV-2 in humans, has led to the mass culling of all mink in Denmark.
Repeated outbreaks of COVID-19 on mink farms, and the detection of mink-adapted SARS-CoV-2 in humans, has led to the mass culling of all mink in Denmark.
Repeated outbreaks of COVID-19 on mink farms, and the detection of mink-adapted SARS-CoV-2 in humans, has led to the mass culling of all mink in Denmark.
The State Serum Institute has noted mutations in the Spike protein that differed from commonly circulating strains and initially showed a decreased susceptibility to neutralizing antibodies.
The State Serum Institute has noted mutations in the Spike protein that differed from commonly circulating strains and initially showed a decreased susceptibility to neutralizing antibodies.
The State Serum Institute has noted mutations in the Spike protein that differed from commonly circulating strains and initially showed a decreased susceptibility to neutralizing antibodies.
The State Serum Institute has noted mutations in the Spike protein that differed from commonly circulating strains and initially showed a decreased susceptibility to neutralizing antibodies.
The State Serum Institute has noted mutations in the Spike protein that differed from commonly circulating strains and initially showed a decreased susceptibility to neutralizing antibodies.
The State Serum Institute has noted mutations in the Spike protein that differed from commonly circulating strains and initially showed a decreased susceptibility to neutralizing antibodies.
The State Serum Institute has noted mutations in the Spike protein that differed from commonly circulating strains and initially showed a decreased susceptibility to neutralizing antibodies.
The State Serum Institute has noted mutations in the Spike protein that differed from commonly circulating strains and initially showed a decreased susceptibility to neutralizing antibodies.
The State Serum Institute has noted mutations in the Spike protein that differed from commonly circulating strains and initially showed a decreased susceptibility to neutralizing antibodies.
The State Serum Institute has noted mutations in the Spike protein that differed from commonly circulating strains and initially showed a decreased susceptibility to neutralizing antibodies.
The main SARS-CoV-2 variant associated with mink outbreaks in the Netherlands involves the Y453F mutation, which has also been identified in humans outside of Europe; this suggests the strain originated in humans.
The main SARS-CoV-2 variant associated with mink outbreaks in the Netherlands involves the Y453F mutation, which has also been identified in humans outside of Europe; this suggests the strain originated in humans.
The main SARS-CoV-2 variant associated with mink outbreaks in the Netherlands involves the Y453F mutation, which has also been identified in humans outside of Europe; this suggests the strain originated in humans.
The main SARS-CoV-2 variant associated with mink outbreaks in the Netherlands involves the Y453F mutation, which has also been identified in humans outside of Europe; this suggests the strain originated in humans.
The main SARS-CoV-2 variant associated with mink outbreaks in the Netherlands involves the Y453F mutation, which has also been identified in humans outside of Europe; this suggests the strain originated in humans.
The main SARS-CoV-2 variant associated with mink outbreaks in the Netherlands involves the Y453F mutation, which has also been identified in humans outside of Europe; this suggests the strain originated in humans.
The main SARS-CoV-2 variant associated with mink outbreaks in the Netherlands involves the Y453F mutation, which has also been identified in humans outside of Europe; this suggests the strain originated in humans.
The main SARS-CoV-2 variant associated with mink outbreaks in the Netherlands involves the Y453F mutation, which has also been identified in humans outside of Europe; this suggests the strain originated in humans.
The main SARS-CoV-2 variant associated with mink outbreaks in the Netherlands involves the Y453F mutation, which has also been identified in humans outside of Europe; this suggests the strain originated in humans.
The main SARS-CoV-2 variant associated with mink outbreaks in the Netherlands involves the Y453F mutation, which has also been identified in humans outside of Europe; this suggests the strain originated in humans.
Several platforms provide digital dashboards summarizing the current status of the pandemic in US states and counties.
Several platforms provide digital dashboards summarizing the current status of the pandemic in US states and counties.
Several platforms provide digital dashboards summarizing the current status of the pandemic in US states and counties.
Several platforms provide digital dashboards summarizing the current status of the pandemic in US states and counties.
Several platforms provide digital dashboards summarizing the current status of the pandemic in US states and counties.
Several platforms provide digital dashboards summarizing the current status of the pandemic in US states and counties.
Several platforms provide digital dashboards summarizing the current status of the pandemic in US states and counties.
Several platforms provide digital dashboards summarizing the current status of the pandemic in US states and counties.
Several platforms provide digital dashboards summarizing the current status of the pandemic in US states and counties.
Several platforms provide digital dashboards summarizing the current status of the pandemic in US states and counties.
Hospital IQ has a dashboard that forecasts hospital and ICU admissions for each county in the US.
Hospital IQ has a dashboard that forecasts hospital and ICU admissions for each county in the US.
Hospital IQ has a dashboard that forecasts hospital and ICU admissions for each county in the US.
Hospital IQ has a dashboard that forecasts hospital and ICU admissions for each county in the US.
Hospital IQ has a dashboard that forecasts hospital and ICU admissions for each county in the US.
Hospital IQ has a dashboard that forecasts hospital and ICU admissions for each county in the US.
Hospital IQ has a dashboard that forecasts hospital and ICU admissions for each county in the US.
Hospital IQ has a dashboard that forecasts hospital and ICU admissions for each county in the US.
Hospital IQ has a dashboard that forecasts hospital and ICU admissions for each county in the US.
Hospital IQ has a dashboard that forecasts hospital and ICU admissions for each county in the US.
COVID Act Now State and county-level dashboard focused on re-opening strategies, showing trends in four metrics related to COVID-19 risk (change in cases, total testing capacity, fraction of positive tests, and availability of ICU beds).
COVID Act Now State and county-level dashboard focused on re-opening strategies, showing trends in four metrics related to COVID-19 risk (change in cases, total testing capacity, fraction of positive tests, and availability of ICU beds).
COVID Act Now State and county-level dashboard focused on re-opening strategies, showing trends in four metrics related to COVID-19 risk (change in cases, total testing capacity, fraction of positive tests, and availability of ICU beds).
COVID Act Now State and county-level dashboard focused on re-opening strategies, showing trends in four metrics related to COVID-19 risk (change in cases, total testing capacity, fraction of positive tests, and availability of ICU beds).
COVID Act Now State and county-level dashboard focused on re-opening strategies, showing trends in four metrics related to COVID-19 risk (change in cases, total testing capacity, fraction of positive tests, and availability of ICU beds).
COVID Act Now State and county-level dashboard focused on re-opening strategies, showing trends in four metrics related to COVID-19 risk (change in cases, total testing capacity, fraction of positive tests, and availability of ICU beds).
COVID Act Now State and county-level dashboard focused on re-opening strategies, showing trends in four metrics related to COVID-19 risk (change in cases, total testing capacity, fraction of positive tests, and availability of ICU beds).
COVID Act Now State and county-level dashboard focused on re-opening strategies, showing trends in four metrics related to COVID-19 risk (change in cases, total testing capacity, fraction of positive tests, and availability of ICU beds).
COVID Act Now State and county-level dashboard focused on re-opening strategies, showing trends in four metrics related to COVID-19 risk (change in cases, total testing capacity, fraction of positive tests, and availability of ICU beds).
COVID Act Now State and county-level dashboard focused on re-opening strategies, showing trends in four metrics related to COVID-19 risk (change in cases, total testing capacity, fraction of positive tests, and availability of ICU beds).
Fundamentally uses an SEIR model fit to observed data.
Fundamentally uses an SEIR model fit to observed data.
Fundamentally uses an SEIR model fit to observed data.
Fundamentally uses an SEIR model fit to observed data.
Fundamentally uses an SEIR model fit to observed data.
Fundamentally uses an SEIR model fit to observed data.
Fundamentally uses an SEIR model fit to observed data.
Fundamentally uses an SEIR model fit to observed data.
Fundamentally uses an SEIR model fit to observed data.
Fundamentally uses an SEIR model fit to observed data.
ESRI estimates the number of active COVID-19 cases in each US county, but validation is needed.
ESRI estimates the number of active COVID-19 cases in each US county, but validation is needed.
ESRI estimates the number of active COVID-19 cases in each US county, but validation is needed.
ESRI estimates the number of active COVID-19 cases in each US county, but validation is needed.
ESRI estimates the number of active COVID-19 cases in each US county, but validation is needed.
ESRI estimates the number of active COVID-19 cases in each US county, but validation is needed.
ESRI estimates the number of active COVID-19 cases in each US county, but validation is needed.
ESRI estimates the number of active COVID-19 cases in each US county, but validation is needed.
ESRI estimates the number of active COVID-19 cases in each US county, but validation is needed.
ESRI estimates the number of active COVID-19 cases in each US county, but validation is needed.
The National Association of County and City Health Officials (NACCHO) provides a dashboard with estimates of county-specific test positivity rates as well as mortality incidence for different racial groups.
The National Association of County and City Health Officials (NACCHO) provides a dashboard with estimates of county-specific test positivity rates as well as mortality incidence for different racial groups.
The National Association of County and City Health Officials (NACCHO) provides a dashboard with estimates of county-specific test positivity rates as well as mortality incidence for different racial groups.
The National Association of County and City Health Officials (NACCHO) provides a dashboard with estimates of county-specific test positivity rates as well as mortality incidence for different racial groups.
The National Association of County and City Health Officials (NACCHO) provides a dashboard with estimates of county-specific test positivity rates as well as mortality incidence for different racial groups.
The National Association of County and City Health Officials (NACCHO) provides a dashboard with estimates of county-specific test positivity rates as well as mortality incidence for different racial groups.
The National Association of County and City Health Officials (NACCHO) provides a dashboard with estimates of county-specific test positivity rates as well as mortality incidence for different racial groups.
The National Association of County and City Health Officials (NACCHO) provides a dashboard with estimates of county-specific test positivity rates as well as mortality incidence for different racial groups.
The National Association of County and City Health Officials (NACCHO) provides a dashboard with estimates of county-specific test positivity rates as well as mortality incidence for different racial groups.
The National Association of County and City Health Officials (NACCHO) provides a dashboard with estimates of county-specific test positivity rates as well as mortality incidence for different racial groups.
The US CDC provides ensemble forecasts of cases and deaths based on the arithmetic mean of many participating groups.
The US CDC provides ensemble forecasts of cases and deaths based on the arithmetic mean of many participating groups.
The US CDC provides ensemble forecasts of cases and deaths based on the arithmetic mean of many participating groups.
The US CDC provides ensemble forecasts of cases and deaths based on the arithmetic mean of many participating groups.
The US CDC provides ensemble forecasts of cases and deaths based on the arithmetic mean of many participating groups.
The US CDC provides ensemble forecasts of cases and deaths based on the arithmetic mean of many participating groups.
The US CDC provides ensemble forecasts of cases and deaths based on the arithmetic mean of many participating groups.
The US CDC provides ensemble forecasts of cases and deaths based on the arithmetic mean of many participating groups.
The US CDC provides ensemble forecasts of cases and deaths based on the arithmetic mean of many participating groups.
The US CDC provides ensemble forecasts of cases and deaths based on the arithmetic mean of many participating groups.
Institute of Health Metrics and Evaluation (IHME) Mechanistic SEIR model combined with curve-fitting techniques to forecast cases, hospital resource use, and deaths at the state and country level.
Institute of Health Metrics and Evaluation (IHME) Mechanistic SEIR model combined with curve-fitting techniques to forecast cases, hospital resource use, and deaths at the state and country level.
Institute of Health Metrics and Evaluation (IHME) Mechanistic SEIR model combined with curve-fitting techniques to forecast cases, hospital resource use, and deaths at the state and country level.
Institute of Health Metrics and Evaluation (IHME) Mechanistic SEIR model combined with curve-fitting techniques to forecast cases, hospital resource use, and deaths at the state and country level.
Institute of Health Metrics and Evaluation (IHME) Mechanistic SEIR model combined with curve-fitting techniques to forecast cases, hospital resource use, and deaths at the state and country level.
Institute of Health Metrics and Evaluation (IHME) Mechanistic SEIR model combined with curve-fitting techniques to forecast cases, hospital resource use, and deaths at the state and country level.
Institute of Health Metrics and Evaluation (IHME) Mechanistic SEIR model combined with curve-fitting techniques to forecast cases, hospital resource use, and deaths at the state and country level.
Institute of Health Metrics and Evaluation (IHME) Mechanistic SEIR model combined with curve-fitting techniques to forecast cases, hospital resource use, and deaths at the state and country level.
Institute of Health Metrics and Evaluation (IHME) Mechanistic SEIR model combined with curve-fitting techniques to forecast cases, hospital resource use, and deaths at the state and country level.
Institute of Health Metrics and Evaluation (IHME) Mechanistic SEIR model combined with curve-fitting techniques to forecast cases, hospital resource use, and deaths at the state and country level.
Institute of Health Metrics and Evaluation (IHME) also provides global forecasts.
Institute of Health Metrics and Evaluation (IHME) also provides global forecasts.
Institute of Health Metrics and Evaluation (IHME) also provides global forecasts.
Institute of Health Metrics and Evaluation (IHME) also provides global forecasts.
Institute of Health Metrics and Evaluation (IHME) also provides global forecasts.
Institute of Health Metrics and Evaluation (IHME) also provides global forecasts.
Institute of Health Metrics and Evaluation (IHME) also provides global forecasts.
Institute of Health Metrics and Evaluation (IHME) also provides global forecasts.
Institute of Health Metrics and Evaluation (IHME) also provides global forecasts.
Institute of Health Metrics and Evaluation (IHME) also provides global forecasts.
Los Alamos National Laboratory Forecasts of state-level cases and deaths based on statistical growth model fit to reported data.
Los Alamos National Laboratory Forecasts of state-level cases and deaths based on statistical growth model fit to reported data.
Los Alamos National Laboratory Forecasts of state-level cases and deaths based on statistical growth model fit to reported data.
Los Alamos National Laboratory Forecasts of state-level cases and deaths based on statistical growth model fit to reported data.
Los Alamos National Laboratory Forecasts of state-level cases and deaths based on statistical growth model fit to reported data.
Los Alamos National Laboratory Forecasts of state-level cases and deaths based on statistical growth model fit to reported data.
Los Alamos National Laboratory Forecasts of state-level cases and deaths based on statistical growth model fit to reported data.
Los Alamos National Laboratory Forecasts of state-level cases and deaths based on statistical growth model fit to reported data.
Los Alamos National Laboratory Forecasts of state-level cases and deaths based on statistical growth model fit to reported data.
Los Alamos National Laboratory Forecasts of state-level cases and deaths based on statistical growth model fit to reported data.
Los Alamos National Laboratory implicitly accounts for effects of social distancing and other control measures.
Los Alamos National Laboratory implicitly accounts for effects of social distancing and other control measures.
Los Alamos National Laboratory implicitly accounts for effects of social distancing and other control measures.
Los Alamos National Laboratory implicitly accounts for effects of social distancing and other control measures.
Los Alamos National Laboratory implicitly accounts for effects of social distancing and other control measures.
Los Alamos National Laboratory implicitly accounts for effects of social distancing and other control measures.
Los Alamos National Laboratory implicitly accounts for effects of social distancing and other control measures.
Los Alamos National Laboratory implicitly accounts for effects of social distancing and other control measures.
Los Alamos National Laboratory implicitly accounts for effects of social distancing and other control measures.
Los Alamos National Laboratory implicitly accounts for effects of social distancing and other control measures.
Google/Harvard University Time-series machine learning model that makes assumptions about which non-pharmaceutical interventions will be in place in the future.
Google/Harvard University Time-series machine learning model that makes assumptions about which non-pharmaceutical interventions will be in place in the future.
Google/Harvard University Time-series machine learning model that makes assumptions about which non-pharmaceutical interventions will be in place in the future.
Google/Harvard University Time-series machine learning model that makes assumptions about which non-pharmaceutical interventions will be in place in the future.
Google/Harvard University Time-series machine learning model that makes assumptions about which non-pharmaceutical interventions will be in place in the future.
Google/Harvard University Time-series machine learning model that makes assumptions about which non-pharmaceutical interventions will be in place in the future.
Google/Harvard University Time-series machine learning model that makes assumptions about which non-pharmaceutical interventions will be in place in the future.
Google/Harvard University Time-series machine learning model that makes assumptions about which non-pharmaceutical interventions will be in place in the future.
Google/Harvard University Time-series machine learning model that makes assumptions about which non-pharmaceutical interventions will be in place in the future.
Google/Harvard University Time-series machine learning model that makes assumptions about which non-pharmaceutical interventions will be in place in the future.
Northeastern University Spatially explicit, agent-based epidemic model used to forecast fatalities, hospital resource use, and the cumulative attack rate (proportion of the population infected) for unmitigated and mitigated scenarios.
Northeastern University Spatially explicit, agent-based epidemic model used to forecast fatalities, hospital resource use, and the cumulative attack rate (proportion of the population infected) for unmitigated and mitigated scenarios.
Northeastern University Spatially explicit, agent-based epidemic model used to forecast fatalities, hospital resource use, and the cumulative attack rate (proportion of the population infected) for unmitigated and mitigated scenarios.
Northeastern University Spatially explicit, agent-based epidemic model used to forecast fatalities, hospital resource use, and the cumulative attack rate (proportion of the population infected) for unmitigated and mitigated scenarios.
Northeastern University Spatially explicit, agent-based epidemic model used to forecast fatalities, hospital resource use, and the cumulative attack rate (proportion of the population infected) for unmitigated and mitigated scenarios.
Northeastern University Spatially explicit, agent-based epidemic model used to forecast fatalities, hospital resource use, and the cumulative attack rate (proportion of the population infected) for unmitigated and mitigated scenarios.
Northeastern University Spatially explicit, agent-based epidemic model used to forecast fatalities, hospital resource use, and the cumulative attack rate (proportion of the population infected) for unmitigated and mitigated scenarios.
Northeastern University Spatially explicit, agent-based epidemic model used to forecast fatalities, hospital resource use, and the cumulative attack rate (proportion of the population infected) for unmitigated and mitigated scenarios.
Northeastern University Spatially explicit, agent-based epidemic model used to forecast fatalities, hospital resource use, and the cumulative attack rate (proportion of the population infected) for unmitigated and mitigated scenarios.
Northeastern University Spatially explicit, agent-based epidemic model used to forecast fatalities, hospital resource use, and the cumulative attack rate (proportion of the population infected) for unmitigated and mitigated scenarios.
Notre Dame University Agent-based model forecasting cases and deaths for Midwest states.
Notre Dame University Agent-based model forecasting cases and deaths for Midwest states.
Notre Dame University Agent-based model forecasting cases and deaths for Midwest states.
Notre Dame University Agent-based model forecasting cases and deaths for Midwest states.
Notre Dame University Agent-based model forecasting cases and deaths for Midwest states.
Notre Dame University Agent-based model forecasting cases and deaths for Midwest states.
Notre Dame University Agent-based model forecasting cases and deaths for Midwest states.
Notre Dame University Agent-based model forecasting cases and deaths for Midwest states.
Notre Dame University Agent-based model forecasting cases and deaths for Midwest states.
Notre Dame University Agent-based model forecasting cases and deaths for Midwest states.
Notre Dame University Includes effectiveness of control measures like social distancing.
Notre Dame University Includes effectiveness of control measures like social distancing.
Notre Dame University Includes effectiveness of control measures like social distancing.
Notre Dame University Includes effectiveness of control measures like social distancing.
Notre Dame University Includes effectiveness of control measures like social distancing.
Notre Dame University Includes effectiveness of control measures like social distancing.
Notre Dame University Includes effectiveness of control measures like social distancing.
Notre Dame University Includes effectiveness of control measures like social distancing.
Notre Dame University Includes effectiveness of control measures like social distancing.
Notre Dame University Includes effectiveness of control measures like social distancing.
University of California, Los Angeles Mechanistic SIR model with statistical optimization to find best-fitting parameter values.
University of California, Los Angeles Mechanistic SIR model with statistical optimization to find best-fitting parameter values.
University of California, Los Angeles Mechanistic SIR model with statistical optimization to find best-fitting parameter values.
University of California, Los Angeles Mechanistic SIR model with statistical optimization to find best-fitting parameter values.
University of California, Los Angeles Mechanistic SIR model with statistical optimization to find best-fitting parameter values.
University of California, Los Angeles Mechanistic SIR model with statistical optimization to find best-fitting parameter values.
University of California, Los Angeles Mechanistic SIR model with statistical optimization to find best-fitting parameter values.
University of California, Los Angeles Mechanistic SIR model with statistical optimization to find best-fitting parameter values.
University of California, Los Angeles Mechanistic SIR model with statistical optimization to find best-fitting parameter values.
University of California, Los Angeles Mechanistic SIR model with statistical optimization to find best-fitting parameter values.
University of California, Los Angeles Estimates confirmed and active cases, fatalities, and transmission rates at the national and state levels.
University of California, Los Angeles Estimates confirmed and active cases, fatalities, and transmission rates at the national and state levels.
University of California, Los Angeles Estimates confirmed and active cases, fatalities, and transmission rates at the national and state levels.
University of California, Los Angeles Estimates confirmed and active cases, fatalities, and transmission rates at the national and state levels.
University of California, Los Angeles Estimates confirmed and active cases, fatalities, and transmission rates at the national and state levels.
University of California, Los Angeles Estimates confirmed and active cases, fatalities, and transmission rates at the national and state levels.
University of California, Los Angeles Estimates confirmed and active cases, fatalities, and transmission rates at the national and state levels.
University of California, Los Angeles Estimates confirmed and active cases, fatalities, and transmission rates at the national and state levels.
University of California, Los Angeles Estimates confirmed and active cases, fatalities, and transmission rates at the national and state levels.
University of California, Los Angeles Estimates confirmed and active cases, fatalities, and transmission rates at the national and state levels.
University of Geneva Country-level forecasts of cases, deaths, and transmissibility (R0).
University of Geneva Country-level forecasts of cases, deaths, and transmissibility (R0).
University of Geneva Country-level forecasts of cases, deaths, and transmissibility (R0).
University of Geneva Country-level forecasts of cases, deaths, and transmissibility (R0).
University of Geneva Country-level forecasts of cases, deaths, and transmissibility (R0).
University of Geneva Country-level forecasts of cases, deaths, and transmissibility (R0).
University of Geneva Country-level forecasts of cases, deaths, and transmissibility (R0).
University of Geneva Country-level forecasts of cases, deaths, and transmissibility (R0).
University of Geneva Country-level forecasts of cases, deaths, and transmissibility (R0).
University of Geneva Country-level forecasts of cases, deaths, and transmissibility (R0).
University of Geneva Uses statistical models fit to reported data, not mechanistic models.
University of Geneva Uses statistical models fit to reported data, not mechanistic models.
University of Geneva Uses statistical models fit to reported data, not mechanistic models.
University of Geneva Uses statistical models fit to reported data, not mechanistic models.
University of Geneva Uses statistical models fit to reported data, not mechanistic models.
University of Geneva Uses statistical models fit to reported data, not mechanistic models.
University of Geneva Uses statistical models fit to reported data, not mechanistic models.
University of Geneva Uses statistical models fit to reported data, not mechanistic models.
University of Geneva Uses statistical models fit to reported data, not mechanistic models.
University of Geneva Uses statistical models fit to reported data, not mechanistic models.
University of Massachusetts, Amherst Aggregation of state and national forecasts to create ensemble model.
University of Massachusetts, Amherst Aggregation of state and national forecasts to create ensemble model.
University of Massachusetts, Amherst Aggregation of state and national forecasts to create ensemble model.
University of Massachusetts, Amherst Aggregation of state and national forecasts to create ensemble model.
University of Massachusetts, Amherst Aggregation of state and national forecasts to create ensemble model.
University of Massachusetts, Amherst Aggregation of state and national forecasts to create ensemble model.
University of Massachusetts, Amherst Aggregation of state and national forecasts to create ensemble model.
University of Massachusetts, Amherst Aggregation of state and national forecasts to create ensemble model.
University of Massachusetts, Amherst Aggregation of state and national forecasts to create ensemble model.
University of Massachusetts, Amherst Aggregation of state and national forecasts to create ensemble model.
Youyang Gu Mechanistic SEIR model coupled with machine learning algorithms to minimize error between predicted and observed values.
Youyang Gu Mechanistic SEIR model coupled with machine learning algorithms to minimize error between predicted and observed values.
Youyang Gu Mechanistic SEIR model coupled with machine learning algorithms to minimize error between predicted and observed values.
Youyang Gu Mechanistic SEIR model coupled with machine learning algorithms to minimize error between predicted and observed values.
Youyang Gu Mechanistic SEIR model coupled with machine learning algorithms to minimize error between predicted and observed values.
Youyang Gu Mechanistic SEIR model coupled with machine learning algorithms to minimize error between predicted and observed values.
Youyang Gu Mechanistic SEIR model coupled with machine learning algorithms to minimize error between predicted and observed values.
Youyang Gu Mechanistic SEIR model coupled with machine learning algorithms to minimize error between predicted and observed values.
Youyang Gu Mechanistic SEIR model coupled with machine learning algorithms to minimize error between predicted and observed values.
Youyang Gu Mechanistic SEIR model coupled with machine learning algorithms to minimize error between predicted and observed values.
Youyang Gu Forecasts deaths and infections at the state and national level, including 60 non-US countries.
Youyang Gu Forecasts deaths and infections at the state and national level, including 60 non-US countries.
Youyang Gu Forecasts deaths and infections at the state and national level, including 60 non-US countries.
Youyang Gu Forecasts deaths and infections at the state and national level, including 60 non-US countries.
Youyang Gu Forecasts deaths and infections at the state and national level, including 60 non-US countries.
Youyang Gu Forecasts deaths and infections at the state and national level, including 60 non-US countries.
Youyang Gu Forecasts deaths and infections at the state and national level, including 60 non-US countries.
Youyang Gu Forecasts deaths and infections at the state and national level, including 60 non-US countries.
Youyang Gu Forecasts deaths and infections at the state and national level, including 60 non-US countries.
Youyang Gu Forecasts deaths and infections at the state and national level, including 60 non-US countries.
Youyang Gu Includes effects of public health control efforts.
Youyang Gu Includes effects of public health control efforts.
Youyang Gu Includes effects of public health control efforts.
Youyang Gu Includes effects of public health control efforts.
Youyang Gu Includes effects of public health control efforts.
Youyang Gu Includes effects of public health control efforts.
Youyang Gu Includes effects of public health control efforts.
Youyang Gu Includes effects of public health control efforts.
Youyang Gu Includes effects of public health control efforts.
Youyang Gu Includes effects of public health control efforts.
Additional forecasting efforts are designed to assess the effects of interventions such as social distancing and vaccination.
Additional forecasting efforts are designed to assess the effects of interventions such as social distancing and vaccination.
Additional forecasting efforts are designed to assess the effects of interventions such as social distancing and vaccination.
Additional forecasting efforts are designed to assess the effects of interventions such as social distancing and vaccination.
Additional forecasting efforts are designed to assess the effects of interventions such as social distancing and vaccination.
Additional forecasting efforts are designed to assess the effects of interventions such as social distancing and vaccination.
Additional forecasting efforts are designed to assess the effects of interventions such as social distancing and vaccination.
Additional forecasting efforts are designed to assess the effects of interventions such as social distancing and vaccination.
Additional forecasting efforts are designed to assess the effects of interventions such as social distancing and vaccination.
Additional forecasting efforts are designed to assess the effects of interventions such as social distancing and vaccination.
Massachusetts Institute of Technology Mechanistic SEIR model that forecasts cases, hospitalizations, and deaths.
Massachusetts Institute of Technology Mechanistic SEIR model that forecasts cases, hospitalizations, and deaths.
Massachusetts Institute of Technology Mechanistic SEIR model that forecasts cases, hospitalizations, and deaths.
Massachusetts Institute of Technology Mechanistic SEIR model that forecasts cases, hospitalizations, and deaths.
Massachusetts Institute of Technology Mechanistic SEIR model that forecasts cases, hospitalizations, and deaths.
Massachusetts Institute of Technology Mechanistic SEIR model that forecasts cases, hospitalizations, and deaths.
Massachusetts Institute of Technology Mechanistic SEIR model that forecasts cases, hospitalizations, and deaths.
Massachusetts Institute of Technology Mechanistic SEIR model that forecasts cases, hospitalizations, and deaths.
Massachusetts Institute of Technology Mechanistic SEIR model that forecasts cases, hospitalizations, and deaths.
Massachusetts Institute of Technology Mechanistic SEIR model that forecasts cases, hospitalizations, and deaths.
CovidSim SEIR model allow users to simulate effects of future intervention policies at state and national levels (US only).
CovidSim SEIR model allow users to simulate effects of future intervention policies at state and national levels (US only).
CovidSim SEIR model allow users to simulate effects of future intervention policies at state and national levels (US only).
CovidSim SEIR model allow users to simulate effects of future intervention policies at state and national levels (US only).
CovidSim SEIR model allow users to simulate effects of future intervention policies at state and national levels (US only).
CovidSim SEIR model allow users to simulate effects of future intervention policies at state and national levels (US only).
CovidSim SEIR model allow users to simulate effects of future intervention policies at state and national levels (US only).
CovidSim SEIR model allow users to simulate effects of future intervention policies at state and national levels (US only).
CovidSim SEIR model allow users to simulate effects of future intervention policies at state and national levels (US only).
CovidSim SEIR model allow users to simulate effects of future intervention policies at state and national levels (US only).
Covasim Agent-based model for testing effects of intervention measures, also available as Python library.
Covasim Agent-based model for testing effects of intervention measures, also available as Python library.
Covasim Agent-based model for testing effects of intervention measures, also available as Python library.
Covasim Agent-based model for testing effects of intervention measures, also available as Python library.
Covasim Agent-based model for testing effects of intervention measures, also available as Python library.
Covasim Agent-based model for testing effects of intervention measures, also available as Python library.
Covasim Agent-based model for testing effects of intervention measures, also available as Python library.
Covasim Agent-based model for testing effects of intervention measures, also available as Python library.
Covasim Agent-based model for testing effects of intervention measures, also available as Python library.
Covasim Agent-based model for testing effects of intervention measures, also available as Python library.
University of Georgia Statistical models used to estimate the current number of symptomatic and incubating individuals, beyond what is reported (e.g., ‚Äö√Ñ√∂‚àö√ë‚àö‚à´nowcasts‚Äö√Ñ√∂‚àö√ë‚àöœÄ).
University of Georgia Statistical models used to estimate the current number of symptomatic and incubating individuals, beyond what is reported (e.g., ‚Äö√Ñ√∂‚àö√ë‚àö‚à´nowcasts‚Äö√Ñ√∂‚àö√ë‚àöœÄ).
University of Georgia Statistical models used to estimate the current number of symptomatic and incubating individuals, beyond what is reported (e.g., ‚Äö√Ñ√∂‚àö√ë‚àö‚à´nowcasts‚Äö√Ñ√∂‚àö√ë‚àöœÄ).
University of Georgia Statistical models used to estimate the current number of symptomatic and incubating individuals, beyond what is reported (e.g., ‚Äö√Ñ√∂‚àö√ë‚àö‚à´nowcasts‚Äö√Ñ√∂‚àö√ë‚àöœÄ).
University of Georgia Statistical models used to estimate the current number of symptomatic and incubating individuals, beyond what is reported (e.g., ‚Äö√Ñ√∂‚àö√ë‚àö‚à´nowcasts‚Äö√Ñ√∂‚àö√ë‚àöœÄ).
University of Georgia Statistical models used to estimate the current number of symptomatic and incubating individuals, beyond what is reported (e.g., ‚Äö√Ñ√∂‚àö√ë‚àö‚à´nowcasts‚Äö√Ñ√∂‚àö√ë‚àöœÄ).
University of Georgia Statistical models used to estimate the current number of symptomatic and incubating individuals, beyond what is reported (e.g., ‚Äö√Ñ√∂‚àö√ë‚àö‚à´nowcasts‚Äö√Ñ√∂‚àö√ë‚àöœÄ).
University of Georgia Statistical models used to estimate the current number of symptomatic and incubating individuals, beyond what is reported (e.g., ‚Äö√Ñ√∂‚àö√ë‚àö‚à´nowcasts‚Äö√Ñ√∂‚àö√ë‚àöœÄ).
University of Georgia Statistical models used to estimate the current number of symptomatic and incubating individuals, beyond what is reported (e.g., ‚Äö√Ñ√∂‚àö√ë‚àö‚à´nowcasts‚Äö√Ñ√∂‚àö√ë‚àöœÄ).
University of Georgia Statistical models used to estimate the current number of symptomatic and incubating individuals, beyond what is reported (e.g., ‚Äö√Ñ√∂‚àö√ë‚àö‚à´nowcasts‚Äö√Ñ√∂‚àö√ë‚àöœÄ).
University of Georgia Available at the state and national level for the US.
University of Georgia Available at the state and national level for the US.
University of Georgia Available at the state and national level for the US.
University of Georgia Available at the state and national level for the US.
University of Georgia Available at the state and national level for the US.
University of Georgia Available at the state and national level for the US.
University of Georgia Available at the state and national level for the US.
University of Georgia Available at the state and national level for the US.
University of Georgia Available at the state and national level for the US.
University of Georgia Available at the state and national level for the US.
Georgia Tech Applied Bioinformatics Laboratory Tool providing probability of at least one infected individual attending an event, accounting for event size and county/state COVID-19 prevalence.
Georgia Tech Applied Bioinformatics Laboratory Tool providing probability of at least one infected individual attending an event, accounting for event size and county/state COVID-19 prevalence.
Georgia Tech Applied Bioinformatics Laboratory Tool providing probability of at least one infected individual attending an event, accounting for event size and county/state COVID-19 prevalence.
Georgia Tech Applied Bioinformatics Laboratory Tool providing probability of at least one infected individual attending an event, accounting for event size and county/state COVID-19 prevalence.
Georgia Tech Applied Bioinformatics Laboratory Tool providing probability of at least one infected individual attending an event, accounting for event size and county/state COVID-19 prevalence.
Georgia Tech Applied Bioinformatics Laboratory Tool providing probability of at least one infected individual attending an event, accounting for event size and county/state COVID-19 prevalence.
Georgia Tech Applied Bioinformatics Laboratory Tool providing probability of at least one infected individual attending an event, accounting for event size and county/state COVID-19 prevalence.
Georgia Tech Applied Bioinformatics Laboratory Tool providing probability of at least one infected individual attending an event, accounting for event size and county/state COVID-19 prevalence.
Georgia Tech Applied Bioinformatics Laboratory Tool providing probability of at least one infected individual attending an event, accounting for event size and county/state COVID-19 prevalence.
Georgia Tech Applied Bioinformatics Laboratory Tool providing probability of at least one infected individual attending an event, accounting for event size and county/state COVID-19 prevalence.
MITRE Dashboards for COVID-19 forecasts and decision support tools, including regional comparisons and intervention planning.
MITRE Dashboards for COVID-19 forecasts and decision support tools, including regional comparisons and intervention planning.
MITRE Dashboards for COVID-19 forecasts and decision support tools, including regional comparisons and intervention planning.
MITRE Dashboards for COVID-19 forecasts and decision support tools, including regional comparisons and intervention planning.
MITRE Dashboards for COVID-19 forecasts and decision support tools, including regional comparisons and intervention planning.
MITRE Dashboards for COVID-19 forecasts and decision support tools, including regional comparisons and intervention planning.
MITRE Dashboards for COVID-19 forecasts and decision support tools, including regional comparisons and intervention planning.
MITRE Dashboards for COVID-19 forecasts and decision support tools, including regional comparisons and intervention planning.
MITRE Dashboards for COVID-19 forecasts and decision support tools, including regional comparisons and intervention planning.
MITRE Dashboards for COVID-19 forecasts and decision support tools, including regional comparisons and intervention planning.
MITRE Uses combinations of SEIR models and curve-fitting approaches.
MITRE Uses combinations of SEIR models and curve-fitting approaches.
MITRE Uses combinations of SEIR models and curve-fitting approaches.
MITRE Uses combinations of SEIR models and curve-fitting approaches.
MITRE Uses combinations of SEIR models and curve-fitting approaches.
MITRE Uses combinations of SEIR models and curve-fitting approaches.
MITRE Uses combinations of SEIR models and curve-fitting approaches.
MITRE Uses combinations of SEIR models and curve-fitting approaches.
MITRE Uses combinations of SEIR models and curve-fitting approaches.
MITRE Uses combinations of SEIR models and curve-fitting approaches.
No trial protocols (e.g., age, ethnicity) or data have been published for Sputnik V.
No trial protocols (e.g., age, ethnicity) or data have been published for Sputnik V.
No trial protocols (e.g., age, ethnicity) or data have been published for Sputnik V.
No trial protocols (e.g., age, ethnicity) or data have been published for Sputnik V.
No trial protocols (e.g., age, ethnicity) or data have been published for Sputnik V.
No trial protocols (e.g., age, ethnicity) or data have been published for Sputnik V.
No trial protocols (e.g., age, ethnicity) or data have been published for Sputnik V.
No trial protocols (e.g., age, ethnicity) or data have been published for Sputnik V.
No trial protocols (e.g., age, ethnicity) or data have been published for Sputnik V.
No trial protocols (e.g., age, ethnicity) or data have been published for Sputnik V.
While memory B and T cells both persist for at least 6 months, there is some variability in the persistence of specific antibodies (e.g., IgG vs. IgA).
While memory B and T cells both persist for at least 6 months, there is some variability in the persistence of specific antibodies (e.g., IgG vs. IgA).
While memory B and T cells both persist for at least 6 months, there is some variability in the persistence of specific antibodies (e.g., IgG vs. IgA).
While memory B and T cells both persist for at least 6 months, there is some variability in the persistence of specific antibodies (e.g., IgG vs. IgA).
While memory B and T cells both persist for at least 6 months, there is some variability in the persistence of specific antibodies (e.g., IgG vs. IgA).
While memory B and T cells both persist for at least 6 months, there is some variability in the persistence of specific antibodies (e.g., IgG vs. IgA).
While memory B and T cells both persist for at least 6 months, there is some variability in the persistence of specific antibodies (e.g., IgG vs. IgA).
While memory B and T cells both persist for at least 6 months, there is some variability in the persistence of specific antibodies (e.g., IgG vs. IgA).
While memory B and T cells both persist for at least 6 months, there is some variability in the persistence of specific antibodies (e.g., IgG vs. IgA).
While memory B and T cells both persist for at least 6 months, there is some variability in the persistence of specific antibodies (e.g., IgG vs. IgA).
Candidates that have received or applied for approval in the US Pfizer/BioNTech ‚Äö√Ñ√∂‚àö√ë‚àö¬® mRNA vaccine named BNT162b2 (international nonproprietary name of Tozinameran), Pfizer/BioNTech ‚Äö√Ñ√∂‚àö√ë‚àö¬® mRNA vaccine named BNT162b2 is given as 2 shots, 21 days apart.
Candidates that have received or applied for approval in the US Pfizer/BioNTech ‚Äö√Ñ√∂‚àö√ë‚àö¬® mRNA vaccine named BNT162b2 (international nonproprietary name of Tozinameran), Pfizer/BioNTech ‚Äö√Ñ√∂‚àö√ë‚àö¬® mRNA vaccine named BNT162b2 is given as 2 shots, 21 days apart.
Candidates that have received or applied for approval in the US Pfizer/BioNTech ‚Äö√Ñ√∂‚àö√ë‚àö¬® mRNA vaccine named BNT162b2 (international nonproprietary name of Tozinameran), Pfizer/BioNTech ‚Äö√Ñ√∂‚àö√ë‚àö¬® mRNA vaccine named BNT162b2 is given as 2 shots, 21 days apart.
Candidates that have received or applied for approval in the US Pfizer/BioNTech ‚Äö√Ñ√∂‚àö√ë‚àö¬® mRNA vaccine named BNT162b2 (international nonproprietary name of Tozinameran), Pfizer/BioNTech ‚Äö√Ñ√∂‚àö√ë‚àö¬® mRNA vaccine named BNT162b2 is given as 2 shots, 21 days apart.
Candidates that have received or applied for approval in the US Pfizer/BioNTech ‚Äö√Ñ√∂‚àö√ë‚àö¬® mRNA vaccine named BNT162b2 (international nonproprietary name of Tozinameran), Pfizer/BioNTech ‚Äö√Ñ√∂‚àö√ë‚àö¬® mRNA vaccine named BNT162b2 is given as 2 shots, 21 days apart.
Candidates that have received or applied for approval in the US Pfizer/BioNTech ‚Äö√Ñ√∂‚àö√ë‚àö¬® mRNA vaccine named BNT162b2 (international nonproprietary name of Tozinameran), Pfizer/BioNTech ‚Äö√Ñ√∂‚àö√ë‚àö¬® mRNA vaccine named BNT162b2 is given as 2 shots, 21 days apart.
Candidates that have received or applied for approval in the US Pfizer/BioNTech ‚Äö√Ñ√∂‚àö√ë‚àö¬® mRNA vaccine named BNT162b2 (international nonproprietary name of Tozinameran), Pfizer/BioNTech ‚Äö√Ñ√∂‚àö√ë‚àö¬® mRNA vaccine named BNT162b2 is given as 2 shots, 21 days apart.
Candidates that have received or applied for approval in the US Pfizer/BioNTech ‚Äö√Ñ√∂‚àö√ë‚àö¬® mRNA vaccine named BNT162b2 (international nonproprietary name of Tozinameran), Pfizer/BioNTech ‚Äö√Ñ√∂‚àö√ë‚àö¬® mRNA vaccine named BNT162b2 is given as 2 shots, 21 days apart.
Candidates that have received or applied for approval in the US Pfizer/BioNTech ‚Äö√Ñ√∂‚àö√ë‚àö¬® mRNA vaccine named BNT162b2 (international nonproprietary name of Tozinameran), Pfizer/BioNTech ‚Äö√Ñ√∂‚àö√ë‚àö¬® mRNA vaccine named BNT162b2 is given as 2 shots, 21 days apart.
Candidates that have received or applied for approval in the US Pfizer/BioNTech ‚Äö√Ñ√∂‚àö√ë‚àö¬® mRNA vaccine named BNT162b2 (international nonproprietary name of Tozinameran), Pfizer/BioNTech ‚Äö√Ñ√∂‚àö√ë‚àö¬® mRNA vaccine named BNT162b2 is given as 2 shots, 21 days apart.
Low genetic diversity early in the epidemic suggests that SARS-CoV-2 was capable of jumping to human and other mammalian hosts, and that additional jumps into humans may occur.
Low genetic diversity early in the epidemic suggests that SARS-CoV-2 was capable of jumping to human and other mammalian hosts, and that additional jumps into humans may occur.
Low genetic diversity early in the epidemic suggests that SARS-CoV-2 was capable of jumping to human and other mammalian hosts, and that additional jumps into humans may occur.
Low genetic diversity early in the epidemic suggests that SARS-CoV-2 was capable of jumping to human and other mammalian hosts, and that additional jumps into humans may occur.
Low genetic diversity early in the epidemic suggests that SARS-CoV-2 was capable of jumping to human and other mammalian hosts, and that additional jumps into humans may occur.
Low genetic diversity early in the epidemic suggests that SARS-CoV-2 was capable of jumping to human and other mammalian hosts, and that additional jumps into humans may occur.
Low genetic diversity early in the epidemic suggests that SARS-CoV-2 was capable of jumping to human and other mammalian hosts, and that additional jumps into humans may occur.
Low genetic diversity early in the epidemic suggests that SARS-CoV-2 was capable of jumping to human and other mammalian hosts, and that additional jumps into humans may occur.
Low genetic diversity early in the epidemic suggests that SARS-CoV-2 was capable of jumping to human and other mammalian hosts, and that additional jumps into humans may occur.
Low genetic diversity early in the epidemic suggests that SARS-CoV-2 was capable of jumping to human and other mammalian hosts, and that additional jumps into humans may occur.
In US hospital patients, COVID-19 prevalence was slightly higher in individuals with non-O-type blood; blood type affected both risk of mechanical ventilation (lower in type A, higher in B and AB compared to O) and death (higher in AB, lower in A and B compared to O), and Rh negative status was protective for all three measures.
In US hospital patients, COVID-19 prevalence was slightly higher in individuals with non-O-type blood; blood type affected both risk of mechanical ventilation (lower in type A, higher in B and AB compared to O) and death (higher in AB, lower in A and B compared to O), and Rh negative status was protective for all three measures.
In US hospital patients, COVID-19 prevalence was slightly higher in individuals with non-O-type blood; blood type affected both risk of mechanical ventilation (lower in type A, higher in B and AB compared to O) and death (higher in AB, lower in A and B compared to O), and Rh negative status was protective for all three measures.
In US hospital patients, COVID-19 prevalence was slightly higher in individuals with non-O-type blood; blood type affected both risk of mechanical ventilation (lower in type A, higher in B and AB compared to O) and death (higher in AB, lower in A and B compared to O), and Rh negative status was protective for all three measures.
In US hospital patients, COVID-19 prevalence was slightly higher in individuals with non-O-type blood; blood type affected both risk of mechanical ventilation (lower in type A, higher in B and AB compared to O) and death (higher in AB, lower in A and B compared to O), and Rh negative status was protective for all three measures.
In US hospital patients, COVID-19 prevalence was slightly higher in individuals with non-O-type blood; blood type affected both risk of mechanical ventilation (lower in type A, higher in B and AB compared to O) and death (higher in AB, lower in A and B compared to O), and Rh negative status was protective for all three measures.
In US hospital patients, COVID-19 prevalence was slightly higher in individuals with non-O-type blood; blood type affected both risk of mechanical ventilation (lower in type A, higher in B and AB compared to O) and death (higher in AB, lower in A and B compared to O), and Rh negative status was protective for all three measures.
In US hospital patients, COVID-19 prevalence was slightly higher in individuals with non-O-type blood; blood type affected both risk of mechanical ventilation (lower in type A, higher in B and AB compared to O) and death (higher in AB, lower in A and B compared to O), and Rh negative status was protective for all three measures.
In US hospital patients, COVID-19 prevalence was slightly higher in individuals with non-O-type blood; blood type affected both risk of mechanical ventilation (lower in type A, higher in B and AB compared to O) and death (higher in AB, lower in A and B compared to O), and Rh negative status was protective for all three measures.
In US hospital patients, COVID-19 prevalence was slightly higher in individuals with non-O-type blood; blood type affected both risk of mechanical ventilation (lower in type A, higher in B and AB compared to O) and death (higher in AB, lower in A and B compared to O), and Rh negative status was protective for all three measures.
Columbia University Model Spatially-explicit SEIR model incorporating contact rate reductions due to social distancing. Estimates total cases and risk of healthcare overrun.
Columbia University Model Spatially-explicit SEIR model incorporating contact rate reductions due to social distancing. Estimates total cases and risk of healthcare overrun.
Columbia University Model Spatially-explicit SEIR model incorporating contact rate reductions due to social distancing. Estimates total cases and risk of healthcare overrun.
Columbia University Model Spatially-explicit SEIR model incorporating contact rate reductions due to social distancing. Estimates total cases and risk of healthcare overrun.
Columbia University Model Spatially-explicit SEIR model incorporating contact rate reductions due to social distancing. Estimates total cases and risk of healthcare overrun.
Columbia University Model Spatially-explicit SEIR model incorporating contact rate reductions due to social distancing. Estimates total cases and risk of healthcare overrun.
Columbia University Model Spatially-explicit SEIR model incorporating contact rate reductions due to social distancing. Estimates total cases and risk of healthcare overrun.
Columbia University Model Spatially-explicit SEIR model incorporating contact rate reductions due to social distancing. Estimates total cases and risk of healthcare overrun.
Columbia University Model Spatially-explicit SEIR model incorporating contact rate reductions due to social distancing. Estimates total cases and risk of healthcare overrun.
Columbia University Model Spatially-explicit SEIR model incorporating contact rate reductions due to social distancing. Estimates total cases and risk of healthcare overrun.
Massachusetts Institute of Technology Also includes estimates of intervention measures, allows users to project based on different intervention scenarios (e.g., social distancing lasting for 3 vs. 4 weeks).
Massachusetts Institute of Technology Also includes estimates of intervention measures, allows users to project based on different intervention scenarios (e.g., social distancing lasting for 3 vs. 4 weeks).
Massachusetts Institute of Technology Also includes estimates of intervention measures, allows users to project based on different intervention scenarios (e.g., social distancing lasting for 3 vs. 4 weeks).
Massachusetts Institute of Technology Also includes estimates of intervention measures, allows users to project based on different intervention scenarios (e.g., social distancing lasting for 3 vs. 4 weeks).
Massachusetts Institute of Technology Also includes estimates of intervention measures, allows users to project based on different intervention scenarios (e.g., social distancing lasting for 3 vs. 4 weeks).
Massachusetts Institute of Technology Also includes estimates of intervention measures, allows users to project based on different intervention scenarios (e.g., social distancing lasting for 3 vs. 4 weeks).
Massachusetts Institute of Technology Also includes estimates of intervention measures, allows users to project based on different intervention scenarios (e.g., social distancing lasting for 3 vs. 4 weeks).
Massachusetts Institute of Technology Also includes estimates of intervention measures, allows users to project based on different intervention scenarios (e.g., social distancing lasting for 3 vs. 4 weeks).
Massachusetts Institute of Technology Also includes estimates of intervention measures, allows users to project based on different intervention scenarios (e.g., social distancing lasting for 3 vs. 4 weeks).
Massachusetts Institute of Technology Also includes estimates of intervention measures, allows users to project based on different intervention scenarios (e.g., social distancing lasting for 3 vs. 4 weeks).
Shen et al. estimate US COVID-19 cases under different scenarios of vaccine efficacy, studying the continued need for non-pharmaceutical interventions such as face masks and physical distancing.
Shen et al. estimate US COVID-19 cases under different scenarios of vaccine efficacy, studying the continued need for non-pharmaceutical interventions such as face masks and physical distancing.
Shen et al. estimate US COVID-19 cases under different scenarios of vaccine efficacy, studying the continued need for non-pharmaceutical interventions such as face masks and physical distancing.
Shen et al. estimate US COVID-19 cases under different scenarios of vaccine efficacy, studying the continued need for non-pharmaceutical interventions such as face masks and physical distancing.
Shen et al. estimate US COVID-19 cases under different scenarios of vaccine efficacy, studying the continued need for non-pharmaceutical interventions such as face masks and physical distancing.
Shen et al. estimate US COVID-19 cases under different scenarios of vaccine efficacy, studying the continued need for non-pharmaceutical interventions such as face masks and physical distancing.
Shen et al. estimate US COVID-19 cases under different scenarios of vaccine efficacy, studying the continued need for non-pharmaceutical interventions such as face masks and physical distancing.
Shen et al. estimate US COVID-19 cases under different scenarios of vaccine efficacy, studying the continued need for non-pharmaceutical interventions such as face masks and physical distancing.
Shen et al. estimate US COVID-19 cases under different scenarios of vaccine efficacy, studying the continued need for non-pharmaceutical interventions such as face masks and physical distancing.
Shen et al. estimate US COVID-19 cases under different scenarios of vaccine efficacy, studying the continued need for non-pharmaceutical interventions such as face masks and physical distancing.
individuals can also transmit infection before symptoms appear.
individuals can also transmit infection before symptoms appear.
individuals can also transmit infection before symptoms appear.
individuals can also transmit infection before symptoms appear.
individuals can also transmit infection before symptoms appear.
individuals can also transmit infection before symptoms appear.
individuals can also transmit infection before symptoms appear.
individuals can also transmit infection before symptoms appear.
individuals can also transmit infection before symptoms appear.
individuals can also transmit infection before symptoms appear.
The US CDC recommends universal masking when indoors to inhibit the spread of COVID-19, alongside physical distancing, avoiding nonessential indoor and crowded outdoor spaces, postponing travel, and increasing ventilation and disinfection.
The US CDC recommends universal masking when indoors to inhibit the spread of COVID-19, alongside physical distancing, avoiding nonessential indoor and crowded outdoor spaces, postponing travel, and increasing ventilation and disinfection.
The US CDC recommends universal masking when indoors to inhibit the spread of COVID-19, alongside physical distancing, avoiding nonessential indoor and crowded outdoor spaces, postponing travel, and increasing ventilation and disinfection.
The US CDC recommends universal masking when indoors to inhibit the spread of COVID-19, alongside physical distancing, avoiding nonessential indoor and crowded outdoor spaces, postponing travel, and increasing ventilation and disinfection.
The US CDC recommends universal masking when indoors to inhibit the spread of COVID-19, alongside physical distancing, avoiding nonessential indoor and crowded outdoor spaces, postponing travel, and increasing ventilation and disinfection.
The US CDC recommends universal masking when indoors to inhibit the spread of COVID-19, alongside physical distancing, avoiding nonessential indoor and crowded outdoor spaces, postponing travel, and increasing ventilation and disinfection.
The US CDC recommends universal masking when indoors to inhibit the spread of COVID-19, alongside physical distancing, avoiding nonessential indoor and crowded outdoor spaces, postponing travel, and increasing ventilation and disinfection.
The US CDC recommends universal masking when indoors to inhibit the spread of COVID-19, alongside physical distancing, avoiding nonessential indoor and crowded outdoor spaces, postponing travel, and increasing ventilation and disinfection.
The US CDC recommends universal masking when indoors to inhibit the spread of COVID-19, alongside physical distancing, avoiding nonessential indoor and crowded outdoor spaces, postponing travel, and increasing ventilation and disinfection.
The US CDC recommends universal masking when indoors to inhibit the spread of COVID-19, alongside physical distancing, avoiding nonessential indoor and crowded outdoor spaces, postponing travel, and increasing ventilation and disinfection.
In the absence of sunlight, infectious SARS-CoV-2 can remain on non-porous (e.g., glass, vinyl) surfaces for at least 28 days at 20¬¨¬®‚Äö√†√ªC and 50% RH; higher temperatures greatly reduce the environmental stability of SARS-CoV-2.
In the absence of sunlight, infectious SARS-CoV-2 can remain on non-porous (e.g., glass, vinyl) surfaces for at least 28 days at 20¬¨¬®‚Äö√†√ªC and 50% RH; higher temperatures greatly reduce the environmental stability of SARS-CoV-2.
In the absence of sunlight, infectious SARS-CoV-2 can remain on non-porous (e.g., glass, vinyl) surfaces for at least 28 days at 20¬¨¬®‚Äö√†√ªC and 50% RH; higher temperatures greatly reduce the environmental stability of SARS-CoV-2.
In the absence of sunlight, infectious SARS-CoV-2 can remain on non-porous (e.g., glass, vinyl) surfaces for at least 28 days at 20¬¨¬®‚Äö√†√ªC and 50% RH; higher temperatures greatly reduce the environmental stability of SARS-CoV-2.
In the absence of sunlight, infectious SARS-CoV-2 can remain on non-porous (e.g., glass, vinyl) surfaces for at least 28 days at 20¬¨¬®‚Äö√†√ªC and 50% RH; higher temperatures greatly reduce the environmental stability of SARS-CoV-2.
In the absence of sunlight, infectious SARS-CoV-2 can remain on non-porous (e.g., glass, vinyl) surfaces for at least 28 days at 20¬¨¬®‚Äö√†√ªC and 50% RH; higher temperatures greatly reduce the environmental stability of SARS-CoV-2.
In the absence of sunlight, infectious SARS-CoV-2 can remain on non-porous (e.g., glass, vinyl) surfaces for at least 28 days at 20¬¨¬®‚Äö√†√ªC and 50% RH; higher temperatures greatly reduce the environmental stability of SARS-CoV-2.
In the absence of sunlight, infectious SARS-CoV-2 can remain on non-porous (e.g., glass, vinyl) surfaces for at least 28 days at 20¬¨¬®‚Äö√†√ªC and 50% RH; higher temperatures greatly reduce the environmental stability of SARS-CoV-2.
In the absence of sunlight, infectious SARS-CoV-2 can remain on non-porous (e.g., glass, vinyl) surfaces for at least 28 days at 20¬¨¬®‚Äö√†√ªC and 50% RH; higher temperatures greatly reduce the environmental stability of SARS-CoV-2.
In the absence of sunlight, infectious SARS-CoV-2 can remain on non-porous (e.g., glass, vinyl) surfaces for at least 28 days at 20¬¨¬®‚Äö√†√ªC and 50% RH; higher temperatures greatly reduce the environmental stability of SARS-CoV-2.
Environmental contamination is not thought to be the principal mode of SARS-CoV-2 transmission in humans.
Environmental contamination is not thought to be the principal mode of SARS-CoV-2 transmission in humans.
Environmental contamination is not thought to be the principal mode of SARS-CoV-2 transmission in humans.
Environmental contamination is not thought to be the principal mode of SARS-CoV-2 transmission in humans.
Environmental contamination is not thought to be the principal mode of SARS-CoV-2 transmission in humans.
Environmental contamination is not thought to be the principal mode of SARS-CoV-2 transmission in humans.
Environmental contamination is not thought to be the principal mode of SARS-CoV-2 transmission in humans.
Environmental contamination is not thought to be the principal mode of SARS-CoV-2 transmission in humans.
Environmental contamination is not thought to be the principal mode of SARS-CoV-2 transmission in humans.
Environmental contamination is not thought to be the principal mode of SARS-CoV-2 transmission in humans.
Positive SARS- CoV-2 patients were twice as likely as negative patients to report that they had recently eaten in restaurants or worked in an office.
Positive SARS- CoV-2 patients were twice as likely as negative patients to report that they had recently eaten in restaurants or worked in an office.
Positive SARS- CoV-2 patients were twice as likely as negative patients to report that they had recently eaten in restaurants or worked in an office.
Positive SARS- CoV-2 patients were twice as likely as negative patients to report that they had recently eaten in restaurants or worked in an office.
Positive SARS- CoV-2 patients were twice as likely as negative patients to report that they had recently eaten in restaurants or worked in an office.
Positive SARS- CoV-2 patients were twice as likely as negative patients to report that they had recently eaten in restaurants or worked in an office.
Positive SARS- CoV-2 patients were twice as likely as negative patients to report that they had recently eaten in restaurants or worked in an office.
Positive SARS- CoV-2 patients were twice as likely as negative patients to report that they had recently eaten in restaurants or worked in an office.
Positive SARS- CoV-2 patients were twice as likely as negative patients to report that they had recently eaten in restaurants or worked in an office.
Positive SARS- CoV-2 patients were twice as likely as negative patients to report that they had recently eaten in restaurants or worked in an office.
Individuals can be infectious while asymptomatic, and asymptomatic and pre-symptomatic individuals have similar amounts of virus in the nose and throat compared to symptomatic patients.
Individuals can be infectious while asymptomatic, and asymptomatic and pre-symptomatic individuals have similar amounts of virus in the nose and throat compared to symptomatic patients.
Individuals can be infectious while asymptomatic, and asymptomatic and pre-symptomatic individuals have similar amounts of virus in the nose and throat compared to symptomatic patients.
Individuals can be infectious while asymptomatic, and asymptomatic and pre-symptomatic individuals have similar amounts of virus in the nose and throat compared to symptomatic patients.
Individuals can be infectious while asymptomatic, and asymptomatic and pre-symptomatic individuals have similar amounts of virus in the nose and throat compared to symptomatic patients.
Individuals can be infectious while asymptomatic, and asymptomatic and pre-symptomatic individuals have similar amounts of virus in the nose and throat compared to symptomatic patients.
Individuals can be infectious while asymptomatic, and asymptomatic and pre-symptomatic individuals have similar amounts of virus in the nose and throat compared to symptomatic patients.
Individuals can be infectious while asymptomatic, and asymptomatic and pre-symptomatic individuals have similar amounts of virus in the nose and throat compared to symptomatic patients.
Individuals can be infectious while asymptomatic, and asymptomatic and pre-symptomatic individuals have similar amounts of virus in the nose and throat compared to symptomatic patients.
Individuals can be infectious while asymptomatic, and asymptomatic and pre-symptomatic individuals have similar amounts of virus in the nose and throat compared to symptomatic patients.
Asymptomatic and mildly ill patients who test positive for SARS-CoV-2 take less time to test negative than severely ill patients.
Asymptomatic and mildly ill patients who test positive for SARS-CoV-2 take less time to test negative than severely ill patients.
Asymptomatic and mildly ill patients who test positive for SARS-CoV-2 take less time to test negative than severely ill patients.
Asymptomatic and mildly ill patients who test positive for SARS-CoV-2 take less time to test negative than severely ill patients.
Asymptomatic and mildly ill patients who test positive for SARS-CoV-2 take less time to test negative than severely ill patients.
Asymptomatic and mildly ill patients who test positive for SARS-CoV-2 take less time to test negative than severely ill patients.
Asymptomatic and mildly ill patients who test positive for SARS-CoV-2 take less time to test negative than severely ill patients.
Asymptomatic and mildly ill patients who test positive for SARS-CoV-2 take less time to test negative than severely ill patients.
Asymptomatic and mildly ill patients who test positive for SARS-CoV-2 take less time to test negative than severely ill patients.
Asymptomatic and mildly ill patients who test positive for SARS-CoV-2 take less time to test negative than severely ill patients.
Patients infected by asymptomatic or young (<20 years old) individuals may take longer to develop symptoms than those infected by other groups of individuals.
Patients infected by asymptomatic or young (<20 years old) individuals may take longer to develop symptoms than those infected by other groups of individuals.
Patients infected by asymptomatic or young (<20 years old) individuals may take longer to develop symptoms than those infected by other groups of individuals.
Patients infected by asymptomatic or young (<20 years old) individuals may take longer to develop symptoms than those infected by other groups of individuals.
Patients infected by asymptomatic or young (<20 years old) individuals may take longer to develop symptoms than those infected by other groups of individuals.
Patients infected by asymptomatic or young (<20 years old) individuals may take longer to develop symptoms than those infected by other groups of individuals.
Patients infected by asymptomatic or young (<20 years old) individuals may take longer to develop symptoms than those infected by other groups of individuals.
Patients infected by asymptomatic or young (<20 years old) individuals may take longer to develop symptoms than those infected by other groups of individuals.
Patients infected by asymptomatic or young (<20 years old) individuals may take longer to develop symptoms than those infected by other groups of individuals.
Patients infected by asymptomatic or young (<20 years old) individuals may take longer to develop symptoms than those infected by other groups of individuals.
Patients being released from the hospital may still exhale detectable levels of SARS-CoV-2 RNA (~7,000 genome copies per hour), though the infectivity of these patients is unknown.
Patients being released from the hospital may still exhale detectable levels of SARS-CoV-2 RNA (~7,000 genome copies per hour), though the infectivity of these patients is unknown.
Patients being released from the hospital may still exhale detectable levels of SARS-CoV-2 RNA (~7,000 genome copies per hour), though the infectivity of these patients is unknown.
Patients being released from the hospital may still exhale detectable levels of SARS-CoV-2 RNA (~7,000 genome copies per hour), though the infectivity of these patients is unknown.
Patients being released from the hospital may still exhale detectable levels of SARS-CoV-2 RNA (~7,000 genome copies per hour), though the infectivity of these patients is unknown.
Patients being released from the hospital may still exhale detectable levels of SARS-CoV-2 RNA (~7,000 genome copies per hour), though the infectivity of these patients is unknown.
Patients being released from the hospital may still exhale detectable levels of SARS-CoV-2 RNA (~7,000 genome copies per hour), though the infectivity of these patients is unknown.
Patients being released from the hospital may still exhale detectable levels of SARS-CoV-2 RNA (~7,000 genome copies per hour), though the infectivity of these patients is unknown.
Patients being released from the hospital may still exhale detectable levels of SARS-CoV-2 RNA (~7,000 genome copies per hour), though the infectivity of these patients is unknown.
Patients being released from the hospital may still exhale detectable levels of SARS-CoV-2 RNA (~7,000 genome copies per hour), though the infectivity of these patients is unknown.
Approximately 15% of hospitalized patients are classified as severe, and approximately 5% of patients are admitted to the ICU.
Approximately 15% of hospitalized patients are classified as severe, and approximately 5% of patients are admitted to the ICU.
Approximately 15% of hospitalized patients are classified as severe, and approximately 5% of patients are admitted to the ICU.
Approximately 15% of hospitalized patients are classified as severe, and approximately 5% of patients are admitted to the ICU.
Approximately 15% of hospitalized patients are classified as severe, and approximately 5% of patients are admitted to the ICU.
Approximately 15% of hospitalized patients are classified as severe, and approximately 5% of patients are admitted to the ICU.
Approximately 15% of hospitalized patients are classified as severe, and approximately 5% of patients are admitted to the ICU.
Approximately 15% of hospitalized patients are classified as severe, and approximately 5% of patients are admitted to the ICU.
Approximately 15% of hospitalized patients are classified as severe, and approximately 5% of patients are admitted to the ICU.
Approximately 15% of hospitalized patients are classified as severe, and approximately 5% of patients are admitted to the ICU.
Early presenters, who are admitted to the hospital within 7 days of symptom onset, have worse clinical outcomes than those admitted later in illness, potentially due to an observed hyperinflammatory response 5-7 days after symptoms begin.
Early presenters, who are admitted to the hospital within 7 days of symptom onset, have worse clinical outcomes than those admitted later in illness, potentially due to an observed hyperinflammatory response 5-7 days after symptoms begin.
Early presenters, who are admitted to the hospital within 7 days of symptom onset, have worse clinical outcomes than those admitted later in illness, potentially due to an observed hyperinflammatory response 5-7 days after symptoms begin.
Early presenters, who are admitted to the hospital within 7 days of symptom onset, have worse clinical outcomes than those admitted later in illness, potentially due to an observed hyperinflammatory response 5-7 days after symptoms begin.
Early presenters, who are admitted to the hospital within 7 days of symptom onset, have worse clinical outcomes than those admitted later in illness, potentially due to an observed hyperinflammatory response 5-7 days after symptoms begin.
Early presenters, who are admitted to the hospital within 7 days of symptom onset, have worse clinical outcomes than those admitted later in illness, potentially due to an observed hyperinflammatory response 5-7 days after symptoms begin.
Early presenters, who are admitted to the hospital within 7 days of symptom onset, have worse clinical outcomes than those admitted later in illness, potentially due to an observed hyperinflammatory response 5-7 days after symptoms begin.
Early presenters, who are admitted to the hospital within 7 days of symptom onset, have worse clinical outcomes than those admitted later in illness, potentially due to an observed hyperinflammatory response 5-7 days after symptoms begin.
Early presenters, who are admitted to the hospital within 7 days of symptom onset, have worse clinical outcomes than those admitted later in illness, potentially due to an observed hyperinflammatory response 5-7 days after symptoms begin.
Early presenters, who are admitted to the hospital within 7 days of symptom onset, have worse clinical outcomes than those admitted later in illness, potentially due to an observed hyperinflammatory response 5-7 days after symptoms begin.
The CFR increases with age (data from China and Italy) 0-19 years < 0.2%; 20-29 years = 0-0.2%, 30-39 years = 0.2-0.3%, 40-49 years = 0.4%, 50-59 years 1.0-1.3%, 60-69 years = 3.5-3.6%, 70-79 years = 8.0-12.8%, >80 years = 14.8-20.2%.
The CFR increases with age (data from China and Italy) 0-19 years < 0.2%; 20-29 years = 0-0.2%, 30-39 years = 0.2-0.3%, 40-49 years = 0.4%, 50-59 years 1.0-1.3%, 60-69 years = 3.5-3.6%, 70-79 years = 8.0-12.8%, >80 years = 14.8-20.2%.
The CFR increases with age (data from China and Italy) 0-19 years < 0.2%; 20-29 years = 0-0.2%, 30-39 years = 0.2-0.3%, 40-49 years = 0.4%, 50-59 years 1.0-1.3%, 60-69 years = 3.5-3.6%, 70-79 years = 8.0-12.8%, >80 years = 14.8-20.2%.
The CFR increases with age (data from China and Italy) 0-19 years < 0.2%; 20-29 years = 0-0.2%, 30-39 years = 0.2-0.3%, 40-49 years = 0.4%, 50-59 years 1.0-1.3%, 60-69 years = 3.5-3.6%, 70-79 years = 8.0-12.8%, >80 years = 14.8-20.2%.
The CFR increases with age (data from China and Italy) 0-19 years < 0.2%; 20-29 years = 0-0.2%, 30-39 years = 0.2-0.3%, 40-49 years = 0.4%, 50-59 years 1.0-1.3%, 60-69 years = 3.5-3.6%, 70-79 years = 8.0-12.8%, >80 years = 14.8-20.2%.
The CFR increases with age (data from China and Italy) 0-19 years < 0.2%; 20-29 years = 0-0.2%, 30-39 years = 0.2-0.3%, 40-49 years = 0.4%, 50-59 years 1.0-1.3%, 60-69 years = 3.5-3.6%, 70-79 years = 8.0-12.8%, >80 years = 14.8-20.2%.
The CFR increases with age (data from China and Italy) 0-19 years < 0.2%; 20-29 years = 0-0.2%, 30-39 years = 0.2-0.3%, 40-49 years = 0.4%, 50-59 years 1.0-1.3%, 60-69 years = 3.5-3.6%, 70-79 years = 8.0-12.8%, >80 years = 14.8-20.2%.
The CFR increases with age (data from China and Italy) 0-19 years < 0.2%; 20-29 years = 0-0.2%, 30-39 years = 0.2-0.3%, 40-49 years = 0.4%, 50-59 years 1.0-1.3%, 60-69 years = 3.5-3.6%, 70-79 years = 8.0-12.8%, >80 years = 14.8-20.2%.
The CFR increases with age (data from China and Italy) 0-19 years < 0.2%; 20-29 years = 0-0.2%, 30-39 years = 0.2-0.3%, 40-49 years = 0.4%, 50-59 years 1.0-1.3%, 60-69 years = 3.5-3.6%, 70-79 years = 8.0-12.8%, >80 years = 14.8-20.2%.
The CFR increases with age (data from China and Italy) 0-19 years < 0.2%; 20-29 years = 0-0.2%, 30-39 years = 0.2-0.3%, 40-49 years = 0.4%, 50-59 years 1.0-1.3%, 60-69 years = 3.5-3.6%, 70-79 years = 8.0-12.8%, >80 years = 14.8-20.2%.
The US FDA also issued an EUA for an at-home test kit capable of testing for both COVID-19 and influenza, and has granted an EUA for the Ellume COVID-19 at-home antigen test, available without a prescription to symptomatic and asymptomatic individuals at least two years of age.
The US FDA also issued an EUA for an at-home test kit capable of testing for both COVID-19 and influenza, and has granted an EUA for the Ellume COVID-19 at-home antigen test, available without a prescription to symptomatic and asymptomatic individuals at least two years of age.
The US FDA also issued an EUA for an at-home test kit capable of testing for both COVID-19 and influenza, and has granted an EUA for the Ellume COVID-19 at-home antigen test, available without a prescription to symptomatic and asymptomatic individuals at least two years of age.
The US FDA also issued an EUA for an at-home test kit capable of testing for both COVID-19 and influenza, and has granted an EUA for the Ellume COVID-19 at-home antigen test, available without a prescription to symptomatic and asymptomatic individuals at least two years of age.
The US FDA also issued an EUA for an at-home test kit capable of testing for both COVID-19 and influenza, and has granted an EUA for the Ellume COVID-19 at-home antigen test, available without a prescription to symptomatic and asymptomatic individuals at least two years of age.
The US FDA also issued an EUA for an at-home test kit capable of testing for both COVID-19 and influenza, and has granted an EUA for the Ellume COVID-19 at-home antigen test, available without a prescription to symptomatic and asymptomatic individuals at least two years of age.
The US FDA also issued an EUA for an at-home test kit capable of testing for both COVID-19 and influenza, and has granted an EUA for the Ellume COVID-19 at-home antigen test, available without a prescription to symptomatic and asymptomatic individuals at least two years of age.
The US FDA also issued an EUA for an at-home test kit capable of testing for both COVID-19 and influenza, and has granted an EUA for the Ellume COVID-19 at-home antigen test, available without a prescription to symptomatic and asymptomatic individuals at least two years of age.
The US FDA also issued an EUA for an at-home test kit capable of testing for both COVID-19 and influenza, and has granted an EUA for the Ellume COVID-19 at-home antigen test, available without a prescription to symptomatic and asymptomatic individuals at least two years of age.
The US FDA also issued an EUA for an at-home test kit capable of testing for both COVID-19 and influenza, and has granted an EUA for the Ellume COVID-19 at-home antigen test, available without a prescription to symptomatic and asymptomatic individuals at least two years of age.
The false-negative rate for RT-PCR tests is lowest between 7 and 9 days after exposure, and PCR tests are more likely to give false-negative results before symptoms begin (within 4 days of exposure) and more than 14 days after exposure.
The false-negative rate for RT-PCR tests is lowest between 7 and 9 days after exposure, and PCR tests are more likely to give false-negative results before symptoms begin (within 4 days of exposure) and more than 14 days after exposure.
The false-negative rate for RT-PCR tests is lowest between 7 and 9 days after exposure, and PCR tests are more likely to give false-negative results before symptoms begin (within 4 days of exposure) and more than 14 days after exposure.
The false-negative rate for RT-PCR tests is lowest between 7 and 9 days after exposure, and PCR tests are more likely to give false-negative results before symptoms begin (within 4 days of exposure) and more than 14 days after exposure.
The false-negative rate for RT-PCR tests is lowest between 7 and 9 days after exposure, and PCR tests are more likely to give false-negative results before symptoms begin (within 4 days of exposure) and more than 14 days after exposure.
The false-negative rate for RT-PCR tests is lowest between 7 and 9 days after exposure, and PCR tests are more likely to give false-negative results before symptoms begin (within 4 days of exposure) and more than 14 days after exposure.
The false-negative rate for RT-PCR tests is lowest between 7 and 9 days after exposure, and PCR tests are more likely to give false-negative results before symptoms begin (within 4 days of exposure) and more than 14 days after exposure.
The false-negative rate for RT-PCR tests is lowest between 7 and 9 days after exposure, and PCR tests are more likely to give false-negative results before symptoms begin (within 4 days of exposure) and more than 14 days after exposure.
The false-negative rate for RT-PCR tests is lowest between 7 and 9 days after exposure, and PCR tests are more likely to give false-negative results before symptoms begin (within 4 days of exposure) and more than 14 days after exposure.
The false-negative rate for RT-PCR tests is lowest between 7 and 9 days after exposure, and PCR tests are more likely to give false-negative results before symptoms begin (within 4 days of exposure) and more than 14 days after exposure.
Symptom-based screening at airports was ineffective at detecting cases (9 identified out of 766,044 passengers screened), and intensive screening on a US military base during mandatory quarantine did not identify any COVID-19 cases.
Symptom-based screening at airports was ineffective at detecting cases (9 identified out of 766,044 passengers screened), and intensive screening on a US military base during mandatory quarantine did not identify any COVID-19 cases.
Symptom-based screening at airports was ineffective at detecting cases (9 identified out of 766,044 passengers screened), and intensive screening on a US military base during mandatory quarantine did not identify any COVID-19 cases.
Symptom-based screening at airports was ineffective at detecting cases (9 identified out of 766,044 passengers screened), and intensive screening on a US military base during mandatory quarantine did not identify any COVID-19 cases.
Symptom-based screening at airports was ineffective at detecting cases (9 identified out of 766,044 passengers screened), and intensive screening on a US military base during mandatory quarantine did not identify any COVID-19 cases.
Symptom-based screening at airports was ineffective at detecting cases (9 identified out of 766,044 passengers screened), and intensive screening on a US military base during mandatory quarantine did not identify any COVID-19 cases.
Symptom-based screening at airports was ineffective at detecting cases (9 identified out of 766,044 passengers screened), and intensive screening on a US military base during mandatory quarantine did not identify any COVID-19 cases.
Symptom-based screening at airports was ineffective at detecting cases (9 identified out of 766,044 passengers screened), and intensive screening on a US military base during mandatory quarantine did not identify any COVID-19 cases.
Symptom-based screening at airports was ineffective at detecting cases (9 identified out of 766,044 passengers screened), and intensive screening on a US military base during mandatory quarantine did not identify any COVID-19 cases.
Symptom-based screening at airports was ineffective at detecting cases (9 identified out of 766,044 passengers screened), and intensive screening on a US military base during mandatory quarantine did not identify any COVID-19 cases.
Combination RT-PCR and serology (antibody) testing may increase the ability to diagnose patients with mild symptoms, or identify patients at higher risk of severe disease.
Combination RT-PCR and serology (antibody) testing may increase the ability to diagnose patients with mild symptoms, or identify patients at higher risk of severe disease.
Combination RT-PCR and serology (antibody) testing may increase the ability to diagnose patients with mild symptoms, or identify patients at higher risk of severe disease.
Combination RT-PCR and serology (antibody) testing may increase the ability to diagnose patients with mild symptoms, or identify patients at higher risk of severe disease.
Combination RT-PCR and serology (antibody) testing may increase the ability to diagnose patients with mild symptoms, or identify patients at higher risk of severe disease.
Combination RT-PCR and serology (antibody) testing may increase the ability to diagnose patients with mild symptoms, or identify patients at higher risk of severe disease.
Combination RT-PCR and serology (antibody) testing may increase the ability to diagnose patients with mild symptoms, or identify patients at higher risk of severe disease.
Combination RT-PCR and serology (antibody) testing may increase the ability to diagnose patients with mild symptoms, or identify patients at higher risk of severe disease.
Combination RT-PCR and serology (antibody) testing may increase the ability to diagnose patients with mild symptoms, or identify patients at higher risk of severe disease.
Combination RT-PCR and serology (antibody) testing may increase the ability to diagnose patients with mild symptoms, or identify patients at higher risk of severe disease.
A large clinical trial (SOLIDARITY, n=2,750 treated patients) found no benefit of remdesivir for patient mortality, regardless of ventilation status or treatment severity.
A large clinical trial (SOLIDARITY, n=2,750 treated patients) found no benefit of remdesivir for patient mortality, regardless of ventilation status or treatment severity.
A large clinical trial (SOLIDARITY, n=2,750 treated patients) found no benefit of remdesivir for patient mortality, regardless of ventilation status or treatment severity.
A large clinical trial (SOLIDARITY, n=2,750 treated patients) found no benefit of remdesivir for patient mortality, regardless of ventilation status or treatment severity.
A large clinical trial (SOLIDARITY, n=2,750 treated patients) found no benefit of remdesivir for patient mortality, regardless of ventilation status or treatment severity.
A large clinical trial (SOLIDARITY, n=2,750 treated patients) found no benefit of remdesivir for patient mortality, regardless of ventilation status or treatment severity.
A large clinical trial (SOLIDARITY, n=2,750 treated patients) found no benefit of remdesivir for patient mortality, regardless of ventilation status or treatment severity.
A large clinical trial (SOLIDARITY, n=2,750 treated patients) found no benefit of remdesivir for patient mortality, regardless of ventilation status or treatment severity.
A large clinical trial (SOLIDARITY, n=2,750 treated patients) found no benefit of remdesivir for patient mortality, regardless of ventilation status or treatment severity.
A large clinical trial (SOLIDARITY, n=2,750 treated patients) found no benefit of remdesivir for patient mortality, regardless of ventilation status or treatment severity.
Hydroxychloroquine (HCQ) does not prevent infection as either pre- or post-exposure prophylaxis, does not benefit mild-moderate COVID-19 cases, was associated with adverse cardiac events in severely ill patients, does not reduce mortality, and increases mortality when combined with azithromycin.
Hydroxychloroquine (HCQ) does not prevent infection as either pre- or post-exposure prophylaxis, does not benefit mild-moderate COVID-19 cases, was associated with adverse cardiac events in severely ill patients, does not reduce mortality, and increases mortality when combined with azithromycin.
Hydroxychloroquine (HCQ) does not prevent infection as either pre- or post-exposure prophylaxis, does not benefit mild-moderate COVID-19 cases, was associated with adverse cardiac events in severely ill patients, does not reduce mortality, and increases mortality when combined with azithromycin.
Hydroxychloroquine (HCQ) does not prevent infection as either pre- or post-exposure prophylaxis, does not benefit mild-moderate COVID-19 cases, was associated with adverse cardiac events in severely ill patients, does not reduce mortality, and increases mortality when combined with azithromycin.
Hydroxychloroquine (HCQ) does not prevent infection as either pre- or post-exposure prophylaxis, does not benefit mild-moderate COVID-19 cases, was associated with adverse cardiac events in severely ill patients, does not reduce mortality, and increases mortality when combined with azithromycin.
Hydroxychloroquine (HCQ) does not prevent infection as either pre- or post-exposure prophylaxis, does not benefit mild-moderate COVID-19 cases, was associated with adverse cardiac events in severely ill patients, does not reduce mortality, and increases mortality when combined with azithromycin.
Hydroxychloroquine (HCQ) does not prevent infection as either pre- or post-exposure prophylaxis, does not benefit mild-moderate COVID-19 cases, was associated with adverse cardiac events in severely ill patients, does not reduce mortality, and increases mortality when combined with azithromycin.
Hydroxychloroquine (HCQ) does not prevent infection as either pre- or post-exposure prophylaxis, does not benefit mild-moderate COVID-19 cases, was associated with adverse cardiac events in severely ill patients, does not reduce mortality, and increases mortality when combined with azithromycin.
Hydroxychloroquine (HCQ) does not prevent infection as either pre- or post-exposure prophylaxis, does not benefit mild-moderate COVID-19 cases, was associated with adverse cardiac events in severely ill patients, does not reduce mortality, and increases mortality when combined with azithromycin.
Hydroxychloroquine (HCQ) does not prevent infection as either pre- or post-exposure prophylaxis, does not benefit mild-moderate COVID-19 cases, was associated with adverse cardiac events in severely ill patients, does not reduce mortality, and increases mortality when combined with azithromycin.
Dexamethasone is associated with substantial reductions in mortality for patients receiving mechanical ventilation, smaller benefits for those receiving supplemental oxygen, and no benefits in patients who did not need oxygen or ventilation.
Dexamethasone is associated with substantial reductions in mortality for patients receiving mechanical ventilation, smaller benefits for those receiving supplemental oxygen, and no benefits in patients who did not need oxygen or ventilation.
Dexamethasone is associated with substantial reductions in mortality for patients receiving mechanical ventilation, smaller benefits for those receiving supplemental oxygen, and no benefits in patients who did not need oxygen or ventilation.
Dexamethasone is associated with substantial reductions in mortality for patients receiving mechanical ventilation, smaller benefits for those receiving supplemental oxygen, and no benefits in patients who did not need oxygen or ventilation.
Dexamethasone is associated with substantial reductions in mortality for patients receiving mechanical ventilation, smaller benefits for those receiving supplemental oxygen, and no benefits in patients who did not need oxygen or ventilation.
Dexamethasone is associated with substantial reductions in mortality for patients receiving mechanical ventilation, smaller benefits for those receiving supplemental oxygen, and no benefits in patients who did not need oxygen or ventilation.
Dexamethasone is associated with substantial reductions in mortality for patients receiving mechanical ventilation, smaller benefits for those receiving supplemental oxygen, and no benefits in patients who did not need oxygen or ventilation.
Dexamethasone is associated with substantial reductions in mortality for patients receiving mechanical ventilation, smaller benefits for those receiving supplemental oxygen, and no benefits in patients who did not need oxygen or ventilation.
Dexamethasone is associated with substantial reductions in mortality for patients receiving mechanical ventilation, smaller benefits for those receiving supplemental oxygen, and no benefits in patients who did not need oxygen or ventilation.
Dexamethasone is associated with substantial reductions in mortality for patients receiving mechanical ventilation, smaller benefits for those receiving supplemental oxygen, and no benefits in patients who did not need oxygen or ventilation.
A large meta-analysis found that 28-day mortality in critically ill patients was reduced in patients (n=678) who received systemic corticosteroids.633 Four separate, smaller trials of corticosteroids (n<152) were stopped early.
A large meta-analysis found that 28-day mortality in critically ill patients was reduced in patients (n=678) who received systemic corticosteroids.633 Four separate, smaller trials of corticosteroids (n<152) were stopped early.
A large meta-analysis found that 28-day mortality in critically ill patients was reduced in patients (n=678) who received systemic corticosteroids.633 Four separate, smaller trials of corticosteroids (n<152) were stopped early.
A large meta-analysis found that 28-day mortality in critically ill patients was reduced in patients (n=678) who received systemic corticosteroids.633 Four separate, smaller trials of corticosteroids (n<152) were stopped early.
A large meta-analysis found that 28-day mortality in critically ill patients was reduced in patients (n=678) who received systemic corticosteroids.633 Four separate, smaller trials of corticosteroids (n<152) were stopped early.
A large meta-analysis found that 28-day mortality in critically ill patients was reduced in patients (n=678) who received systemic corticosteroids.633 Four separate, smaller trials of corticosteroids (n<152) were stopped early.
A large meta-analysis found that 28-day mortality in critically ill patients was reduced in patients (n=678) who received systemic corticosteroids.633 Four separate, smaller trials of corticosteroids (n<152) were stopped early.
A large meta-analysis found that 28-day mortality in critically ill patients was reduced in patients (n=678) who received systemic corticosteroids.633 Four separate, smaller trials of corticosteroids (n<152) were stopped early.
A large meta-analysis found that 28-day mortality in critically ill patients was reduced in patients (n=678) who received systemic corticosteroids.633 Four separate, smaller trials of corticosteroids (n<152) were stopped early.
A large meta-analysis found that 28-day mortality in critically ill patients was reduced in patients (n=678) who received systemic corticosteroids.633 Four separate, smaller trials of corticosteroids (n<152) were stopped early.
In several studies, high doses of steroids were associated with elevated mortality, though low-moderate doses can reduce mortality in patients with ARDS.
In several studies, high doses of steroids were associated with elevated mortality, though low-moderate doses can reduce mortality in patients with ARDS.
In several studies, high doses of steroids were associated with elevated mortality, though low-moderate doses can reduce mortality in patients with ARDS.
In several studies, high doses of steroids were associated with elevated mortality, though low-moderate doses can reduce mortality in patients with ARDS.
In several studies, high doses of steroids were associated with elevated mortality, though low-moderate doses can reduce mortality in patients with ARDS.
In several studies, high doses of steroids were associated with elevated mortality, though low-moderate doses can reduce mortality in patients with ARDS.
In several studies, high doses of steroids were associated with elevated mortality, though low-moderate doses can reduce mortality in patients with ARDS.
In several studies, high doses of steroids were associated with elevated mortality, though low-moderate doses can reduce mortality in patients with ARDS.
In several studies, high doses of steroids were associated with elevated mortality, though low-moderate doses can reduce mortality in patients with ARDS.
In several studies, high doses of steroids were associated with elevated mortality, though low-moderate doses can reduce mortality in patients with ARDS.
At the final study endpoint (170 confirmed COVID-19 cases out of 43,000 participants), vaccine showed 95% efficacy at 7 days after the second vaccine dose (28 days after first dose), which was consistent across age, sex, race, and ethnicity.
At the final study endpoint (170 confirmed COVID-19 cases out of 43,000 participants), vaccine showed 95% efficacy at 7 days after the second vaccine dose (28 days after first dose), which was consistent across age, sex, race, and ethnicity.
At the final study endpoint (170 confirmed COVID-19 cases out of 43,000 participants), vaccine showed 95% efficacy at 7 days after the second vaccine dose (28 days after first dose), which was consistent across age, sex, race, and ethnicity.
At the final study endpoint (170 confirmed COVID-19 cases out of 43,000 participants), vaccine showed 95% efficacy at 7 days after the second vaccine dose (28 days after first dose), which was consistent across age, sex, race, and ethnicity.
At the final study endpoint (170 confirmed COVID-19 cases out of 43,000 participants), vaccine showed 95% efficacy at 7 days after the second vaccine dose (28 days after first dose), which was consistent across age, sex, race, and ethnicity.
At the final study endpoint (170 confirmed COVID-19 cases out of 43,000 participants), vaccine showed 95% efficacy at 7 days after the second vaccine dose (28 days after first dose), which was consistent across age, sex, race, and ethnicity.
At the final study endpoint (170 confirmed COVID-19 cases out of 43,000 participants), vaccine showed 95% efficacy at 7 days after the second vaccine dose (28 days after first dose), which was consistent across age, sex, race, and ethnicity.
At the final study endpoint (170 confirmed COVID-19 cases out of 43,000 participants), vaccine showed 95% efficacy at 7 days after the second vaccine dose (28 days after first dose), which was consistent across age, sex, race, and ethnicity.
At the final study endpoint (170 confirmed COVID-19 cases out of 43,000 participants), vaccine showed 95% efficacy at 7 days after the second vaccine dose (28 days after first dose), which was consistent across age, sex, race, and ethnicity.
At the final study endpoint (170 confirmed COVID-19 cases out of 43,000 participants), vaccine showed 95% efficacy at 7 days after the second vaccine dose (28 days after first dose), which was consistent across age, sex, race, and ethnicity.
There were 30,000 study participants in the trial, with 185 cases (30 severe, 1 death) in the placebo group and 11 cases (0 severe) in the vaccine group.
There were 30,000 study participants in the trial, with 185 cases (30 severe, 1 death) in the placebo group and 11 cases (0 severe) in the vaccine group.
There were 30,000 study participants in the trial, with 185 cases (30 severe, 1 death) in the placebo group and 11 cases (0 severe) in the vaccine group.
There were 30,000 study participants in the trial, with 185 cases (30 severe, 1 death) in the placebo group and 11 cases (0 severe) in the vaccine group.
There were 30,000 study participants in the trial, with 185 cases (30 severe, 1 death) in the placebo group and 11 cases (0 severe) in the vaccine group.
There were 30,000 study participants in the trial, with 185 cases (30 severe, 1 death) in the placebo group and 11 cases (0 severe) in the vaccine group.
There were 30,000 study participants in the trial, with 185 cases (30 severe, 1 death) in the placebo group and 11 cases (0 severe) in the vaccine group.
There were 30,000 study participants in the trial, with 185 cases (30 severe, 1 death) in the placebo group and 11 cases (0 severe) in the vaccine group.
There were 30,000 study participants in the trial, with 185 cases (30 severe, 1 death) in the placebo group and 11 cases (0 severe) in the vaccine group.
There were 30,000 study participants in the trial, with 185 cases (30 severe, 1 death) in the placebo group and 11 cases (0 severe) in the vaccine group.
In the US, each day of delay in emergency declarations and school closures was associated with a 5-6% increase in mortality.
In the US, each day of delay in emergency declarations and school closures was associated with a 5-6% increase in mortality.
In the US, each day of delay in emergency declarations and school closures was associated with a 5-6% increase in mortality.
In the US, each day of delay in emergency declarations and school closures was associated with a 5-6% increase in mortality.
In the US, each day of delay in emergency declarations and school closures was associated with a 5-6% increase in mortality.
In the US, each day of delay in emergency declarations and school closures was associated with a 5-6% increase in mortality.
In the US, each day of delay in emergency declarations and school closures was associated with a 5-6% increase in mortality.
In the US, each day of delay in emergency declarations and school closures was associated with a 5-6% increase in mortality.
In the US, each day of delay in emergency declarations and school closures was associated with a 5-6% increase in mortality.
In the US, each day of delay in emergency declarations and school closures was associated with a 5-6% increase in mortality.
In the US, shelter-in-place orders (SIPOs) and restaurant and bar closures were associated with large reductions in exponential growth rate of cases.
In the US, shelter-in-place orders (SIPOs) and restaurant and bar closures were associated with large reductions in exponential growth rate of cases.
In the US, shelter-in-place orders (SIPOs) and restaurant and bar closures were associated with large reductions in exponential growth rate of cases.
In the US, shelter-in-place orders (SIPOs) and restaurant and bar closures were associated with large reductions in exponential growth rate of cases.
In the US, shelter-in-place orders (SIPOs) and restaurant and bar closures were associated with large reductions in exponential growth rate of cases.
In the US, shelter-in-place orders (SIPOs) and restaurant and bar closures were associated with large reductions in exponential growth rate of cases.
In the US, shelter-in-place orders (SIPOs) and restaurant and bar closures were associated with large reductions in exponential growth rate of cases.
In the US, shelter-in-place orders (SIPOs) and restaurant and bar closures were associated with large reductions in exponential growth rate of cases.
In the US, shelter-in-place orders (SIPOs) and restaurant and bar closures were associated with large reductions in exponential growth rate of cases.
In the US, shelter-in-place orders (SIPOs) and restaurant and bar closures were associated with large reductions in exponential growth rate of cases.
Always wearing masks, maintaining physical distance >1m, and frequently washing hands were all associated with reduced risk of COVID-19 infection in individuals who had direct contact with infected individuals.
Always wearing masks, maintaining physical distance >1m, and frequently washing hands were all associated with reduced risk of COVID-19 infection in individuals who had direct contact with infected individuals.
Always wearing masks, maintaining physical distance >1m, and frequently washing hands were all associated with reduced risk of COVID-19 infection in individuals who had direct contact with infected individuals.
Always wearing masks, maintaining physical distance >1m, and frequently washing hands were all associated with reduced risk of COVID-19 infection in individuals who had direct contact with infected individuals.
Always wearing masks, maintaining physical distance >1m, and frequently washing hands were all associated with reduced risk of COVID-19 infection in individuals who had direct contact with infected individuals.
Always wearing masks, maintaining physical distance >1m, and frequently washing hands were all associated with reduced risk of COVID-19 infection in individuals who had direct contact with infected individuals.
Always wearing masks, maintaining physical distance >1m, and frequently washing hands were all associated with reduced risk of COVID-19 infection in individuals who had direct contact with infected individuals.
Always wearing masks, maintaining physical distance >1m, and frequently washing hands were all associated with reduced risk of COVID-19 infection in individuals who had direct contact with infected individuals.
Always wearing masks, maintaining physical distance >1m, and frequently washing hands were all associated with reduced risk of COVID-19 infection in individuals who had direct contact with infected individuals.
Always wearing masks, maintaining physical distance >1m, and frequently washing hands were all associated with reduced risk of COVID-19 infection in individuals who had direct contact with infected individuals.
After 3 hours (22¬¨¬®‚Äö√†√ªC, 65% RH), no infectious virus was detected on printing and tissue papers; on day 2, none was found on treated wood and cloth; on day 4, none was found on glass or banknote; on day 7, none was found on stainless steel or plastic.
After 3 hours (22¬¨¬®‚Äö√†√ªC, 65% RH), no infectious virus was detected on printing and tissue papers; on day 2, none was found on treated wood and cloth; on day 4, none was found on glass or banknote; on day 7, none was found on stainless steel or plastic.
After 3 hours (22¬¨¬®‚Äö√†√ªC, 65% RH), no infectious virus was detected on printing and tissue papers; on day 2, none was found on treated wood and cloth; on day 4, none was found on glass or banknote; on day 7, none was found on stainless steel or plastic.
After 3 hours (22¬¨¬®‚Äö√†√ªC, 65% RH), no infectious virus was detected on printing and tissue papers; on day 2, none was found on treated wood and cloth; on day 4, none was found on glass or banknote; on day 7, none was found on stainless steel or plastic.
After 3 hours (22¬¨¬®‚Äö√†√ªC, 65% RH), no infectious virus was detected on printing and tissue papers; on day 2, none was found on treated wood and cloth; on day 4, none was found on glass or banknote; on day 7, none was found on stainless steel or plastic.
After 3 hours (22¬¨¬®‚Äö√†√ªC, 65% RH), no infectious virus was detected on printing and tissue papers; on day 2, none was found on treated wood and cloth; on day 4, none was found on glass or banknote; on day 7, none was found on stainless steel or plastic.
After 3 hours (22¬¨¬®‚Äö√†√ªC, 65% RH), no infectious virus was detected on printing and tissue papers; on day 2, none was found on treated wood and cloth; on day 4, none was found on glass or banknote; on day 7, none was found on stainless steel or plastic.
After 3 hours (22¬¨¬®‚Äö√†√ªC, 65% RH), no infectious virus was detected on printing and tissue papers; on day 2, none was found on treated wood and cloth; on day 4, none was found on glass or banknote; on day 7, none was found on stainless steel or plastic.
After 3 hours (22¬¨¬®‚Äö√†√ªC, 65% RH), no infectious virus was detected on printing and tissue papers; on day 2, none was found on treated wood and cloth; on day 4, none was found on glass or banknote; on day 7, none was found on stainless steel or plastic.
After 3 hours (22¬¨¬®‚Äö√†√ªC, 65% RH), no infectious virus was detected on printing and tissue papers; on day 2, none was found on treated wood and cloth; on day 4, none was found on glass or banknote; on day 7, none was found on stainless steel or plastic.
In an analysis of ~3,500 COVID-19 patients, researchers identified 17 SARS-CoV-2 genome variants that were consistently associated with severe illness, and 67 SARS-CoV-2 genome variants consistently associated with mild disease.
In an analysis of ~3,500 COVID-19 patients, researchers identified 17 SARS-CoV-2 genome variants that were consistently associated with severe illness, and 67 SARS-CoV-2 genome variants consistently associated with mild disease.
In an analysis of ~3,500 COVID-19 patients, researchers identified 17 SARS-CoV-2 genome variants that were consistently associated with severe illness, and 67 SARS-CoV-2 genome variants consistently associated with mild disease.
In an analysis of ~3,500 COVID-19 patients, researchers identified 17 SARS-CoV-2 genome variants that were consistently associated with severe illness, and 67 SARS-CoV-2 genome variants consistently associated with mild disease.
In an analysis of ~3,500 COVID-19 patients, researchers identified 17 SARS-CoV-2 genome variants that were consistently associated with severe illness, and 67 SARS-CoV-2 genome variants consistently associated with mild disease.
In an analysis of ~3,500 COVID-19 patients, researchers identified 17 SARS-CoV-2 genome variants that were consistently associated with severe illness, and 67 SARS-CoV-2 genome variants consistently associated with mild disease.
In an analysis of ~3,500 COVID-19 patients, researchers identified 17 SARS-CoV-2 genome variants that were consistently associated with severe illness, and 67 SARS-CoV-2 genome variants consistently associated with mild disease.
In an analysis of ~3,500 COVID-19 patients, researchers identified 17 SARS-CoV-2 genome variants that were consistently associated with severe illness, and 67 SARS-CoV-2 genome variants consistently associated with mild disease.
In an analysis of ~3,500 COVID-19 patients, researchers identified 17 SARS-CoV-2 genome variants that were consistently associated with severe illness, and 67 SARS-CoV-2 genome variants consistently associated with mild disease.
In an analysis of ~3,500 COVID-19 patients, researchers identified 17 SARS-CoV-2 genome variants that were consistently associated with severe illness, and 67 SARS-CoV-2 genome variants consistently associated with mild disease.
Other regions associated with severe disease include locus 3p21.31, where certain alleles are found more often in patients with respiratory distress requiring ventilation, as well as those with severe disease.
Other regions associated with severe disease include locus 3p21.31, where certain alleles are found more often in patients with respiratory distress requiring ventilation, as well as those with severe disease.
Other regions associated with severe disease include locus 3p21.31, where certain alleles are found more often in patients with respiratory distress requiring ventilation, as well as those with severe disease.
Other regions associated with severe disease include locus 3p21.31, where certain alleles are found more often in patients with respiratory distress requiring ventilation, as well as those with severe disease.
Other regions associated with severe disease include locus 3p21.31, where certain alleles are found more often in patients with respiratory distress requiring ventilation, as well as those with severe disease.
Other regions associated with severe disease include locus 3p21.31, where certain alleles are found more often in patients with respiratory distress requiring ventilation, as well as those with severe disease.
Other regions associated with severe disease include locus 3p21.31, where certain alleles are found more often in patients with respiratory distress requiring ventilation, as well as those with severe disease.
Other regions associated with severe disease include locus 3p21.31, where certain alleles are found more often in patients with respiratory distress requiring ventilation, as well as those with severe disease.
Other regions associated with severe disease include locus 3p21.31, where certain alleles are found more often in patients with respiratory distress requiring ventilation, as well as those with severe disease.
Other regions associated with severe disease include locus 3p21.31, where certain alleles are found more often in patients with respiratory distress requiring ventilation, as well as those with severe disease.
The WHO COVID-19 modeling parameter working group has released updated parameter ranges for several key COVID-19 parameters, including the reproduction number (R0), serial interval, generation time, and fatality rate.
The WHO COVID-19 modeling parameter working group has released updated parameter ranges for several key COVID-19 parameters, including the reproduction number (R0), serial interval, generation time, and fatality rate.
The WHO COVID-19 modeling parameter working group has released updated parameter ranges for several key COVID-19 parameters, including the reproduction number (R0), serial interval, generation time, and fatality rate.
The WHO COVID-19 modeling parameter working group has released updated parameter ranges for several key COVID-19 parameters, including the reproduction number (R0), serial interval, generation time, and fatality rate.
The WHO COVID-19 modeling parameter working group has released updated parameter ranges for several key COVID-19 parameters, including the reproduction number (R0), serial interval, generation time, and fatality rate.
The WHO COVID-19 modeling parameter working group has released updated parameter ranges for several key COVID-19 parameters, including the reproduction number (R0), serial interval, generation time, and fatality rate.
The WHO COVID-19 modeling parameter working group has released updated parameter ranges for several key COVID-19 parameters, including the reproduction number (R0), serial interval, generation time, and fatality rate.
The WHO COVID-19 modeling parameter working group has released updated parameter ranges for several key COVID-19 parameters, including the reproduction number (R0), serial interval, generation time, and fatality rate.
The WHO COVID-19 modeling parameter working group has released updated parameter ranges for several key COVID-19 parameters, including the reproduction number (R0), serial interval, generation time, and fatality rate.
The WHO COVID-19 modeling parameter working group has released updated parameter ranges for several key COVID-19 parameters, including the reproduction number (R0), serial interval, generation time, and fatality rate.
University of Georgia Researchers use a rolling window analysis incorporating uncertainty in the generation time distribution to estimate time-varying transmission rates in US states (the effective reproduction number, Reff or Rt).
University of Georgia Researchers use a rolling window analysis incorporating uncertainty in the generation time distribution to estimate time-varying transmission rates in US states (the effective reproduction number, Reff or Rt).
University of Georgia Researchers use a rolling window analysis incorporating uncertainty in the generation time distribution to estimate time-varying transmission rates in US states (the effective reproduction number, Reff or Rt).
University of Georgia Researchers use a rolling window analysis incorporating uncertainty in the generation time distribution to estimate time-varying transmission rates in US states (the effective reproduction number, Reff or Rt).
University of Georgia Researchers use a rolling window analysis incorporating uncertainty in the generation time distribution to estimate time-varying transmission rates in US states (the effective reproduction number, Reff or Rt).
University of Georgia Researchers use a rolling window analysis incorporating uncertainty in the generation time distribution to estimate time-varying transmission rates in US states (the effective reproduction number, Reff or Rt).
University of Georgia Researchers use a rolling window analysis incorporating uncertainty in the generation time distribution to estimate time-varying transmission rates in US states (the effective reproduction number, Reff or Rt).
University of Georgia Researchers use a rolling window analysis incorporating uncertainty in the generation time distribution to estimate time-varying transmission rates in US states (the effective reproduction number, Reff or Rt).
University of Georgia Researchers use a rolling window analysis incorporating uncertainty in the generation time distribution to estimate time-varying transmission rates in US states (the effective reproduction number, Reff or Rt).
University of Georgia Researchers use a rolling window analysis incorporating uncertainty in the generation time distribution to estimate time-varying transmission rates in US states (the effective reproduction number, Reff or Rt).
Children are estimated to shed virus for 15 days on average, with asymptomatic individuals shedding virus for less time (11 days) than symptomatic individuals (17 days).
Children are estimated to shed virus for 15 days on average, with asymptomatic individuals shedding virus for less time (11 days) than symptomatic individuals (17 days).
Children are estimated to shed virus for 15 days on average, with asymptomatic individuals shedding virus for less time (11 days) than symptomatic individuals (17 days).
Children are estimated to shed virus for 15 days on average, with asymptomatic individuals shedding virus for less time (11 days) than symptomatic individuals (17 days).
Children are estimated to shed virus for 15 days on average, with asymptomatic individuals shedding virus for less time (11 days) than symptomatic individuals (17 days).
Children are estimated to shed virus for 15 days on average, with asymptomatic individuals shedding virus for less time (11 days) than symptomatic individuals (17 days).
Children are estimated to shed virus for 15 days on average, with asymptomatic individuals shedding virus for less time (11 days) than symptomatic individuals (17 days).
Children are estimated to shed virus for 15 days on average, with asymptomatic individuals shedding virus for less time (11 days) than symptomatic individuals (17 days).
Children are estimated to shed virus for 15 days on average, with asymptomatic individuals shedding virus for less time (11 days) than symptomatic individuals (17 days).
Children are estimated to shed virus for 15 days on average, with asymptomatic individuals shedding virus for less time (11 days) than symptomatic individuals (17 days).
Russias Gamaleya Institute announced that their adenovirus (Sputnik V) vaccine is 91.4% effective 28 days after the first dose, and over 95% effective 42 days after the first dose (21 days after the second dose), based on 39 COVID-19 cases in 19,000 participants.
Russias Gamaleya Institute announced that their adenovirus (Sputnik V) vaccine is 91.4% effective 28 days after the first dose, and over 95% effective 42 days after the first dose (21 days after the second dose), based on 39 COVID-19 cases in 19,000 participants.
Russias Gamaleya Institute announced that their adenovirus (Sputnik V) vaccine is 91.4% effective 28 days after the first dose, and over 95% effective 42 days after the first dose (21 days after the second dose), based on 39 COVID-19 cases in 19,000 participants.
Russias Gamaleya Institute announced that their adenovirus (Sputnik V) vaccine is 91.4% effective 28 days after the first dose, and over 95% effective 42 days after the first dose (21 days after the second dose), based on 39 COVID-19 cases in 19,000 participants.
Russias Gamaleya Institute announced that their adenovirus (Sputnik V) vaccine is 91.4% effective 28 days after the first dose, and over 95% effective 42 days after the first dose (21 days after the second dose), based on 39 COVID-19 cases in 19,000 participants.
Russias Gamaleya Institute announced that their adenovirus (Sputnik V) vaccine is 91.4% effective 28 days after the first dose, and over 95% effective 42 days after the first dose (21 days after the second dose), based on 39 COVID-19 cases in 19,000 participants.
Russias Gamaleya Institute announced that their adenovirus (Sputnik V) vaccine is 91.4% effective 28 days after the first dose, and over 95% effective 42 days after the first dose (21 days after the second dose), based on 39 COVID-19 cases in 19,000 participants.
Russias Gamaleya Institute announced that their adenovirus (Sputnik V) vaccine is 91.4% effective 28 days after the first dose, and over 95% effective 42 days after the first dose (21 days after the second dose), based on 39 COVID-19 cases in 19,000 participants.
Infection risk is particularly high indoors.
Infection risk is particularly high indoors.
Infection risk is particularly high indoors.
Infection risk is particularly high indoors.
Infection risk is particularly high indoors.
Infection risk is particularly high indoors.
Infection risk is particularly high indoors.
Infection risk is particularly high indoors.
Infection risk is particularly high indoors.
Infection risk is particularly high indoors.
Several studies have identified plausible transmission on airplanes.
Several studies have identified plausible transmission on airplanes.
Several studies have identified plausible transmission on airplanes.
Several studies have identified plausible transmission on airplanes.
Several studies have identified plausible transmission on airplanes.
Several studies have identified plausible transmission on airplanes.
Several studies have identified plausible transmission on airplanes.
Several studies have identified plausible transmission on airplanes.
Several studies have identified plausible transmission on airplanes.
Several studies have identified plausible transmission on airplanes.
The role of children in SARS-CoV-2 transmission is unclear.
The role of children in SARS-CoV-2 transmission is unclear.
The role of children in SARS-CoV-2 transmission is unclear.
The role of children in SARS-CoV-2 transmission is unclear.
The role of children in SARS-CoV-2 transmission is unclear.
The role of children in SARS-CoV-2 transmission is unclear.
The role of children in SARS-CoV-2 transmission is unclear.
The role of children in SARS-CoV-2 transmission is unclear.
The role of children in SARS-CoV-2 transmission is unclear.
The role of children in SARS-CoV-2 transmission is unclear.
The capacity of deer mice as a reservoir species is unknown.
The capacity of deer mice as a reservoir species is unknown.
The capacity of deer mice as a reservoir species is unknown.
The capacity of deer mice as a reservoir species is unknown.
The capacity of deer mice as a reservoir species is unknown.
The capacity of deer mice as a reservoir species is unknown.
The capacity of deer mice as a reservoir species is unknown.
The capacity of deer mice as a reservoir species is unknown.
The capacity of deer mice as a reservoir species is unknown.
The capacity of deer mice as a reservoir species is unknown.
Fever is most often the first symptom.
Fever is most often the first symptom.
Fever is most often the first symptom.
Fever is most often the first symptom.
Fever is most often the first symptom.
Fever is most often the first symptom.
Fever is most often the first symptom.
Fever is most often the first symptom.
Fever is most often the first symptom.
Fever is most often the first symptom.
Symptoms can persist for months.
Symptoms can persist for months.
Symptoms can persist for months.
Symptoms can persist for months.
Symptoms can persist for months.
Symptoms can persist for months.
Symptoms can persist for months.
Symptoms can persist for months.
Symptoms can persist for months.
Symptoms can persist for months.
Hydroxychloroquine provides limited to no clinical benefit.
Hydroxychloroquine provides limited to no clinical benefit.
Hydroxychloroquine provides limited to no clinical benefit.
Hydroxychloroquine provides limited to no clinical benefit.
Hydroxychloroquine provides limited to no clinical benefit.
Hydroxychloroquine provides limited to no clinical benefit.
Hydroxychloroquine provides limited to no clinical benefit.
Hydroxychloroquine provides limited to no clinical benefit.
Hydroxychloroquine provides limited to no clinical benefit.
Hydroxychloroquine provides limited to no clinical benefit.
Fluvoxamine may reduce clinical symptoms.
Fluvoxamine may reduce clinical symptoms.
Fluvoxamine may reduce clinical symptoms.
Fluvoxamine may reduce clinical symptoms.
Fluvoxamine may reduce clinical symptoms.
Fluvoxamine may reduce clinical symptoms.
Fluvoxamine may reduce clinical symptoms.
Fluvoxamine may reduce clinical symptoms.
Fluvoxamine may reduce clinical symptoms.
Fluvoxamine may reduce clinical symptoms.
There is no clinical benefit from ritonavir/lopinavir.
There is no clinical benefit from ritonavir/lopinavir.
There is no clinical benefit from ritonavir/lopinavir.
There is no clinical benefit from ritonavir/lopinavir.
There is no clinical benefit from ritonavir/lopinavir.
There is no clinical benefit from ritonavir/lopinavir.
There is no clinical benefit from ritonavir/lopinavir.
There is no clinical benefit from ritonavir/lopinavir.
There is no clinical benefit from ritonavir/lopinavir.
There is no clinical benefit from ritonavir/lopinavir.
Reinfection with SARS-CoV-2 is possible but appears rare, though the true frequency is unknown.
Reinfection with SARS-CoV-2 is possible but appears rare, though the true frequency is unknown.
Reinfection with SARS-CoV-2 is possible but appears rare, though the true frequency is unknown.
Reinfection with SARS-CoV-2 is possible but appears rare, though the true frequency is unknown.
Reinfection with SARS-CoV-2 is possible but appears rare, though the true frequency is unknown.
Reinfection with SARS-CoV-2 is possible but appears rare, though the true frequency is unknown.
Reinfection with SARS-CoV-2 is possible but appears rare, though the true frequency is unknown.
Reinfection with SARS-CoV-2 is possible but appears rare, though the true frequency is unknown.
Reinfection with SARS-CoV-2 is possible but appears rare, though the true frequency is unknown.
Reinfection with SARS-CoV-2 is possible but appears rare, though the true frequency is unknown.
The infectiousness of re-infected individuals is unknown.
The infectiousness of re-infected individuals is unknown.
The infectiousness of re-infected individuals is unknown.
The infectiousness of re-infected individuals is unknown.
The infectiousness of re-infected individuals is unknown.
The infectiousness of re-infected individuals is unknown.
The infectiousness of re-infected individuals is unknown.
The infectiousness of re-infected individuals is unknown.
The infectiousness of re-infected individuals is unknown.
The infectiousness of re-infected individuals is unknown.
Efficacy was 94% for those individuals over 65.
Efficacy was 94% for those individuals over 65.
Efficacy was 94% for those individuals over 65.
Efficacy was 94% for those individuals over 65.
Efficacy was 94% for those individuals over 65.
Efficacy was 94% for those individuals over 65.
Efficacy was 94% for those individuals over 65.
Efficacy was 94% for those individuals over 65.
Efficacy was 94% for those individuals over 65.
Efficacy was 94% for those individuals over 65.
Telework policies may reduce new cases.
Telework policies may reduce new cases.
Telework policies may reduce new cases.
Telework policies may reduce new cases.
Telework policies may reduce new cases.
Telework policies may reduce new cases.
Telework policies may reduce new cases.
Telework policies may reduce new cases.
Telework policies may reduce new cases.
Telework policies may reduce new cases.
Rolling interventions may be necessary.
Rolling interventions may be necessary.
Rolling interventions may be necessary.
Rolling interventions may be necessary.
Rolling interventions may be necessary.
Rolling interventions may be necessary.
Rolling interventions may be necessary.
Rolling interventions may be necessary.
Rolling interventions may be necessary.
Rolling interventions may be necessary.
DHS has developed a tool for estimating the decay of airborne SARS-CoV-2 in different environmental conditions.
DHS has developed a tool for estimating the decay of airborne SARS-CoV-2 in different environmental conditions.
DHS has developed a tool for estimating the decay of airborne SARS-CoV-2 in different environmental conditions.
DHS has developed a tool for estimating the decay of airborne SARS-CoV-2 in different environmental conditions.
DHS has developed a tool for estimating the decay of airborne SARS-CoV-2 in different environmental conditions.
DHS has developed a tool for estimating the decay of airborne SARS-CoV-2 in different environmental conditions.
DHS has developed a tool for estimating the decay of airborne SARS-CoV-2 in different environmental conditions.
DHS has developed a tool for estimating the decay of airborne SARS-CoV-2 in different environmental conditions.
DHS has developed a tool for estimating the decay of airborne SARS-CoV-2 in different environmental conditions.
DHS has developed a tool for estimating the decay of airborne SARS-CoV-2 in different environmental conditions.
EPA has released a list of SARS-CoV-2 disinfectants that have been found effective against SARS-CoV-2 specifically.
EPA has released a list of SARS-CoV-2 disinfectants that have been found effective against SARS-CoV-2 specifically.
EPA has released a list of SARS-CoV-2 disinfectants that have been found effective against SARS-CoV-2 specifically.
EPA has released a list of SARS-CoV-2 disinfectants that have been found effective against SARS-CoV-2 specifically.
EPA has released a list of SARS-CoV-2 disinfectants that have been found effective against SARS-CoV-2 specifically.
EPA has released a list of SARS-CoV-2 disinfectants that have been found effective against SARS-CoV-2 specifically.
EPA has released a list of SARS-CoV-2 disinfectants that have been found effective against SARS-CoV-2 specifically.
EPA has released a list of SARS-CoV-2 disinfectants that have been found effective against SARS-CoV-2 specifically.
EPA has released a list of SARS-CoV-2 disinfectants that have been found effective against SARS-CoV-2 specifically.
EPA has released a list of SARS-CoV-2 disinfectants that have been found effective against SARS-CoV-2 specifically.
Efforts are ongoing to create paint-on surfaces or other surface coatings190 that can rapidly inactivate SARS-CoV-2.
Efforts are ongoing to create paint-on surfaces or other surface coatings190 that can rapidly inactivate SARS-CoV-2.
Efforts are ongoing to create paint-on surfaces or other surface coatings190 that can rapidly inactivate SARS-CoV-2.
Efforts are ongoing to create paint-on surfaces or other surface coatings190 that can rapidly inactivate SARS-CoV-2.
Efforts are ongoing to create paint-on surfaces or other surface coatings190 that can rapidly inactivate SARS-CoV-2.
Efforts are ongoing to create paint-on surfaces or other surface coatings190 that can rapidly inactivate SARS-CoV-2.
Efforts are ongoing to create paint-on surfaces or other surface coatings190 that can rapidly inactivate SARS-CoV-2.
Efforts are ongoing to create paint-on surfaces or other surface coatings190 that can rapidly inactivate SARS-CoV-2.
Efforts are ongoing to create paint-on surfaces or other surface coatings190 that can rapidly inactivate SARS-CoV-2.
Efforts are ongoing to create paint-on surfaces or other surface coatings190 that can rapidly inactivate SARS-CoV-2.
Current sampling of pangolin viruses does not implicate them as an intermediate to human SARS-CoV-2.
Current sampling of pangolin viruses does not implicate them as an intermediate to human SARS-CoV-2.
Current sampling of pangolin viruses does not implicate them as an intermediate to human SARS-CoV-2.
Current sampling of pangolin viruses does not implicate them as an intermediate to human SARS-CoV-2.
Current sampling of pangolin viruses does not implicate them as an intermediate to human SARS-CoV-2.
Current sampling of pangolin viruses does not implicate them as an intermediate to human SARS-CoV-2.
Current sampling of pangolin viruses does not implicate them as an intermediate to human SARS-CoV-2.
Current sampling of pangolin viruses does not implicate them as an intermediate to human SARS-CoV-2.
Current sampling of pangolin viruses does not implicate them as an intermediate to human SARS-CoV-2.
Current sampling of pangolin viruses does not implicate them as an intermediate to human SARS-CoV-2.
Very few outbreaks have occurred in outdoor settings.
Very few outbreaks have occurred in outdoor settings.
Very few outbreaks have occurred in outdoor settings.
Very few outbreaks have occurred in outdoor settings.
Very few outbreaks have occurred in outdoor settings.
Very few outbreaks have occurred in outdoor settings.
Very few outbreaks have occurred in outdoor settings.
Very few outbreaks have occurred in outdoor settings.
Very few outbreaks have occurred in outdoor settings.
Very few outbreaks have occurred in outdoor settings.
Outbreaks have also occurred on public buses.
Outbreaks have also occurred on public buses.
Outbreaks have also occurred on public buses.
Outbreaks have also occurred on public buses.
Outbreaks have also occurred on public buses.
Outbreaks have also occurred on public buses.
Outbreaks have also occurred on public buses.
Outbreaks have also occurred on public buses.
Outbreaks have also occurred on public buses.
Outbreaks have also occurred on public buses.
Dome-shaped N95 respirators also failed fit tests after extended use.
Dome-shaped N95 respirators also failed fit tests after extended use.
Dome-shaped N95 respirators also failed fit tests after extended use.
Dome-shaped N95 respirators also failed fit tests after extended use.
Dome-shaped N95 respirators also failed fit tests after extended use.
Dome-shaped N95 respirators also failed fit tests after extended use.
Dome-shaped N95 respirators also failed fit tests after extended use.
Dome-shaped N95 respirators also failed fit tests after extended use.
Dome-shaped N95 respirators also failed fit tests after extended use.
Dome-shaped N95 respirators also failed fit tests after extended use.
There have been no documented cases of SARS-CoV-2 prior to December 2019.
There have been no documented cases of SARS-CoV-2 prior to December 2019.
There have been no documented cases of SARS-CoV-2 prior to December 2019.
There have been no documented cases of SARS-CoV-2 prior to December 2019.
There have been no documented cases of SARS-CoV-2 prior to December 2019.
There have been no documented cases of SARS-CoV-2 prior to December 2019.
There have been no documented cases of SARS-CoV-2 prior to December 2019.
There have been no documented cases of SARS-CoV-2 prior to December 2019.
There have been no documented cases of SARS-CoV-2 prior to December 2019.
There have been no documented cases of SARS-CoV-2 prior to December 2019.